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ABSTRACT 
Background: Type 2 diabetes [T2D] is a chronic, debilitating condition often 
associated with obesity. People with T2D rarely fully comply with their medication 
regime whether it is tablets or injections. Yet, weight gain is a common side effect of 
most diabetes medicines and, therefore, can be problematic for patients already 
overweight.  
Study Aim: To measure how expectations, beliefs and attitudes towards different 
diabetes treatments change over time focusing on medicines which cause weight 
loss, weight gain or are weight neutral. To investigate the impact of this 
belief/attitude change on adherence, and explore ideas for future interventions 
which improve both diabetes management and adherence.  
Methods: A mixed methods observational study was conducted in parallel with a 
systematic review. Individuals self-completed validated questionnaires (n=190) and 
selected purposively to be interviewed (n=24/190) before and three months after a 
change in treatment. A change was defined as the addition of, or a change to, a new 
glucose-lowering or anti-obesity drug to the patient’s current therapy.  
Results: The systematic review identified that T2D patients go through a constant 
self-evaluation as a result of daily emotional and cognitive experiences with their 
condition and medicines. However, weight loss was not perceived as strategy in 
managing diabetes. The questionnaires and interviews revealed that patients’ views 
of their medicines and the severity of their condition changes over time. Overall they 
were ambivalent about the effectiveness of their diabetes treatment, whilst most 
were concerned about their body weight. Although there was evidence of reluctance 
to make treatment changes and a desire to stop them, most patients appeared to 
accept new medicines if they portray a dual purpose, particularly if they help weight 
loss and/or in reduction medication number or doses. Nevertheless, despite 
significantly positive appraisals at 3-month follow-up from participants prescribed 
medicines promoting weight loss, 70% of the whole group had suboptimal adherence 
levels. Adherence was influenced by perceptions of medicine’s effectiveness, 
concerns and convenience, experience of side effects and self-efficacy levels. 
Interviewees who had an established routine and took their medicines in conjunction 
with other events, such as self-monitoring of blood glucose, were classified as highly 
adherent. Yet, perceptions of blood glucose and lack/excessive self-monitoring could 
hinder appropriate management of diabetes and weight loss. Whilst health 
professionals, family and other people with T2D can have both a positive and 
negative impact on individual’s perceptions and treatment adherence, interviewees 
valued most the support they received from their health care team, particularly if this 
was intensive, diverse and timely.  
Conclusion: Study findings demonstrate that the needs and desired outcomes of T2D 
patients change over time after a treatment change, but the new medicine’s weight-
effect does not influence adherence. Instead, patients could benefit from NHS 
services that give support in increasing confidence levels in taking medicines as well 
as exploring medicines concerns and adherence, through the use of the visual models 
developed in this study. 
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I. Introduction 
Prevalence of Type 2 Diabetes [T2D] is increasing alarmingly and regarded as a major 
public health concern. In the United Kingdom [UK], currently, there are 3 million 
individuals who have been diagnosed with T2D. However, it is projected that by 2025 
there will be 5 million in total with this condition (Diabetes UK [DUK], 2012). T2D is a 
complex heterogeneous and progressive disease associated with insulin resistance 
and obesity. Failure to control diabetes can lead to serious macrovascular and 
microvascular complications leading to great disability and premature mortality 
(DUK, 2012). Therefore, T2D requires management of a range of factors including 
blood glucose, blood lipids, blood pressure and body weight (Philippe & Raccah, 
2009; Aicher et al., 2010; Lau, 2010).   
 
In the UK, T2D is managed at both primary and secondary care level. Its treatment 
consists of lifestyle interventions and subsequently addition of glucose-lowering 
drugs (National Institute for Health and Clinical Excellence [NICE], 2009a). Although 
there are a number of medication treatments for T2D, many promote weight gain, 
which then adversely affects diabetes control. Hence, health care providers face a 
challenge in maintaining the balance between achieving normoglycaemia while 
simultaneously minimising hypoglycaemia and weight gain (Lau, 2010). Despite the 
effectiveness of glucose-lowering drugs in controlling hyperglycaemia (Turner et al., 
1999; Inzucchi et al., 2012), there is limited information about patients’ experiences 
and expectations of these drugs.  
 
It is already known that T2D patients rarely fully comply with their medication regime 
(Cramer, 2004). A number of factors have been identified to explain lack of 
adherence to the medication regime, including; polypharmacy, complex dosing 
regimens, routines (or lack of) in medication behaviour, safety concerns, experiences 
with medications and complications, patient education and beliefs, social support,  
information about the prescribed medication, socioeconomic issues and ethnicity 
(Borgsteede, 2011; Bailey & Kodack, 2011). However, recent studies have suggested 
that fear of weight gain may also contribute to low adherence levels (Farmer et al., 
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2006; Peyrot et al., 2009; Pi-Sunyer, 2009). To date, there have been few studies of 
T2D patients’ expectations, beliefs and attitudes towards their diabetes medication, 
and their medication taking behaviour as a result of their medications’ effects on 
their body weight. In addition, previous studies have not explicitly addressed how 
patients’ beliefs and attitudes change over time as a result of taking their diabetes 
medications. Furthermore, there is little evidence of patients’ experiences with 
medications through qualitative studies.   
II. Purpose- Aims and Objectives 
This study involves a mixed methodology and aims to address the following 
questions: 
1. How do the expectations, beliefs and attitudes of people with T2D towards 
different diabetes treatments that either promote weight loss, are weight 
neutral or result in weight gain, change over time? 
2. What is the impact of the change on patients’ adherence to their medicine(s)? 
3. What type(s) of intervention(s) promoting treatment options, focusing on 
effects on body weight, are acceptable to patients in order to increase their 
understanding of their diabetes treatment and improve adherence?  
 
The subsequent objectives were formulated to consider the above research 
questions:  
 Measure the change in patients’ expectations, beliefs and attitudes towards 
glucose-lowering (and/or anti-obesity) drugs (including those with different 
body weight effects) prior to, during and after taking medicine(s) (where 
appropriate), within primary and secondary care using self-completed 
validated questionnaires. (Question 1) 
 Explore in depth, using semi-structured interviews, the expectations, beliefs 
and attitudes towards these drugs (including those with different body weight 
effects) and associated lifestyle advice in a subsample of patients, and verify 
and compare the findings with the data from the above questionnaires. 
(Question 1) 
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 Investigate the relationship of these changes with patients’ diabetes 
management (adherence) using self-completed validated questionnaires.  
(Question 2) 
 Utilise integrated findings from the above questionnaires and interviews and 
the systematic review in chapter 2 to explore ideas for intervention(s) which 
promote understanding of diabetes treatment and adherence in patients 
with T2D. (Question 3) 
Understanding patients’ experiences, and how these change over time should help 
inform guidance on how to improve health care services for overweight and obese 
T2D patients in the National Health Service [NHS] and make the experiences of 
patients more positive. The development of this research programme is in line with 
the Medical Research Council [MRC] framework for developing complex 
interventions (MRC, 2008). 
III. Thesis Structure 
In chapter 1, T2D is outlined, focusing on the impact on people’s health and the 
National Health Service. This chapter gives an overview of diabetes management 
interventions providing more detail on current pharmacological agents used for the 
treatment of T2D, their effectiveness on glycaemic control and their effects on body 
weight. This chapter also summarises current guidance on using glucose-lowering 
(and anti-obesity) drugs in the UK and outcomes of studies in primary care. In chapter 
2, the central theme of the study, presents information from a limited area of 
research studies on patients’ perspectives of drug use in long term conditions, with 
a focus particularly on T2D through a systematic review and identifies potential 
theoretical models in investigating such perspectives.  
 
Chapter 3 describes the general methodology of this research programme starting 
with the aims and justification of the thesis. Detailed description of the study design, 
and information about group selection and sample size are also provided in this 
chapter. Also, this chapter provides a detailed account of the recruitment strategy, 
as well as ethical considerations and an outline of ethical approval and amendments. 
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Chapter 4 presents the validity and reliability of all data collection tools, as well as 
relevant pilot procedures and statistical and qualitative analysis conducted.  
 
Chapter 5 provides the first results chapter based on questionnaire analysis and 
Chapter 6 provides the second results chapter based on qualitative interviews 
analysis. The scope of the two result chapters is to answer the research questions as 
set out in chapter three.  
 
Finally, in chapter 7 all the data are brought together, informing the audience about 
the key issues emerged from the study in terms of expectations and experiences of 
patients taking glucose-lowering and/or anti-obesity drugs, as well as patterns of 
adherence. This chapter provides a discussion of key findings, underpinning theory, 
and recommendations. The strengths and limitations of the research study are 
covered here too. This final chapter concludes of the findings of this research and 
implications for health care services (primary and secondary care), and direction for 
future research.  
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1.1 What is type 2 diabetes? 
Type 2 Diabetes is a complex heterogeneous and progressive disease associated with 
insulin resistance and failure of the pancreas to produce sufficient insulin due to a 
gradual loss of beta-cell function resulting in chronic hyperglycaemia1. Insulin is a 
hormone that helps absorb glucose from the bloodstream, which then provides 
energy to the cells and body organs. Individuals with T2D can be undiagnosed for 
many years, and subsequently when they are diagnosed they have already lost 50% 
of their beta-cell function. Due to the progressive nature of T2D, individuals may only 
have 25% of their normal beta-cell function 6 years following diagnosis (UK 
prospective diabetes study [UKPDS], 1995).     
 
Although hyperglycaemia in diabetes is associated with various symptoms, these 
often can be mild or ignored by individuals which leads to delayed diagnosis (Singh 
et al, 1992). Common symptoms include polydipsia (excessive thirst), polyuria, 
particularly at night, lethargy, weight loss, visual disturbance and genital irritation or 
thrush. 
1.2 Causes and complications of T2D 
Prevalence of T2D is increasing alarmingly and regarded as a major public health 
concern worldwide (International Diabetes Federation [IDF], 2013). In the UK, 
currently, there are 3 million people who have been diagnosed with T2D. However, 
it is projected that by 2025 there will be 5 million in total with this condition (DUK, 
2012). In Merseyside, the prevalence of diabetes is close (3.87-4.99%) to the average 
prevalence for England (4.75%) (Health and Social Care Information Centre [HSCIC], 
2013), and even higher in some areas. Type 2 diabetes is closely related to obesity2 
and it is estimated that up to 85% of individuals with T2D are either overweight or 
obese (DUK, 2012). In addition, obese people are more likely to develop T2D than 
those who maintain a healthy weight (DUK, 2005).   
                                                     
1 Increased/excess plasma/blood glucose levels 
2 Overweight and obesity is a condition of excess body fat; where overweight is defined as a Body 
Mass Index [BMI] of 25.0kg/m² to 29.9kg/m² and obesity as a BMI of greater than 30.0kg/m² (WHO, 
2000). 
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People with T2D are usually over the age of 40, although increasingly younger people 
are also being affected (Wilmot et al., 2010; IDF, 2013). Other determinants include 
family history and ethnicity (IDF, 2013). Failure to control diabetes can lead to serious 
macro and microvascular complications, such as heart disease, stroke, renal disease, 
retinopathy and neuropathy leading to great disability and premature mortality 
(DUK, 2012; IDF, 2013). Diabetes is also the leading cause of blindness and lower 
extremity amputations. Therefore, it requires the management of a range of factors 
including blood glucose, blood lipids and blood pressure (Philippe & Raccah, 2009).   
 
Long term glycaemic control is monitored by measurements of glycated haemoglobin 
[HbA1c]; a gold standard measurement which provides a biological marker over a 2-
3 month period (Hanas & John, 2010). Diabetes is regarded well controlled if HbA1c 
is below 6.5% (48mmol/mol) but for certain individuals a range between 7.0-7.5% 
(53-59mmol/mol) can be acceptable (NICE, 2009a; Inzucchi et al., 2012), particularly 
for those who find it difficult to achieve the target despite intensive self-
management, education and glucose-lowering therapy.  
 
A fundamental aspect of T2D management is to control not only hyperglycaemia in 
general but also pay attention to pre-prandial (before a meal) and post-prandial 
(after a meal) glucose levels. Evidence suggests that failure to control either of these 
will result in long term hyperglycaemia (HbA1c>8.0%, 64mmol/mol) and may directly 
increase the risk of cardiovascular events (Haffner, 1998; Stratton et al., 2000).  
 
In addition, an increase in body weight in patients with T2D can have major adverse 
effects in the management of their condition leading to an increased risk of the 
aforementioned micro and macrovascular complications (Daousi et al., 2006; 
Dhaliwal & Welborn, 2009). Therefore, weight is considered as an important 
outcome for the management and delayed progression of diabetes (Aicher et al., 
2010; Lau, 2010) 
 
Evidence shows that a reduction in HbA1c by 10mmol/mol (1%) reduces the risk of 
microvascular complications by 37% and diabetes related deaths by 21% (Stratton et 
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al., 2000). In addition, a decrease of 5-10% of body weight is associated with 
significant reduction in diabetes, cardiovascular risk and mortality rates (Lau, 2010; 
Ross et al., 2011).  
1.3 Impact and cost to NHS and patients 
In recent years, there has been a shift in the management of T2D from secondary 
care to primary care, to potentially improve patient outcomes by encouraging 
patients to self-manage their condition (Liebl, Rutten & Abraira, 2010). The aim is to 
improve patients’ quality of life and to reduce service costs (Department of Health 
[DOH], 1999).  
 
However, the increasing prevalence of obesity and diabetes is generating additional 
cost and time pressures in primary care (Counterweight Project Team, 2005). This 
has implications for the NHS, as the cost of obesity and diabetes is escalating (DUK, 
2012; NICE, 2009a), reaching almost £10 billion in 2011 for all aspects of diabetes 
care and projected to increase to £16.9 billion by 2035 (Hex et al., 2012). Over a 10 
year period (1997-2007) primary care treatment costs for T2D increased considerably 
without an improvement in HbA1c (Currie, Gale, & Poole, 2010). The cost of 
prescribing glucose-lowering drugs alone has increased by £30 million from 2011 to 
2012 (HSCIC, 2012). Evidence demonstrates that direct medical costs associated with 
the treatment of T2D are significantly higher for individuals with poor glycaemic 
control than those with optimal control (Gilmer et al., 1997) and such individuals are 
more likely to have increased hospital admissions further impacting the health 
service (Wagner et al., 2001; Jiang et al., 2003). It is apparent that after nine years 
since diagnosis of T2D, only a quarter of patients are able to control their diabetes 
with a single drug. Hence, most patients require combination therapy (oral glucose 
lowering drugs [OGDs] and/or insulin) within 5-10 years of diagnosis (Turner et al., 
1999).  
 
Self-management is the cornerstone of diabetes treatment, and is defined as the 
behaviours and skills that an individual employs on a daily basis to manage their 
diabetes (DUK, 2009; Shrivastava et al., 2013). Such behaviours include following a 
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healthy diet, participating in physical activity, quitting smoking, monitoring their 
blood glucose, screening of their eyes, looking after their feet, and body weight on a 
regular basis and adhering to their medicines’ regime in order to prevent hyper- and 
where relevant hypoglycaemia3 (Ismail, Winkley, & Rabe-Hesketh, 2004; Shrivastava 
et al., 2013). The behaviours and decisions employed are based on their knowledge, 
beliefs, attitudes, resources and support systems available to them (Longo et al., 
2010; Nam et al., 2011).  
 
These everyday tasks described above can be seen by patients as a burden (Vijan et 
al., 2005a; Vijan et al., 2005b), as T2D patients have to follow them for the duration 
of their life. This may lead to low self-efficacy and subsequently to suboptimal 
adherence to any or all of the above tasks (Grant et al., 2003; Agborsangaya et al., 
2013) which then impacts on patients’ well-being (Sacco et al., 2007). 
 
Often individuals with T2D suffer from other comorbidities such dyslipidaemia, 
hypertension, depression and thyroid dysfunction, which requires them to take more 
medicines to control these conditions (Rubin, 2005; Huang et al, 2009). A suboptimal 
adherence to any of these tasks will have detrimental effects to their health and 
progression of diabetes and micro- and macrovascular complications (Kuo et al., 
2003; Shrivastava et al., 2013), further impacting patients’ physical and mental health 
well-being. Diabetes diagnosis, lifestyle adjustment, incidence of hypoglycaemia and 
onset of complications are associated with psychosocial problems (Cox & Gonder-
Frederick, 1992). The presence of diabetes and obesity in an individual also 
significantly reduces health related quality of life [HRQOL] (Gough et al., 2009), in 
fact self-perception of weight gain without evidence of weight gain also impacts on 
HRQOL (Grandy, Fox, & Bazata, 2013). It is believed also that hypoglycaemia can 
cause psychological and physiological morbidity (Davis et al., 2005; Marrett et al., 
2009). 
                                                     
3 Hypoglycaemia is a state when the blood glucose levels fall below normal range (< 3.9mmol/l) (Bonds 
et al, 2010). Symptoms can be relatively minor such as sweating, hunger and anxiety or very severe 
such as behavioural changes, cognitive impairment, seizures and coma. Other symptoms include 
shakiness, dizziness, headache, pale skin colour, confusion/ feeling disoriented, clumsy/jerky 
movements, tingling sensations around the mouth and difficulty concentrating. 
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1.4 Management of T2D in UK 
In the UK, NHS primary and secondary care are key providers of medical support and 
appropriate treatment for people with T2D. The UK government has made efforts to 
improve the quality of NHS services for patients with diabetes (DOH, 2004a). 
Diabetes has been identified as a priority for action with the National Service 
Framework [NSF] for Diabetes (DOH, 2001a). Furthermore, since 2004, primary care 
teams are financially rewarded to undertake specified clinical activities and achieve 
tight glycaemic and metabolic targets in patients under their care through the Quality 
and Outcomes Framework [QOF] (Campbell et al., 2007; Khunti et al., 2007).  Such 
targets and standards have been recently emphasized within the document about 
quality standards for diabetes in adults by NICE (NICE, 20114).   
1.5 Lifestyle Interventions for T2D 
The foundation of the management of T2D incorporates lifestyle modification 
including dietary and exercise strategies which are of most importance in order to 
maintain a healthy body weight and aid glycaemic control, as an integral component 
of diabetes self-management education (American Diabetes Association [ADA], 
2008). 
 
Dietary advice for people with T2D includes a healthy balanced diet. Although, 
specifically for diabetes, there is no certain advice on macronutrients or 
micronutrients, an emphasis on fibre rich foods (fruits, vegetables, whole grains, and 
legumes) and a reduction of foods high in saturated and trans fats is recommended 
for blood lipid lowering and reduction of cardiovascular risk (Van Horn et al., 2008). 
Guidelines also recommend to monitor carbohydrate intake through carbohydrate 
counting, exchanges, or estimation, as there is evidence that carbohydrate is the 
primary determinant of post-prandial blood glucose response (ADA, 2008; Franz et 
al., 2010). Furthermore, the glycaemic index, which measures how quickly a 
carbohydrate-containing food raises blood glucose levels, may be a helpful addition 
                                                     
4 This NICE Quality Standard was updated in August 2016, however the PhD study was conducted 
between years 2011-2014, so the thesis is referring to the guidelines that were available at the time 
for health professionals and people with Type 2 Diabetes.  
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to carbohydrate counting. However, when the focus is on weight management, then 
a reduction of total energy intake is required rather than changing the source of 
energy in the diet (ADA, 2008; DUK, 2011).  
 
Lifestyle interventions that entail diet, physical activity and behavioural interventions 
help with reductions in body weight by up to 1.7kg after one year (Norris et al., 2005). 
Physical activity interventions also have clear benefits on cardiovascular risk 
reduction and glycaemic control in people with T2D, showing an improvement of 
HbA1c by 0.6% (Thomas, Elliott, & Naughton, 2006). 
1.6 Pharamacotherapy 
Although lifestyle interventions are the first line of treatment of this condition, most 
people subsequently need sequential addition of glucose-lowering drugs (NICE, 
2009a5). There are a number of medication treatments for T2D (see 1.6.1-1.6.10), 
however many promote weight gain, which then adversely affects diabetes control. 
Hence, one of the main challenges facing health care providers in diabetes 
management is maintaining the balance between achieving normoglycaemia while 
simultaneously minimising hypoglycaemia and weight gain that may negatively affect 
adherence to therapy and subsequent health outcomes (Lau, 2010). 
 
There is clear guidance (NICE, 20066; 2009a) for the pharmacotherapy management 
of obesity and T2D, using various algorithms following lifestyle interventions (diet, 
physical activity and behaviour modification), emphasising that when a drug is being 
recommended, health professionals [HPs] must offer advice and support to alter 
lifestyle and make lifelong changes (Nunes et al., 2009). In summary, NICE guidelines 
recommend a combination of metformin and insulin secretagogues (and/or 
Dipeptidyl peptidase-4 [DPP-4] or Sodium-Glucose Co-Transporter 2 [SGLT-2] 
inhibitors) in those who have inadequate blood glucose control with monotherapy 
                                                     
5 The NICE guidance for newer agents for blood glucose control in T2D was replaced in July 2016 by 
the new NICE guidance NG28 titled “Type 2 diabetes in adults: management”, however this PhD thesis 
refers to the old guidelines as explained in footnote 4.   
6 The NICE guidance about Obesity was last updated in March 2015 and as explained in footnote 4, 
the thesis refers to the old guidance. 
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(i.e. HbA1c≥6.5%, 48mmol/mol) (NICE, 2009a). Furthermore, a glucagon-like peptide 
-1 [GLP-1] analogue may be added to dual therapy to help with glucose control in the 
most severely obese patients with a Body Mass Index [BMI] greater than 35.0kg/m2 
with some exceptions if it is considered that weight loss will benefit other 
comorbidities. However, for those whom dual or triple therapy has been 
unsuccessful in terms of both glucose control (i.e. HbA1c≥7.5%, 59mmol/mol) and 
weight loss (i.e. <3% at 6 months), will move on to insulin.  
 
Due to the progressive nature of T2D, treatment may include increasing the dose of 
OGDs and introduction of additional medicines either in oral or injectable form in 
order to achieve treatment goals (Turner et al., 1999; Nathan et al., 2009). Numerous 
studies have shown glucose-lowering drugs to be effective in controlling 
hyperglycaemia. Sections 1.6.1-1.6.10 describe the various available drugs for 
diabetes and their effects on glycaemic control and body weight including common 
side effects [SE]. Table 1.1 also gives an overview of each class of medicine for T2D 
that were available at the time of the PhD study.  
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Table 1.1: Overview of Medicines Prescribed for Type 2 Diabetes 
Drug Class/ 
medicine 
Regime Taken Impact on 
HbA1c % 
Weight change 
(+ gain, - loss) 
Side Effects 
Biguanides 
(tablets) 
Metformin: 500mg/850mg OD-
TDS, 1000mg OD-BD 
Metformin ER: 500mg/ 
1000mg/ 1500mg/ 2000mg OD 
Up to three times a day, with meals ↓0.14% - 1% Neutral diarrhoea 
abdominal 
cramping, rare 
lactic acidosis 
Sulphonylureas 
(tablets) 
Glimepiride : 1-8mg OD 
Glipizide: 5-20mg OD-BD, 
Glipizide ER: 5mg/20mg OD 
Gliclazide: 40-160mg OD-BD 
Gliclazide ER: 30-120mg OD 
Glimepiride: once daily shortly before or during 
breakfast or main meal 
Glipizide: Once or twice a day, shortly before a meal 
Gliclazide: Once or twice a day with main meals 
↓1% +3kg hypoglycaemia 
Glitazone  
(tablets) 
Pioglitazone: 15-45mg OD Once daily with or without food ↓1% +3.9kg oedema, bone 
fractures 
Metiglinides 
(tablets) 
Repaglinide: 0.5-4mg TDS 
Nateglinde: 60-120mg TDS 
Three times per day, 10 - 30 minutes before meals ↓0.1%- 2.1% +3kg hypoglycaemia 
diarrhoea 
AGI 
(tablets) 
Acarbose: 50mg TDS Three times per day, should be chewed with first 
mouthful of food, or swallowed whole with little 
liquid directly before the meal 
↓0.14% -1%  Neutral flatulence, stomach 
ache, diarrhoea 
DPP-4 inhibitor 
(tablets) 
Sitagliptin 100mg OD 
Saxagliptin 2.5-5mg OD 
Linagliptin 5mg OD 
Vildagliptin 50mg BD 
Once daily, taken with or without a meal at any time 
of the day 
↓0.6-0.7% Neutral Raised blood lipids 
raised, all cause 
infections (see 
1.6.6), pancreatitis  
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GLP-1 agonists 
(injectables) 
Liraglutide: 0.6/1.2/1.8mcg OD 
Exenatide: 5-10mcg BD 
Exenatide ER: 2mg Once weekly 
 
Liraglutide: once daily at any time, independent of 
meals, but recommended to be injected around the 
same time each day 
Exenatide: Twice a day, at any time within the 60-
minute period before the morning and evening 
meal, or two main meals of the day, approximately 
6 hours or more apart 
Exenatide ER: Once weekly on the same day each 
week, at any time of day, with or without meals 
↓~1% -(2.3–5.5 kg) nausea, diarrhoea, 
vomiting, 
pancreatitis 
SGLT-2 inhibitor 
(tablets) 
Dapagliflozin 10mg OD once daily, at any time of day, with or without food ↓0.5-1% - 4.5kg Urinary, genital 
infections 
Insulin 
(injectables) 
Human Insulin and Insulin 
Analogues 
No dose limit 
Varies from once daily at the same time each day 
with or without a meal (Detemir/ Glargine), up to 
three times a day immediately before a meal (rapid 
acting insulin aspart/intermediate acting isophane 
insulin) or  twice daily immediately before a meal 
(rapid  and intermediate acting insulin aspart/ 
soluble and isophane insulin)  
↓1.5-2.5% 
(as additional 
therapy) 
+6.5kg hypoglycaemia 
GI Lipase 
Inhibitor 
(Tablets) 
Orlistat 
120mg TDS 
Three times a day, with water immediately before, 
during or up to one hour after each main meal. Dose 
should be omitted if a meal contains no fat  
↓0.74% -3kg fatty/ oily stool, 
↑defecation, 
faecal incontinence 
Details taken from a) Summary of Product Characteristics for individual drugs retrieved June 2013 from http://emc.medicines.org.uk and b) references in 
sections 1.6.1- 1.6.10. Regime: OD/BD/TDS/QDS refers to “once”/“twice”/ “three”/“four” times per day as a direction for prescriptions. 
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1.6.1. Biguanides 
Metformin is a highly effective first line glucose lowering drug for managing T2D. It is 
a biguanide that reduces hepatic glucose output, increases insulin sensitivity and 
uptake, and utilises glucose by peripheral tissues (Saenz et al, 2005). Its effectiveness 
was established through the UKPDS trial (UKPDS, 1998), where intensive treatment 
over a median duration of 10.7 years significantly reduced diabetes related outcomes 
and all-cause mortality. When metformin is compared with other glucose-lowering 
medicines and dietary interventions, the reductions in HbA1c range from as little as 
0.14% up to 1% (Saenz et al., 2005; Qaseem et al., 2012). Exceptions to this are drugs 
like metiglinides, alpha-glucosidase inhibitors and insulin. However metformin has an 
advantage over these drugs due to its neutral effect on body weight (UKPDS, 1998; 
Saenz et al., 2005); an important consideration for T2D individuals who are 
overweight or obese. In addition, metformin has less risk of hypoglycaemia (Saenz et 
al, 2005). Yet, metformin is associated with gastrointestinal side effects such as 
diarrhoea, and abdominal cramping, which can lead to discontinuation of the drug 
for a small percentage of individuals (Chacra, 2014). On the other hand, newer drug 
formulations such as Extended Release Metformin (Metformin MR), appear to be 
better tolerated and dose frequency is reduced to once a day compared with 
standard metformin [up to 3 times per day] (Chacra, 2014). 
 
1.6.2 Sulphonylureas 
Sulphonylureas are the oldest drugs in the treatment of T2D but second (gliclazide, 
glipizide) and third (glimepiride, gliclazide MR) generations of this class of medicines 
are now more commonly used (Hemmingsen et al., 2013). They are very effective at 
reducing HbA1c levels by up to 1% as monotherapy (Hemmingsen et al., 2013) or in 
combination with other medications (Bennett et al, 2012). They stimulate insulin 
secretion from beta-cells in pancreas and, therefore, there is an increased risk of 
hypoglycaemia with this treatment (Hemmingsen et al., 2013). Intensive treatment 
with this class of medicines has been associated with weight gain by about 3kg at 10 
years (UKPDS, 1998). However third generations of sulphonylureas appear to be 
associated with less weight gain than second generations (Mitri & Hamdy, 2009) and 
there is significantly lower incidence of hypoglycaemia (Wang et al.,  2011). Similarly 
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with biguanides, the extended release forms of sulphonylureas daily dose is reduced 
to once a day instead of twice a day.     
 
1.6.3 Thiazolidinediones (or Glitazones) 
Thiazolidinediones [TZDs] are peroxisome proliferator activated receptor γ (PPAR-γ) 
activators that improve insulin sensitivity in skeletal muscle and reduce hepatic 
glucose production (Inzucchi et al., 2012). Pioglitazone is the only drug in this 
category available for prescription for T2D. This drug is associated with increase in 
body weight (up to 3.9kg) as monotherapy or in combination with other glucose-
lowering drugs (Richter et al., 2006; Mitri & Hamdy, 2009) and increased risk of 
oedema and bone fractures, but does not increase the risk of hypoglycaemia (Richter 
et al., 2006, Inzucchi et al., 2012). Its effect on HbA1c is similar to those other OGDs 
(~1%) (Richter et al., 2006; Qaseem et al., 2012), with an advantage that it requires a 
single daily dose.   
 
1.6.4. Meglitinides 
Meglitinides are short-acting insulin secretagogues that enhance insulin synthesis 
and release. Two analogues are currently available for clinical use: repaglinide and 
nateglinide and both are used as monotherapy or in combination with metformin, 
TZDs or long-acting insulin (Landgraf, 2000; Black et al., 2007). The range of HbA1c 
reductions from these drugs is between 0.1-2.1% depending on the brand (Black et 
al., 2007). Meglitinides generally cause weight gain by up to approximately 3kg either 
as monotherapy or in combination with metformin or insulin and most common 
adverse events include hypoglycaemia and diarrhoea (Black et al., 2007). The dose 
for this class of medicine is taken typically three times per day.  
 
1.6.5 α-Glucosidase Inhibitors [AGI] 
In most guidelines, this type of drug is rarely frequently used for T2D patients 
(Innunchi et al., 2012; NICE, 2009a). Acarbose is the most common drug in this 
category that is prescribed (Van de Laar et al., 2005) and it is used as an addition to 
other drugs when treatment goals are not met, or in case of contra-indications for 
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other medications. Its main action is to inhibit the alpha-glucosidase enzyme in the 
small intestine and therefore delay gut carbohydrate absorption (Inzucchi et al., 
2012). This inhibits postprandial glucose peaks thereby leading to decreased 
postprandial insulin levels (Van de Laar et al., 2005). Due to its mode of action, 
abdominal discomfort like flatulence, diarrhoea and stomach ache are the most 
frequently occurring adverse effects but it does not cause hypoglycaemia (Van de 
Laar et al., 2005; Inzucchi et al., 2012). Alpha-Glucosidase Inhibitors reduce HbA1c by 
up to 0.8% but they have no significant body weight effects (Van de Laar et al., 2005). 
Acarbose has a single dose which is taken three times per day.  
 
1.6.6 Gliptins (DPP-4 inhibitors) 
Dipeptidyl  peptidase-4 inhibitors improve glycaemic control by preventing rapid 
degradation of the incretin hormones, gastric inhibitory polypeptide [GIP] and in 
particular glucagon-like peptide -1 [GLP-1] by the enzyme DPP-4 (Inzucchi et al., 2012; 
Deacon, 2011). There are four approved DPP-4 inhibitors in the global market, 
sitagliptin, vildagliptin, linagliptin and saxagliptin (Deacon, 2011; Traynor, 2011). 
Alogliptin was the latest drug in this class to be approved after the completion of this 
PhD study. Gliptins are available in the form of oral tablets and are taken once a day 
in a single dose, with the exception of Vildagliptin which is taken twice per day. They 
are very effective in reducing HbA1c between 0.6-0.7% similarly to other glucose 
lowering drugs (Deacon, 2011; Inzucchi et al., 2012), although there is evidence that 
metformin is more effective than DPP-4 in reducing HbA1c by up to 0.5% more than 
DPP-4 inhibitors (Bennett et al., 2012).  On the whole, these drugs are well tolerated 
with some of the drugs associated with all cause infections (e.g. nasopharyngitis, 
gastroenteritis, upper respiratory tract infection, urinary tract infection), but their effect on 
body weight is neutral and there is no risk of hypoglycaemia (Richter et al., 2008; 
Goke et al., 2010; Gallwitz et al., 2012).  
 
1.6.7 Incretin mimetics GLP-1 
The GLP-1 receptor agonists mimic the action of endogenous GLP-1 (a gut hormone 
that is secreted from the intestine in response to food ingestion), in stimulating 
glucose-dependent insulin secretion and by suppressing glucagon secretion, thereby 
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improving glucose homoeostasis. Gastric emptying is delayed, especially in the early 
weeks of therapy, resulting in appetite suppression and thus loss of body weight 
(Inzucchi et al., 2012). These drugs are injectable and there are three drugs available 
on prescription; Exenatide (twice daily injection), Liraglutide (one daily injection) and 
Exenatide extended release (once weekly injection). These drugs are associated with 
nausea, diarrhoea, and vomiting, which appear to subside after the first weeks of 
treatment in most cases (Shyangdan et al., 2010; Vilsbøll et al., 2012). Nevertheless, 
GLP-1 drugs have favourable outcomes in regards to weight loss (around 2.3–5.5kg 
in bodyweight), they lower HbA1c by up to 1%. (Shyangdan et al., 2010, 2011) and 
they do not increase the risk of hypoglycaemia (Vilsbøll et al., 2012). After the PhD 
study was completed, three further drugs became available; lixisenatide, dulaglutide 
and albiglutide.  
 
1.6.8 Sodium-Glucose Co-Transporter 2 [SGLT-2] Inhibitors  
Dapagliflozin is a SGLT‑2 inhibitor that blocks the reabsorption of glucose in the 
kidneys and promotes excretion of excess glucose in the urine. At the time of 
conducting this PhD study, it was the only drug in this class available on the NHS 
(NICE, 2013), but canagliflozin and empagliflozin have subsequently also been 
approved. It comes in the form of a tablet and it is taken once a day. Dapagliflozin 
reduces HbA1c by about 0.5-1% and contributes to weight loss of up to 4.5kg (Clar et 
al., 2012). Although there appears to be a slight increase in urinary and genital tract 
infections with this treatment, there is no risk of hypoglycaemia (Clar et al., 2012).  
 
1.6.9 Insulin 
Insulin therapy is the most effective treatment in T2D when all other glucose-
lowering agents begin to fail, achieving 1.5-2.5% reduction in HbA1c as an additional 
therapy to OGDs (Nathan et al., 2006; Goudswaard et al., 2004). Compared with 
human insulin (NPH), insulin analogues have either delayed and prolonged 
absorption called long acting or basal insulin (insulin glargine and insulin detemir), or 
act relatively faster and absorbed rapidly after injection called short acting insulin 
(insulin lispro, insulin aspart, and insulin glulisine). These analogues can be used 
either alone (basal insulin) or in combination (basal bolus – injection up to 4 times 
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per day or premixed insulin- injection twice per day) to mimic a  relatively normal 
physiological insulin profile of low constant secretion of insulin (basal) as well as short 
bursts of insulin release in response to meals (bolus) (Hermansen & Mortensen, 
2007). The choice of insulin in T2D depends on the individual; generally is related to 
HbA1c values, the pre and post prandial glycaemic control, the age of the individual 
and the risk of hypoglycaemia as well as the risk of weight gain and adverse outcomes 
associated with these (Lavernia, 2011). Evidence suggests there is no difference 
between human insulin and long–acting analogues in relation to metabolic control 
(i.e. HbA1c), however long acting insulin analogues have significantly lower rate of 
overall and nocturnal hypoglycaemia (Horvath et al., 2007). Although most 
individuals start with low doses of insulin, these can considerably increase if 
hyperglycaemia persists (Inzucchi et al., 2012). Insulin has long been associated with 
increased risk of hypoglycaemia and most preparations induce weight gain of 6.5kg 
on average (Holman et al., 2008). 
 
1.6.10 Orlistat 
Orlistat is the only anti-obesity drug currently for the treatment of obesity on the NHS 
(NICE, 2006). Orlistat frequently is used in patients with T2D to help with weight loss. 
Orlistat is a gastrointestinal lipase inhibitor that reduces the absorption of dietary fat 
by about 30%. In combination with a hypocaloric diet, it has shown to produce a 3kg 
weight loss greater than placebo, therefore it is an important aid in losing and 
maintaining weight (Torgerson et al., 2004). Moreover, it can improve glycaemic 
control by decreasing HbA1c by 0.74% in patients with T2D with or without weight 
loss (Hollander et al, 1998, Jacob et al, 2009). However, its widespread use is limited 
by adverse effects such as fatty/oily stool, increased defecation and occasional faecal 
incontinence (Wittert, Caterson & Finer, 2007; Padwal & Majumdar, 2007), which 
generally are associated with increased dietary fat. Also after the discontinuation of 
this medicine weight gain could be expected (Halpern & Mancini, 2003). Orlistat 
comes in the form of a tablet which is taken three times per day with meals.  
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1.7 Summary and Future Medication and Management of T2D  
In summary, changes to medications take place often in T2D and could therefore 
affect adherence levels, beliefs, attitudes and quality of life. On average, any second 
agent added to an individual’s diabetes therapy is typically associated with an 
approximate further reduction in HbA1c of 1% (11mmol/mol) (Inzucchi et al., 2012). 
However, the effects of current glucose-lowering drug treatments on body weight 
vary markedly between classes (Campbell, 2010), with sulphonlyureas, pioglitazone 
and insulin causing weight gain; biguanides, DPP-4 inhibitors and acarbose being 
weight neutral and only incretin mimetics, SGLT-2 inhibitors and orlistat having 
favourable outcomes on body weight. An increase in our understanding of the 
physiological control of energy balance and the pathophysiology of obesity and 
diabetes will hopefully lead to the development of newer drugs that are better 
tolerated and more efficacious in diabetes and weight management (Salem & Bloom, 
2010). As more drugs become available, a more complex combination of 
pharmacotherapy is likely to be adopted, possibly alongside shifting dosing 
schedules, to overcome adverse effects and promote weight loss and blood glucose 
control in patients with diabetes (Wilding, 2007; Aicher et al., 2010; Salem & Bloom, 
2010).  
 
Despite the emphasis on the long term control of diabetes, evidence shows that in 
2008/2009, 67% of people with T2D achieved a recommended HbA1c of less than 
7.5% (IFCC HbA1c 58mmol/mol) (NICE, 2009a). Generally, one in ten of the 
population has glycaemic control over 10% (≥86mmol/mol) (Khan et al., 2011). 
Furthermore, the National Diabetes Audit (HSCIC, 2016) showed that large 
proportions of patients with diabetes continue to have poor glycaemic (34%), blood 
pressure (26%), and cholesterol (23%) control, with only 41% of patients achieving all 
the above targets.  
 
It is well known that T2D patients rarely fully comply with their medication regime 
whether it is with oral tablets or insulin injections (Cramer, 2004). Patients are 
generally reluctant to take medicines and would prefer to take as few as possible 
(Pound et al., 2005). Although a number of factors have been explored related to 
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non-adherence and very poor glycaemic control (Khan et al., 2011), little is known 
about individuals’ expectations, beliefs and attitudes towards their blood glucose-
lowering drugs, particularly in relation to body weight effects.  
 
Non-adherence amongst patients with diabetes has been associated with concern 
about weight gain (Peyrot et al., 2009). Since weight gain is a common side effect of 
most diabetes medicines, it can be problematic for individuals with T2D as most of 
them will be overweight prior to starting glucose-lowering drugs. Also, it is unknown 
how individuals’ past experiences with glucose-lowering treatments and body weight 
effects may affect adherence with current and newer drugs on the market. Therefore, 
it is imperative that HPs understand patients’ experiences with their diabetes 
medications in order to provide responsive health care services within the NHS to 
meet patients’ needs, improve quality of life and minimise costs.   
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CHAPTER TWO: SYSTEMATIC REVIEW OF QUALITATIVE 
RESEARCH 
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2.1 Background 
As described in the previous chapter; T2D is now considered a major global public 
health problem with over 80% of patients with this condition in the UK being either 
overweight or obese (DUK, 2005). Long term hyperglycaemia (HbA1c>8.0%, 
64mmol/mol) and weight gain above a healthy weight can increase the risk of 
disabling secondary complications such as retinopathy, neuropathy, coronary 
vascular disease, and cerebrovascular accident. Weight management is, therefore, 
important in managing T2D along with managing blood glucose control, blood lipids 
and blood pressure (Philippe & Raccah, 2009).  
 
Despite the availability and effectiveness of a number of glucose-lowering drugs for 
the management of diabetes, systematic reviews have shown that patients with T2D 
rarely adhere to their medication (Cramer, 2004; Krass et al., 2015) and currently, 
there are no effective interventions that consistently support and improve adherence 
in this group of patients (Haynes et al., 2008; Vermeire et al., 2009; Sapkota et al., 
2015).  
 
Compliance and adherence are often synonymously used in the literature with 
apparently little consensus of meaning and appropriate usage. However, ‘adherence’ 
describes the extent to which a person’s behaviour, in this case taking medication, 
corresponds with agreed recommendations from a health care provider (WHO, 
2003). This term is used as it suggests that patients are actively participating in their 
care and agree to recommendations provided. The consultation process that results 
in agreement between the patient and the health provider (shared-decision making) 
is termed concordance (Hearnshaw & Lindenmeyer, 2005). Both adherence and 
concordance terms are in line with the increase in patient autonomy and self-
management of diabetes and their active involvement in decision making processes. 
However, the term adherence is specifically focused on patient behaviour. In recent 
years, two additional terms emerged in the literature which describe the extent 
which patients intentionally or unintentionally adhere to their medication regimens 
(Hearnsahw & Lindenmeyer, 2005). That is when a patient makes a specific decision 
not to take the prescribed medication (intentional) or when a patient does not take 
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the medicine as a result of forgetting, misunderstanding the medication regime or 
other psychosocial factors (unintentional). Nevertheless, patterns of adherence can 
be determined as early as at the point of prescription. It has been suggested that the 
first year of medication therapy is critical as up to 50% of patients will fail to take at 
least 80% of their medication doses; hence “new users” will almost certainly have 
lower levels of adherence than “experienced users” (Blackburn et al., 2013). 
Blackburn et al (2013), defines three types of non-adherence levels that appear in the 
first year of therapy; primary non-adherence (receives prescription but fails to obtain 
medication); non-persistence (begins to take medication but later stops taking it 
altogether) and poor execution (continues to take medication but fails to take the 
recommended quantity consistently). Regardless of types of adherence, this 
medicine taking behaviour is complex and multifactorial (Vermeire et al., 2001) 
particularly in diabetes (Hearnshaw & Lindenmeyer, 2005; Blackburn et al., 2013). It 
has implications for patients as it may mean a lost opportunity for health gain (Horne 
& Weinman, 1999) or more rapid disease progression which risks further more 
intensive medical intervention, alongside the financial burdens this can impose on 
health care budgets.    
 
Many systematic reviews have been conducted which have explored patients’ views 
of their medicines or medication adherence. These are either based solely on 
qualitative or quantitative research or have a mixed methods approach. A qualitative 
synthesis of Pound et al. (2005) explored patients’ views of medicines in general 
showing that patients are usually reluctant to take medicines and would prefer to 
take as few as possible. This review did not include any papers with individuals on 
T2D medicines.  
 
However, other reviews are specific to diabetes. Campbell et al. (2003) used a 
qualitative synthesis through a meta-ethnographic approach about individuals’ 
experiences of diabetes and diabetes care. They argued that people have to go 
through critical stages and overcome obstacles to managing their diabetes effectively 
and to achieving a degree of balance and control. Most importantly it appeared that 
the approach to life balance was characterised by a “strategic non-compliance” which 
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involved monitoring of symptoms and manipulating diet and medication regimes in 
order to live life as fully as possible rather than restricting social and work activities. 
This review included patients with both Type 1 Diabetes [T1D] and T2D. It also 
included only the first 7 papers (10 original) that met their criteria due to time 
limitations and therefore, this synthesis may not fully represent diabetes patients’ 
experiences of their condition, nor does it assess any changes in experiences with 
diabetes care over time.  
 
Gomersall et al. (2011) attempted to synthesise qualitative and mixed methods 
research on patient perspectives on self-management of T2D in the first 10 years of 
the 21st Century. The synthesis uncovered multiple, complex and competing factors 
that influence self-management of diabetes including interpersonal relations, gender 
and sociocultural context. Similarly, a systematic review by Nam et al. (2011) 
identified several barriers to T2D management including adherence, beliefs, 
attitudes, knowledge, ethnicity/culture, financial resources, comorbidities, and social 
support. These two reviews did not focus only on medication taking behaviour but 
on all other aspects of self-management including self-monitoring of blood glucose 
[SMBG], physical activity, healthy eating, and regular foot examination.  
 
A meta-analysis by Gherman et al. (2011) investigating the association between 
diabetes related beliefs and adherence to diabetes regimens, revealed that people 
who are more adherent to self-care behaviours are more confident that they can 
perform these behaviours as recommended (e.g. taking medication), they expect to 
achieve relevant and meaningful benefits, and they intend to engage in such 
behaviours. The opposite is true for those individuals who are less adherent, they are 
more likely to perceive barriers to adherence, are less confident in dealing with these 
barriers, worry about medication side effects and have negative attitudes towards 
insulin. However, this review included studies of both T1D and T2D as well as one 
study in gestational diabetes. Furthermore, many of the papers included in the 
analysis did not report type of diabetes treatment, for example whether on diet 
alone, OGDs, or injectable medication.  
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Two systematic reviews were also undertaken in relation to diabetes medication 
adherence. Odegard and Capoccia (2007) identified common barriers to medication 
adherence for both oral and injectable (insulin) glucose-lowering drugs such as 
regimen complexity (more than 1 diabetes drug/frequency of daily dosing), 
remembering doses, obtaining refills and depression. Peeters et al. (2011) identified 
factors that may influence adherence to OGDs such as demographic, disease-related, 
treatment-related, socio-economic and cultural factors. However, these reviews 
were combined for people with T1D and T2D (Odegard & Capoccia, 2007), or for 
people with T2D but from different ethnic groups other than those of Caucasian 
background (Peeters et al., 2011). The latter review also indicated that there is an 
unclear picture of medication adherence in different ethnic groups in part due to: 
measurements of ethnicity and adherence, diversity of settings, study designs, and 
drugs used in the studies they reviewed. Furthermore, neither of these systematic 
reviews explored patients’ views on their perceptions of their adherence levels to 
their medicines. 
 
Majeet-Ariss et al. (2013) employed a mixed-method systematic review (but mostly 
qualitative research) on self-management of black and ethnic minority [BME] 
patients with T2D. The review identified specific themes on medication adherence 
and insulin use. They described that most patients recognised the importance of 
taking medication correctly but motivation varied and some would reduce doses if 
they felt well. This particular BME group also appeared to worry about western 
medicines’ side effects, long-term health implications and often discussed alternative 
remedies. Furthermore, there appeared negative perceptions and stigmatisation 
with use of insulin, particularly due to its injectable form. Participants viewed insulin 
as symbol of severity and further complications of their diabetes. However, there 
were participants for whom, following experiences of taking insulin, they felt that it 
helped control their symptoms and had better quality of life and that insulin worked 
faster than oral medicines. Nevertheless, the review was limited to papers published 
between 1986 and 2008, it excluded those of Caucasian background, and included 
participants from a wide range of backgrounds and countries thereby synthesising 
factors that might not be relevant or appropriate for all countries. 
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A mixed methods systematic review by Wang and Yeh (2012), focused on T2D insulin 
therapy. It suggested that there is a psychological resistance to insulin involving both 
processes of cognitive appraisal and negative emotional reactions for individuals. Due 
to the approach of this review, a small number of papers were included which were 
assessing or developing a tool around resistance to insulin or willingness to take 
insulin. From these studies, one paper included both T1D and T2D patients, another 
did not specify in their methodology whether patients had T1D or T2D and the third 
included participants with T2D treated with diet only.   
 
A systematic review by Polinski et al. (2013) specifically looked at barriers to insulin 
initiation and intensification for patients with T2D and explored whether barriers 
differ from those individuals who were insulin-naïve or insulin-experienced. Seven 
articles in total were identified in this review; however these were all cross-sectional 
surveys using self-report questionnaires (with validated and non-validated scales) or 
discrete choice experiments (Jendle et al., 2010). The review showed that those 
individuals with prior experience in taking insulin had less barriers related to 
injections and the burden of insulin progression than those who were insulin-naïve. 
Those who were insulin-experienced were more concerned with side effects, 
glycaemic control, weight gain, and hypoglycaemic events of insulin treatment than 
with the need for injections. However, this review included three studies which 
recruited both T1D and T2D patients and one study which excluded anyone below 
30yrs of age with the assumption that they will have T1D. Furthermore, the authors 
reported that the methodological rigor of the studies included was low.  
 
Another systematic review by Purnell et al. (2014) synthesised evidence of T2D 
patients’ preferences for non-insulin diabetes medications (oral and injectable). The 
review revealed that patients’ preferences are driven by their medications’ ability to 
support weight loss or control, as well as blood glucose control when compared with 
treatment burden and side effects. Additionally, gastrointestinal effects were also 
ranked by patients in this review as more important than hypoglycaemia. The review 
included ten cross-sectional studies using methods of discrete choice experiments, 
trade off exercises (Jendle et al., 2010), standard gamble (Boye et al., 2011) and 
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surveys, for which most of them did not focus on specific medications, or used 
hypothetical scenarios. Only one study compared patient preferences between 
liraglutide and exenatide (GLP-1 agonists), drugs which both result in weight loss but 
can have unpleasant gastrointestinal side effects (Shyangdan et al., 2010; Vilsbøll et 
al., 2012). The authors also reported their exclusion criteria but did not report 
whether they excluded studies with T1D patients, neither did they report the 
treatments patients were prescribed (diet therapy, oral or injectable glucose-
lowering drugs) and whether their analysis considered patients’ prior experiences 
with diabetes medications. 
 
One more recent qualitative meta-synthesis by Brundiisini et al. (2015) focused on 
T2D patients’ and HPs’ perspectives on medication non-adherence. They identified 
seven categories that influence adherence: (1) emotional experiences as positive and 
negative motivators to adherence, (2) intentional non-compliance, (3) patient-
provider relationship and communication, (4) information and knowledge, (5) 
medication administration, (6) social and cultural beliefs, and (7) financial issues. 
However, the authors did include all the data from three papers with both T1D and 
T2D patients as they could not distinguish which data came from T2D patients only.  
 
In summary, this critical review has shown that although there are many reviews that 
describe diabetes patients’ barriers to medication adherence and self-management, 
many of them are focused on both types of diabetes, despite some of them claiming 
that their review was on T2D only. While, Brundiisini et al.’s (2015) meta-synthesis 
focused on patients’ perspectives of medication non-adherence, they included all 
articles that met their criteria without carefully appraising the research prior to 
inclusion. Many of the studies in these reviews; whether qualitative or quantitative, 
did not explore patients’ barriers to medication adherence over time and how their 
views or attitudes are changed by their experiences of taking medication for diabetes. 
Qualitative research focuses on the person and their lived experiences as well as 
exploring the meanings people attach to these experiences. Yet, this critical review 
found a limited number of qualitative syntheses with focus on T2D individuals and 
their experiences with their diabetes medications.   
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Furthermore, the latest literature search was conducted up to August 2013 
(Brundiisini et al., 2015). Medication adherence and particularly non-adherence is a 
timeless topic that concerns everyone; both patients and HPs, due to its implications 
to health and health care. Research on medication non-adherence is on-going, 
especially as the array of medications for treating T2D is increasing. Therefore, since 
2013, there are more published research papers that have the potential to illuminate 
further on T2D patients’ experiences and views of their medications. In addition, of 
those reviews which focus on diabetes medicines, only one review (Purnell, et al., 
2014) considered studies with injectable treatments other than insulin, but this 
focused on patients’ preferences to these treatments looking at specific pre-defined 
attributes and did not describe patients’ experiences with these kinds of treatments. 
The experience of receiving insulin, a drug that results in weight gain, compared to 
other injectable treatments, such as GLP-1 agonists which promote weight loss, can 
be fundamentally very different despite similar clinical outcomes (Reaney et al., 
2013; Ostenson et al., 2013). It is unclear how acceptable are to patients treatments 
such as GLP-1 agonists or other diabetes treatments that either promote weight loss 
or are weight neutral when considering the associated side effects with each 
treatment. Therefore an up-to-date search is justified given that there is a gap in 
relation to a systematic review qualitatively investigating only T2D patients’ lived 
experiences and individual perspectives of their diabetes medicines including oral 
medicines, as well as all forms of injectable medicines.  
 
This systematic review aims to fill this gap by addressing the following research 
questions: 
1. How do people with T2D view their glucose-lowering and/or weight loss 
medicines?  
2. How do people’s views towards their diabetes/weight loss medicines 
affect their adherence levels or medicine taking behaviour?  
3. Do the effects of these drugs on glucose control and body weight affect 
peoples’ perceptions and adherence levels or medicine taking behaviour?    
4. What theoretical perspectives have been used to study beliefs, attitudes 
and behaviour towards these medicines? 
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To answer these questions, the review focuses on the following aspects:  
 Beliefs and attitudes about relevant medications for diabetes and 
overweight/obesity.  
 Expectations and perceptions about relevant medications prior to, during and 
after taking these medicine(s) in relation to their diabetes management 
 Adherence behaviours including intentional or unintentional non-adherence 
to medications and reasons why 
 Types of research designs and theoretical perspectives used to study the 
above 
 
The purpose of this review is to identify areas for future research and practice 
including informing empirical research exploring the personal experiences of adults 
with T2D; and identifying appropriate interventions to improve adherence to 
treatment for T2D patients self-managing their condition. This systematic review 
forms the basis of the development of this PhD study which is in line with the Medical 
Research Council [MRC] framework for developing complex interventions (MRC, 
2008) 
2.2 Methods 
2.2.1 Design 
As the focus was to identify only qualitative empirical research, a meta-synthesis 
review of the literature was undertaken based on the meta-ethnographic approach 
as described by Noblit and Hare (1988) which was later adopted by Britten et al. 
(2002), Campbell et al. (2003) and Pound et al. (2005). The subsequent adaptations 
to this approach were all related to medicine taking and/or diabetes management 
and are therefore highly relevant to this review. Meta-ethnography involves 
induction and interpretation, and translating individual studies into one another, 
whilst allowing the researcher to use metaphors or concepts across the studies in a 
way that illuminates understanding of the phenomenon under review. The aim is to 
develop a new interpretation and conceptual insight (Noblit & Hare, 1988). The 
translations can be literal or idiomatic, and the meaning(s) of the text can be 
preserved. Therefore the original interpretations and explanations in the studies can 
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be used as data in the synthesis and studies included can relate to one another in 
three ways: (i) directly comparable as reciprocal translations; (ii) oppositional to one 
another as refutational translations, or (iii) taken together to represent a line of 
argument. Noblit and Hare (1988) outlined a seven step process for conducting a 
meta-ethnography as shown in Table 2.1.  
 
Table 2.1 Seven Steps for conducting meta-ethnography (Adapted from Noblit & Hare, 
1988 and Campebell et al., 2011) 
Seven steps of Meta-
ethnography 
Description of each step Reference to 
sections 
1 Getting started 
 
Identifying topic that qualitative research 
will inform 
Research 
Questions of 
Systematic 
Review and 
Section 2.2.2 
2 Deciding what is 
relevant 
Selecting research relevant to the topic of 
interest, Set inclusion and exclusion 
criteria 
Section 2.2.3, 
Tables 2.3-
2.4 
3 Reading the 
studies 
 
Critical appraisal of retrieved studies, 
Repeated reading of studies and noting 
metaphors and initial extraction of data 
from papers 
Sections 
2.2.4-2.2.5, 
Table 2.5 
4 Determining how 
studies are 
related 
organising papers into medicine groups, 
creating a list of metaphors, key phrases, 
concepts for each account 
Table 2.6, 
Section 2.2.6 
5 Translating the 
studies into one 
another 
(reciprocal or 
refutational) 
The metaphors and/or concepts in each 
account are compared with other 
accounts (one-level synthesis), first within 
medicine groups and then across groups, 
initial production of medicine maps 
Section 2.2.7, 
Figures 2.2-
2.3 
 
6 Synthesising 
translations (line 
of argument 
synthesis) 
 Analysing competing  interpretations to 
produce a new interpretation/ conceptual 
development (second-level of synthesis), 
initial production of final model 
Section 2.2.7, 
Figure 2.4 
 
7 Expressing 
synthesis 
Communicating and presenting synthesis 
taking into account intended audience- 
use concepts and language understood 
Section 2.4, 
Figures 2.2-
2.4 
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2.2.2 Search Strategy 
An effective combination of search terms was defined based on the research 
questions and included: Type 2 Diabetes, Medication Taking, Treatment, Medication, 
Oral Hypoglycaemic Drugs/Agents, Insulin, Adherence, Compliance, Beliefs, Attitudes, 
and Weight. A broad and specific approach was used to identify appropriate 
qualitative studies. Pound et al. (2005) suggested that either method can be used, 
indicating that the broad search they used was as efficient as the detailed one, with 
a higher sensitivity in some of the databases such as CINAHL. Electronic databases 
were searched for relevant articles until February 2016. Databases included Cochrane 
Library (via Cochrane Library 1985 to 12/February/16), DARE/CRD/NHS7 (via 
www.crd.york.ac.uk/ all dates to 12/February/16), PROSPERO (via 
www.crd.york.ac.uk/PROSPERO all dates to 12/February/16), Web of Science (via 
Web of Knowledge 1900 to 12/February/16), Scopus (via SCOPUS and Science Direct 
all years to 12/February/16), PsychINFO/ Articles (via EBSCO 1924 to 
12/February/16), CINAHL Plus (via EBSCO 1937 to 12/February/16), MEDLINE (via 
Ovid 1946 to 12/February/16), EMBASE (via Ovid 1946 to 12/February/16), AMED 
(via EBSCO 1924 to 12/February/16). References of all retrieved articles were 
checked for relevant studies, and experts/authors were contacted for advice, and to 
collect further information that may have not been provided in the original published 
article. Appendix 2.1 shows a detailed description of the search terms and 
combinations. Table 2.2 shows the number of articles retrieved from each search 
engine as well as the number of titles and abstracts screened. Additionally, articles 
already known by the researcher which were potentially relevant for this synthesis 
were included in the list of articles to be screened, even though they were not 
identified by the above search. It is well known that there are still deficiencies in the 
indexing of studies and in the study filters of search engines, therefore additional 
techniques are required to ensure a comprehensive search for identification of 
relevant articles for a systematic review (CRD, 2008).  
 
 
                                                     
7 DARE stands for The Database of Abstracts of Reviews of Effects and CRD stands for Centre for 
Reviews and Dissemination. PROSPERO is an international prospective register of systematic reviews. 
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Table 2.2: Engine Search and number of articles screened 
 Articles Retrieved   
(excluding duplicates) 
February 2016  
Titles/Abstracts 
screened  
February 2016 
Cochrane Library 235 99 
DARE/NHS/CRD 199 195 
PROSPERO 75 75 
Web of Science 965 608 
Scopus 2262 1971 
PsychINFO/Articles, CINAHL Plus, 
AMED (via EBSCO) 
803 735 
MEDLINE, EMBASE (via Ovid) 3017 1454 
Researchers list of articles 12 12 
Total 7556 +12 5137 + 12 
NB: When all databases combined in EndNote X5 there were 2419 duplicates. 
 
2.2.3 Selection and eligibility of studies 
Studies were selected if the population was adult (>18yrs) living with T2D and using 
pharmacological therapy to manage their diabetes and weight. All types of study 
designs were included if they reported qualitatively medication taking behaviour or, 
beliefs or attitudes towards diabetes and weight loss medicines. Qualitative data 
reported in mixed methods studies were also included. Only literature published in 
the English language from inception to February 2016 was included. Table 2.3 shows 
in detail the inclusion and exclusion criteria for this review and Table 2.4 shows the 
reasons for exclusion of the articles retrieved.  
 
Table 2.3: Inclusion and Exclusion Criteria 
 Inclusion Criteria Exclusion Criteria 
Population Adults with T2D over 18 years 
of age 
Studies based on T1D and T2D 
participants unless sub-group analysis 
presented by type of diabetes 
Gestational diabetes 
 Treated with glucose-lowering 
drugs and/or anti-obesity 
drugs 
Treated with: 
- Diet therapy only 
- Bariatric surgery 
Setting Managed by primary care  or 
community or outpatient 
clinics in a secondary care 
setting (hospital) 
Inpatients/patients admitted to hospital 
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 UK based studies Other countries unless multinational and 
sub-group analysis was done by country 
Focus Participants’ medication 
taking personal perspectives 
and/or behaviour (adherence) 
- Health professionals (or other than 
patients) beliefs or attitudes 
- Reporting prevalence of non-
adherence 
Study 
Design 
Qualitative 
Mixed Method Studies 
(including only qualitative 
data) 
Existing systematic reviews/ 
qualitative syntheses 
RCTs 
Observational Studies 
Cross-sectional Studies 
Cohort Studies 
Publication 
Type 
English language 
Articles with available full text  
Other language 
Abstracts/Theses, Grey literature 
 
Table 2.4: Reasons for exclusion of articles screened 
 Clinical Recommendations/Expert opinions/ algorithms and guidelines 
 T2D patients not on pharmacological treatment/ studies related to non-diabetes 
patients or patients at high risk of T2D 
 Clinical trials on efficacy, safety and cost-effectiveness of diabetes medicines or 
insulin regimes 
 Effectiveness of: dietary interventions, SMBG, psychological/behavioural 
interventions not related to medication adherence/medication taking, HP 
interventions on glycaemic control not related to medication adherence or 
medication taking, educational interventions/computerised systems 
 Focus on: dietary patterns and eating habits, postprandial glycaemia, 
cardiovascular and microvascular events, GLP-1 levels, neuroscience, treatment 
adherence in mental illness, physiological aspects of diabetes medicines,  diabetes 
medicines prescription rates, mobile health applications, adherence to guidelines 
for hospital inpatient treatment, dental care 
 Family physicians/Specialist diabetologists’ perceptions of diabetes care and 
attitudes/beliefs towards diabetes medicines, HPs’ perceptions of patients’ 
barriers to insulin 
 Articles relates to a research/review protocol 
 Association of weight change with incidence of diabetes/prevalence of T2D 
 Research study in rats or other animals 
 Conference abstracts/poster presentations 
 
Figure 2.1 shows the flowchart of number of articles identified, screened and finally 
included in the final list of articles for critical appraisal based on PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis) guidance (Liberati et al., 
2009).  
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According to the meta-synthesis by Brundiisini et al. (2015), countries such as Canada, 
United States, Australia, Netherlands, Romania, Sweden, UK and other countries 
(multi-country studies that include Croatia, Norway, Germany, and Belgium) have 
similar health care systems for T2D management. However, the UK is the only country 
which has a fully paid NHS through taxes, where people with diabetes are exempt 
from all prescription charges (Garrofe et al., 2014). Many of the countries mentioned 
above use private or government insurance which is partly reimbursed when it comes 
to medication prescriptions. In addition, health care systems related to delivery of 
diabetes care are varied across countries; particularly with guidelines to medication 
treatment, HbA1c targets, and availability and/or licences of prescribed drugs. 
Therefore, due to the timeframe and to ensure that studies appraised are in context 
with current PhD study, the final number of articles was further reduced to focus on 
UK based studies or multinational papers where UK data were shown separately. This 
enabled us to produce an in-depth understanding of the unique culture and health 
care system in the UK.  
 
Five articles that appeared in Brundiisini et al. (2015) synthesis were based in UK and 
these were selected and screened for potential eligibility in this review (not shown in 
Figure 2.1). These included: Courtenay et al. (2010), Hinder and Greenhalgh (2012), 
Mc Sharry et al. (2013), Bissell et al. (2004) and Parry et al. (2006). The first three 
articles included patients with both types of diabetes, however they were screened 
to ensure that data could be distinguished between the two types. Likewise, Majeed-
Ariss et al. (2013) also identified a further five potentially relevant qualitative 
research articles with UK participants. These included: Lawton et al. (2006a), Lawton 
et al. (2006b), Macaden et al. (2006), Scott (1997), and Stone et al. (2005). These were 
also screened for potential eligibility in this review.  
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Figure 2.1: Adapted PRISMA Flowchart  
 
2.2.4 Quality Assessment 
Titles and abstracts checked by one reviewer (AP) and a sample was verified by a 
second reviewer (HC, PhD supervisor). Full texts of selected studies were critically 
appraised for synthesis by one reviewer (AP) and a sub-sample checked by the second 
reviewer (HC) followed by a discussion meeting to examine those papers that scored 
low during critical appraisal in order to reach a consensus. There is currently no 
agreement on the best method to appraise the quality of qualitative studies 
(Campbell et al., 2011) and the value of appraisal remains controversial. In this review 
the quality of included studies was assessed in accordance with the Critical Appraisal 
Skills Programme [CASP] criteria for quality appraisal for qualitative research (CASP, 
2010), using version 31.05.13. The CASP tool for qualitative research included an 
additional question in relation to whether the studies described their theoretical 
perspective as illustrated in the adapted version of the CASP tool by Campbell et al. 
(2011). The final adapted CASP tool for qualitative research that was used can be 
found in Appendix 2.2. Only articles with a score of seven and above (maximum score 
11) were included in this review. A score of seven meant that only rigorous studies 
that provided sufficient information on recruitment strategy, data collection and 
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analysis and participants quotes to support study findings were included in this 
review.  
 
Of the ten additional studies identified through the systematic review of Marjeet-
Ariss et al. (2013) and the qualitative synthesis of Brundiisini et al. (2015), only three 
articles were considered eligible and added to the list of articles to be critically 
appraised. These three articles were: Parry et al., 2006; Stone et al., 2005 and Bissell 
et al., 2004. Reasons for excluding the other articles were due to: inability to 
distinguish data of T2D patients from T1D patients, from HPs or health development 
workers, from those who were on diet therapy only, and when the focus was not on 
participants’ medication taking personal perspectives. 
 
Table 2.5 shows all papers underwent critical appraisal (17+3=20) with their 
individual CASP scores. The appraisal process identified areas that papers either 
failed to report clearly or did not report at all. In descending order, these included: i) 
the relationship between researcher and participants, ii) a theoretical perspective, iii) 
justification for data collection methods, and iv) ethical considerations. In addition, 
the paper from Frandsen and Kristensen (2002) was a mixed methods research study, 
reporting both qualitative and quantitative research within the paper but failed to 
report many of the areas in qualitative assessment so was excluded from this review. 
All of the above are similar issues identified by other researchers undertaking critical 
appraisal for reviews of qualitative research (Atkins et al., 2008; Newton et al., 2012).   
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Table 2.5: Eligible papers examined and quality appraisal outcome  
Author Date Title Type of study CASP 
Score 
Bissell et al 2004 From compliance to concordance: barriers to accomplishing a re-framed model of 
health care interactions 
Qualitative 9 
Bower et al  2012 Illness representations in patients with multimorbid long-term conditions: 
Qualitative study. 
Qualitative- part of 
mixed methods 
programme 
8 
Brod et al  2014 Barriers to initiating insulin in type 2 diabetes patients: development of a new 
patient education tool to address myths, misconceptions and clinical realities 
Mixed Methods 9 
Brown et al  2007 Health beliefs of African-Caribbean people with type 2 diabetes: a qualitative study. Qualitative 9 
Frandsen and 
Kristensen 
2002 Diet and lifestyle in type 2 diabetes: the patient's perspective Mixed Methods 5- 
Excluded 
Hood et al  2009 'With age comes wisdom almost always too late': Older adults' experiences of 
T2DM. 
Qualitative 8 
Jenkins et al 
 
2010 Initiating Insulin as Part of the Treating To Target in Type 2 Diabetes (4-T) Trial An 
interview study of patients' and health professionals' experiences. 
Qualitative- part of 
Research Trial 
8 
Jenkins et al 
 
2011 Participants' experiences of intensifying insulin therapy during the Treating to Target 
in Type 2 Diabetes (4-T) trial: qualitative interview study. 
Qualitative- part of 
Research Trial 
11 
Khan et al  
 
2008 Prevalence and reasons for insulin refusal in Bangladeshi patients with poorly 
controlled Type 2 diabetes in East London. 
Mixed Methods 7 
Lawton et al  
 
2005a Perceptions and experiences of taking oral hypoglycaemic agents among people of 
Pakistani and Indian origin: qualitative study. 
Qualitative 11 
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Lawton et al 2005b Lay perceptions of type 2 diabetes in Scotland: bringing health services back in. Qualitative 9 
Lawton et al  
 
2008 Patients' perceptions and experiences of taking oral glucose-lowering agents: a 
longitudinal qualitative study. 
Qualitative 8 
Morris et al  
 
2005 Experiences of people with type 2 diabetes who have changed from oral medication 
to self-administered insulin injections: a qualitative study 
Qualitative 9 
Noakes  2010 Perceptions of black African and African-Caribbean people regarding insulin. Qualitative 9 
Parry et al  2006 Issues of cause and control in patient accounts of Type 2 diabetes Qualitative 8 
Patel et al  2015 Concerns and perceptions about necessity in relation to insulin therapy in an 
ethnically diverse UK population with type 2 diabetes: a qualitative study focusing 
mainly on people of south Asian origin.  
Qualitative 9 
Phillips 2007 Experiences of patients with type 2 diabetes starting insulin therapy Qualitative 10 
Stack et al  
 
2008 A qualitative exploration of multiple medicines beliefs in co-morbid diabetes and 
cardiovascular disease 
Qualitative  10 
Stone et al  2005 Empowering patients with diabetes: a qualitative primary care study focusing on 
South Asians in Leicester, UK 
Qualitative 8 
Vermeire et al  2007 Obstacles to adherence in living with type 2 diabetes: An international qualitative 
study using meta-ethnography (EUROBSTACLE) 
Qualitative 8 
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2.2.5 Data abstraction and synthesis 
A data abstraction tool was created to collect a broad range of information including: 
year of publication, research design, theoretical perspectives and other 
methodological aspects (sampling, data collection method, location, setting of study), 
participant characteristics, type of diabetes/weight loss medicine(s) and duration of 
experience, any details about BMI or weight, and theoretical models or conceptual 
frameworks used to analyse or interpret the data relating to self-management of 
diabetes and adherence behaviour. Papers that reported data from the same 
research study were collated as one.   
 
All eligible papers (n=19) were separated into groups according to their research 
focus which was either according to type of diabetes medicines reviewed or 
multimorbidity/polypharmacy (Table 2.6), following the meta-synthesis approach 
adopted by Pound et al. (2005). For example, articles which only described 
participants’ experiences with OGDs was part of the first group, these articles were 
then reviewed based on chronological order. The chronological approach was used 
to form the synthesis rather than an “index paper” that other reviewers have used in 
the past (Campbell et al., 2003). The timeframe of the published studies spanned over 
10 years and there was not enough citation tracking to consider any one of these 
papers as an “index paper”. Table 2.6 describes the four research focus groups as well 
as the order in which each article was reviewed.  
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Table 2.6: Research focus of review papers based on types of medicines 
Research Focus Groups Papers in Order of Synthesis 
Oral glucose-lowering drugs [OGDs] Lawton et al., 2005a 
Lawton et al., 2005b, 2008 
Parry et al., 2006 (related to Lawton 2005b, 2008) 
Insulin  Morris et al., 2005 
Phillips, 2007 
Khan et al., 2008 
Noakes, 2010 
Jenkins et al., 2010, 2011 
Brod et al., 2014 
Patel et al., 2015 
Diabetes Medicines (includes both 
OGDs and insulin) 
Bissell et al., 2004 
Stone et al., 2005 
Vermeire et al., 2007 
Brown et al., 2007 
Hood et al., 2009 
Polypharmacy/multimorbidity Stack et al., 2008 
Bower et al., 2012 
 
2.2.6 Determining how the studies are related 
The initial approach to synthesis included reading and re-reading the articles from 
each research focus group, and identifying relevant passages and themes. To manage 
the synthesis process a Microsoft Excel spreadsheet was used to collate extracts from 
the papers that included both first and second order constructs (direct participants’ 
quotes and authors’ interpretations) by inserting each passage under a column which 
was assigned a theme. Each paper was entered into a separate row and passages 
were extracted in the same words as the published work of the authors. The themes 
included passages relating to participants’ views about their diabetes/weight loss 
medicines prior to starting their treatment and their views of these after initiation of 
the treatment. This was done purposefully to identify changes in their views about 
their medicines and changes in medication-taking behaviour over time. These two 
categories of Prior and After, were a way of organising a large amount of data and 
they do not represent themselves third order constructs. Themes also included 
passages related to quality of care and weight to identify if these aspects influenced 
medicine taking behaviour.  
 
67 
 
2.2.7 Translating studies into one another and synthesising translations 
Following data extraction for each paper, the studies were translated into each other, 
one by one, following a systematic approach as described by Campbell et al. (2011). 
Briefly, the synthesis of the first two papers was compared with the third paper, and 
the subsequent synthesis was compared with fourth paper and so on, until all the 
studies were translated into each other. For example, first paper had findings X, Y and 
Z, whilst second paper had findings x and y (similar to paper 1) and finding w 
(something new not in paper 1), but nothing like Z as in first paper. This was an 
attempt to “match” themes/concepts from one paper to another in order to capture 
a central theme, as well as adding or incorporating new separate themes (Britten et 
al., 2002; Munro et al., 2007).  This process was done separately for the “oral glucose-
lowering drugs” and “insulin” groups. The findings from the “diabetes medicines” 
group were then compared with each of the first two groups where relevant. Finally 
the “polypharmacy/ multimorbidity” group was compared with each of the “oral 
glucose-lowering drugs” and “insulin” groups. Noblit and Hare (1988) identified this 
process of translating studies into each other as either “reciprocal” or “refutational” 
translation, where the findings from studies when compared had similar issues, or 
refuted each other. In the process of comparing the studies against each other, 
explicit differences between the studies in relation to a range of factors including 
their geographic location, socioeconomic conditions, cultural differences, 
participants’ diabetes control, body weight, diabetes duration, diabetes treatment 
types, initiation and/or duration of treatment and use of primary and/or secondary 
care services were noted. This synthesis produced two separate “maps”; one for 
OGDs and one for insulin (Figures 2.2-2.3) and the two groups were then finally 
compared to identify how the findings related or not, across the two medicine 
groups, an example of the translational synthesis with the themes identified can be 
found in appendix 2.3. The synthesis of medicines maps in this study used the 
reciprocal approach, except where one paper appeared to refute (Jenkins et al., 
2010), although not strongly, what other similar studies described. Finally, a “line-of-
argument” synthesis (Noblit & Hare, 1988) was constructed by developing an 
overarching model that linked together the translations and authors interpretations 
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in order to address the main aims of the review. This was particularly important as 
papers focused on different aspects but the line of argument brought them together.  
2.3 Results 
In total 16 studies were reviewed (19 papers), as two papers were related to the same 
study by Lawton et al (2005b) and one paper was related to the study by Jenkins et 
al. (2010). Key features of the studies are summarised in Table 2.7 and are discussed 
next. Each paper included in the review was assigned a numeric identification [ID] 
code (and alphabetic code for related studies), which can be seen in Table 2.7. The 
sections below use these ID codes in superscript form to refer to the relevant papers.  
 
2.3.1 Research Design and Methodology 
Most participants were recruited from primary (n=9 1, 2A, 2B, 2C, 9, 10, 11, 12, 14, 15, 16) and 
secondary care (outpatient hospital clinic, n=7 2A, 2B, 2C, 3, 4, 5, 6, 10, 14); one study 
recruited participants from clinical trial centres7A, 7B, one study recruited from 
professional organisations8 and one study did not mention the research setting13. 
Studies were conducted in Scotland (n=2 1, 2A, 2B, 2C), in the North West of England 
(n=33, 10, 16), in London (n=4 5, 6, 8, 14), in the West Midlands (n=1, Coventry/ 
Warwickshire4), and in the East Midlands (n=3, Leicester, Nottingham9, 11, 12). One was 
a UK wide study (n=17A, 7B) therefore capturing a range of areas in the UK, but two 
studies did not specify region (n=2 13, 15).  
 
The majority of the studies used grounded theory approach (n=8, 1, 2A, 2B, 2C, 7A, 7B, 8, 9, 
10, 13, 15) for their methodology, of which two used a modified version. Two studies 
used phenomenology, of which one was interpretive3, 4. However, six studies did not 
mention any methodological details5, 6, 11, 12, 14, 16. Qualitative data collection methods 
included in depth or semi-structured one-to-one interviews (n=12, 1, 2A, 2B, 2C, 3, 4, 7A, 7B, 
9, 10, 11, 12, 14, 15, 16), focus groups (n=45, 6, 8, 13) and/or field notes/participant observation 
notes (n=2,2A, 2B, 2C, 3, 4). Data was collected at participants’ own homes (n=91, 2A, 2B, 2C, 
4, 9, 10, 11, 12, 14, 15), in a Hospital or GP Practice (n=63, 4, 5, 6, 11, 12), at a university (n=29, 15) 
and/or at a professional research organisation8. Three studies did not specify where 
the interviews took place(7A, 7B, 13, 16), although Jenkins et al. (2010, 2011)(7A,7B), 
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mentioned it was at a location convenient to participants. Most studies were cross-
sectional in study design, where interviews or focus groups were conducted at one 
point in time, but there were two studies which employed a longitudinal approach to 
identify changes in participants’ views(2B,3). Despite the longitudinal approach of 
these studies, only Lawton et al. (2008)(2B) were able to analyse data longitudinally. 
All studies used purposive sampling techniques except Brown et al. (2007)(12) where 
theoretical sampling was used. Lawton et al. (2005a)(1) and Bissell et al. (2004)(10) used 
snowballing sampling in addition to their purposive sampling. 
 
2.3.2 Participants’ characteristics 
There were 173 men and 151 women, but there were another 36 participants for 
whom their gender was not reported (n=360). Participants were from a range of 
ethnic backgrounds, with the majority being Caucasians (n=133), followed by those 
of South Asian Origin (Indian, Pakistani, Bangladeshi, n=122), African-Caribbean 
(n=29), Black-African (n=5), White European (n=1), and 70 for whom ethnicity was 
not described. The age range of participants across all studies was 21-89 and they 
were either recently diagnosed with T2D or had diabetes for a maximum of 35 years 
(range 0-35). Three studies reported participants had diabetes related complications 
including: neuropathy, retinopathy and Cardiovascular Disease [CVD](3, 5, 12, 14). Three 
studies reported socioeconomic status(1, 2A, 2B, 2C, 12). Two studies reported glycaemic 
control(7A, 7B, 5), although one study reported the glycaemic control of participants 
following their completion of a clinical trial(7A, 7B). None of the studies in this review 
reported either participants’ BMI or weight; however one study was part of a clinical 
trial(7A, 7B) for insulin initiation and therefore inclusion criteria to the trial indicated 
that participants had a BMI of less than 40.0kg/m2 (Holman et al., 2009). The original 
4-T trial paper (Holman et al., 2009) indicated that all participants had gained weight 
by the end of the trial (3 years later; average weight gain ranged from 3.6-6.4kg).  
 
The two multimorbidity studies reported the number of medicines participants were 
taking which ranged from 2-12, combined medicines for diabetes and other co-
morbidities such as hypertension, hyperlipidaemia and others(16, 15). Although other 
studies did not specifically report the mean number of medicines or the range, many 
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participants’ quotes indicated that they were on multiple diabetes and non-diabetes 
medicines.  
 
2.3.3 Types of medicines 
Broadly the studies can be separated in examining issues around two types of 
diabetes medicines; OGDs and insulin. None of the studies examined specifically 
other injectable medications for diabetes such as GLP-1 agonists or weight loss 
medicines (i.e. orlistat). In most studies, no specific diabetes medication was 
mentioned as part of the inclusion criteria.  
 
2.3.3.1. Oral glucose lowering drugs 
Of those studies specific to OGDs, some mentioned specific names such as 
metformin, gliclazide (or sulphonylurea) and pioglitazone usually through 
participants’ quotes; whereas others reported whether they were on monotherapy 
or combination therapy or on maximum oral therapy. None of the studies mentioned 
DPP-4 inhibitors, or SGLT-2 inhibitors, or other diabetes medicines described in 
Chapter 1. Patel et al. (2015)(9) described one interviewee who was on insulin therapy 
as well as exenatide, a GLP-1 analogue, however the focus was solely on insulin. Only 
two studies specified the length of OGD treatment, which ranged from 4 months to 
10 years(2A, 2B, 2C, 6).  
 
2.3.3.2 Insulin 
Of those studies specific to insulin, few described whether patients were on basal 
insulin (once daily injection), biphasic insulin (twice daily injection) and prandial 
insulin (thrice daily injection)(3, 4, 7A, 7B). Three studies mentioned participants were on 
both tablets and insulin(6, 8, 9). Although Lawton et al., (2008)(2B) was specifically 
focused on participants’ views of OGDs, at their final interview there was one patient 
who had started on insulin (2A, 2B, 2C).  
 
Of the studies concerned specifically for insulin, three were related to participants’ 
views around insulin initiation and all participants had started insulin for at least one 
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month3, but others had been taking insulin for longer than two years (4, 7A, 7B). Two 
more studies were related to barriers and refusal to initiate insulin, however in one 
study all participants had refused starting insulin in the last three months prior to the 
focus group5, and in the other study half of the participants had started insulin in the 
last six months, whereas the other half had refused to start8. A further two studies 
were related to perceptions about insulin, and both studies included participants who 
either were already taking insulin (5 months-22 years) or were insulin-naïve(6, 9). Six 
of the general studies looking at diabetes management and experiences, and 
multimorbidity or polypharmacy, did not specify the length of insulin duration (10,11, 
12, 13, 14, 15).  
 
2.3.3.3 Weight Loss Medicines and Weight related Issues 
The literature search did not find any relevant studies on patients’ experiences and 
medicine taking behaviours for weight loss medicines that met the inclusion criteria. 
There was one study on patients’ views of anti-obesity drugs (Psarou & Brown 2010), 
however it was not clear whether all participants had T2D. None of the studies 
included in this review investigated views of weight loss medicines and associated 
adherence. Nonetheless, some weight related issues were found. Weight gain 
appeared to be a concern for patients with T2D(2A, 2C, 5, 6, 8, 10, 12, 13, 14, 15), however this 
was not always related to their diabetes medicines. Fear of weight gain was 
associated as a barrier to insulin initiation (5, 8, 12). Patients understood that weight is 
related to lifestyle measures (2A, 2C,10, 14, 15), however many discussed difficulties with 
adhering to the diet commenting on being “naughty” and “cheating” (2A, 10), or not 
understanding how to cut down on calories from the foods that they eat (6), and that 
HPs do not understand the difficulties they face (10, 13). Conversely, others suggested 
that they would lose weight if they were to avoid taking medicines (2C,15), although 
not all believed that it would be diabetes medicines (15), as the following quote 
describes: 
 
"What diabetes is really, erm you can’t really repair it, unless of course it is a weight 
problem. The weight loss would stop the strain on the heart, it’s not going to sort your 
pancreas out, because that’s gone isn’t it? Once the damage is done it doesn’t matter 
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if you lose the weight anyway you still have to take tablets or insulin, you probably 
wouldn’t have to take the cholesterol, perhaps or maybe the aspirin, if you got down 
to a proper weight level." (White British male, aged 53, prescribed five medicines) (15). 
 
It was evident from the studies that those who managed to lose weight had higher 
self-efficacy and coping levels (2C, 14) by taking control and becoming more confident 
over time about managing their diabetes. This review identified that people varied in 
their perceptions of lifestyle measures and particularly weight loss as an effective 
way in managing their diabetes, a finding that conflicts with current medical advice 
(Lau, 2010; Ross et al., 2011).  
 
2.3.4. Conceptual Framework 
Behavioural and social theories are considered important in identifying determinants 
of effective behaviour change. Many have been established to describe treatment 
behaviour, in this case medicine taking behaviour, which is either related to chronic 
disease or illness, or to patients’ beliefs and attitudes. The models and theories used 
most often to inform the research studies in this systematic review were those that 
relate to individuals’ health-related behaviour. Although studies did not provide 
much detail beyond stating the theory or model applied, generally they used these 
to inform the analysis of their data, or to validate their findings through triangulation.  
 
Four studies described psychological insulin resistance as a phenomenon for people 
who refuse insulin initiation (Polonsky & Jackson, 2004), although not all applied this 
framework to inform analysis/validation (Khan et al., 2008(5); Noakes, 2010(6); Patel 
et al., 2015(9); Brod et al., 2014(8). One study (Jenkins et al., 2010)(7A) described 
psychological insulin receptiveness for their participants in the study, indicating that 
not all individuals are resistant to insulin initiation. Psychological insulin resistance, 
although not a theoretical model in itself, has links to social cognitive theory 
(Bandura, 1977) where individuals learn from watching what others do. Individuals’ 
behaviour is influenced by several factors including personal beliefs and attitudes, 
existing behaviours, and the social and physical environment. In addition, a change 
in an individuals’ behaviour is related to the expectations of outcomes that will result 
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from engaging in the behaviour, and the perceived ability to perform the behaviour 
i.e. self-efficacy. Although social cognitive theory predicts and explains behaviour 
change, it has been criticised for its emphasis on the individual behaviour as opposed 
to acknowledging other social, economic and political factors (Clark & Janevic, 2014). 
One study (Bower et al., 2012)(16) used the common sense model linking it with the 
ways multimorbidity can impact on individuals’ illness representations. The common 
sense model (or illness representations model or self-regulation model) (Leventhal et 
al., 1980 cited in Bower et al., 2012) is a system of conscious health management 
containing a number of processes which influence health behaviour and its principle 
is directly drawn from social cognitive theory (Clark & Janevic, 2014). The processes 
include (1) extracting information from the environment (social network/external 
cues), (2) generating a representation of the illness as dangerous to oneself (owns 
beliefs/attitudes based on internal cues), (3) planning and acting, taking into account 
emotions that are generated from the potential coping strategies (e.g. to take or not 
to take medication), to achieve specific effects or goals, and finally (4) monitoring or 
appraising the success or failure of coping efforts. It is believed that in T2D these 
processes occur in parallel involving both cognitive representations (illness identity, 
cause, consequences, time-line, control/cure, perceptions of self–efficacy and coping 
efficacy) and emotional representations of illness (Cooper et al., 2003a). Hence, these 
illness representations may affect patient outcomes.  
 
Bower et al. (2012)(16) used the common sense model with the added dimension of 
multimorbidity (defined as the presence of two or more conditions in the same 
patient) to identify whether multimorbidity impacts on patient representations of 
their individual conditions, or leads to representations about their relationships (i.e. 
as interrelated or distinct entities), or other emergent dimensions that only occur in 
the presence of multiple conditions. In the common sense model external factors do 
play a part in predicting health behaviour but it has been criticised as some external 
factors for example, health related policies, political dynamics, and community 
infrastructure are generally beyond the ability of one individual to change (Clark & 
Janevic, 2014).   
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Patel et al. (2015)(9) as well as Bower et al. (2012)(16) used the necessity-concerns 
framework in the analysis of their findings. This framework developed by Horne et al. 
(1998, 1999), is an extension to the common sense model by Leventhal et al., in that 
additional constructs about the beliefs of necessity and concerns related to 
treatment (in this case medication) can predict medication adherence. The beliefs 
about necessity and concerns about the treatment are specific to the condition (that 
is diabetes medications) rather than beliefs in general about medicines, and 
adherence is determined by the balance between these two constructs. Aikens et al. 
(2005) extended the necessity-concerns framework further to determine four 
individual groups based on the necessity–concerns balance and association with 
adherence. The groups include those who are; sceptical (low necessity, high 
concerns), ambivalent (high necessity, high concerns), indifferent (low necessity, low 
concerns) and accepting (high necessity, low concerns). Those who are accepting are 
more adherent to their medicines than those who are sceptical, with the other two 
groups having adherence levels somewhere in between. Only Patel et al. (2015)(9) 
used the above groups to analyse their data.  
 
One study used the Health Belief Model [HBM] to inform data collection and analysis 
(Brod et al., 2014)(8), but claimed that it was not used rigidly for organising and 
interpreting the findings. The HBM was developed in the 1950s within the psychology 
discipline to predict health behaviour. It has five main constructs; perceived 
susceptibility, perceived severity, perceived barriers, perceived benefits and cues to 
action. However other related constructs from the social cognitive theory could be 
added to the model, such as self-efficacy (Rosenstock et al., 1988). The model has 
been criticised for not adequately explaining health behaviour because of: (1) other 
influential factors which may not relate to the constructs in the model and are not 
explained by individuals’ beliefs or attitudes, (2) not explaining how individuals come 
to have certain beliefs (past experiences/habits) (Clark & Janevic, 2014), and (3) not 
explaining irrational behaviours (Horne & Weinman, 1998).  
 
Other studies were influenced by sociological and anthropological perspectives. One 
study used the theoretical framework of chronic illness as biographical disruption 
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(Hood et al., 2009)(14). In this, disruption, such as chronic illness, is key to 
understanding the complex relationship between an individual and society (Bury, 
1982), and how individuals making sense of their illness, of themselves, and how they 
adapt through their experience and practices in society, and also mobilise resources. 
This framework is deeply rooted to medical sociology.  
 
Another study (Bissell et al., 2004)(10) discussed in their findings that participants 
raised concerns that relate to the biographical model of care, where again chronic 
illness is represented as profoundly disruptive, and where individuals present with 
many sociocultural dimensions and variations of their illness (Kleinman, 1988 cited in 
Bissell et al., 2004). The biographical model of care is based on Kleinman’s 
explanatory model of illness (1978), which was developed to help improve patient-
provider communication. It has been suggested that low patient adherence to 
treatment regimens may be related to different frames of understanding of the 
disease between patients and providers (Cohen et al., 1994). Therefore, HPs need to 
understand those illness narratives and acknowledge their existence for patient 
meaningful outcomes (Mishler, 1984) and improved communication (Kleinman et al., 
1978). This framework is deeply rooted to medical anthropology. 
 
Stack et al. (2008)(15) mentioned in their findings that some participants exemplified 
“strategic non-compliance”, a term situated within the model developed by Campbell 
et al. (2003), on reaching a balance in the management of diabetes. The model 
suggests that people have to pass through critical stages and overcome certain 
obstacles, in no particular order, to manage their diabetes effectively and to achieve 
a degree of balance and control. Strategic non-compliance is a key concept at the 
centre of this model which indicates that individuals thoughtfully and selectively use 
medical advice rather than blindly adhering to it. Campbell et al. (2003) argued that 
their findings resonate with the theoretical framework of chronic illness as a 
biographical disruption by Bury (1982), as people with diabetes appear to have 
commonalities in the ways in which they experience this disruption and, the elements 
described above, seem to be required in order to repair or reconstruct their 
biography. Stack et al. (2008)(15) also discussed terms of “intentional” and “non-
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intentional” non-adherence, which derived from two key theoretical models; the 
necessity-concerns framework (as described above) (Clifford et al., 2008) and the 
construct of locus of control (Wallston & Wallston, 1978). Locus of control describes 
an individuals’ perceived degree of control (either internal or external) in predicting 
an outcome behaviour including taking medication. For example, if an individual feels 
they have control over their illness this may positively influence adherence to 
medication, however if they feel their illness is outside of their control, they may not 
adhere to their medication.  
 
Other key findings from studies included the notions of “contextual knowing” 
(Lawton et al., 2005b)(2A) and “down to me and up to them” (Parry et al., 2006)(2C). 
Although not explicitly mentioned, both constructs can be related to the 
aforementioned behavioural and social theories. Contextual knowing – a way that 
individuals embody illness (Gordon, 1990), by manipulating and cultivating 
uncertainty so that they can dissociate themselves from the diabetic identity can be 
directly associated with chronic illness as a biographical disruption. Parry et al. 
(2006)(2C) compared the “down to me and up to you” constructs with known 
explanatory models of illness for T2D (Cohen et al., 1994). However, descriptions of 
how patients express the cause of their condition (within or outside of their control) 
with accounts of how actively (or not) they are managing their condition (adhere or 
not adhere to lifestyle and medication regime) resembles the health locus of control 
construct. Parry et al. also argued that some participants were characterised by the 
concept of self-conscious change through telling certain types of stories to conﬁrm 
and reafﬁrm the new identity (Frank, 1993). Therefore, negative experiences, over 
time, can be shaped into new positive outcomes.  
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Table 2.7: Summary of key characteristics of studies included in meta-ethnography 
Author 
Date 
[Study ID] 
Region/ 
Country  
Research 
Topic 
Research 
Design 
Methodological 
Perspective  
Data Collection 
Methods  
Sampling 
Technique 
Research Setting 
Participant Characteristics 
(Sample size (n), Gender, Age 
(yrs), Diabetes Duration (yrs), 
Ethnicity, Other) 
 
Medicine Type(n) 
 
 
 
Weight/ 
BMI 
Theoretical Model/ 
Conceptual 
Framework 
Lawton et al. 
(2005a)  
[1] 
Edinburgh, 
UK 
 
Perception 
and 
experience 
of OGD 
Cross 
Sectional 
 
Grounded theory 
In depth face-to-
face interviews 
Purposive, 
snowballing 
sampling  
Research Setting:  
5 GP practices, 
Pakistani and 
Indian 
Communities. 
Home Interviews 
N=32 (15M, 17F) 
Age: 30- ≥71  
Diabetes Duration: 0-≥16 
Ethnicity: Pakistani/Indian  
Religion: Muslim, Christian, 
Hindu, Sikh 
Occupation (includes prior 
occupation for those retired): 
Professional/ higher 
managerial, semiskilled , 
Unskilled, unknown 
4 Sulphonylurea  
12 Metformin 
13 Sulphonylurea 
and Metformin      
3 Diet only 
No details given 
about medication 
taking duration. 
none 
mentioned 
none mentioned 
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Lawton et al. 
(2005b) 
[2A],  
(2008)[2B] 
Parry et al. 
(2006) [2C]  
Edinburgh, 
UK 
Perception 
of T2D, 
issues of 
cause and 
control, 
perception 
and 
experience 
of OGD 
Longi-
tudinal 
Grounded Theory 
Field notes  
Face-to-face semi-
structured 
interviews x 4 per 
participant (first 3 
in year 1- baseline, 
6months, 
12months and 4th 
in yr 3) Purposive 
sampling 
Research Setting: 
17 GP Practices, 3 
Hospital Clinics 
Most home 
interviews 
Interviews 1-3 
N=40 (22M, 18F)  
Age:21-71+ 
Diabetes Duration:≤6months 
Ethnicity: 39 Caucasians, 1 
Pakistani 
Socioeconomic Status: I -V  
Diabetes Care: 5 GP Practices, 
35 Hospital/ other services 
Interview 4:   
N=20 (11M, 9F)   
Age: 40-80  
Socioeconomic Status: I-V 
Structured education 
received post diagnosis=17  
Interview 1: 
9 Diet only,  
11 OGD 
monotherapy,  
0 OGD combination 
therapy 
0 insulin and OGDs 
Interview 4:  
6 Diet only, 
5 OGD 
monotherapy (3 
increased dose),  
8 OGD combination 
therapy 
1 Insulin and OGDs 
Mentioned 
Metformin and 
Gliclazide. 
Medication taking 
duration: 6months - 
3years depending 
on time of interview 
none 
mentioned 
None mentioned but 
key findings related 
to: “Contextual 
Knowing” (Gordon, 
1990) 
“Down to me and up 
to you” (Cohen et al., 
1994; Frank, 1993) 
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Morris et al. 
(2005) [3] 
Manchester, 
UK 
Insulin 
initiation 
Longi-
tudinal 
Interpretive 
Phenomenology 
Participant 
observation notes 
2x interviews per 
participant (2 
weeks after start of 
insulin and then 1 
month after) 
Purposive sampling  
Research Setting: 
Manchester 
Diabetes Centre 
N=6 (3M, 3F).  
Age: 59-73  
Diabetes Duration: 6-31 
Ethnicity: 1 Asian, 1 African-
Caribbean, 4 Caucasian  
Marital Status:  
Single/Married 
DM complications: 2 erectile 
dysfunction, 3 neuropathy, 5 
microalbuminuria 
BD injections of 
biphasic insulin.  
All participants 
experienced with 
OGDs.  
Insulin taking 
duration=1 month  
No details given 
about OGD taking 
duration. 
none 
mentioned 
none mentioned 
Phillips 
(2007) [4] 
Coventry/ 
Warwick-
shire, UK 
Insulin 
initiation 
Cross 
Sectional 
Phenomenology 
In depth face-to-
face unstructured 
interviews, Field 
notes  
Purposive sampling  
Research setting:   
3 Home interviews 
5 Hospital 
interviews  
N=8 (4M, 4F).  
Women Age range: 59-72 
Men age range: 49-72  
 
Women: 4 BD 
insulin  
Men: 3 BD insulin, 1 
OD insulin  
Insulin taking 
duration: 2-4yrs 
No other medicines 
specified 
none 
mentioned 
none mentioned 
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Khan et al. 
(2008) [5] 
Inner City 
London 
UK 
Reasons for 
insulin 
refusal 
Cross 
Sectional 
Focus groups 
(single -sex groups) 
purposive sampling 
Research setting:  
large inner-city 
hospital diabetes 
unit 
N= 36 (20M, 16 F),  
Characteristics provided only 
for 43 invited to Focus 
Groups.  
Stated Age, Diabetes duration 
and glycaemic control did not 
differ significantly from those 
attended focus groups  
Age: 34.2- 77.2  
Diabetes Duration:2.3-27.1 
Ethnicity: Bangladeshi 
Glycaemic control - HbA1c:  
8-13.8% or 64-127mmol/mol 
Diabetes Complications: 11 
CVD, 10 Retinopathy, 20 
Micro and Macroalbuminuria  
No OGDs specified 
but inclusion 
criteria indicate 
they should be on 
maximum oral 
therapy i.e. 
Metformin, 
Sulphonylurea and 
glitazone where not 
contraindicated  
All participants 
continued to refuse 
insulin initiation 
after one-one 
education 
consultation and 
written material 
provided over a 3- 
month period.  
No details given 
about OGD taking 
duration 
none 
mentioned 
Psychological insulin 
resistance (Polonsky 
& Jackson, 2004) but 
does not link it with 
study data 
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Noakes 
(2010) [6] 
London- 
South East 
UK 
Perception 
of insulin 
therapy 
Cross 
Sectional 
Focus groups 
(tablet and insulin 
groups)  
purposive sampling 
Research Setting:  
Diabetes Hospital 
outpatient clinics, 
Interviews at 
Education Centre 
NHS Trust 
N=13 (5M, 8F);  
tablet group=5F, 2M  
insulin group=3F, 3M  
Age: tablet group 44-77 
insulin group 53-69 
Diabetes Duration: tablet 
group=4months-11yrs  
insulin group=4-26yrs 
Ethnicity: 5 Black Africans,  
8 African-Caribbeans 
OGDs and insulin 
None specified 
Treatment 
Duration:  
Tablet group= 
4months-10yrs,  
insulin group= 
5months-22yrs 
none 
mentioned 
Psychological insulin 
resistance but does 
not link it with study 
data (Polonsky & 
Jackson, 2004) 
Jenkins et al. 
(2010) [7A] 
(2011) [7B] 
Nationwide 
UK 
Insulin 
initiation 
and 
intensifi-
cation 
Cross 
Sectional 
Grounded Theory 
In depth face-to- 
face interviews  
Purposive sampling  
Research setting: 
11 Clinical trial 
centres to reflect 
diversity in centre 
size and 
geographical 
location 
N=45 (29M, 16 F)  
Age: Mean 64.7 ±8.5  
Ethnicity: majority White 
British  
Glycaemic control HbA1c at 
year three of trial: 5.3-9.9%/ 
34-85mmol/mol 
26 participants with HbA1c 
≤7% (53mmol/mol)  
19 participants with HbA1c 
≤6.5% (48mmol/mol) 
Insulin Initiation:  
Arm 1:15 Basal 
Insulin (OD)  
Arm 2: 15 Biphasic 
Insulin (BD)  
Arm 3: 15 Prandial 
Insulin (TDS)  
Metformin and/or 
Sulphonylurea  
Insulin 
Intensification 
(n=41 at year 2/3 of 
trial)  
Inclusion 
criteria 
indicated 
BMI≤40.0 
kg/m2. All 
gained 
weight by 
end of 
trial: 
Biphasic 
group 
mean 
5.7±0.5kg 
Psychological insulin 
receptiveness 
(Jenkins et al., 2010) 
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Interview setting 
location convenient 
to participants 
Arm 1: Basal and 
Prandial  
Arm 2: 13 Biphasic 
and Prandial 
Arm 3: 14 Prandial 
and Basal.  
On Metformin if 
tolerated, 
Sulphonylurea 
discontinued  
Insulin Taking 
duration:>2yrs 
(calculated from 
original 4-T Trial 
paper) 
 No details given 
about OGD taking 
duration 
Prandial 
group: 
mean 
6.4±0.5kg  
Basal 
group: 
mean 
3.6±0.5kg 
(taken 
from 
original 4-
T trial 
paper) 
Brod et al. 
(2014) [8] 
Multi-
national 
Barriers to 
insulin 
initiation 
Cross 
Sectional 
Modified Grounded 
Theory 
Focus groups (per 
country- 2 in UK) 
Purposive sampling  
N=15 in UK 
Demographics given but not 
separated by country 
Equal mix of 
participants 
initiated or refused 
insulin when 
none 
mentioned 
Health Belief Model 
(Rosenstock et al., 
1988), Psychological 
Insulin resistance 
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including  
London, UK 
Research setting: 
international 
professional 
research 
organization that 
recruited and 
hosted the focus 
groups at their 
afﬁliates’ facilities 
in each country 
recommended by 
physician 
All participants 
faced this decision 6 
months prior to 
focus groups  
All taking OGDs. 
Insulin taking 
duration for those 
initiated: <6months 
No other medicines 
specified  
(Polonsky et al., 
2005) 
Patel et al. 
(2015) [9] 
Leicester, 
UK 
Concerns 
and 
perception 
of insulin 
therapy 
Cross 
Sectional 
Grounded Theory 
Semi-structured 
face-to-face 
interviews 
Purposive sampling  
Research setting: 
recruited from 4 GP 
practices  
1 university 
premises interview, 
17 home interviews 
N=18 (9M, 9F) 
Diabetes Duration:  
<10years ->20years  
Ethnicity: South Asian- mainly 
Indian Origin=13,  
Caucasians=5 
 
7 Insulin (two were 
taking it for >2yrs, 
no details given for 
the others) 
11 Not on insulin 
(two on OGDs, no 
details given for 
others).  
No medicines 
specified 
none 
mentioned 
Necessity- Concerns 
Framework (Horne et 
al., 1999; Aikens et 
al., 2005). 
Psychological Insulin 
resistance (Polonsky 
et al., 2005) but does 
not link with data. 
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 No details given 
about diabetes 
medication taking 
duration  
Bissell et al. 
(2004) [10] 
North West 
England, UK 
Views and 
experience 
of T2DM 
treatment- 
from 
compliance 
to 
concordance 
Cross 
Sectional 
Grounded Theory 
Face-to-face 
interviews 
Purposive and 
snowballing 
sampling  
Research setting: 2 
primary care 
practices, 1 
secondary care 
diabetes centre/ 
local community 
Home interviews  
N=21  
Ethnicity: Pakistani Origin.  
Quotes from 
participants on 
metformin.   
No other medicines 
specified  
No details given 
about diabetes 
medication taking 
duration  
none 
mentioned 
Biographical model 
of care (Kleinman, 
1988) with a link to 
concordance. 
Stone et al. 
(2005) [11] 
Leicester, 
UK 
Experience 
and attitude 
of T2D and 
its 
treatment 
Cross 
Sectional 
Semi-structured 
face-to-face 
interviews (one of 
two interviewers in 
either English or 
Gujarati or Punjabi) 
N=19 with T2D  
Age:37-80 (South Asians)  
Diabetes Diagnosis <1-35 
(South Asian) 
1 Diet only 
13 OGD 
2 Insulin  
No details given 
about diabetes 
none 
mentioned 
none mentioned 
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Purposive sampling 
Research setting: 
2x GP practices 
Home or GP 
practice interviews  
Ethnicity: 15 (6M, 9F) South 
Asians Indian origin, 1M 
Caucasian  
All South Asian sample T2D, 4 
Caucasians T2D but only one 
identified taking OGDs 
medication taking 
duration 
Brown et al. 
(2007) [12] 
Nottingham, 
UK 
Health 
beliefs of 
T2D 
Cross 
Sectional 
Face-to-face 
interviews 
Theoretical 
sampling  
Research setting: 
Self -help groups 
and GP practices. 
Home or GP 
practice Interviews 
N=16 (6M, 10F)  
Age: 40-76 
Diabetes Duration: 0.3-29yrs 
Ethnicity: African Caribbean  
Diabetes Complications: n=10  
Mean Townsend score based 
on postcode residence =4.23 
(-4.08-7.32)  
5 Diet only 
6 Insulin  
5 OGDs 
No medicines 
specified 
No details given 
about diabetes 
medication taking 
duration 
none 
mentioned 
none mentioned 
Vermeire et 
al.(2007) 
[13] Multi-
national 
including 
UK, no 
specific 
Obstacles to 
adherence in 
living with 
T2D 
Cross 
Sectional 
Grounded Theory- 
individual focus 
groups; then meta-
ethnography all 
groups  
Focus groups (per 
country- 5 in UK) 
No research setting 
N=19 from UK (9M, 10F)  
Age:<50-75 
Diabetes Duration: 1-22 
Mentioned insulin  
No other medicines 
specified 
No details given 
about diabetes 
medication taking 
duration 
none 
mentioned 
Stated no theoretical 
framework used, 
which facilitated 
direct comparison of 
the focus groups 
86 
 
region 
mentioned 
mentioned or 
sampling method 
Hood et al. 
(2009) [14]  
East End 
London, UK 
Experience 
of T2D 
Cross 
Sectional 
In depth semi-
structure 
interviews - twice 
per participant 
Purposive sampling 
Registered with DM 
centre in local 
hospital, but some 
managed by GPs 
Home interviews 
N=28 (19M, 9F)  
Age: mean 70yrs 
DM duration: >20yrs 
Ethnicity: White British 
Socio-economic status: 
working class, primarily 
residing in council housing  
DM complications:  
impaired eyesight=21,  
heart surgery/attacks=11.  
Disable/Housebound: 3 
23 Insulin 
5 OGDs (1 about to 
commence insulin,  
2 stopped insulin 
due to weight loss) 
No other medicines 
specified 
No other details 
given about 
diabetes medication 
taking duration 
none 
mentioned 
Theoretical 
framework of 
Chronic illness as a 
biographical 
disruption (Bury, 
1982) 
Stack et al. 
(2008) [15] 
 UK 
Multiple 
medicines 
beliefs 
Cross 
Sectional 
Modified Grounded 
Theory 
Semi-structured 
interviews 
Purposive sampling 
Research Setting: 2 
inner city Primary 
Care General 
Practices  
N=19 (9M, 10F) 
Age: 41-82 
Ethnicity:  
4 African-Caribbean  
3 South Asian  
11White British  
1White-European  
Number of Meds taken: 
mean 4.8 (range 3-12). 
Medicines numbers 
prescribed for 
whole group: 
24 OGDs  
5 Insulin 
Other meds: 32 
anti-hypertensive, 
18 Lipid-lowering, 
13 anti-platelet 
Mentioned 
none 
mentioned 
None mentioned but 
commented about 
strategic compliance- 
does not link with 
study data. 
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16 Home 
interviews  
3 University 
interviews  
metformin,  
gliclazide,  
pioglitazone 
No other details 
given about 
diabetes medication 
taking duration 
Bower et al. 
(2012) [16] 
Greater 
Manchester, 
UK 
Illness 
represe-
ntations 
with multi-
morbid 
conditions 
Cross 
Sectional 
Face-to-face semi 
structured 
interviews  
Purposive sampling 
Research Setting:  
6 GP practices; all 
part of local 
comprehensive 
research network 
No interview 
setting mentioned 
N=28 (16M, 12F) of which  
23 T2D 
Age: 39-89 
Comorbidities: (T2D, Chronic 
Obstructive Pulmonary 
Disease [COPD], Coronary 
Heart Disease [CHD], arthritis, 
Depression, Cancer, Thyroid 
Disease, Hypertension) mean 
number =4 (range 2-10).  
 
Various medicines 
for chronic 
conditions including 
diabetes medicines- 
none specified.  
No details given 
about diabetes 
medication taking 
duration 
none 
mentioned 
Common sense 
model (Leventhal et 
al., 1980) with 
presence of 
Multimorbidity and 
Necessity- Concerns 
Framework (Horne et 
al., 1999; Horne & 
Weinman, 2002).  
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2.4 Synthesis results  
The synthesis starts with the description of the two medicine maps. These maps show 
a timeline illustrating (a) patients’ emotions arising from the prospect of initiating 
medication for their T2D, (b) factors that influenced their acceptance (or non-
acceptance) in receiving such medication, and (c) patterns of medication taking 
behaviour and lifestyle behaviour including their relationship with point (b) above. 
Finally, the line-of-argument synthesis is presented, demonstrating in a final 
conceptual model the key processes to understanding patients’ journeys in 
medication management. The following sections refer to the aspects as presented in 
the relevant figures, and individually are discussed on how they relate to each other.  
 
2.4.1 Oral Glucose Lowering Drugs and Insulin Maps  
A visual representation of the final synthesis of all studies that described aspects 
related to OGDs (Figure 2.2) and insulin (Figure 2.3) can be found below. The first 
map portrays patients who moved on from diet therapy into taking tablets and the 
second map portrays patients who either moved on from tablet therapy into taking 
insulin, or resisted insulin and continued taking tablets.  
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                                          Figure 
2.2: Synthesis of Oral Glucose-Lowering Drugs 
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Figure 2.3: Synthesis of Insulin Treatment 
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2.4.1.1 Negative Feelings 
For most of the patients, the prospect of taking medicines for diabetes brought 
feelings of devastation(1), “trepidation”(1, 2B), shock(3, 4, 7A, 14), anger(3, 14) and 
disappointment(7A). Taking medicines was associated with becoming a “patient” or 
that their identity will change to that of a “sick person”(1, 2B), as the following quotes 
demonstrate: 
 
“when I was diet-controlled, I always thought just well “Am I a diabetic?” and since 
she’s given me the tablets for it, well, you know, I thought I was ok and obviously I’m 
not,…” (M20.2)(2B)  
 
“This is diabetes to me. Before I was just taking pills and you just didn’t eat your sweet 
stuff, and you know. But then all of a sudden now I’ve got diabetes ’cause it’s needles 
you know and that IS diabetes. That is an illness now, wasn’t before.”(3) 
 
Patients started OGDs described it as entering “a slippery slope”  or “stage 2”(2B), and 
“...that’s a bit closer to stage 3” (M20.2)(2B) where once you start on taking the first 
medicine, then this will lead to take insulin, often associated as “the last resort”(5, 9, 
6). Insulin, as a symbol of severity, was also found in the review by Majeet–Ariss et al. 
(2013). These negative feelings towards the diabetes medicines appear, ultimately, 
to be related to patients’ experiences in managing their diabetes with either lifestyle 
measures (OGDs map) or tablets (Insulin map). Patients referred to being “defeated” 
and letting themselves down for not taking advantage of all the chances they had, 
and failing to manage their diabetes and diabetes treatment through their own 
efforts(2B,4,6,8). Feelings of personal failure also emerged at the point when patients 
were told they need to start insulin particularly if the initiation was imminent: (4). Part 
of the self–blame was related to feelings that others with diabetes would judge them 
as being a “bad diabetic”(14):  
 
“Oh yes. Some people feel very proud of themselves that not having gone on the 
insulin because they were clever and took their tablets.” (Mrs 07, aged 71 years, 
insulin)(14)  
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“What you would find if you went outside and asked all the other diabetics, they think 
you’ve failed if you go onto insulin.”(3) 
 
Feelings of personal failure about self-managing diabetes were reported to be 
extremely rare in the study by Jenkins et al. (2010)(7A). However these patients were 
interviewed almost 2 years after they had started their insulin treatments, compared 
to the patients from Brod et al.’s (2014)(8) study who were initiated insulin within the 
last 6 months prior to focus group interviews.  
 
Despite the negative feelings associated with starting medicines, all patients who 
took OGDs appeared to accept taking these medicines, in contrast to studies related 
to insulin (Figures 2.2-2.3). Nevertheless, as a result of exploring people’s perceptions 
of their medicines, two distinct groups were formed; those who believed that their 
diabetes is serious and those who did not. 
 
2.4.1.2 My diabetes is serious 
Overtime patients rationalised that their diabetes is a progressive disease(1, 2B, 15), 
believing that lifestyle can cause it but cannot cure it(2C). This rationalisation was more 
prominent to those who started developing symptoms(14) as this man describes: 
 
 “…something generally happens like you know, you notice some physical symptom, 
the feet, pins and needles and then someone says, carry on the way you are and you 
will lose a limb or your circulation will cause this, that or the other and so eventually 
something happens that you actually do start taking it much more seriously.”(Mr 11, 
aged 60 years)(14).  
 
Those taking/starting insulin justified that insulin is an integral part of managing their 
diabetes(3, 4, 6, 14, 15), while others conclude this after realising their tablets were not 
helping to control their diabetes(7A, 9).  The use of self–regulation strategies was 
crucial in accepting insulin as treatment for diabetes and reinforced to patients that 
their diabetes was serious (top box in Figure 2.3). The combination of SMBG and/or 
testing of blood glucose control with HbA1c tests as well as observing over-time an 
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increase in the number of tablets and doses for their diabetes were good indicators 
of poor diabetes control despite the fact that they were following the treatment(7A, 
9). However, taking insulin for this group of patients meant that they had lost their 
identity(3, 14) and normality(3). There was a sense that this was now “…ﬁnal. This is the 
worst this can now get because now you’re having to take insulin. (London, UK)”(8), 
and “… the end of things like when you go on like that, you know, there’s nothing else 
out there for me like.”(3).  
 
For many awareness of diabetes as a condition and its treatment came from family 
and relatives(11), so they were familiar with the need to control blood glucose and 
diabetes-associated complications (11). This group of patients placed importance on 
the role of medicines in managing diabetes. They often expressed that once they start 
on medicines they have to be on them for the rest of their life(1, 15, 16) otherwise 
something is going to happen to them(15), they would be in “danger”(1) or “risk 
dying”(1). Understanding diabetes better, following initiation of insulin, meant that 
patients were more willing to inform others (family, friends, public through the 
media) about the condition(4, 6). Those who were taking insulin for a long time(6), or 
those who were symptomatic but found insulin relieved their symptoms(3) were 
suggesting that insulin has helped them to feel normal again(3), saved their life(6), or 
regained their health(6). 
 
2.4.1.3 My diabetes is not serious  
This group of patients consists of those prescribed OGDs but who had no experience 
of taking insulin, including those who had been advised to take insulin but refused to 
do so(5, 6, 8, 9, 10). For some patients, there was a sense of denial towards diabetes, as 
for them it is largely “invisible”,  
 
“…You can only see diabetes in your blood. You cannot see it visually inside the human 
body. …it’s invisible, you can’t see it. Unfortunately, for everyone, what we can’t 
see…we ignore. It’s not ignorance, we just ignore it, because we can’t see it.” (Mr 07, 
aged 67 years)(14).  
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Fear about acknowledging that diabetes was serious was described as “contextual 
knowing” (Lawton et al., (2005b)(2A). Patients often expressed how they wanted to 
push their diagnosis to the back of their minds(11, 2B), believing that their diabetes is 
not serious if they are taking tablets(4, 5, 8, 9, 14, perceived insulin as an indicator of the 
worse type of diabetes(4,5,6), or a “pre-terminal event”(5, 6) with more side effects than 
tablets(6) , denying the possibility of future complications(12), or believing these are 
not imminent, as described by these patients: 
 
“…If I stop taking medicine for diabetes I’m not likely to go blind or lose my feet 
tomorrow, and I might get hit by a truck in the next 20 years. If I stop taking the 
medication to control my blood pressure I might have a stroke tomorrow and I don’t 
want to do that.” (Interview 13)(15)   
 
“I feel fine—why do I need insulin? I can control this by exercise and diet. I know what 
to do. My body will tell me if it is unbalanced.” (Bangladeshi Man, aged 48 years)(5)  
 
Reluctance to take insulin was also associated with specific aspects, most commonly 
with needle anxiety. For example, needle size(3, 9), act of injecting(6, 9), frequency of 
injections(5), fear of feeling pain (5,9), and fear of consequences of taking injections all 
the time(9). In addition, patients mentioned fear of weight gain(5) and 
hypoglycaemia(5, 6), the most common side effects of insulin (Horvath et al., 2007, 
Holman et al., 2008). Hence, concerns of loss of freedom and dependence on others(5, 
6) because of increased  risk of hypoglycaemia and the act of injecting were voiced, as 
these quotes illustrate, 
 
“I will always have to have someone near me in case my blood sugar goes low.” 
(Bangladeshi Woman, aged 61 years)(5)  
 
“If we take insulin then we have eat food immediately you know or our sugar goes 
down and you have to take insulin on time extremely regularly, with the tablets, if our 
timing is misplaced by either a hour lost or gained, it is not a source of worry for us... 
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it’s only that it’s hard to manage when going out and doing things.” Case Study 2 
(Interview 17- South Asian female, 58yrs, T2D duration 10yrs, on OGDs 5yrs)  
 
Insulin perceived as restricting and interfering with their lives(5), including their daily(6) 
and social(6) activities and travelling(5, 8). Therefore these patients expressed they 
would rather take more medicines than injecting insulin(9), in order to avoid this 
stigma: 
 
“When they gave tablets it began to go low and I thought but then it started going up 
and the doctor said you will have to come onto injections, four years on. I said do not 
say the name injections. I will take as many tablets I as I need to. I don’t have any 
problems with that...”(9). 
 
Past experiences with their medicines, particularly if perceived them unsuccessful in 
managing their diabetes, made them reluctant to accept insulin, as this woman 
explained: 
 
“The tablets don’t work. Why should the insulin work any better?” (Bangladeshi 
Woman, aged 57 years)(5) 
 
Insulin was also perceived as a threat by patients(3, 6, 8), often used by HPs to 
encourage them to better control their diabetes: 
 
“I know several times the doctor told me your sugar is up, your sugar is up and he said 
it has to come down or else we put you on the insulin. I’ve been dreading that.” 
(African Female, tablet group)(6). Consequently, insulin was linked with failure to 
control diabetes with lifestyle and tablets (5, 6).  
 
On the other hand, some patients although symptomatic prior to diagnosis of their 
diabetes and initiation of their medication, also made references to their diabetes as 
“not being serious at all”, “very insignificant in the big scheme of things”(2A), and 
“never affected me one way or the other”(2A). This appears to be as a consequence of 
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starting medication straight after diagnosis and, therefore, troublesome symptoms 
disappearing. Additionally, Lawton et al. (2005b)(2A) suggested the type and location 
of the service newly diagnosed T2D patients receive can change people’s perceptions 
of their diabetes. In this case, the patient had received care at her own GP practice 
which she then associated as not as serious as those who receive care from the 
hospital(2A).  
 
2.4.1.4 Expectations of Treatment  
Some patients described key motivators which influenced their decision to accept 
and take their diabetes medicines. Some had expectations of instant success 
particularly with injectable treatment, while others were influenced by interactions 
with HPs who had informed them that these medicines could help both with weight 
loss and diabetes control, as the following quotes demonstrate: 
 
“They started me on tablets. They weren’t making no difference [evidence from 
HbA1c test result]. They upped the tablets. They still didn’t make no difference, so for 
a start they started me on a night injection, just have it at night, nothing through the 
day, carry on with the tablets. But it still weren’t going down as it should have done, 
so they started me on insulin.” (Interview 18: white female, on insulin therapy)(9)  
 
"When I was put on metformin it was almost sold as a good one that would help lose 
weight as well…”(2C), and could help with relief of symptoms(2A) 
 
2.4.1.5 Expectations of Care 
The moment patients are prescribed a diabetes medication, there appears to be an 
increased need for further information about their diabetes and their new medicine, 
particularly prior to and during treatment initiation (Figures 2.2-2.3). Generally, 
individuals wish to consult an expert(1, 2A, 6), someone who, in their view, is 
trustworthy and makes them feel confident that their medications are appropriately 
prescribed(1, 11) and wished for continuity of care between primary and secondary 
care, or even between HPs (4). Most information needs about insulin were associated 
with the advantages and disadvantages of taking insulin(4, 9, 14), the type of insulin and 
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doses required to control their diabetes and any changes required in the type and 
doses of insulin(3, 6, 7B), as well as guidance on dietary changes(6), and training to inject 
insulin correctly(6). Following experience from taking their diabetes medicines, 
patients’ needs for information are still high(2B, 2C,15, 16), despite not questioning  any 
medication changes(2B) and expecting ongoing prescription of them(2A, 2B). At the 
outset, they want to receive information about their medicines that it is easy to 
understand(11) using “layman’s” language and avoiding “technical terms’’ (White 
male, tablets, interview no. 20)(16). Also, they want non-judgemental guidance(2B) on 
alleviating any negative experiences with their medicines and how to deal with 
missed doses.   
 
Furthermore, patients want to be better informed about the need for their 
medicines; “…I don’t want to take drugs unless they are necessary…” (White British 
male, aged 55, prescribed five medicines)(15), “…I have no idea what that’s for… ‘cos I 
go to my doctor; they don’t tell me what the tablets are for....” (male 60–64 years 
with diabetes, cancer, asthma, tuberculosis)(16). This is also important if they hold 
negative views about their medicines, for example  
 
“… if you are on certain tablets and it doesn’t work they don’t take you off that tablet. 
They give you a next tablet to go on with the other rest that you take. I don’t find that 
very helpful, because if the tablets are not working why should you go on taking a 
next tablet on top of there, and a next tablet.” (African-Caribbean male, aged 72, 
prescribed seven medicines)(15).   
 
2.4.1.6 Negative Perceptions of medicines 
Negative perceptions associated with taking medicines were common in these 
patients. Although these may appear as general concerns rather than specific to their 
diabetes medicines, they are ongoing issues that require to be discussed with HPs. 
One of their major concerns is medicines’ effects on their body and health. Patients 
described medications as being unnatural(1, 2B, 3, 12) because, “you don’t know what 
you’re putting in your system” (Female, Round 4)(2B) and hence, they were concerned 
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about the chemical nature of tablets(12). The possibility of taking multiple medicines 
or doses long-term could be damaging to their health(1, 2B, 12) as this man describes,  
 
“Initially it was just two metformins a day, and then it was increased to four by the 
doctor. And then there’s blood pressure tablets to take and then aspirins and so on. 
So it all adds up and, y’know, if you take seven, eight pills a day and you wonder 
[laugh] is it the right thing? This can’t be good for me in the long run.”  (Indian, male)(1)   
 
Also, patients do have preferences in the amount of medicines per day that they can 
cope with taking(16); suggesting that “…I’ve more in the house than they have in a 
chemist shop” (female 80–84 years with asthma, angina, diabetes, rheumatoid 
arthritis)(16), and “…anyway the point is that I just don’t want to take, I take enough 
medication for diabetes” (male 70–74 years with osteoarthritis, diabetes, gastric 
reflux)(16). Most patients on complex diabetes and non-diabetes medication regimes 
were worried that taking these medicines together could counteract their individual 
effects (1) or “that’s three lots attacking the kidney” (2B), after patient information 
leaflets confirmed their suspicions. Therefore, they expressed the need to minimise 
the amount medicines or simplify the medication regime “Like the metformin, I often 
wish it would double (strength), and it wouldn’t be so many pills, y’know. Or instead 
of being 4 gliclizide, 4 metformin, I could just take one pill in the morning” (F36.4)(2B), 
in order to help overcome their concerns and cope with the demands of managing 
their diabetes. 
 
Patients taking insulin also feared developing possible complications(4), as well as 
worry about hypoglycaemia(4, 6, 8) whether they had already experienced it(6) or not(4): 
 
“I think it’s rather dangerous for a diabetic to be on his or her own you know, because 
I find that when I go into hypoglycaemic, sometimes it’s a struggle to maybe get to 
the kitchen.” (Caribbean, Male, insulin group)(6). 
 
Similar to patients who refused insulin, patients who started insulin were, too, 
worried about needle size and mastering the technical skill of injecting(3, 7A, 14). 
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Interestingly, patients’ perceptions of insulin as a “threat” (see 2.4.1.3) had now 
transformed to a form of “punishment”(4), perhaps originated from the way in which 
insulin was introduced, believing it was unjust(3) and its association with negative 
stigma(4, 9). Nevertheless, not all patients saw insulin in such a negative way. The study 
by Morris et al. (2005)(3) indicated that there was a gender divide, with women seeing 
insulin as a punishment whereas men saw it as a form of treatment which would help 
them(3). However, Phillips (2007)(4) stated that most of her participants saw insulin as 
punishment. Both studies had small sample sizes (n=14), however, with equal 
numbers of men and women, so it is difficult to ascertain whether women are more 
likely to view insulin as a punishment than men. 
 
Furthermore, an ongoing concern with insulin was the burden they experienced since 
they started taking it. Patients described anxiety about losing or affecting their driving 
licence(4) because of having to renew it every three years. They also described worry 
about their holiday insurance as they were required to complete extra forms(4), “I 
can’t do anything and I can’t go abroad. I can’t do anything ’cause I’ve got to take this 
insulin, and it devastated me”(3). Injecting in public was an issue; particularly for those 
who needed to inject at least once with meals: 
 
“It didn’t bother me about using a needle but if people are watching you […] you don’t 
know how they feel about seeing people inject themselves. So, normally, I try to do it 
in, like a private way.” (Participant 42), “I just don’t think I would like to do anything 
like that (inject) in public, whether I did it in my stomach, on my arm or anywhere, no. 
No. They might think I’m a junkie!” (Participant 31)(7B) 
 
Having to take insulin for some patients was seen as an inability to live a normal life 
(3, 14) and that it is hard to manage their diabetes (4) and harder to lose weight (8): 
 
“You become a slave to it. I know I still am a slave to it but not to that extent and if I 
can get off it altogether again I will. I will go down fighting – I will!” (Mr 15, aged 65 
years) (14) 
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2.4.1.7 Negative Experiences with medicines  
Once patients started taking their OGDs they experienced difficulties mostly related 
to the side effects from their medicines(1, 2B,16), such as “wooziness”,  “really bad 
stomach cramps”, “bad diarrhoea” or “having hypos”(2B) (Figure 2.2). On the other 
hand, initiation of insulin was described by patients as a traumatic experience “It was 
… totally frightening. You don’t look it and you don’t like to say it, but you’re really, 
really scared.”(3) (Figure 2.3).  
 
Negative experiences and feelings of disappointment and failure were also the result 
of realising that their medicines had not helped them to feel better or worked for 
them(3,4,11), particularly when others had found great benefit from the same 
medicines, or when they expected to feel better instantly,  as the following quotes 
demonstrate: 
 
 “...It’s like my friend who came over and said ‘I have got diabetes and I am taking 
these tablets and it is all normal for me’ and then I said ‘I take the same tablets—so 
why is it not working for me?’ I just got worried on top.’’ (South Asian male, interview 
no. 3)(11) 
 
“[my] son …He says, “When you take this needle, the first one mam, you’ll feel great.” 
He said, ‘you’ll feel like dancing on the top of the world’ …And I took my first needle 
and I sat there waiting for the euphoria and it didn’t happen…" (3 taking insulin for 
one month)  
 
Managing diabetes with insulin was often described as “frustrating” and “hard”(4): 
“You do exactly the same thing, the same food everything the same, but then suddenly 
you see these high sugars again and you sit down and go through everything, but you 
can't find a reason” (4 taking insulin for at least 2yrs). 
 
2.4.1.8 Positive Experiences with medicines  
Patients had positive experiences once they started taking their diabetes medicines, 
commonly claiming that they “feel better”(2B, 2C, 3) and healthier(4), they have “much 
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more energy now”(2B) and that these medicines “are what really work”(1). Those who 
presented with symptoms prior to prescription, found relief from their symptoms(6) 
because they had either gone “instantly”(1) or had lessened; “I’m only going to the 
toilet twice at night, so I feel that’s come down a good bit” (F16.4)(2B).  
 
Once patients initiated insulin they were surprised to find they were using pens, 
which they saw as more discrete and easier to transport(7A). Also, they claimed that 
injections were not as painful as they had anticipated(3, 4, 6, 7A) nor as difficult to do(3, 
6), as the following two quotes describe:  
 
“Let people realise that having insulin is just as easy as having the tablet. Before, I did 
not think that” (Caribbean Male, insulin group)(6) 
 
“Wow it was mega that, when I put it in me belly. I was dead chuffed ’cause I hardly 
felt anything”(3) 
 
2.4.1.9 Positive Perceptions of medicines 
The positive experiences with medicines reinforced their positive perceptions, i.e. 
they are beneficial(2B, 15) and effective(1, 3, 7B) and help control diabetes and preserve 
health(3, 4, 6, 7B).  Some patients indicated that their medicines are more effective in 
managing their diabetes than lifestyle(2B), and insulin is better than tablets(4, 6), 
particularly when its effects were seen over time(3, 7B). Patients also seem to prioritise 
certain medicines over others (1, 15) even if they are for the same condition, for 
example:  
 
“The gliclazide, comes with the er—the pioglitazone after that and then after that the 
ramipril to do with my blood pressure…” (South Asian male, aged 53, prescribed four 
medicines),  
 
“...metformin. This is one of the most important drugs to take for it.” (Indian, male) 
(Pakistani, male)(1), and  
102 
 
“Well if the sugar and the blood pressure get high then you could have a heart attack. 
But with taking that (aspirin) it lowers the risk. But the metformin is the main one 
that’s the main one that’s helping.” (African-Caribbean female, aged 82, prescribed 
three medicines)(15).  
 
2.4.1.10 Self-Regulation 
As seen in section 2.4.1.7, some patients found the self-regulation strategies brought 
negative feelings associated with the negative experiences of taking medicines. 
However, for others, the use of SMBG(2B, 11), or evidence from other external results 
from HbA1c tests(2B) (Figure 2.2, bottom box in figure 2.3) reinforced their positive 
experiences and perceptions of their medicines. These strategies, over time, proved 
that medicines had helped with blood glucose control(3, 7B, 11), as this man describes: 
 
 “…I’ve got this stick thing to measure it with and I have also got this machine and 
with that you know what it is, whether it is 7.5 or 8.5 or whatever.’’ (South Asian male, 
tablets, interview no. 11)(11)  
 
These strategies seemed to have more impact on those who were asymptomatic or 
were “unconvinced” that their medicines were effective until they attended a review 
of their diabetes in which the general practitioner “tested it, and it’s come down to 
seven point something and he’s really pleased”(2B) or tested themselves “everyday for 
a week, take all the readings, then start taking the metformin and see if it makes a 
difference.” Subsequently, the lower readings recorded provided the “proof” they 
needed that their “tablets were working”(2B). 
 
Conversely, those patients who saw their diabetes medicines as useful for instant 
relief of symptoms, used these self-regulation strategies and predominantly took all 
their tablets when they considered their readings to be high(1). Others expressed 
thoughts about coming off their tablets, as highlighted by this patient who was 
prescribed metformin, 
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“I don’t even consider myself having diabetes you know because the blood sugar has 
stayed within normal ranges since the ﬁrst sort of month or two after being 
diagnosed...while I’m managing it myself then I don’t need any real intervention at 
the moment from anybody else… now that the weight’s gone my initial thought was 
‘well maybe I need to change what I’m on’. But I just asked when I was down there I 
said ‘Is there any merit in me just coming off everything for a trial period?” [male, 
40yrs, round 3, off Metformin](2C). 
 
2.4.1.11 Patterns of Medicine Taking Behaviour 
Three different patterns of adherence were identified in this review; full adherence, 
unintentional non-adherence, and intentional non-adherence. These were then split 
into five different patterns depending on the level of emotions felt in relation to 
whether guilt was attached to the behaviour.   
 
(i) Adherence and Unintentional non-adherence with guilty emotions (Figures 
2.2-2.3) 
Those patients who fully adhere to their diabetes medicines seem to strongly believe 
on the positive aspects of these medicines, specifically that they are beneficial and 
effective for their diabetes management, and seem to give greater importance to 
these medicines than other medicines for comorbid conditions(15, 16).  
 
“And like I said the heart tablets and the diabetes and the warfarin I never fail to take, 
like I said it’s just sometimes it the cholesterol that I’ve forgotten.” (White British 
female, aged 67, prescribed four medicines)(15). 
 
On the other hand, there were patients who despite strongly believing in the positive 
aspects of their diabetes medicines, they sometimes unintentionally non-adhered to 
their medicines(2A, 2B, 7B, 15). In most cases, this was due to forgetfulness when routines 
were broken, particularly when they ate out and “forgot to take them with me” 
(M1.2), or if they are asymptomatic, as diabetes is not “at the forefront of your 
mind”(2B), or due to confusion when taking multiple medicines, as these quotes 
demonstrate, 
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“What (name of nurse) said to me was to take it at bedtime.  Which is fine except that 
I tend to go to bed very late and so we agreed that I would take the insulin at about 
10 o’clock. Sometimes depending on what’s happening and what I’m doing, sort of 10 
o’clock’s gone past and I haven’t taken it and it might be 11 o’clock or half past 11 
before I remember to take it.”(7B) 
 
“…believe me, if you take a lot of tablets, you’ve no idea when you’ve taken them, and 
what you’ve taken” (M37.4)(2B).  
 
Guilty emotions were attached to this medicine taking behaviour, “really conscious 
stricken if I forget or think I’ve missed it” (M17.4)(2B). Yet, despite the positive 
perceptions and their personal attempts to increase their adherence level, these 
patients voiced concerns about the negative perceptions of these medicines (See 
2.4.1.6). This group of patients (adherent and unintentional non-adherents) 
attempted a number of strategies that promoted adherence (Figures 2.2-2.3). These 
included establishing routines in order to fit the medication into their life(2B, 7B), using 
medication boxes, carrying insulin pens in pockets/bags or keeping their basal insulin 
next to their bed or their prandial insulin in the kitchen, or identifying the logistics of 
where and when to inject(7B) or other visual reminders such as keeping drugs by the 
bedroom window and only closing the curtains after they had taken them(2B). Family 
and friend support was also important as they would remind patients to take their 
pills(2B) or injections(4,7B), and partners would also encourage them(4, 7B). Some patients 
found support in a group setting when they initiated insulin(4).  
 
(ii) Unintentional non-adherence without guilty emotions (Figure 2.2) 
Some patients unintentionally non-adhered to their medicines as a result of 
forgetfulness. It appears that this is also due to not having any diabetes related 
symptoms(2A). However these patients did not appear to feel guilty as they 
rationalised their behaviour expressing that they are ‘‘a bit erratic’’ about taking their 
tablets, ‘‘I’m very bad for the one during the day, I forget that’’ (Mary, 47yrs, Round 
2, Metformin)(2A). The relationship between lack of guilt and lack of symptoms was 
therefore reinforcing their belief that diabetes is not serious.  
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(iii) Intentional non-adherence with guilty emotions (Figure 2.2) 
There was one patient who intentionally non–adhered to his diabetes medicines by 
skipping doses in order to avoid side effects from this. This patient felt unable to ask 
his HPs whether he could skip doses of gliclazide “to avoid hypos” on “a rare boozy 
night out”, fearing he might get his “knuckles rapped”(2B).  
 
(iv) Intentional non-adherence without guilty emotions (Figure 2.2.-2.3) 
This group of people engaged in intentionally non-adherent practices without feeling 
guilty, but did so for different reasons. In line with Campbell et al.’s (2003) review, 
guilt was not an issue for those who exemplified intentional non-adherence, as they 
were fully aware of what they were doing and the reasons for it. Some patients 
adjusted the amount of tablets by reducing their medicines’ doses, or stopped taking 
them altogether because they strongly believed that their medicines would have a 
detrimental effect on their overall health and body(1, 16), as this patient explained: 
 
“No, but that’s not to say I wasn’t prescribed them, yeah, I didn’t take them, I don’t 
want nothing to do with tablets, i.e. my diabetes tablets, I’ve got boxes of them. When 
I get to about fifteen, twenty, I take them back to the chemist and say they over 
prescribed them and say I don’t need them…” (male 45–49years with cancer, 
diabetes, hypertension, asthma, depression)(16)  
 
While, patients on insulin described that they either advanced or delayed their 
mealtime injections so that they could inject in the car on route to the restaurant, or 
upon arriving home(7B), as a result of avoiding the associated stigma with injecting 
insulin in public. Other patients skipped tablet doses in order to avoid experiencing 
side effects from their medicines, like when “suddenly become dizzy” (Pakistani, 
female)(1) or when “they make you dry if you take too many” (Pakistani, female)(1). 
 
Patients who believed in the benefits and effectiveness of their medicines also 
adjusted the amount of tablets particularly if they strongly believed that these 
medicines work by instantly alleviating the symptoms of diabetes, as described by 
two Pakistani patients: 
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“…for the last three months I’m just taking them twice a day. It’s just when I feel I’m 
tired I take another one. If I’m fine then I won’t.” (R26, Pakistani, male)(1) 
 
“Oh I feel fine and I’ll take one today, I won’t take two.” (Pakistani, female)  
 
These patients also used SMBG as a strategy to take all tablets when they considered 
readings to be too high(1); others manipulated their tablets according to their diet, as 
shown by this man: 
 
“(I take)…two [tablets] when I don’t spread too much jam on my toast or even 
sometimes I don’t even spread any. If I feel like a bit of a pleasure then I will put some 
on and then I will take the extra tablets.” (Pakistani, male)(1)  
 
Health professionals also seem to influence patients’ medicine taking behaviour. 
Participants who were advised by them to adjust their amount of tablets for religious 
purposes (such as during Ramadan), did so at other times usually without seeking 
medical advice(1).  
 
2.4.1.12 Strategies to overcome negative aspects of insulin (Figure 2.3) 
Patients appeared to be driven to return to some form of normality in order to avoid 
or overcome any of the negative aspects of insulin as discussed above (2.4.1.6-
2.4.1.7). Strategies employed included talking to friends and family about how to 
treat hypoglycaemia(4), starting insulin in a group setting(4), or initiating group support 
in their work place(4). They regularly referred to the original written material provided 
by HPs when they started insulin and actively sought further information on diabetes 
treatments(4), often encouraged by  their partners and family(3, 4). Some patients also 
became self-reliant in adjusting insulin doses, and this gave them a great boost of 
confidence(3). In actively doing all of the above, many patients stated they became 
experts in diabetes over time(4, 14), even better than some HPs(4). However, some 
patients consciously decided to change their social life in order to avoid injecting in 
public and would rather avoid eating out: 
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“I wouldn’t go out to lunch with them (friends) and in the end I had to tell them why. 
I said, ‘I can’t. I have got to have insulin. And I am not going to go into a toilet” 
(participant 23)(7B).  
 
Others mentioned they ate regularly to avoid feeling weak, which according to the 
authors was unlikely to be linked with low blood glucose(12). Although most patients 
manipulated their diet and medication regimes to live a life as full as possible, some 
patients limited their social activities in order to adhere rigidly to medical advice; a 
finding in contrast to that of Campbell et al.’s (2003) review.   
 
2.4.1.13 Lifestyle behaviour (Lifestyle Adherence and Non-Adherence) 
Adherence to lifestyle measures was generally a first self-treatment attempt by 
patients following diabetes diagnosis or when they were prompted that they will 
need to take medicines for it(2B, 2C): 
 
“…we changed our diet overnight, for the whole of the family. The sugars went out 
and the fat went out and healthy food just came in immediately and that 
helps.”(South Asian male, aged 53, prescribed four medications)(15)  
 
Those patients who thought that their diabetes was not serious and  those converted 
to insulin, also gave great importance to lifestyle measures(2C), making changes such 
as adhering to healthy eating plan(4), with some patients referring to being 
“…cautious what I eat like” (Caribbean Male, insulin group)(6), whereas others used a 
moderate approach(4, 6, 14) as highlighted by the following quotes: 
 
“Yeah but sometimes I taste a little thing what I know I don’t supposed to really eat… 
You can eat everything but small amount of it.” (Caribbean Female, insulin group)(6)  
 
“I’m trying to pass on my experiences. A little bit of what you fancy. Don’t stop ice 
cream, don’t stop biscuits, don’t stop eating.” (Mr 06, aged 71 years)(14)  
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However, over time patients struggled to keep up with the diet and the physical 
activity(2A, 2B, 4, 10) realising that their diabetes progresses “…no matter how careful you 
are” (Pakistani, female)(1). Hence, they accepted that eventually they would be 
dependent on their medicines and changed their attitudes towards them, so that 
they believed them to be more effective in managing their diabetes than any lifestyle 
measures(2B, 2C, 15).  Moreover, those on insulin, often felt frustrated when they could 
not see the results of their efforts(4) and led to feelings of not wanting to bother(4) 
because it was impossible to achieve good diabetes control. 
 
“You have to be more proactive on insulin' (Luke), and 'When you go onto insulin you 
take your diabetes more seriously. If I eat the wrong thing I start to feel sluggish”(4)  
 
Some even indicated that the lifestyle and medication are two alternative ways in 
which they could manage their diabetes, suggesting that once you take medicines 
they could eat what they want(2C, 6, 14), as medicine is the only way to control blood 
glucose levels(6). Additionally, some patients taking insulin indulged on foods that 
they would have restricted whilst on tablets; “With the insulin I eat ANYTHING.” 
(African Female, insulin group)(6).  
 
Others were uncertain how to control their diabetes with diet as they could not 
identify if any changes to their lifestyle had an impact on their diabetes control (11), 
whereas when they take medicines they could see their effects through SMBG. Those 
who thought that their diabetes was not serious indicated “being naughty” and to 
‘‘doing wrong’’ with their eating habits, probably ‘‘because I’ve got a bit complacent, 
I must admit’’(2A). Therefore, it is no surprise that a four-year longitudinal study of 
retired T2D patients (aged 50-62) found that lifestyle behaviours, such as being on a 
special diet, following an exercise regime, or trying to lose weight, diminished over 
time (Nothwehr & Stump, 2000). The authors indicated that their participants 
showed lack of commitment to self-management practices but perseverance to 
lifestyle measures could be associated with individuals’ change of views and attitudes 
towards their diabetes treatment including medications.   
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2.4.2 Line of Argument Synthesis: Patient’s journey - the impact of diabetes medicines 
on re-evaluating oneself  
This is the final stage of synthesis. After consideration of the two medicine maps 
separately and behaviour theories examined in section 2.3.4, they were, then, 
brought together to construct a line of argument (Noblit & Hare, 1988). Figure 2.4 
visually represents this final synthesis. It illustrates patients’ trajectories from 
receiving diagnosis and/or the prospect of prescribed medicines for their diabetes. 
Alongside the patients’ journeys can be seen relevant HP labelling which has emerged 
through the review of the studies. Although patients’ journeys were the main focus 
of this review, HP labelling was necessary as patients inevitably interact with HPs for 
managing their diabetes at various stages. Many of the studies were conducted by 
HPs or with health-related backgrounds. Health professionals, particularly GPs or 
consultants, are the first point of contact for confirming the diagnosis of diabetes and 
for prescribing medication. They also interact with patients through clinic 
appointments and various tests offering advice about how to best manage the 
condition.  
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Figure 2.4: Line of Argument Synthesis  
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2.4.2.1 Severity 
Both medicine maps revealed that patients associate the severity of their diabetes 
with the type of treatment (lifestyle versus medicine) and the type of medicine they 
are prescribed (tablet versus insulin). However, perceptions of severity of their 
diabetes appear to change over time. Interactions with HPs can influence patients’ 
perceptions of severity of their disease, as indicated by these two patients: 
 
“My GP said my blood sugar was okay. He told me to keep my blood pressure down 
and my cholesterol good, and I would be fine.” (Man, aged 55 years, advised to start 
insulin but refused) (5)  
 
“The doctor said anything under ten (mmol/l) was acceptable. I started testing my 
blood glucose levels and that was really when I began to realize that tablets weren’t 
helping me. So I went to the doctor and said, ‘I want to go on insulin.” Patient 20 (7B)  
 
The types of health care service they received also influenced their perceptions 
(Lawton et al., 2005b; Noakes, 2010)(2A, 6). Patients generally recognised diabetes as 
a progressive disease and accepted that certain treatments may be required in the 
future for its management, as these quotes show: 
 
“I think I was told it was in the gradual stages... These are the type of tablets that you 
need to take. If you control your diet, you know, cut down on your sugars and fatty 
food that you’d be eating, it will take a long while, but eventually you will need to go 
on to insulin… So each time I went there was a bit more progress on there so they said 
‘Alright, okay this is what will happen. This will happen. This is the type of insulin you 
may have to take but not yet.’ So it was all gradual. It wasn’t all blunt and 
straightforward saying ‘Right tablets for three years, insulin next year.’ It wasn’t like 
that. They said it will build up gradually. Eventually in the later years in your life you 
will be going on to insulin as all diabetics do.” (Interview 09: South-Asian male, not 
on insulin therapy)(9) 
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“...from my experience of diabetes, it’s just an inevitable part of it that you’re going 
to end up being on insulin anyway...I was expecting it...” (Case study 4 interview 7 
South Asian Male, 57yrs, DM duration 20yrs, on insulin for 5yrs)(9) 
 
Health professionals and patients do share common views about diabetes (Cohen et 
al., 1994; Hunt et al., 2001), although these views are not totally congruent, partly 
because patients’ views are influenced by many other factors (see 2.4.2.6).   
 
2.4.2.2 Difficulties 
Authors described the many difficulties that patients faced in managing their 
diabetes on a daily basis which included: confusion with taking multiple medications 
or understanding the purpose of their medications, injecting in public, integrating the 
regime (medication, diet and exercise) into their lives, acquiring relevant knowledge, 
and coping with social events(2B, 7B, 10, 11, 12, 13, 16). These are common difficulties 
identified in other studies (Cohen et al., 1994; Haslbeck & Schaeffer, 2009). Studies 
in this review did not delve into HPs’ views on managing their patients but the limited 
quotes suggested that patients and professional discussions were based on lifestyle 
and medication changes in order to control blood glucose or lose weight and reduce 
complications. While pathophysiological difficulties are a concern for health care 
providers (Cohen et al., 1994; Hunt et al., 2001), patients did not expect anything 
other than being prescribed an appropriate medication and consulting an expert for 
advice relating to avoiding medication side effects and practical ways for managing 
their medicines on a daily basis or special occasions.  
 
2.4.2.3 Passive- Active Patient Role  
Patients indicated that the decision for new prescription and changes to their 
medications were made by doctors(1, 2B, 3, 4, 6, 7B, 10, 11), often without questioning it or 
discussing it with them, and not fully understanding the reason for taking their 
medicines, unless supported by clinical evidence(2B, 7B). Hence, they were seen by 
authors as having a passive role with regard to their diabetes self-management. 
Whereas, patients who indicated that they tried to negotiate their medication regime 
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or requested to be put on insulin were seen as being active participants(2B, 3, 9). 
However, patients appeared to trust doctors and their expertise in making 
medication changes(1, 7B) as the following quotes suggest: 
 
“[patient] The doctors are trained to tell us what to do.  
[interviewer] You could discuss the problems you are having in the rest of your life—
like your housing, work or any of those things and tell the doctor how much they are 
effecting you.  
[patient] Doctor is not there to do that, doctor is there to give us medicine, to make, 
to tell us what is wrong and then we take medicines”(R5) (10)  
 
‘‘I’m sort of following doctor’s orders. As far as I know the stuff he’s giving me is 
holding me nice and steady.’’ (White male, tablets, interview no. 20)(11) 
 
2.4.2.4 Adherence or Non- Adherence 
Authors often described participants’ actions towards their medications and lifestyle 
behaviours as patterns of adherence or non-adherence(2B, 2C, 7B, 15). The term 
adherence, as seen before, relates to the extent an individual takes their medicine or 
follows other health-related treatments which corresponds with agreed 
recommendations from a health care provider (WHO, 2003). Although this term is 
used in medical literature, it does not correspond with patients’ perceptions of how 
well they are managing their diabetes medicines and lifestyle (see 2.4.2.9). 
 
2.4.2.5 Grief Reaction 
In this review, patients’ journeys started either at the time of diagnosis and/or at 
medication prescription. What was identified throughout this review was the 
emotional reactions to changes in medication, which paralleled those seen at 
diagnosis. These reactions can be described as representations of grief (Brown, 1985) 
with emotions such as shock, guilt, denial, anger, bargaining, depression and finally 
acceptance/adjustment, as captured in these quotes: 
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“In January of o seven they shocked me by saying, ‘Well, we’re going to have to put 
you onto a different injection’ and I thought what, just the different injection? And 
they said ‘No, no, as well, and by the way, up three times a day.’ So I then realized, 
five times a day!” (Participant 28)(7B) 
 
“My health will remain good, by the Grace of God, so long as I keep praying.” 
(Bangladeshi Man, aged 70 years)(5) 
 
“So why have I got this diabetes when I’ve looked after me’self all these years? Why?"  
(Ruth 3) 
 
“I was devastated [about being prescribed glipizide]. I wasn’t happy at all. But it was 
explained to me that diabetes always progresses…” (1, Pakistani female) 
 
It is acknowledged that grieving takes time (Brown, 1985), and the revival of grief 
reactions during changes in medication have been referred to as chronic sorrow i.e. 
the reactions connected with repeated losses of independence, control, status, loss 
of identity as a healthy person generating a disparity between the current reality and 
the desired reality (Ahlstrom, 2007). This review identified that as patients 
progressed from diet to tablets to insulin, their emotional reactions were stronger 
and impacted upon the way they coped.  
 
2.4.2.6 Diabetes and medication related beliefs 
Authors often described that patients’ understanding of diabetes and its treatment 
was influenced by the community and culture they live in and family experiences(3, 5, 
6, 9, 11). Patients’ presentation or lack of symptoms and complications also appeared 
to have an impact on their perceptions of the condition and specifically about their 
own diabetes and its management(2A, 2C, 4, 9, 11, 12, 13, 14). Authors discussed how patients 
perceived the lack of symptoms as their diabetes not being serious whereas the 
presence of complications was seen as a more serious form of the disease.  
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In addition, patients own beliefs about medications had a direct impact on the 
perceptions of their disease and vice versa as seen from the medicine maps and the 
final model. Those who had negative perceptions (greater concerns) over their 
diabetes medicines were more likely to report practices that suggested intentional 
non-adherence, whilst those who had more positive perceptions of their medicines 
(greater necessity) were more likely to report fully adhering to their medicines or the 
ways they had adopted to promote adherence. This balance of concerns over the 
negative effects of medicines and necessity for diabetes management is consistent 
with the necessity-concerns framework (Horne & Weinman, 1999). Furthermore, 
those who believed that their diabetes is serious were more likely to report greater 
necessity about their medication treatment and, therefore greater adherence.  
 
2.4.2.7 Re-evaluation of one self 
Together beliefs and emotions reinforced an evaluation of oneself leading to either 
accepting the “altered self-image”(3) or reconstructing a new self by adjusting their 
beliefs, or resistance to change, as the following quotes describe:  
 
“I just said to myself one day, ‘you’ve got this diabetes, and you need the insulin to 
keep you well. You either don’t take the insulin and you’re not well, or you take the 
insulin and you’re well. The choice is yours’ …I [now] see insulin as something that will 
keep me healthy.” (Ruth) (3)  
 
“…So I am being a fool to meself where that is concerned, because I have been told 
I’ve got to take them [diabetes tablets], but I find that so long as I behave myself, then 
I’m fine." (male 45–49 years with cancer, diabetes, hypertension, asthma, 
depression) (16)  
 
2.4.2.8 Acceptance-Denial 
Generally, acceptance to change meant that medicines were accepted as part of the 
successful management of diabetes. However, resistance to change did not 
necessarily mean resistance to taking medicine as seen from the first medicine map 
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(Figure 2.2). Different levels of resistance and acceptance of their diabetes identity 
and self-management have been found in other research (Savoca et al., 2004; 
Ockleford et al., 2008). In this review, regardless of the patients’ positions to either 
accept their new self or resist, they all employed a variety of strategies to regain self-
control. This was apparent from the authors’ use of descriptions such as, “getting 
right or losing control” (4), “down to me, up to them”(2C), “losing normality”(3).  
 
2.4.2.9 Strategies to regain control 
Medication taking behaviour, lifestyle behaviour and SMBG were all tactics patients 
engaged with to regain control. Such strategies were often associated with patients’ 
levels of adherence or non-adherence to treatment, and to being passive or active in 
managing their diabetes. Although these terms (adherence/non-adherence, 
passive/active) are used in clinical research and practice (Figure 2.4), for patients 
these are rational decisions or actions which enable them to live as normally as 
possible and to minimise the impact of their diabetes and medicines in everyday life. 
This approach to life is often seen in patients with chronic conditions (Haslbeck & 
Schaeffer, 2009), although patients have different levels of self-efficacy and coping 
efficacy. Authors often described patients’: “commitment to taking medicines” (2B), a 
“sense of growing confidence”(3), “responsibility”(2B, 4) and “self-determinacy”(2C). 
Patients were “willing”, “keen”, and making conscious and deliberate “effort”(4, 7B) 
and “attempts”(2B) to find out about diabetes and adapt their daily practices to fit 
their medication, with some “requesting” new medicine(7B) or “negotiating” their 
regime(2B). Still others reported feeling “powerless”(3), and expressed “concern” or 
“worry”(6) because they had “tried hard”(4) but had been unable to make successful 
changes leaving them with feelings of “not wanting to bother”(4).  
 
Although not all strategies as outlined in the medicines maps appeared appropriate 
for health improvement, those patients who seemed to effectively manage their 
diabetes medicines were those who identified specific strategies to help them adhere 
to their medicines. These strategies related to having established routines to 
overcome problems with taking multiple medicines, inconvenient schedules, and lack 
of reminders. From this data, it can be suggested that those patients with better 
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medication adherence have increased self-efficacy and coping-efficacy levels. Self-
efficacy, as a factor predicting treatment adherence, was found in the meta-analysis 
by Gherman et al. (2011). The experience of successful and unsuccessful practices 
reinforces or undermines patients’ beliefs about their diabetes treatment and leads 
yet again to a re-evaluation of self.  
 
 2.5 Summary  
This systematic review was based on the meta-ethnographic approach as developed 
by Noblit and Hare (1988), which has become established in health research and 
enables to make evidence from qualitative research accessible to health 
professionals and policy makers (Campbell et al., 2011). This synthesis of 16 studies 
(19 papers) has shown how patients view and take their diabetes medicines, and how 
the experience of starting or changing to a new treatment results in a re-evaluation 
of themselves that they either accept or deny. The re-evaluation of self is an endless 
cyclic process depending on the daily positive and negative emotional and cognitive 
experiences of self-managing their diabetes alongside interactions with HPs. All 
patients engage with strategies to enable them to regain control of their life. Those 
who self-manage well are those who are confidently able to modify their daily 
routines to fit medication regimes overcoming challenging areas such as 
polypharmacy, inconvenient schedules and lack of reminders. Nevertheless, patterns 
of non-adherence (intentional and unintentional) were more common than patterns 
of adherence reflecting findings from other ‘adherence’ systematic reviews (Cramer, 
2004; Krass et al., 2015). 
 
Lack of sufficient information from health care providers around problematic areas 
of medicines such as negative beliefs and experience of side effects, can impact 
adherence and have detrimental effects on patients’ health and quality of life. In 
addition, if patients’ expectations of new diabetes medicines result in positive 
experiences, this can re-inforce the positive perceptions of their medicines and 
acceptance of them. It is apparent that acceptance of diabetes as a serious disease, 
acceptance of medicines as necessary for managing the condition, high levels of self-
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efficacy and coping-efficacy, as well as positive experiences following new treatment 
are important for medication adherence. However, as people accept their medicines 
it seems that they have less faith in lifestyle changes as a way of managing their 
diabetes. Although weight loss is acknowledged by patients as part of making healthy 
lifestyle changes it seems it is not associated with self-managing their diabetes, 
despite the fact that many treatments are having an undesirable effect on body 
weight. Only a few people were aware of the effects of their medicines on their 
weight. Furthermore, as patients are not involved in the decision making about their 
medication treatment, it is unclear whether they are likely to choose a medication 
based on its ability to support weight loss or control (Purnell et al., 2014) and whether 
knowing the impact of the medicine on their body weight will affect adherence levels.  
 
2.5.1 Application of theory in medicine taking behaviour for T2D 
A number of theories were applied to individual studies in this review to explain 
medicine taking behaviour. The medicines map and the final line of argument 
synthesis prove that no single theory can be used to fully illuminate this kind of 
behaviour. Therefore, more than one theory is needed to explain medication taking 
practices for people with T2D. These include, in no particular order: 
(i) Model of illness representations (Leventhal et al., 1980 cited in Bower et 
al., 2012) where emotional (guilt and grief reaction) and cognitive factors 
(illness and medication related beliefs, perceived self-efficacy and coping-
efficacy) are involved in changing the self-view and self-practices.  
(ii) Necessity-Concerns framework (Horne et al., 1998, 1999) relates to 
patients who showed they have ongoing concerns about their medicines 
and this coupled with their perceived need for their diabetes medicines 
influenced their medication adherence levels.   
(iii) Although, the studies in this review did not specifically include HPs’ views, 
from patients’ accounts and authors’ interpretations there was a sense 
that patients and HPs portray different explanatory models of illness 
(Kleinman et al., 1978) which led to the different medical labelling in the 
final model. So, what HPs see as non-adherence, patients see as rational 
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ways of taking control of their life. Discrepancy in patient and HP illness 
models can potentially impact adherence.  
(iv) Starting a new medicine for T2D, and not just the onset of chronic illness, 
indicates a biographical disruption (Bury, 1982). Some of the studies 
described psychological insulin resistance whereas Jenkins et al. (2010) 
described psychological receptiveness. However, resistance and 
receptiveness are concepts very much related to the concepts of denial 
and acceptance to medicines based on patients’ perceived seriousness of 
their diabetes. Overtime, patients who initiated insulin and were taking 
insulin for longer than two years were more accepting of this treatment. 
The final model shows the elements that can have an impact on 
evaluation of self and the ways in which patients reconstruct their 
biography.  
 
2.5.2 Strengths and limitations of review 
A number of strengths and limitations of this review are worth noting. This review 
was limited to English language studies and included only published papers, so 
relevant work in other languages, grey literature or book chapters is not represented. 
The studies and concepts analysed only focused on participants from the UK, 
therefore the findings and the final conceptual model may only be accurate for this 
country and may not be transferable to patients from other countries.  
 
The medicine map, which focused on OGDs was mainly based on two studies and by 
the same group of authors with three papers derived from one study (see Table 2.6). 
Nevertheless, similar issues were found in other papers from the polypharmacy and 
the general diabetes medicines groups. Furthermore, only first and second order 
constructs were used which explicitly identified patients with experiences of diabetes 
medication, therefore constructs related to experiences of those patients on diet 
therapy only are not represented here.  
 
The study by Bissell et al. (2005)(10), although included in the review, did not describe 
specific patterns of adherence or views about medicines. This was in spite of the 
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study’s focus being on patients’ views and experiences of T2D treatment with 
adequate information provided on the types of diabetes medicines patients were 
prescribed. One possible explanation for this, is that the paper was more narrowly 
focused than the others as it was centred on exploring the relationship between 
peoples’ approaches to self-care and to their consultation encounters with HPs. 
Although issues of difficulties in managing self-care were reported, these were 
mainly on dietary regimens and how these were affected by other social (type of job- 
taxi driver) and psychological factors (depression). Nevertheless, the study fitted well 
within the areas of polypharmacy and multimorbidity and had a pivotal role in 
elucidating the different explanatory models of illness between patients and HPs.  
 
The intention of the synthesis was to retain rich context of the data looking 
systematically at the influences of various contextual factors such as diabetes 
control, body weight, duration of diabetes, type of diabetes treatment, initiation 
and/or duration of treatment, and use of primary and/or secondary care services but 
this was difficult due to the failure of many authors to provide adequate descriptions 
of context or of the impact of context on findings. Furthermore, the process of 
synthesising is inherently interpretive, so other reviewers may produce different 
conceptual frameworks. However, many qualitative and quantitative reviews 
(Polinski et al.,  2011; Gherman et al., 2011; Majeet-Ariss et al., 2013; Brudissini et 
al., 2015) and the meta-ethnographic review by Campbell et al. (2003) identified 
similar findings and models to this review suggesting that findings are triangulated 
and credible.  
 
Most studies were descriptive or used a thematic analysis, therefore there were few 
papers which provided rich and insightful data to fully appreciate patients’ 
experiences and practices with their diabetes medicines. There were only two 
longitudinal studies, but most studies were based on peoples’ memories of past 
experiences and their views after medication changes had occurred and, therefore, 
prior to interviews or focus groups. Nonetheless, 19 papers provided sufficient data 
to reach a “line of argument” that resonates with other published reviews as noted 
before. 
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A strength of this synthesis is reflected by the systematic identification of papers 
including the use of different search strategies (broad and specific) and use of 
multiple databases. The critical appraisal by two of the research team and the 
inclusion of high quality papers with CASP scores equal or above seven certainly 
enhanced the rigour of the review. In addition, detailed discussions among the 
research team about the interpretation of the findings was conducted at each stage 
and this ensured the transparency and trustworthiness of the findings.  
 
2.5.3 Research gaps 
The synthesis shows that to understand medication adherence, more than one 
theory is needed. The final model and medicines maps demonstrate how the theories 
could be interlinked and applied to future research. Based on the findings of this 
synthesis further research is needed both to understand peoples’ experiences of 
diabetes and its treatment in order to develop informed patient-centred approaches 
to improving treatment adherence among people with T2D. Research should focus 
on understanding how patients’ views of their medicines change over time based on 
longitudinal studies. To go deeper into the “subjective story” we need to see and hear 
how it develops as it is lived (Charmaz, 2000), therefore we need to understand 
peoples’ views prior to starting a new medicine and follow-them up to understand 
their experiences. Research should also examine the impact on adherence by 
investigating peoples’ beliefs about other factors such as glycaemic control change, 
age, gender, diabetes duration, type of treatment including other injectable 
medicines, treatment duration, and degree of medication burden, as well as types of 
services and amount of information received. Most importantly, none of the studies 
in this review reported participants’ BMI or body weight (see Table 2.7), therefore 
the relationship of medicine taking behaviour and body weight changes, as a result 
of their medication treatment, has not been explored in patients with T2D. Without 
knowing what causes changes in people’s perceptions and behaviours there will be 
uncertainty as to which interventions can help support patients to improve their 
health and quality of life. 
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CHAPTER THREE: GENERAL METHODOLOGY AND 
RECRUITMENT STRATEGY 
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3.1 Introduction 
This chapter provides information on the methodology of the current study and the 
recruitment strategy. Initially, an overview of what constitutes mixed methods 
research is given, followed by a justification for the methodology adopted in this 
study. Then, an outline of the aims is illustrated with questions and objective 
statements; with a justification of the study design, sample selection and sample size. 
Finally, a summary is provided of the recruitment strategy, and detailed information 
about ethical approval and considerations. 
 
3.2 Mixed Methods Research 
Tashakkori and Teddlie (2003, p.711) defined mixed methods research simply as the 
research design in which qualitative and quantitative approaches are used in types 
of questions, research methods, data collection and analysis procedures and 
inferences within a single study. It is important to note that there are different terms 
used in the literature to describe this approach, such as multimethod, mixed 
methodology, quantitative and qualitative methods. However in recent literature the 
term “mixed methods” is used, and will be used in this thesis. 
 
Mixed methods research is an emerging dominant paradigm in health care research 
(Doyle et al., 2009). It has been described as the third paradigm, often called 
Pragmatism (Johnson & Onwuegbuzie, 2004). Paradigm is defined by Morgan (2007) 
as the set of beliefs and practices that guide a field, and most commonly associated 
with four distinct elements that are used to compare different paradigms. These 
elements include; Epistemology (how we know what we know), Ontology (nature of 
reality), Axiology (values) and Methodology (the process of research) (Morgan, 2007; 
Guba & Lincoln, 1994; Creswell, 2009). Traditionally, researchers proposed that 
constructivism and/or interpretivism (qualitative research) and positivism 
(quantitative research) are paradigms that have different world views, each with a 
distinct epistemological stance and conceptual framework (Sale et al., 2002; Morgan 
2007). Many believe that these paradigms cannot be mixed or combined because of 
those distinct differences (Holloway & Wheeler, 2010). However, Allwood (2012) 
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argues that this distinction, which is often taken for granted, can be problematic and 
limited to the development of new research methods. According to Morgan (2007), 
the pragmatism approach offers a new framework that does not necessarily reject 
the two paradigms of positivism and constructivism. Instead, it shows how this new 
approach offers opportunities for advancing our knowledge and research practice. 
Despite the controversial debates about the issues surrounding mixed methods 
research, which started almost three decades ago, this has become a popular 
approach (Morgan, 2007) within the last decade (Wisdom et al, 2012), particularly in 
Health Care (Teddlie & Tashakkori, 2009). This is evident through published articles 
and funding (Weitzman & Levkoff, 2000; Cooper et al., 2003b; Walters et al., 2008; 
O’Cathain, et al., 2007; Clarke, 2009; Carr, 2009; Latter et al., 2010).  
 
It is believed that the problems that are addressed by social and health scientists are 
complex. Therefore, the use of either quantitative or qualitative research individually 
is not adequate enough to address this complexity (Creswell, 2009). The combined 
use of methods provides a practical and outcome-oriented method of inquiry 
producing superior research compared to monomethod studies and an expanded 
understanding of research problems (Johnson & Onwuegbuzie, 2004; Creswell, 
2009). This has huge potential in health care research where there are many different 
and complex factors that can influence health.  
 
Many proposed motivations suit the combination of qualitative and quantitative 
research (Morgan, 1998; Johnson & Onwuegbuzie 2004; Bryman, 2006; Small, 2011). 
Often the descriptions of these motivations resemble one another, even though 
different terms have been reported in the literature. However, these motivations can 
be merged into three categories; Complementarity, Confirmation, and 
Expansion/Development. The function of Complementarity lies with the idea of 
maximising the strengths and minimising the weaknesses of both qualitative and 
quantitative research methods (Johnson & Onwuegbuzie, 2004). This, in turn, 
provides stronger inferences (Teddlie & Tasshakkori, 2009) producing a complete and 
comprehensive picture which contributes to the understanding of the study object 
(Tritter, 2007). Mixed methods research is used for Confirmation purposes in order 
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to verify and/or explain findings of one research method with another. For example, 
a small qualitative study is used to explain the findings [the statistical results of a 
survey] of a larger quantitative study by exploring participants’ views in more depth 
(Creswell, 2009). It is also used to identify findings that either converge, diverge, or 
both (Creswell, 2009). Mixed methods research is used for Expansion/Development 
purposes resulting in our knowledge and understanding being expanded following 
one research method from another (Greene, 2008; Creswell, 2009). For example, 
themes/findings from a small qualitative research study are used to develop new 
hypothesis or an instrument (i.e. intervention or scale/ questionnaire) for follow-up 
quantitative research (Creswell, 2009).  
 
In mixed methods research, there have been several typologies (research designs) 
described to identify mixed method strategies; however, a substantial amount of 
overlap exists. Regardless of which typology researchers adopt, it is understood that 
there are some significant characteristics which can influence the design of 
procedures for a mixed methods study (Creswell & Plano-Clark, 2007; Leech & 
Onwegbuzie, 2007; Creswell, 2009; Teddlie & Tashakkori, 2009; Small, 2011). These 
include; Time Ordering (whether the qualitative and quantitative data collection will 
be gathered sequentially or concurrently), Nesting (the extent to which multiple data 
types are collected from the same individuals, organisations or entities), Weighting 
(whether the weight of qualitative and quantitative research is equal or priority is 
given to one method over the other), Mixing (at which stage integration of the 
multiple data occurs- options are during data collection, data analysis, data 
interpretation or all three), and Theorising (whether theory will be made explicit or 
implicit in a study).  
 
Doyle et al. (2009) state that choosing an appropriate design for a mixed methods 
study depends on a) which approach is best suited to answering the particular 
research question, b) the overall motivation for pursuing a mixed methods study and 
c) which typology is most appropriate to meet the aims and objectives of the 
research. However, Guest (2012) is concerned that researchers could be forced to 
use such typologies even when they do not fit adequately the study’s design. Johnson 
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and Onwuegbuzie (2004) suggest that researchers can develop mixed method 
designs with multiple phases and features and they should not limit themselves to 
the designs that are suggested by leading authors. They recommend that researchers 
should mindfully create designs that effectively answer their research questions. In 
addition, Guest (2012) proposes to shift the focus to the point of inference between 
two data sets, which refers to any point in a study where two or more data sets are 
mixed or connected in some way. This provides an alternative way to describe the 
inherent complexity and fluidity of many mixed methods studies.  
 
3.2.1. Justification for methodology   
A mixed methodology is very common in health services research as it allows for 
exploration of issues from a range of angles (Borkan, 2004). As mentioned earlier, 
the use of either quantitative or qualitative research is inadequate to address the 
complex problems that social and health science encounter every day (Creswell, 
2009). This is particularly true in complex conditions such as diabetes. Quantitative 
research in diabetes adherence has shown that many people with T2D rarely fully 
adhere to their medicines; both oral and injectable (Cramer, 2004, Krass et al., 2015). 
Although many factors have been identified which influence adherence to diabetes 
medicines (Borgsteede, 2011; Bailey & Kodack, 2011), some authors argued that this 
lack of adherence is due to fear of weight gain (Peyrot et al., 2009). However, this 
relationship has not been fully examined (see Table 2.7 under column weight/BMI). 
If this relationship is true, quantitative research alone would not be able to explain 
and verify the reasons why patients are not adhering to their diabetes medicines 
(including the types of medicines with different body weight effects), and how fear 
of weight gain and other factors affect adherence. Furthermore, we know little about 
individuals’ experiences with diabetes medicines; past and present. In particular, we 
do not know enough about the transition prior to taking a new medicine and after 
experiencing its effects, and how patients’ views of their medicines are shaped during 
this transition. Qualitative research, on the other hand, focuses on the complexities 
of how human beings make sense of their experiences, and therefore, how 
individuals with T2D perceive their medicines in ways that make sense to them, 
based on what is important to them. Therefore, a more complete understanding of 
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this phenomenon can be obtained by integrating qualitative and quantitative 
research in a single study.  
 
Research that builds on the health needs expressed by a population group being 
studied, such as those with T2D, is relevant when the objective is to evaluate or 
develop health services (Tritter, 2007). Health outcomes can no longer be 
understood by medical and/or pharmaceutical interventions alone; patient 
participation on health care decisions means that health can be managed better or 
more successfully (Tritter, 2007).  Measuring patients’ health care outcomes as well 
as understanding their beliefs and expectations about their health and treatments, 
should enable the development of more effective health care services (Bowling, 
2009; NICE, 2012). Clinical knowledge must be integrated with social science 
expertise and other disciplines in order to explore and understand contemporary 
health care (Tritter, 2007). Both qualitative and quantitative research, in mixed 
methods research, contribute to clinical practice (Holloway & Wheeler, 2010) and 
provide knowledge that could be used to determine health care policies (Doyle et al., 
2009). Thus, a mixed methods approach will be used in this study.  
 
3.3 Research Questions  
This study addresses the following questions: 
1. How do the expectations, beliefs and attitudes of people with T2D towards 
different diabetes treatments that either promote weight loss, are weight 
neutral or result in weight gain, change over time? 
2. What is the impact of the change in beliefs and attitudes on patients’ 
adherence to their medicine(s)? 
3. What type(s) of intervention(s) promoting treatment options, focusing on 
effects on body weight, are acceptable to patients in order to increase their 
understanding of their diabetes treatment and improve adherence?  
 
The subsequent objectives were formulated to consider the above research 
questions:  
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 Measure the change in patients’ expectations, beliefs and attitudes towards 
glucose-lowering (and/or anti-obesity) drugs (including those with different 
body weight effects) prior to, during and after taking medicine(s) (where 
appropriate), within primary and secondary care using self-completed 
validated questionnaires. (Question 1) 
 Explore in depth, using semi-structured interviews, the expectations, beliefs 
and attitudes towards these drugs (including those with different body weight 
effects) and associated lifestyle advice in a subsample of patients, and verify 
and compare the findings with the data from the above questionnaires. 
(Question 1) 
 Investigate the relationship of these changes with patients’ diabetes 
management (adherence) using self-completed validated questionnaires.  
(Question 2) 
 Utilise integrated findings from the above questionnaires and interviews and 
the systematic review in chapter 2 to explore ideas for intervention(s) which 
promote understanding of diabetes treatment and adherence in patients 
with T2D. (Question 3) 
 
3.4 Study design 
This study incorporated a mixed methods approach to research adopting a 
complementary and confirmatory, multiple sequenced (sequential and concurrent), 
nested design using questionnaires, and qualitative interviews. The study can also be 
described as longitudinal in nature; that is the same type of information is collected 
on the same subjects at multiple points in time, due to the sequence of the data 
collection (Figure 3.1).  
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Figure 3.1: Visual Representation of Mixed Methods Study Design 
 
The study used two self-completed validated questionnaires followed by qualitative 
face-to-face interviews in a subset of patients (See section 3.4.3). These investigated 
the experiences of T2D service users at different stages in their diabetes care after a 
medication change in their diabetes treatment; from diagnosis to long-standing 
diabetes and from monotherapy to complex medication management in primary and 
secondary care. A “change” in treatment was defined as the addition of, or change 
to, a new glucose-lowering or anti-obesity drug to the patient’s current diabetes 
therapy. It was important to capture each patient’s beliefs and attitudes prior to 
starting a new medication, as these may change as soon as they take it. For that 
reason, questionnaire 1 and interview 1 data, were conducted prior to a change in 
patients’ diabetes treatment and questionnaire 2 and interview 2 data were 
collected three months after starting the new treatment. The three-month period 
was considered adequate to detect any changes in beliefs and attitudes as seen in 
other studies (Clifford et al., 2006; Aikens & Klinkman, 2012). The study integrated 
the findings from questionnaires and interviews with the findings from the 
systematic review. The steps undertaken were appropriate as a preliminary work for 
the development of an intervention and consistent with MRC Framework for 
evaluating complex interventions (MRC, 2008). 
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3.4.1 Justification of study design 
The purpose of using this study design was to engage in the mixing of qualitative and 
quantitative approaches to view a specific phenomenon (i.e. medicine taking 
behaviour) using different perspectives to build up a clearer picture of the whole, 
therefore justifying the use of different methods (Morgan, 1998; Teddlie & 
Tashakkori, 2009). In addition, this study aimed to expand our knowledge using 
integrated data from the systematic review and the analysis and interpretation of 
data acquired from the same participants. The latter can be described as exploratory 
in nature (Creswell 2009). Also, the review in Chapter 2 demonstrated that there are 
a number of theories that could be applied in future research in order to understand 
medication adherence (section 2.5.1). This PhD study explored how these theories 
are interlinked to explain medication taking practices for people with T2D.  
 
Although, the majority of the data collection (questionnaires and interviews) were 
concurrent, for a small subsample of participants a sequential approach was taken 
which allowed for the development of the interview guide and sampling strategy 
(Small, 2011; Schatz, 2012; Mayoh et al., 2012). This approach had the advantage of 
focusing on the next data collection in order to identify discrepancies, clarify issues 
sought in the first data set which were not adequately explained, and add value to 
the overall study (Mayoh et al., 2012). The concurrent design was appropriate in 
order to understand every stage of the transition for the participants who had a 
change in their diabetes treatment (Small, 2011); that is the transition from the 
unfamiliar new medicine to the experience of taking it and managing it.  
 
Finally, this study used a nested approach, collecting quantitative and qualitative 
data from the same subsample of participants adding context to the responses from 
the questionnaires to the qualitative interviews (Small, 2011). This nested design is 
commonly used in studies where qualitative approaches (interviews or focus groups) 
are followed by surveys/questionnaires (Mayoh, 2012; Schatz, 2012). The qualitative 
and quantitative approaches in this study had equal weighting. In addition, it has 
been suggested that linking qualitative findings over time to longitudinal changes in 
quantitative data is a valuable contribution to our understanding of social 
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phenomena (Clarke, 2009) which has particular relevance to medicine taking in real 
life.  
 
3.4.2 Study population (inclusion and exclusion criteria) 
Type 2 diabetes prevalence in Liverpool for the period of 2010-2011 was 3.87%, 
however in the surrounding areas (St Helens & Halton, Knowsley, Wirral and Sefton) 
prevalence ranged from 4.25-4.99%, exceeding the England average of 4.07% (HSCIC, 
National Diabetes Audit, 2013). It was estimated that more than 2000 patients are 
diagnosed with diabetes every year locally (Liverpool Primary Care Trust [PCT], 2009; 
Rooney et al., 2010; Nayak, 2010). Therefore, GP practices and community 
pharmacies [CPs] were selected from the above locality areas to represent the socio-
economic diversity of the populations they served as primary care providers. Also, 
this locality area was chosen as it mostly represented the catchment area for the only 
secondary care diabetes centre [SCDC], where GP practices were referring the more 
complex patients. All patients with T2D, eligible for glucose-lowering and/or anti-
obesity drug prescriptions that were registered with these primary or secondary care 
services and required a medication change, as described above, were potentially 
eligible for the study. Table 3.1 provides a list of potential medication changes and 
their delivery system.  
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Table 3.1: List of diabetes and anti-obesity medications for eligibility criteria (not an 
exhaustive list) 
Drug Name- Generic Drug Name- Brand Delivery 
System 
Metformin/ Metformin MR Glucophage/ Glucophage MR Oral Tablet 
Gliclazide/ Gliclazide MR Diamicron;Zircon / Diamicron  MR Oral Tablet 
Glimepiride Amaryl Oral Tablet 
Repaglinide   Prandin Oral Tablet 
Acarbose Glucobay Oral Tablet 
Pioglitazone Actos Oral Tablet 
Pioglitazone & Metformin   Competact Oral Tablet 
Sitagliptin Januvia Oral Tablet 
Sitagliptin & Metformin       Janumet  Oral Tablet 
Saxagliptin  Onglyza Oral Tablet 
Vildagliptin Galvus Oral Tablet 
Linagliptin Trajenta Oral Tablet 
Dapagliflozin Forxiga Oral Tablet 
Exenatide   Byetta Injection 
Exenatide Extended Release Bydureon Injection 
Liraglutide   Victoza Injection 
All types of insulin  (Human/ 
Analogue or Animal) 
Long Acting insulin analogues (insulin 
detemir, insulin glargine) 
Rapid Acting insulin analogues 
(Novorapid/ Humalog [insulin lispro, 
insulin aspart, insulin glulisine]) 
Short Acting (Actrapid, Humulin S, 
Insuman Rapid) 
Intermediate Acting (Humulin I, 
Insulatard) 
Mixed (Hypurin Porcine 30/70,  
Novomix30) 
Injection 
Orlistat  Xenical Oral Tablet 
 
It was anticipated that 80% of the participants would be recruited from primary care 
and 20% from secondary care, to represent the current management of T2D in the 
NHS. The study excluded anyone under 18 years of age and adults with difficulty 
understanding English. In addition, patients were excluded if they suffered from 
terminal cancer or severe heart failure or if they were unable to provide informed 
consent due to mental incapacity or communication problems, and/or had difficult 
family circumstances (e.g. recent bereavement). Patients were excluded from the 
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interview stage if GP/consultant considered it to be clinically unsafe for patients to 
delay starting their new medication for up to one week prior to first interview, as 
outlined in section 3.5.2.  
 
3.4.3 Justification of sample size 
The primary outcome of this research was to measure the change in expectations, 
beliefs and attitudes of patients towards their glucose-lowering or anti-obesity drugs 
over time. As the focus was also on the body weight effects of the diabetes 
medicines, the secondary outcomes were to measure the change in expectations, 
beliefs and attitudes between users of the different classes of drugs that promote 
weight loss or result in weight gain, and the association of expectations with 
adherence with these medicines.  
 
The sample size was based on the validated scales used in Naegeli and Hayes paper 
(2010) related to the expectations and experiences of insulin treatment (named 
EAITQ and EWITQ respectively). From this paper (2010), a clinically significant change 
score of ≥0.58 indicates patients’ pre-treatment expectations exceeded their 
experience (treatment perceptions) of taking new medication compared to those 
whose expectations were met or not met by experience. The same paper (Naegeli & 
Hayes, 2010) also reported a standard deviation of 9.4 of the change score and a 
reliability coefficient of 0.69. Therefore, using this information, a sample size of 300 
people was required using a 5% significance level at 80% power. Since response rates 
in survey questionnaires among patients vary considerably and generally generate a 
response of about 60% with a standard deviation of 21% (Asch et al., 1997), it was 
predicted that the first questionnaire would have an acceptable minimum response 
rate of 40%, however, the second questionnaire will yield an acceptable good 
response rate of 75% (Bowling, 2009). Therefore the study required a total of 1000 
patients to be initially approached.  
 
                                                     
8 The change score was calculate by subtracting the EAITQ score from the EWITQ score (see section 
4.2.1.1). 
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With the assistance of the GP practices and the local CPs involved in the Primary Care 
Research Network [PCRN]9 (10 large GP practices with over 4000 T2D patients 
registered), and with the SCDC (over 3500 patients seen each year), it was anticipated 
that the sample size would be feasible over a 22-24 month period. Furthermore, a 
sub-sample of approximately 30 patients (10%) who completed the questionnaires 
would be required to participate in qualitative interviews (a total of two interviews 
per participant). This qualitative sample size was estimated to provide the most 
relevant and comprehensive information until saturation was reached (Lewis, 2003).  
3.5 Recruitment strategy 
The recruitment strategy details procedures of how potential participants were 
approached and who was responsible for informed consent processes as well as the 
timescales for each aspect of the study. A diagrammatic flowchart of the recruitment 
strategy can be seen in Figure 3.2.  
                                                     
9 The PCRN based in the North West was part of the National Institute for Health Research and the 
UK Clinical Research Network during the period of the PhD study. Since, it has merged into the 
Clinical Research Network North West Coast. One of its role was to collate a register with GP 
practices, pharmacies and the public interested in being involved in research and provide ongoing 
support.  
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Figure 3.2: Research Study Flowchart  
 
3.5.1 Recruitment for Questionnaire (Quantitative) Data  
The self-completed validated questionnaires were administered at two different 
stages in patients’ management identified before and 3 months after a “change” in 
treatment (see definition in section 3.4). This was following either a clinical review in 
identified clinics across primary and secondary care, or when potential participants 
collected new prescriptions for their diabetes management from identified CPs. A 
research flyer [Appendix 3.1] was distributed to encourage uptake amongst potential 
participants should they be eligible according to the inclusion criteria. The flyer was 
distributed at the following locations: 
 
 GP practices, CPs and the SCDC already signed up to the research study 
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 Phlebotomy centres around the recruitment sites - this helped to raise 
awareness amongst potential participants when they went for their blood 
tests which were usually done prior to their annual diabetes review or 3-
monthly follow-up appointments at their practice.   
 With annual diabetes review appointment letters via GP practices and the 
SCDC, as well as prescription packs through the CPs, to raise patient 
awareness. It was hoped that this also served as a reminder to health care 
staff. 
 
Potential participants were identified by the Health Care Team [HCT- 
GPs/Consultants, Nurses, CPs], in the first instance, based on the eligibility criteria at 
identified clinics in GP practices and SCDC. The research team [RT-Lead researcher or 
Research Nurses] then met the potential participants, explained the study and 
provided them with a covering letter [Appendix 3.2], the consent form [Appendix 3.3] 
and the participant information sheet [PIS] [Appendix 3.4]. The first questionnaire 
booklet [Appendix 3.5] and a prepaid envelope were administered via research team 
following consent to the study. Participants were also approached by pharmacists 
when they attended identified CPs to pick up their new prescription or by their HCT 
in GP practices that did not provide dedicated clinics for their T2D patients. In this 
case, pharmacists and/or practice staff approached patients, explained the study and 
provided them with the information, as described above.  
 
The participants had a choice to either complete the consent form and questionnaire 
whilst in clinic or pharmacy in a private room, should they wish to take part in the 
study, or take the forms home and return them via a prepaid reply envelope. If 
participants did not respond at this stage, there was no further contact from the RT. 
If, however, participants did consent but they took the questionnaire with them, the 
RT contacted participants the following day by telephone to remind them to post it 
back to the research team. The participants were given 24 hours to consider taking 
part in the study, as recommended by national ethics guidance (IRAS QSG, 2009). This 
timeframe did not interfere with patient care in any way, and was used to minimise 
any delay in starting their new treatment. Where potential participants contacted 
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the RT directly as a result of the research flyer, the team explored their eligibility for 
the study based on the inclusion and exclusion criteria (section 3.4.2) and took verbal 
consent. The team then contacted participants’ GPs to ascertain eligibility. 
 
The second questionnaire [Appendix 3.5] was posted to participants after 3 months 
with two follow-up reminders at this stage. Three weeks after the first administration 
of the second questionnaire, the RT followed up with a phone call as a reminder to 
those who had not responded. After five weeks, a further copy was mailed to those 
who had still not responded. Reminders for questionnaire returns are common, and 
it is accepted that two reminders at two to three week intervals to non-responders 
can return up to 25%-33% of responses (Bowling, 2009).  
 
3.5.2 Recruitment for Interview (Qualitative) Data 
Participants who indicated in the consent form [Appendix 3.3] they wished to take 
part in the semi-structured, individual interviews, were invited to take part soon after 
completion of questionnaires before and 3 months after the medication change. 
Respondents’ GPs/Consultants were informed to ensure that it was safe for patients 
to delay starting their new medication for up to one week prior to the first interview, 
in order to capture their expectations and attitudes before they take it. One week 
was allowed in order to arrange a suitable time and place to conduct the interview 
following completion of the first questionnaire and to minimise delays in starting the 
new treatment. Interviews were conducted primarily at the secondary care site 
within the first week following consent. However, under special circumstances, 
participants were offered an interview at a place of the patient’s choice (in their own 
home or GP practice or other Primary Health Care venue). Prior to the first interview, 
participants were asked to sign a further consent form (Appendix 3.6). The interviews 
were digitally recorded and transcribed verbatim. Participants were also informed 
that interviews would last approximately 40 minutes to 1 hour.  
3.6. Ethical considerations and Ethical Approval 
The study was carried out in accordance with current NHS Research Governance 
requirements and approval was granted by the South-Central-Berkshire Research 
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Ethics Committee (12/SC/0076) under the proportionate review service on 9th 
February 2012, and the relevant NHS Trusts. A number of minor and substantial 
amendments were granted during the study and rationale for all changes can be 
found in Table 3.2.  
 
Table 3.2: Rationale for Minor and Substantial Ethics Amendments 
Amendment 
Number 
Approval 
Date 
Rationale 
Substantial – 
number 1 
23/4/2012 -Many GP practices throughout Merseyside do not provide 
regular T2D or chronic disease management clinics – care is 
mostly provided ad hoc in regular nurse/GP clinics. 
Therefore, we proposed GPs/PN staff to consent potential 
participants based on eligibility criteria and follow consent 
procedures as outlined in original application. All practice 
staff and pharmacists who consented patients received 
study specific training prior to recruitment.  
-Submitted newer version of questionnaires following 
formatting and addition of all copyright information.  
Minor – 
number 2 
2/7/2012 -Two letters drafted to inform the GPs of their patients’ 
participation in the study and request to obtain clinical data 
and other relevant information as agreed by the patient on 
the consent form 1 (baseline and 3-month follow-up data).  
Minor – 
number 3 
30/8/2012 -Addition of new NHS Trust site to enhance recruitment 
Substantial – 
number 4 
14/1/2013 -Submission of Interview Guides (1 and 2) 
-Study Research Flyer development to enhance participation 
and recruitment into study 
-Project Timeline Plan changes due to delays in: R&D 
approvals, identification of suitable sites followed by 
training for consent procedures, and slow return of first 
questionnaire for preliminary analysis, which, consequently, 
delayed compilation of the interview guides.  
 
The study was conducted with careful regard to the rights, interests and feelings of 
participants in accordance with ethical standards of voluntary participation, 
informed consent, confidentiality and security of collected data (DOH, 2001b).  All 
participants were assigned an anonymity identification number and confidential data 
were stored in a password protected Excel spreadsheet on the University of Liverpool 
networked drive. Also, to ensure the confidentiality of interviewees, and to 
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anonymise their responses to questions in producing interview transcripts, all 
interviewees were given a pseudonym.    
 
It was also possible that some participants would find the topic of diabetes and 
weight management sensitive during interviews. The researcher has the 
responsibility of providing personal safety and well-being to participants (Corbin & 
Morse, 2003; DOH, 2005a). Therefore, the lead researcher considered steps to be 
taken should an interviewee became upset, including stopping the interview and 
offering support, as appropriate. If the participant experienced distress, requiring 
further action, they were encouraged to seek avenues of support from their own GP 
and related health services. Although, none of the interviews were stopped due to 
upset, there were five interviewees who were given guidance at the end of the 
interview. This was to seek advice from their general practice or diabetes teams in 
terms of the new drugs that they were prescribed, or advice about managing their 
T2D or body weight. Also, to minimise the risk of harm to the researcher, the lone 
worker policy of the University of Liverpool and NHS organization was followed. The 
lone worker policy stipulates practical actions, processes and physical measures that 
can be put in place to help prevent incidents from occurring, such as violence, abuse 
or injuries (NHS Protect, 2017). 
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CHAPTER FOUR: DATA COLLECTION TOOLS AND 
DATA ANALYSIS METHODS 
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4.1 Introduction 
This chapter lists all quantitative and qualitative instruments employed in this 
research study and provides details of their validity and reliability, as well as relevant 
pilot procedures. First, it begins with the quantitative data collection tools and the 
statistical analysis plan, continues with the qualitative interviews and the qualitative 
analysis plan, and concludes with the integrated analysis of the mixed methods data.  
4.2 Quantitative Data Collection Tools 
This study used two data collection tools for the questionnaire part of the study, 
including collection of demographic and clinical data. The sections below describe 
the development and formatting of these tools, as well as the rationale for their use 
in this research.  
 
4.2.1. Questionnaires 
An initial literature review through Medline, Pubmed, Web of Knowledge/Science 
and PsychINFO identified a range of scales used in health care research related to 
medication beliefs, satisfaction and adherence. Scales identified needed to be valid 
and reliable for the T2D population that this research was intended to study (Bowling, 
2009). Broadly, the measure of validity assesses whether an instrument measures 
what it is supposed to measure, whereas reliability assesses the extent to which scale 
items measure the same construct consistently on different occasions, or by different 
observers, or similar tests. Instruments also needed to be responsive to changes and 
free from random error (Bowling, 2009; Streiner & Norman, 2008). This was 
important in this study in order to assess the change of people’s expectations before 
and after a change in medication treatment.  
 
After close examination of the validity and reliability criteria (Cohen, 1988; Husted et 
al., 2000; Salkind, 2008; Streiner & Norman, 2008), nine validated scales were used 
in both questionnaires (Table 4.1) and sections 4.2.2.1 to 4.2.1.7 describe them in 
more detail. These scales were appropriate for this study, as it is known that patients’ 
judgements of satisfaction with their medication(s) can be mediated by their 
expectations and beliefs of their treatment (Shikiar & Rentz, 2004). These can form 
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as a result of a medication’s impact on symptom relief, side effects, quality of life and 
functional status, but also as a result of other factors such as how easy or convenient 
patients find it to follow the regime, their self-confidence in managing taking their 
medication, how satisfied they are with the information they have received about 
their medication, their previous experiences with similar medications or medications 
in general and their disease and treatment history (Shikiar & Rentz, 2004).  
 
Although some modifications were made to the scales used, minor ones related to 
wording which do not alter the meaning of the items/scale, for example replacing 
word “insulin” with “medicines” or specifying types of medicines as “diabetes/ 
weight loss” medicines, do not require revalidation (Streiner & Norman, 2008). 
However, modifications to scales such as increasing the scale items or the response 
options (i.e. number of Likert Scale points) may affect reliability/validity (Streiner & 
Norman, 2008). Hence, all reliability coefficients were recalculated and compared 
with the original values of Cronbach’s alphas to ensure the consistency of the 
measurement scales in this study’s population sample.  
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Table 4.1: Validated scales used in the questionnaires  
Scale Name Description of measurement Number of 
Items 
Modifications Reference 
Experience with Insulin Treatment 
(EITQ)/ Perceptions with Insulin 
Treatment (PITQ) 
The expectations and perceptions 
of insulin treatment before and 
after treatment 
10 Wording- changed “insulin” to 
“medicine”  
Delivery system questions to reflect 
both oral and injectable treatments 
Naegeli & Hayes, 
2010; Hayes & 
Naegeli, 2010 
Beliefs about Medicines 
Questionnaire- Specific (BMQ) 
The beliefs about Necessity and 
Concerns about specific disease 
medicines, i.e. diabetes 
11 made to 12 Wording- “diabetes and/or weight loss 
medicines” 
One item added related to weight gain 
Horne et al., 1999 
Horne et al., 2004 
Beliefs about Medicines 
Questionnaire- General (BMQ) 
The beliefs about Benefits, Harm 
and Overuse of medicines in 
general 
11 none Horne et al., 1999 
Horne et al., 2004 
The Morisky Medication Adherence 
Scale (MMAS-8) 
Intentional and unintentional non-
adherence to medications 
8 made to 10 Wording- “diabetes and/or weight loss 
medicines” 
Two items added related to skipping 
medicines and not taking medicines on 
holidays 
Morisky et al., 
2008 
Satisfaction with Medication 
Information (SIMS) 
Patient satisfaction with 
information received about 
prescribed medicines; related to 
Potential Problems with Medicine 
and its Action and Usage.  
17 made to 18 One item added related to medicine’s 
effect on body weight 
Horne et al., 2001 
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Satisfaction About Diabetes Medicines 
(DiabMedSat) 
Satisfaction with diabetes 
medicines related to Efficacy, 
Burden and Symptoms 
23 Wording- “diabetes and/or weight loss 
medicines” 
 
Brod et al., 2009a 
Treatment Related Impact Measure of 
Weight (TRIM- Weight) 
Impact of weight loss medication in 
areas of Daily Life, Weight 
Management and Psychological 
Health  
22 made to 
13* 
Wording- “diabetes and/or weight loss 
medicines” 
 
Brod et al., 2010 
Self-Efficacy for Appropriate 
Medication Use (SEAMS) 
Patient’s self-efficacy with 
medication adherence, particularly 
Under Difficult Circumstances and 
Under Conditions of Uncertainty 
13 From 3-point Likert scale to 5-point 
Likert scale 
Wording to two items from US English 
to UK English 
Risser, 2007 
Obesity and Weight Loss Quality of Life 
(OWLQOL) 
Evaluation of patients weight, 
weight loss and treatment 
17 None Patrick et al., 
2004 
(*Only used three out of the five subscales, see details in 4.2.1.5) 
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4.2.1.1. Expectations About and Experiences with Insulin Treatment 
There were two scales identified that measured a change in people’s expectations 
and experiences before and after a new treatment. These were the Expectations 
About and Experiences With Insulin Therapy Questionnaires (EAITQ and EWITQ)10 
developed by Naegeli and Hayes (2010). Each scale includes 5 items that concerned 
insulin therapy in general, 5 items that concerned insulin delivery systems and 5 
items on self-efficacy. This study only used the first 10 items from each scale which 
corresponded to the insulin therapy and delivery systems. The scales were adapted 
to fit the current study’s aims by omitting the word “insulin” and replacing it with 
“medicine”. In addition, question items were adapted to reflect all glucose-lowering 
and anti-obesity drugs investigated in this study, and delivery systems were defined 
to include all types of medicines i.e. oral tablets and injections. An advantage of the 
two scales was that they were originally developed and tested with T2D populations 
and included an item related to weight gain. Internal consistency, as described in 
Naegeli and Hayes’s paper (2010), was also acceptable (Streiner & Norman, 2008) 
with Cronbach’s alpha 0.80 for the EITQ and 0.72 for the PITQ. These scales are 
relatively short including 10 items in each on a 7-point Likert scale ranging from 1 
(Strongly Disagree) to 7 (Strongly Agree). Out of the ten items in each scale, six were 
positively worded items and four were negatively worded items. The negatively 
worded items on the two questionnaires were reverse scored so that higher scores 
on both positively and negatively worded items corresponded to more positive 
expectations and experiences. The responses of the ten items were summed and 
divided by the number of items, giving a range of scores in each scale from 1 to 7, 
with a higher total score corresponding to more positive expectations or experiences 
(perceptions) respectively.  
 
                                                     
10 The name of the two scales changed following a subsequent publication by Hayes and Naegeli 
(2010), where the EAITQ was renamed as “Expectation about Insulin Therapy Questionnaire” (EITQ) 
and the EWITQ was renamed as “Perceptions of Insulin Therapy Questionnaire” (PITQ). This thesis will 
be using the new acronyms throughout. 
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4.2.1.2. Beliefs and Attitudes about Medicines 
Four scales were identified through the literature review, of which three were 
specifically for medicines (Horne et al., 1999; Farmer et al., 2006; Monahan et al., 
2009) and the fourth scale, with its number of versions, was in general about illness 
perceptions with domains around treatment perceptions and efficacy (Weinman et 
al., 1996; Moss-Morris et al., 2002; Broadbent et al., 2006). In this study the scales 
based on peoples’ specific and general beliefs about medicines questionnaire [BMQ] 
were used. These were developed by Horne, et al. (1999) originally for chronic 
conditions including diabetes.  
 
The BMQ-specific assesses patients’ beliefs about medications prescribed for a 
particular illness, in this case diabetes. It comprises of two scales assessing personal 
beliefs about the necessity of prescribed medication for controlling their illness, and 
concerns about the potential adverse consequences of taking it. The specific scale 
items were adapted for glucose lowering and anti-obesity drugs and an additional 
item was added that was related to worries about weight gain (item 12). The total 
items for the specific scale were 12, and respondents indicated their level of 
agreement with each statement about medicines on a 5-point Likert scale ranging 
from 1 (Strongly Disagree) to 5 (Strongly Agree). The sum of scores for each scale was 
divided by the number of items for each scale ranging from 1 to 5 for necessity (5 
items) and 1-5 for concerns (7 items). A high score on the concern scale indicates 
high concerns about potential adverse effects of prescribed medicines, and a high 
score on the necessity scale indicates strong beliefs in necessity and efficacy of 
prescribed medicines (Horne, 2000). Cronbach’s alpha measuring internal 
consistency in the original paper from Horne at al. (1999) was found to be 0.74 for 
the Necessity items and 0.80 for the Concerns items for patients who had diabetes. 
Another paper (Aitkens & Piette, 2009) also found similar internal consistency for 
Necessity (=0.78) and Concern (=0.68) items for T2D patients on glucose lowering 
medicines.  
 
The BMQ- general assesses general beliefs about medicines and it comprises three 
scales assessing personal beliefs about the extent to which doctors place too much 
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trust in medicines (Overuse), beliefs about the intrinsic properties of medicines and 
the degree to which they are perceived as essentially harmful and, finally, beliefs 
about beneficial effects of medicines (Benefit) (Horne et al., 1999, 2004). The total 
items for the general scale were 11; three items for the Overuse scale, four items for 
the Harm scale, and four items for the benefit scale (Horne et al., 2004). Respondents 
indicated their level of agreement with each statement about medicines on a 5-point 
Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree). The sum of 
scores for each scale was divided by the number of items for each scale ranging from 
1 to 5 for all three subscales. A high score on the Overuse scale indicates strong 
beliefs that medicines are overused by doctors, a high score on the Harm scale 
indicates strong beliefs that medicines are “harmful” and “addictive”, and a high 
score on the Benefit scale indicates strong beliefs about the benefits of taking 
medicines (Horne, 2000). Previous validation studies (Horne et al., 1999, 2004; 
Ramström et al., 2006) showed an acceptable internal consistency for all three scales 
ranging from 0.65-0.72 for the 3-item Overuse, 0.62-0.70 for the 4-item Harm, and 
0.62-0.66 for the 4-item Benefit scales.   
 
4.2.1.3. Medication Adherence 
There were four scales identified that estimated medication adherence (Morisky et 
al., 1986, Horne et al., 1999; Morisky et al., 2008; Aikens & Piette, 2009; Stetson et 
al., 2011). The Reported Adherence to Medication [RAM] scale reported in Horne et 
al.’s paper (1999) was a non-validated measure devised for their study, which was 
reported again in another paper by Farmer et al. (2006); however the Cronbach’s 
alpha ranged between 0.6-0.83. No other validity or reliability tests were reported in 
Horne et al.’s paper (1999). Stetson et al. (2011) developed a scale called the Personal 
Diabetes Questionnaire (PDQ) for both T1D and T2D individuals. This scale included 
a sub-scale for medication adherence, however no Cronbach’s alpha was reported 
for this subscale.  
 
A self-reported medicine adherence scale developed by Morisky et al. (2008) was 
used in this study. The Morisky Medication Adherence Scale [MMAS] originally had 
four items (MMAS-4) scored with Yes or No answers (Morisky et al., 1986). However, 
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recently, it was extended to eight items (MMAS-8) in order to measure intentional 
(e.g. due to side effects) and unintentional (e.g. forgetfulness) non-adherence to 
medications (Morisky et al., 2008).  
 
The new MMAS-8 was significantly correlated with the original scale (MMAS-4) in a 
study on hypertensive patients (r= 0.64; p<0.5) (Morisky et al., 2008), and in a study 
with T2D Malaysian patients (r=0.792; p<0.01) (Al-Qazaz et al., 2010). In addition, the 
MMAS-8 has been shown to have greater reliability (=0.83) than the original MMAS-
4 (=0.61) (Morisky et al., 1986; Morisky et al., 2008). The new 8-item scale has seven 
items with Yes or No response categories and the last item is based on a 5-point Likert 
scale. The last item asks how often participants have difficulty remembering to take 
all their medicines, ranging from Never/Rarely to All the Time. Scores on the MMAS-
8 range from 0 to 8 with scores less than 6 reflecting low adherence, 6 to 7 reflecting 
medium adherence and 8 reflecting high adherence (Morisky et al., 2008). 
Furthermore, studies with T2D patients showed that those with a higher score on the 
MMAS had a lower associated HbA1c measurement (Krapek et al., 2004; Gonzalez et 
al., 2013).  
 
In this study, the MMAS-8 was adapted for glucose-lowering and anti-obesity drugs 
and two additional items were added that were related to whether patients skipped 
their diabetes or weight loss medicines when they went on holidays or if they gained 
weight (items 5 and 6). The total items for the medication adherence scale in this 
study were 10.  
 
4.2.1.4 Satisfaction with Medication Information 
One scale was identified that measured patient satisfaction with the information 
they received about their prescribed medicines. This was developed by Horne et al. 
(2001) and is called the Satisfaction with Information about Medicines Scale [SIMS]. 
This is a 17-item scale that includes a range of topics that are related to the action 
and usage of medicines and the potential problems with them. Respondents in this 
scale indicated the amount of information they received about each aspect of their 
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prescribed medicine. Those participants reporting that the information was about 
right or indicating none needed were classified as satisfied (scored 1). Those reporting 
that the information was too little, too much or indicating none received were 
classified as dissatisfied (scored 0). Scores range from 0-17 with high scores indicating 
a high degree of overall satisfaction with the amount of medicine information 
received. In addition, items in SIMS can be divided into two sub-scales; the Action 
and Usage subscale [AU] and the Potential Problems of Medication subscale [PPM].    
 
Horne et al. (2001) reported an acceptable Cronbach’s alpha overall for people with 
diabetes (=0.81 insulin treated, =0.88 on oral glucose-lowering agents). In 
addition, both of the subscales showed satisfactory internal consistency ranging from 
0.77-0.79 for both diabetes groups with the exception of the PPM subscale in insulin 
treated diabetes patients where Cronbach’s alpha was 0.61. The SIMS scale (Horne 
et al., 2001) appeared to be positively correlated (r=0.31, p<0.05) with patients’ self-
reported adherence (RAM scale, see 4.2.1.3) and negatively correlated (r=-0.33, 
p<0.05) with the BMQ-Concern specific scale (see 4.2.1.2) in a cardiac rehabilitation 
sample. In addition, two more studies which adapted the SIMS scale (reduced to 15 
and 16 items) for people on glucose-lowering medicines reported Cronbach’s alpha 
of 0.89 (Aikens & Piette, 2009) and 0.94 (van Geffen et al., 2011) respectively.  
 
In this study, the SIMS was adapted by increasing the scale with an additional item 
making a total of 18 items. The new item was related to information received about 
whether the medicine will affect patient’s weight (item 16).  
 
4.2.1.5. Satisfaction about Diabetes/ Weight Loss Medicines 
Satisfaction about Diabetes Medicines 
Seven scales were identified that explored patients satisfaction with their diabetes 
medicines and/or treatment (Bradley et al., 1990; Atkinson et al., 2004; Brod et al., 
2006; Donatti et al., 2008; Ruiz et al., 2008; Anderson et al., 2009; Brod et al., 2009b). 
Only two scales reported being sensitive to change (Bradley et al, 1990; Bradley, 
1999; Brod et al., 2009a). Although the Diabetes Treatment Satisfaction 
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Questionnaire (DTSQ) measures satisfaction with diabetes medicines, including 
tablets and insulin injections, there are two separate versions of the scale for each 
delivery system (Bradley, 2006). However, the Diabetes Medication Satisfaction 
[DiabMedSat] scale developed by Brod et al. (2006) has been used for all delivery 
systems of diabetes medicines (i.e. oral, injectable) and also includes items related 
to weight gain, which the DTSQ does not include. The DiabMedSat scale contains 22 
items that assesses treatment satisfaction in three related domains: Efficacy, 
Treatment Burden and Symptoms (side effects) as well as Overall Treatment 
Satisfaction. Each item is scored out of 100, and some items are on a 5-point and 
others on a 7-point Likert scale. Higher domain scores indicate greater treatment 
satisfaction for the concept measured by each domain.  
 
The DiabMedSat has a Cronbach’s alpha of 0.90 for the whole scale, and an 
acceptable internal consistency for each domain (Burden =0.87, Efficacy =0.87, 
Symptoms =0.89) as well as correlation coefficients within acceptable range 
(r=0.48-0.85) suggesting moderate to strong associations between domains 
establishing construct validity (Brod et al., 2006). In addition, Brod et al. (2009a) 
reported that the effect size of DiabMedSat ranged from 0.535 and 1.645 indicating 
its ability to detect a moderate to large change for people with T2D who had been 
on biphasic insulin aspart 30 for 26 weeks. Also, Brod et al. (2009a) measured 
responsiveness of the DiabMedSat, using the Minimal Important Difference [MID] 
and the Standardised Response Means [SRM]. The study showed that MID ranged 
from 5.3-11.7 and indicated a medium to large SRM in all domains (range=0.43-1.16) 
between the group of patients who were slightly satisfied with their medication 
compared to the group of patients who were “neither dissatisfied nor satisfied”.  
 
Satisfaction about Weight Loss Medicines 
Only one scale was identified that assesses the impact of anti-obesity drug 
medications in areas such as Daily Life, Psychological Health, Weight Management, 
Treatment Burden and Experience of Side Effects (Brod et al., 2010). The scale is called 
Treatment Related Impact Measure of Weight [TRIM-Weight] and consists of 22 
151 
 
items related to the areas mentioned above which also represent the 5 sub-domains. 
This measure was developed to be used either as a whole scale or to use the 
subdomains independently. This study has used the three following sub-domains; 
Daily Life [TRIM-Wt-DL], Psychological Health [TRIM-Wt-PH], Weight Management 
[TRIM-Wt-WM]. The other two subdomains were omitted as similar items can be 
found in the DiabMedSat subdomains of Treatment Burden and Symptoms. The 
TRIM-Wt-DL, the TRIM-Wt-PH and the TRIM-Wt-WM domains contain 6, 4 and 3 
items respectively, all based on a 5-point Likert scale. Some of the items were 
reversed scored so that higher summed scores on each domain corresponded to a 
better health state with less negative impact related to the concept measured by 
each domain.  
 
The TRIM-Weight has a Cronbach’s alpha of 0.93 for the whole scale, and an 
acceptable to good internal consistency for the following domains: TRIM-Wt-WM 
(=0.70), TRIM-Wt-PH (=0.87), TRIM-Wt-DL (=0.91). It also has correlation 
coefficients within acceptable range (r=0.48-0.85) suggesting moderate to strong 
associations between domains establishing construct validity (Brod et al., 2006). 
 
In this study, both DiabMedSat and the three subscales of TRIM-Weight were 
adapted for glucose-lowering and anti-obesity drugs. It is well known that many 
diabetes medicines have different effects on body weight, i.e. promote weight loss 
or result in weight gain, and therefore can affect the psychological health and daily 
life of patients with diabetes (Inzucchi et al., 2012). In addition the only anti-obesity 
drug available currently on the NHS (Orlistat) has been shown to have side effects of 
similar severity to other diabetes medicines and positive effects on glycaemic control 
(Hollander et al., 1998; Miles et al., 2002, Kelley et al., 2002; Inzucchi et al., 2012).    
 
4.2.1.6. Self–Efficacy for Appropriate Medication Use 
One scale was identified that measured patients’ self-efficacy with medication 
adherence suitable for chronic diseases developed by Risser et al. (2007), called the 
Self-Efficacy for Appropriate Medication Use Scale [SEAMS]. The scale contains 13 
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items that can be divided into two subscales; the self-efficacy on taking medicines 
Under Difficult Circumstances [UDC] and the self-efficacy on taking medicines under 
conditions of uncertainty [UCU]. The scale was assessed on a sample of patients with 
Coronary Heart Disease, of which 45% had diabetes. Cronbach’s alpha was 0.89 for 
the overall scale and 0.86 and 0.79 for the UDC and UCU subscales respectively. In 
addition, SEAMS was positively correlated with Morisky Adherence Scale (MMAS-4); 
Spearmans rho=0.51 (p<0.0001). The original scale was based on a 3-point Likert 
scale ranging from 1 (not confident) to 3 (very confident), however the scale in this 
study was adapted to a 5-point Likert scale ranging from 1 (Not at all confident) to 5 
(Extremely confident), as described in Carpenter et al.’s paper (2010). In addition, 
items 6 (“your” instead of “the”) and 11 (“unwell” instead of “sick”) were adapted 
slightly to ensure understanding of the questions by the sample population. The sum 
of scores for the modified SEAM scale was divided by the number of items of the 
scale and ranged from 1 to 5. A high score represents greater levels of adherence 
self-efficacy.  
 
4.2.1.7. Obesity and Weight Loss Quality of Life Measure 
Two obesity specific quality of life scales were considered, the Impact of Weight on 
Quality of Life-Lite [IWQOL-Lite] by Kolotkin et al. (2001, 2003) and the Obesity and 
Weight Loss Quality-of-Life [OWLQOL] by Patrick et al. (2004). However, the OWLQOL 
was used in this study. Although OWLQOL and IWQOL-Lite measurements show good 
construct validity and reliability (=0.93-0.96, ICC=0.95 and =0.84-0.96, ICC=0.94 
respectively), the OWLQOL had less items (n=17) compared to IWQOL-Lite (n=31). 
This meant less of a burden to the participant with a mean completion time of 5 
minutes, as they had to complete, in addition, all the other scales as reported above. 
Furthermore, both measurements have shown responsiveness to change, but 
OWLQOL has shown moderate to large responsiveness to shorter- and longer-term 
reductions in body weight (SRM=0.32-1.63) and has been assessed in pre- and post-
treatment situations, which were similar to this study design. The OWLQOL measures 
a person’s global evaluation of their weight, weight loss and weight loss treatment 
and hence, assesses a person’s perceptions of body weight and trying to lose weight. 
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This is in contrast with the IWQOL-Lite that assesses function/ behaviour due to body 
weight and ability to complete simple tasks. Moreover, the OWLQOL is intended to 
be used alongside other patient reported outcomes including adherence to and 
satisfaction with treatment (Patrick et al., 2004).  
 
The OWLQOL consists of 17 items all on a 7-pont Likert scale with responses ranging 
from Not at all (scored 0) to A very great deal (scored 6). All items are used to derive 
a single quality of life score by reversing scores for each item, then summing each 
item and transforming the raw score to a standardised scale of 0 to 100. A score of 0 
indicates the greatest impact (i.e. poor quality of life) whereas a score of 100 
indicates the lowest impact, therefore implying better quality of life. No change was 
made to this scale for this study.  
 
4.2.2. Additional demographic and clinical data  
Demographic data were also collected within the first questionnaire (Appendix 3.5, 
section A) to determine factors that predict discrete subgroups of the population. For 
example, subgroups included individuals with low, medium or high adherence levels 
or individuals prescribed a new diabetes medicine that has different effects on body 
weight. Demographic data included age (in years) calculated from date of birth at the 
time of entering the study, gender (male/female), ethnicity, marital status, education 
status, employment status, and socioeconomic status based on the Index of Multiple 
Deprivation [IMD] for 2010 by using the participant’s home postcode in the 
Deprivation Map Explorer  
(http://apps.opendatacommunities.org/showcase/deprivation).11 The dataset 
provides all Lower layer Super Output Areas (LSOAs) for England and Wales ranked 
by their 2010 IMD score. A rank of 1 is the most deprived (out of 32,482 areas). These 
scores are then also ranked in 5 categories from those who live in 20% most deprived 
                                                     
11 The IMD is a composite score for a small neighbourhood, derived from aggregated responses to the 
ten-yearly national census and with some but not all components updated annually using local 
statistics. It consists of 38 indicators of deprivation grouped in 7 domains: household income, 
employment, health status and disability, crime, skills and training (including but not limited to formal 
education), barriers to housing and services, and living environment (including access to open spaces 
and leisure facilities). (Communities and Local Government, 2011) 
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areas to those who live in 20% least deprived areas (Communities and Local 
Government, 2011).  
 
In addition, clinical data were also collected from medical records following 
participants’ consent to the study [Appendix 4.1]. These data were collected to 
explore associations with subgroups as described above and identify total medication 
burden based on the number of medicines participants had to take every day. These 
clinical data were collected twice from the medical records; before and 3 months 
after a change in participants’ diabetes treatment, to assess change overtime and 
compare with subgroups as described above.  
 
4.2.3 Piloting of Questionnaire 
The lead researcher (AP) engaged with a research steering group involving a service-
user with T2D and relevant HPs (consultant, GP, diabetes specialist and research 
nurses, pharmacist and dietitian), who provided feedback on the questionnaire 
format and content, establishing face and content validity (Streiner & Norman, 2008). 
In addition, both questionnaires were piloted with two people with T2D on oral 
medication, in order to assess readability and avoid ambiguities (Streiner & Norman, 
2008). Following feedback from both research steering group and individuals with 
T2D, a few American terms were changed to more common English terms (i.e. 
“feeling sick” to “feeling unwell”). Furthermore, it was decided to format the 
questionnaires using guidelines from DUK (www.diabetes.org) and National 
Research Ethics Service (www.nres.nhs.uk) in relation to background, font colour, 
font type and size, logos and language used. In addition, licence agreements for the 
scale measurements in sections 4.2.1.1-4.2.1.7 were drawn up, and changes as 
described above were approved from the relevant copyright author(s)/institution(s) 
prior to printing the questionnaires.   
 
4.2.4 Data management and statistical analysis 
Data from questionnaires and the clinical data forms at baseline and 3-month follow-
up were inserted into a database on the Statistical Package for the Social Sciences 
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[SPSS] version 21. This statistical package was used to manage data coding and 
analysis. Prior to entering any data onto SPSS, all items for scales in sections 4.2.1.1.-
4.2.1.7 that required reverse scoring where changed accordingly. All data entered on 
the database were manually checked for accuracy prior to any statistical analysis. 
Scale scores were transformed using the compute function on SPSS, creating 
additional variables in the form of a numeric expression (summed scores for whole 
scales or subscales as described in sections 4.2.1.1.-4.2.1.7). Descriptive statistics 
were used to explore the demographic characteristics of the sample. Frequencies (%) 
were calculated for gender, ethnicity, marital status, employment status, educational 
status and social status. In addition, frequencies (%) were calculated to determine 
the percentage of different categories of glucose lowering drugs; biguanides, 
sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, and 
insulins. Furthermore, frequencies were calculated for weight reducing, weight 
neutral and weight increasing drugs, as well as medication burden, and diabetes 
complications present.  
 
Tests for normal distribution of the data were conducted using the Kolmogorov-
Smirnov (for sample size over 100) or Shapiro-Wilk (for sample size less than 100) 
test when the data showed a reasonably normal distribution using histograms, and 
homogeneity of variance using the Levene’s test (Coakes & Steed, 2006, Field, 2009). 
Mean and Standard Deviation [SD] values were used when the data showed normal 
distribution, otherwise median values and interquartile range [IQR] were used.  
 
Analysis was carried out, firstly, using the whole group and then using the three 
subgroups based on the effect of a new medicine on body weight. The three weight-
effect groups were classified as Weight Reducing [WR], Weight Neutral [WN] and 
Weight Increasing [WI]. The thesis will use these labels throughout for presenting the 
results. The primary outcome was to identify the change in expectations, beliefs, 
attitudes and adherence following the experience of taking glucose-lowering drugs 
(or anti-obesity drugs) that promote weight loss, are weight neutral or result in 
weight gain. Since the scale data were mostly skewed, then the non-parametric 
Wilcoxon signed-rank test (as opposed to the paired t-test) was used for comparing 
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dependent samples. This test was used for example for comparing attitudes and 
beliefs before and after change of medication.  The non-parametric Kruskal-Wallis 
test was used to compare scales between the three independent weight- effect 
groups (WR, WN, WI) and adherence level groups (low, medium, and high), and the 
Mann Whitney U test for comparing skewed data between two independent groups, 
for example for comparing attitudes and beliefs between the WR and the WI group. 
Probability values (p-values) equal to or below 0.05, were considered significant. The 
Bonferroni correction method was used to minimise Type I error when there was 
multiple testing. In this case the criterion for statistical significance was modified by 
dividing the probability value of 0.05 by the number of comparisons to create a new 
cut–off value, for example, when there were 3 multiple comparisons between the 
weight-effect groups, the new probability cut-off value became 0.017.  
 
In addition, the Standard Error of Measurement [SEM] (Wyrwich et al., 1999) was 
used to measure differences amongst individuals in the amount of change between 
baseline and three month follow-up, such as those whose expectations, attitudes and 
beliefs changed positively (improved), negatively (decreased) or remained stable. A 
change of one-SEM was used to determine whether participants had achieved a 
minimal significant change or MID (Wyrwich et al., 1999; Rejas et al., 2008). The SEM 
was calculated for each scale by multiplying the standard deviation of the baseline 
scale score (or the change score) by the square root of 1 minus its reliability 
coefficient (or reliability of the change score). All scales used the baseline standard 
deviation scores and the reliability coefficient, except for the EITQ/PITQ scale where 
the standard deviation of the change score was used and the reliability of the change 
score (Hayes et al., 2010). The reliability was measured by Cronbach’s alpha 
coefficient (Appendix 5.4).   
 
Using the one-SEM value for each scale as a reference and the difference score 
between baseline and follow-up scores, the participants were identified as [1] 
improved if the change score was greater than one-SEM (>1SEM), [2] no 
change/stable, if the change score was zero or within plus or minus one-SEM 
(±1SEM), and [3] decreased if the change score was equal or less than minus one-
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SEM (≤-1SEM) (Wyrwich et al., 1999). For the EITQ and PITQ scales the difference 
scores were then used to categorise how expectations were met by experiences. If 
the difference score was zero, plus or minus one-SEM (±1SEM), expectations were 
met by experience. If the difference score was greater than zero plus one-SEM 
(>1SEM), expectations were exceeded by experience. If the difference score was less 
than zero minus one-SEM (<-1SEM), expectations were not met by experience (Hayes 
et al., 2010). 
 
In order to assess the impact of participants’ expectations, beliefs and attitudes as 
well as any change in these on medication adherence, univariate and multivariate 
regression analyses were performed with one or more independent variables. The 
type of regression analysis was based on whether the dependent variable of interest 
was binary, ordinal or nominal.  Logistic regression is used when the dependent 
variable is binary, for example predicting medication adherence (MMAS-8) to be high 
(than low to medium). This regression analysis is concerned with the probability of a 
single outcome/event occurring given the level/s of one or more explanatory 
(independent) variables using the logit transformation (Log of the Odds) (Norušis, 
2011). The models take the following form: 
Log [p/(1-p)] = β0 + βx (for one explanatory variable) 
Log [p/(1-p)] = β0 + β1x1+ β2x2 + β3x3 + ... + βnxn (for more than one explanatory 
variables) 
Where p is the probability of the outcome occurring, β0 (beta coefficient) is the 
constant, x1,…, xn are the explanatory variables and β1, …, βn the corresponding 
regression coefficients attached to that variable.  
 
The log odds/logits can be converted into (relative) odds by applying the exponential 
to both sides of the equation and so, it is expressed as p/(1-p)= Exp (β0 + βx), which 
in return can be used to find the probabilities with the following formula: p= Exp(β0 
+ βx)/ [1+ Exp(β0 + βx)] (Norušis, 2011). Hence the odds of being high adherent is 
defined as the ratio of the probability of having high adherence level over the 
probability of having low to medium adherence levels, so if the value is greater than 
1 then it indicates that the predictor increases the odds of being high adherent, whilst 
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a value less than 1 indicates that the predictor decreases the odds of being high 
adherent (Field, 2009). SPSS gives the OR for the explanatory variables labelled as 
Exp(B), as well as displaying 95% confidence intervals.  
 
Ordinal regression (or ordinal logistic regression) is used when the 
outcome/dependent variable has more than one category and is ordinal, such as the 
medication adherence (MMAS-8) which has three ordered categories (low, medium, 
high). The ordinal regression is concerned with the cumulative probabilities of an 
outcome/event occurring using the cumulative logit/ proportional odds model, i.e. 
the probability of an event occurring and all events that are ordered before it 
(Norušis, 2011). The model takes the following form:  
Log [pj/(1-pj)] = αj - βx (for one explanatory variable) 
Log [pj/(1-pj)] = αj – (β1x1+ β2x2 + β3x3 + ... + βnxn) (for more than one explanatory 
variables) 
where j goes from 1 to the number of categories minus 1. Each logit has its own 
intercept αj but the same coefficient β, that means the effect of the independent 
variables is the same across the different thresholds (outcome levels). This is the key 
assumption of the ordinal regression and is termed the assumption of proportional 
odds (or parallel lines in SPSS) (O’Connell, 2006).  
 
In SPSS, the effects of the independent variables are subtracted rather than added to 
the intercepts. This is done so that positive coefficients suggest that higher values of 
the explanatory variable are associated with higher outcomes, while negative 
coefficients suggest that higher values of the explanatory variable are associated with 
lower outcomes (Norušis, 2011). For example, an analysis based on the dependent 
variable of medication adherence (MMAS-8) will create two models; one that 
predicts the likelihood of those who are medium to high adherent compared to those 
with low adherence levels and the second predicts the likelihood of high adherents 
compared to those with low to medium adherence levels. The test of parallelism is 
used to determine the validity of the assumption of the ordinal model compared to 
a model with separate coefficients for each threshold, so if the test is non-significant 
(i.e. p>0.05), then the ordinal model is significantly better, and the assumption of 
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proportionality is upheld suggesting that all parameters are the same across all 
thresholds (O’Connell, 2006). 
 
The cumulative logits (i.e. threshold coefficients/parameter estimates) associated 
with being at or below a particular category j can be exponentiated to arrive at the 
estimated cumulative odds for that category. Then, predicted cumulative 
probabilities associated with being at or below category j can be calculated from the 
cumulative odds using the following formula: 1/ [1+ exp (cumulative logit)], however 
to find the predicted probability in a specific outcome the subtraction method is used 
(Norušis, 2011). Hence, the odds of becoming highly adherent is calculated by using 
the exponential value of the predictive cumulative logit. SPSS gives the estimate beta 
for the explanatory variables displaying 95% confidence intervals and calculates the 
predicted probabilities for each score/category.  
 
Finally, when the outcome variable has more than two categories which are 
considered to be unordered, such as the variable related to the change in medication 
adherence levels (MMAS-8 improved, stable or decreased), then the regression 
analysis used is called multinomial regression. This analysis is the same as the logistic 
regression analysis with binary outcomes, in that it breaks the outcome variable into 
a series of comparisons between two categories. In this case, the analysis is made 
into two comparisons between “stable” and “improved” or “stable” and 
“decreased”, whilst using one category (“stable”) as the reference category for 
comparison (Field, 2009).  
 
A univariate analysis was conducted initially to assess which variables were 
significant predictors of medication adherence (MMAS-8) and change in medication 
adherence levels including any demographic or clinical covariates and these were 
entered individually one at a time. Then, a multiple ordinal regression was used to 
identify a model that better predicts medication adherence at three months 
following an initiation of a new treatment (high adherence Vs medium and low 
adherence). The multivariate model was constructed based on the most significant 
variables in a forward stepwise method, starting with those with the highest 
160 
 
significant value (i.e. p<0.001). If the variables were significant with p<0.05, these 
were then retained in the model, however any variable with p>0.05 was later 
excluded. However, multiple logistic regression analysis was performed when the 
assumption of proportional odds was violated (i.e. p<0.5) to explore the variation in 
the odds or the explanatory variables at the different thresholds of the ordinal 
outcome. Furthermore, a multinomial regression was used, based on the forward 
stepwise method as explained above, to identify a model that detects significant 
predictors to medication adherence change, that is an increase or decrease in 
adherence levels over time by using those participants with stable adherence over 
time as the reference point (Field, 2009).  The variable regarding the weight-effect of 
the new medicine (weight reducing, weight neutral, weight increasing) was forced 
into all final models as a covariate, to ascertain whether the weight-effect of the 
medicine can predict and/or influence medication adherence levels.  
 
To determine the ability whether a multivariate model improves the ability to predict 
the outcome, the chi-square statistic was used to indicate whether the multivariate 
model was performing better (p<0.05) than the baseline intercept-only model which 
has no independent variables. The goodness of fit tests, Hosmer & Lemeshow and 
the Pearson’s chi square (and deviance) test for logistic and ordinal regressions 
respectively, were used to indicate that the multivariate model is a good fit to the 
data when p>0.05 (Field, 2009; Norušis, 2011). In addition, the Nagelkerke’s R2 value, 
a pseudo R2 statistic, was used to explain how much variation in the outcome is 
explained by the model (Field, 2009; Norušis, 2011). Multicollinearity was assessed 
with a correlation matrix. Pearson’s r values of less than 0.8 between any two 
explanatory variables suggested that there was no perfect relationship and no 
concern for multicollinearity (Filed, 2009). However, if values of 0.8 and above were 
found, SPSS provided further collinearity diagnostics such as the Variance Inflation 
Factor (VIF) and the tolerance statistic. A VIF value of less than 10 and tolerance of 
close to 1 for each explanatory variable suggest no multicollinearity (Field, 2009).   
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4.3. Qualitative Data Collection Tools 
4.3.1 Interviews 
Unlike quantitative approaches, qualitative inquiry does not always generalise 
findings but provides rich accounts of peoples’ experiences and the meanings they 
attach in relation to their everyday lives and different settings (Brown, Crawford & 
Hicks, 2003). In doing so, the researcher needs to present the research process which 
resulted in a set of conclusions, so that the research study can be regarded as reliable, 
trustworthy, valid and transferable (Lewis & Richie, 2003). Crucial aspects to consider 
throughout the research process include: a “symbolically” representative sample 
with known features for non-response (where applicable), a consistent approach to 
interviewing which effectively allows participants to portray their experiences; a 
comprehensive and systematic data analysis procedure which is triangulated by 
other methods and allows for all perspectives to be explored, and finally, 
identification and interpretation of the data that reflects the meanings assigned by 
the participants and is supported by evidence and displayed in such a way that 
remains “true” to the original data (Lewis & Richie, 2003). Finally, a qualitative 
research study can be regarded as transferable if the findings can be applied to a 
wider population, to other contexts, or to the development or enhancement of 
theory (Lewis & Richie, 2003). 
 
The aim of the interview, as a data collection tool, was to explore ideas, perceptions, 
experiences, feelings and thoughts of the participants in their own unique words 
(Taylor, 2005; Wilkinson & Birmingham, 2003). It also aimed to enrich understanding 
of the quantitative findings and participants’ experiences through their treatment 
changes. Although the questionnaires included a number of domains assessing 
patients’ satisfaction with medication, in order to understand their impact on 
adherence, satisfaction measurements alone are not sufficient to understand patient 
adherence (Shikiar & Rentz, 2004). The topics under examination were potentially 
sensitive and, therefore, it was beneficial for them to be explored in depth (Wilkinson 
& Birmingham, 2003). Semi-structured face–to-face (individual) interviews are 
focused interviews with a relatively small number of open-ended questions that 
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allow the researcher to identify respondent’s own ideas, views and attitudes. In this 
way the questions become more relevant to the participants and they gain an 
element of control over the interview (Corbin & Morse, 2003). Employing semi-
structured interviews allowed for flexibility to generate insights that otherwise could 
not have been accessed if the method was more structured (Taylor, 2005). The semi-
structure nature of the interview permitted consistency to the conduct of the 
interview with the intention of enriching study credibility (Lewis & Ritchie, 2003).  
 
Interviews were conducted by the lead researcher, who has a background as a 
dietitian and experience in counselling patients, in particular dealing with overweight 
and obese clients with T2D, and experience in conducting research interviews. As a 
health professional who has worked in the past in similar research (Psarou & Brown, 
2010) it was important to note during the conduct of the interviews the potential 
effects on the participants, as well as the potential resource and benefits of prior 
experience and background brought into the research process (Holloway, 2005). 
Furthermore, conducting repeated interviews helped to increase the rapport 
between interviewer and participant (Schatz, 2012).  
 
4.3.1.1 Purpose of Interviews 
The purpose of the interviews was to explore participants’ expectations and 
perceptions of diabetes/weight loss medication in relation to their: 
1. past experiences of taking medicines in general, diabetes/weight loss 
medicines and effects on their blood glucose and body weight (1st interview) 
2. lived experiences in taking their new medication and effects on blood glucose 
and body weight (2nd  interview) 
3. past and current experiences of diabetes services re: medication prescription 
and guidance received (including lifestyle changes i.e. diet, physical activity 
and behaviour) (1st and 2nd interview) 
4. past and current experiences of barriers and facilitators for managing 
(accepting) new diabetes/weight loss medicines [based on previous 
experiences, beliefs about medicines and interaction with HPs] (1st and 2nd 
interview) 
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This study used two data collection tools for the interviews, labelled “Interview 
Guides 1 and 2” (Appendix 4.2). The sections below describe the development and 
formatting of the interview guides and the data management and analysis of the 
interview data.  
 
4.3.1.2 Development of interview guides 
The interview guides were developed following a preliminary analysis of the 
quantitative findings from the first participants completing the questionnaires 
(questionnaire 1 n=45, questionnaire 2 n=30) triangulated with literature and after 
consultation with the research steering group. The preliminary analysis of the 
questionnaires identified areas to be explored further, which resulted in the 
interview guides being designed around the following relevant themes: 
 Benefits and disadvantages of taking medicines – including any lifestyle 
changes as a result of taking medicines 
 Experiences of medication use for diabetes (or weight loss) and impact on 
daily life prior to new medicine and as a result of new medicine 
 Expectations of new medicine prescribed and perceptions of outcomes for 
now and in the future related to diabetes and body weight.  
 Factors that impact on managing and adhering to medicines and to new 
medicine 
 Practical aspects that help with adherence to medicines and to new medicine 
 Perceptions of support provided and interactions with HPs prior to 
prescription of and whilst taking the new medicine 
 Potential help and support  
 
The interview guides were piloted verbally with two HPs (one specialist diabetes 
nurse and one practice nurse with an interest in diabetes), and four patients with 
T2D who were not participating in the interviews (one commencing on liraglutide, 
one on insulin and two on oral tablets). The pilot work was done to ensure 
understanding of the questions and remove any ambiguity. Following this a few 
minor changes were made which were mainly due to the order of some of the 
questions within each interview guide.  
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4.3.1.3 Sampling techniques and sample size 
The sampling technique employed was purposive, in order to achieve adequate 
representation of participants and avoid selecting a biased sample (Schatz, 2012). 
This sampling approach has an element of process that relates to, and ensures, 
theoretical saturation (Oppong, 2013).The choice of this purposive sample of T2D 
patients was to achieve representation in relation to the phenomenon being 
researched and the setting, i.e. participants prescribed new glucose-lowering or anti-
obesity drugs, which were either oral or injectable, in primary or secondary care 
(Lewis, 2003). Furthermore, participants were recruited from each stage of disease, 
i.e. from diagnosis to complex management by years since diagnosis, drug experience 
and gender. The sampling frame (Figure 4.1) was developed from a second 
preliminary analysis from the questionnaires (n=98), and participant characteristics 
(Table 4.2). It was estimated that approximately 30 participants would be sufficient 
to explore in depth the phenomenon under study, and that the sample could be more 
or less depending on whether saturation was reached i.e. the point at which no new 
findings were emerging from interviews (Holloway & Wheeler, 2010).     
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Figure 4.1: Sampling Framework  
 
Table 4.2: Participant characteristics for the development of sampling framework 
Participant characteristics 
Gender (n=98) 58.2% Male  
41.8% Female 
Marital Status (n=96) 14.6% single,  
65.6% married,  
7.3% separated,  
12.5% widowed 
Education status (n=96) 7.3% University or higher 
9.4% A level equivalent 
19.8% GCSE or equivalent 
3.1% Diploma 
13.5% Vocational 
46.9% No formal qualifications 
Employment Status 
(n=94) 
25.5% Full-time 
6.4% Part-time 
12.8% unemployed 
45.7% retired 
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9.6% other 
Class of medicines 
(n=98) 
10.2% Biguanides 
7.1% Sulphonylureas 
31.6% GLP-1 
19.4% DPP-4 
29.6% Insulin 
1% Meglitinides 
1% Anti-obesity drugs 
37.7% WI Drugs 
29.6% WN Drugs 
32.6% WR Drugs 
Age (n=98) 59.0yrs ± 11.5yrs 
Years of T2D diagnosis 
(n=88) 
8.9yrs ±8.1yrs 
BMI kg/m2 (n=44) 35.8 ±8.0 
HbA1c mmol/mol 
(n=43) 
79 ±19 
Data are % or mean±SD 
 
4.3.1.5 Data management and analysis 
All interviews were transcribed by a professional and independent transcription 
company which signed a confidentiality agreement prior to any transcription. All 
transcriptions were quality checked by the lead researcher and most items labelled 
“unclear” by the transcriber were identified. These were items related to 
participants’ regional accents or local expressions. Clarification was obtained by 
replaying the digital recordings and referring to interview notes which were collated 
as part of an audit trail. Furthermore, transcripts were anonymised prior to analysis, 
by removing names that could identify the participants themselves or health care 
professionals involved in their care. 
 
Data coding and analysis was managed using QSR NVivo version 10. Transcripts were 
coded into themes using the framework approach developed in Britain for policy 
research (Richie et al., 2003). This 'framework' approach consists of five steps; 
familiarisation with the data set, identification of descriptive codes from 
independent repeated readings of transcripts, then identification of emerging 
themes on the basis of initial indexing, hierarchical grouping of codes, and discussion 
of individual transcripts. The framework approach is a systematic method of 
qualitative data analysis based on a matrix, and therefore, enables the researcher to 
explore the data in depth whilst maintaining a rigorous and transparent audit trail 
167 
 
(Richie et al., 2003). In this study, the familiarisation process continued until the 
diversity of circumstances and characteristics of the data set had been understood, 
followed by an initial identification of recurring themes or ideas. Each individual 
participants’ transcripts were reviewed to determine what aspects changed for these 
individuals following the new medicine prescription, what aspects remained stable 
during the study period, and the process of change over time. These were recorded 
as summaries for each case in Nvivo.  
 
Nvivo facilitated the creation of an index of the emerging open themes, which later 
were grouped into smaller numbers of broader “main” themes creating an initial 
hierarchy of a thematic framework (Appendix 4.3). Transcript passages were added 
to relevant themes in a systematic way, and, where newer themes emerged, previous 
transcripts were revisited to ensure consistent labelling and indexing. Any changes 
to names of themes or process of indexing was recorded in Nvivo with dates via the 
“Memo” function. Throughout the process of indexing and coding, emergent ideas, 
spontaneous thoughts or conceptual themes were also noted in a separate memo to 
facilitate analysis particularly if there were signs of interconnections between 
themes or participants characteristics, such as adherence level and everyday 
medication practices. In Nvivo, framework matrices were produced for each 
individual main theme which included all sub-themes in columns and all participants 
in rows. Data were summarised and synthesised within the matrix by linking these 
with the raw data. Furthermore, participants’ expressions and phrases were retained 
within the summary, so context and content was not lost. The framework matrices 
enabled the researcher to study and synthesise data across all participants, noting 
the range of perceptions, experiences and behaviours as part of a theme (Richie et 
al., 2003) paying particular attention to “outliers” or “deviant cases” (Holloway, 
2005). This allowed the researcher to display the diversity of the phenomenon 
explored.  
 
The effects of patient characteristics, such as gender, age, degree of overweight or 
obesity, type of medication experienced, expectations, beliefs and attitudes and 
adherence levels, were explored in the analysis by entering these data as attributes 
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from the questionnaire results. This is a common approach to an initial integration of 
mixed method data (Bazeley, 2010). The framework matrices were also used to 
compare and contrast findings between subgroups (i.e. weight-effect groups) whilst 
maintaining context for individual cases. The process of such analysis helped for the 
identification of associative patterns within the data and plausible explanations of 
why such patterns occur. Interpretation of the findings was verified using 
independent transcript analysis by the lead researcher and through discussions with 
the supervisors, and the research steering group who examined emerging themes to 
guide development of the initial thematic framework.  
 
4.3.1.6 Presentation of Findings 
Although participants’ interpretations can be diverse and multifaceted, it is also 
accepted that these are influenced by the researcher’s understanding of the 
phenomenon whilst striving to be as objective and neutral in their presentation 
(Ritchie & Lewis, 2003). Where findings were generalised these were supported with 
use of quotes from the original data, yet only a limited amount of quotes per theme 
or sub-theme were presented to avoid overuse of quotes and distraction from the 
clarity of the main commentary (White et al., 2003). Quotes often represented more 
than one theme/sub-theme, therefore a quote was used only once to avoid 
repetitious reading and, its length was edited by the use of ellipses (…). Words added, 
to aid comprehension, were inserted in brackets (White et al., 2003). Furthermore, 
the frequency or dominance of  findings were displayed with the use of the following 
words; “few”, “most”, “all”, “rare”, “commonly” or “recurrent”, instead of specific 
numbers or proportions (White et al., 2003).  
 
4.3.2 Mixed Method Data Management and Analysis  
Quantitative and qualitative data analysis was combined into a matrix created in 
NVivo. This common mixed method analysis (Caracelli & Greene, 1993, Bazeley, 
2012) serves to compare the two data types through data transformation, i.e. 
questionnaire data transformed into narrative descriptions of the variables that they 
represent. This type of analysis helps to observe any overlapping or inconsistent 
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aspects when the two data types are transferred into the matrix. The data from this 
combined analysis were then consolidated to uncover fresh insights or new 
perspectives (Caracelli & Greene, 1993). Finally, a group case analysis was 
undertaken (i.e. comparing the three weight-effect groups and/or adherence level 
groups) to gain an in-depth understanding of the reasons for any inconsistencies 
between the qualitative and quantitative data (Caracelli & Greene, 1993). This mixed 
method analysis served to legitimise (otherwise validate) the findings that stem from 
both qualitative and quantitative data of the PhD study to portray combination of 
both data into a coherent whole (Onwuegbuzie et al., 2011) to explain the 
phenomenon of medicine taking behaviour in people with T2D.  
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CHAPTER FIVE: QUESTIONNAIRE RESULTS 
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5.1 Introduction 
This chapter presents the results of the analysis of the questionnaires (pre and post 
new diabetes treatment) and clinical data collected in this study. It starts with the 
presentation of the response rates to the survey, reliability of the scales used and 
proportion of missing data.  The demographic characteristics of participants and their 
clinical data follow.  In addition, each section then presents the results for each scale 
within the two questionnaires, as well as information on the responses to questions 
and overall individual change for each scale. These sections answer the first key 
research question: 
1. How do the expectations, beliefs and attitudes of people with T2D towards 
different diabetes treatments that either promote weight loss, are weight 
neutral or result in weight gain, change over time? 
Then, the multivariate analysis is presented which focuses on the second key 
research question:  
2. What is the impact of this change on patients’ adherence to their 
medicine(s)? 
Finally, a summary of the key findings is provided at the end of the chapter.  
5.2 Recruitment, Survey Response and Data Screening 
The study recruited participants from both primary and secondary care. There was 
one secondary care site, a hospital diabetes centre, and in primary care there were 
forty-two sites. The primary care sites consisted of twenty-five GP sites and 
seventeen community pharmacies; these were spread across the Merseyside and 
included the following PCTs; Knowsley, Sefton, Liverpool, Halton and St Helens, and 
Wirral. The figure 5.1 shows the number of potential participants approached and 
eventually recruited by NHS Trust.   
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Figure 5.1: Number of potential participants approached and recruited in in primary and 
secondary care NHS Trusts 
 
The disposition of patients approached to take part in the study is shown in Figure 
5.2. The study achieved a response rate of 77% for the first questionnaire, which is 
much higher than the expected 40% rate commonly seen in surveys. Of those who 
returned the first questionnaire, 86% returned the second questionnaire following 
the two reminders.  
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Figure 5.2: Recruitment Flowchart 
 
Missing data for most scales was negligible and random, ranging between 0 and 5% 
for the first questionnaire. However, 6.6% of data for the DiabMedSat and the 
MMAS-8 scales were not applicable data, as those participants were prescribed 
diabetes medication for the first time. Missing data ranged between 0 and 2% for the 
second questionnaire. In addition, negligible data were missing from the 
demographics of the participants (0.8-1.2%), however overall baseline clinical data 
ranged from 1.6% to 25.4% (Appendices 5.2 and 5.3). Furthermore, missing follow-
up clinical data ranged from 18.3%- 69.5% most notably for the blood lipids (Table 
5.2). However, it is common practice to repeat such measures on a 6-monthly or 
yearly basis, than at three months. Clinical data such as BMI and HbA1c were not 
always available at the 3-month cut off point (~25%), so these were recorded 
whenever they were available from the medical notes at the GP/Hospital and usually 
ranged between 2 and 4 months from the baseline measure.  
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5.3 Internal Reliability  
The reliability of the scales used in the questionnaires was tested for internal 
reliability using Cronbach’s α shown in Appendix 5.1. The internal reliability ranged 
from 0.59 to 0.98, and scales performed similar or better in this study than other 
related studies with the exception of EITQ, TRIM-Wt and MMAS-8. The difference in 
the reliability of the scales could be due to the sample population, as the study by 
Naegeli and Hayes (2010) was based on a sample recruited via a clinical trial for an 
inhaled insulin, the study by Brod et al. (2010) was based on an online sample 
prescribed anti-obesity drugs and the study by Morisky et al. (2008) was based on a 
hypertensive sample. However, it is acknowledged that values of Cronbach’s alpha 
are dependent on the length of the scale, the sample size and the type of response 
within the items (binary Vs Likert scale) (Streiner and Norman, 2008). For example, 
the TRIM-WT subscales have a small number of items with the TRIM-Wt-WM only 
consists of three items and the MMAS-8 scale consists mostly items with a binary 
response, therefore, such characteristics could reduce the value of alpha (Streiner 
and Norman, 2008). Furthermore, Cronbach’s alpha values found for both of the 
questionnaires were equally similar indicating that the majority remained above 
0.70. To retain consistency between baseline and follow-up, no changes were made 
to the scales. However, the 10-item medication adherence version (4.2.1.3) although 
it had improved its reliability with the additional two items, this was only a slight 
improvement (α=0.64). Hence, the thesis used the original MMAS-8 scale (α=0.60) 
for subsequent analysis in order to be comparable to previous research.  
 
5.4 Participants  
5.4.1. Whole Group 
Information on the characteristics of the whole group (n=248), as well as those 
participants completing only questionnaire one and those completing both 
questionnaires is provided in Appendices 5.2 and 5.3. Those in retirement were more 
likely to return the second questionnaire than those in full-time employment 
(p<0.01). In addition, significantly lower creatinine and higher eGFR values were 
found (p<0.05) in those who returned only questionnaire one compared to those 
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who returned both questionnaires. It is common practice with patients whose kidney 
function is not well controlled to move onto insulin therapy and there was a non-
significant trend for those patients to have a lower eGFR. There was no other 
statistical difference between the two groups. 
 
On inspection of the first questionnaire, 89% of participants completed 
questionnaire one prior to taking the first dose of their new medicine (n=190)12, 
whereas 11% completed it after the first dose (n=23). A sensitivity analysis shown 
that there were no differences in most demographic or clinical data between those 
two groups, except that those who were widowed were significantly more likely to 
complete the first questionnaire after they had taken their first dose of their new 
medicine (p=0.021). Furthermore, those who completed the questionnaire after they 
had taken the first dose of their medicine, were found to have significantly stronger 
beliefs that prescribed medicines are overused by doctors (Median=3.33 Vs 
Median=2.67, p=0.034), and that medicines are “harmful” and “addictive” 
(Median=2.75 Vs Median=2.50, p=0.001), and were significantly less satisfied with 
their diabetes medicines in relation to how burdensome they are (Median=75 Vs 
Median=81.81, p=0.030). Tables 5.1 and 5.2 present the demographic and clinical 
characteristics of those participants who completed questionnaire 1 prior to taking 
the first dose and include the final sample in this study (n=190). On review of the 
second questionnaire, 76.3% (n=145) of participants indicated that they still 
continued to take the new medicine, whereas 7.4% (n=14) indicated that they had 
discontinued this treatment, and 16.3% (n=31) were missing data.  
 
Table 5.1: Sample Characteristics (n=190) - Demographic 
 Baseline n(%) 
Centre Site: 
  GP Practice 
  SCDC 
  CP 
 
107(56) 
66(35) 
17(9) 
Age(yrs)  60.5 (51.0, 69.0)    [Range 24-86] 
Gender   
                                                     
12 Participants who completed the first questionnaire within 24 hours of taking the first dose of their 
new medicine were included in the final sample (see section 3.4). 
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  Men 
  Women 
103(54) 
87(46) 
Ethnicity  
  Caucasian 
  Asian 
  Mixed 
 
188(99) 
1(0.5) 
1(0.5) 
Marital Status  
  Alone/Single  
  Married/with partner 
  Divorced/Separated  
  Widowed 
 
21(11) 
141(74) 
16(9) 
12(6) 
Level of Education  
  University/Higher Degree 
  Diploma   
  Vocational  
  A level  
  GCSE  
  No Formal Qualifications  
  Missing Data  
 
19(10) 
9(5) 
28(15) 
19(10) 
36(19) 
78(41) 
1(0.5) 
Employment Status  
  Full time  
  Part-time  
  Unemployed 
  Retired  
  Other [most on benefits] 
 
40(21) 
15(8) 
21(11) 
90(47) 
24(13) 
IMD 
  20% most deprived 
  21% to 40%  
  41% to 60%  
  61% to 80% 
  20% least deprived 
 
114(60) 
27(14) 
24(13) 
15(8) 
10(5) 
Data are % or Median and IQR reported as (Q1, Q3)
177 
 
Table 5.2: Sample Characteristics (n=190)-Clinical 
 Baseline n(%) Follow-up n(%) 
Years Diagnosed with T2D  
Missing Data  
7.0 (3.0,13.0) [Range 0-59yrs] 
3(1.6) 
 
No of Diabetes Complications-  
None  
One  
Two  
Three  
Four  
Five 
Missing Data  
 
85(44.7) 
58(30.5) 
28(14.7) 
13(6.8) 
2(1.1) 
2(1.1) 
2(1.1) 
 
74(38.9) 
41(21.6) 
19(10) 
16(8.4) 
1(0.5) 
2(1.1) 
37(18.9) 
Total Medicine Burden (number per day)  
Missing Data  
7 (5,10) [Range 1-21] 
8(4.2) 
7(5,11) [Range 2-21] 
39(20.5) 
Diabetes Regime-  
None 
Tablets only 
Tablets & insulin 
Insulin only 
Insulin & GLP-1 
Tablets, insulin & GLP-1 
Tablets and GLP-1 
GLP-1 Only 
 
18(9.5) 
111(58.4) 
30(15.8) 
10(5.3) 
1(0.5) 
1(0.5) 
17(8.9) 
0(0) 
 
 
53(27.9) 
38(20.0) 
6(3.2) 
5(2.6) 
14(7.4)  
37(19.5) 
3(1.6) 
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Missing Data  2(1.1) 34(17.9) 
Total Diabetes Medicine Burden  (number per day) 2 (1,2) Range (0-4) 2 (2,3) Range (1-5) 
BMI (kg/m2)  
Missing Data  
35.0 (31.0, 40.6) [Range 22.10-61.10] 
5 (2.6) 
35.5 (31.5, 40.7) [Range 22.7-59.6] 
48 (25.3) 
HbA1c(mmol/mol)  
Missing Data  
77 (66, 92) [Range 42-134] 
7 (3.7) 
67 (56, 80) [Range 35-123] 
45 (23.7) 
Systolic Blood Pressure(mmHg) 
Missing Data  
134±15 
8 (4.2) 
130±16 
87 (45.8) 
Diastolic Blood Pressure(mmHg)  
Missing Data  
75±11 
8 (4.2) 
75±11 
87 (45.8) 
Cholesterol(mmol/L)  
Missing Data  
4.1 (3.5, 5.0) 
36 (18.9) 
3.7 (3.5, 4.6) 
117 (61.6) 
LDL(mmol/L)  
Missing Data  
2 (1.5, 2.8) 
56 (29.5) 
1.8 (1.4, 2.4) 
132 (69.5) 
HDL (mmol/L)  
Missing Data  
1.1 (0.9, 1.2) 
39 (20.5) 
1.1 (0.9, 1.3) 
120 (63.2)  
Triglycerides(mmol/L)  
Missing Data  
2.12 (1.5, 2.9) 
46 (24.2) 
1.85 (1.4, 3.15) 
126 (66.3) 
eGFR(ml/min)  
Missing Data  
78 (56, 90) 
15 (7.9) 
73 (56, 88) 
73 (38.4) 
Creatinine(µmol/L)  
Missing Data  
79 (67, 102) 
16 (8.4) 
81 (69, 109) 
69 (36.3) 
Data are % or Median and IQR reported as (Q1, Q3), or mean±SD 
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5.4.2 Groups according to effect of new medicine on body weight 
A wide range of medicines were prescribed in this study that cover all glucose–
lowering drugs available for T2D. These medicines were classified according to effects 
on body weight as WR, WN or WI (Table 5.3). The most common new treatment 
prescribed was liraglutide, a GLP-1 agonist (Table 5.3). The highest proportion of 
prescribed drugs in the weight reducing group were GLP-1 analogues (85%); in the 
weight neutral group were DPP-4 inhibitors (62%) and in the weight increasing group 
were insulin injections (72%). These three drug classes had also the highest 
proportion of prescribed drugs within the whole group (31%, 19%, and 24% 
respectively). When comparing the three weight-effect groups in relation to 
participants who completed just the first questionnaire and those who completed 
both questionnaires, a similar number of participants in each group completed both 
questionnaires (Figure 5.3).  
 
 
Figure 5.3: Number of participants completing questionnaires in each weight-effect group. 
The first set of bar charts shows the number of participants who completed the first questionnaire 
and the second set of bar charts shows the number of participants who completed both 
questionnaires.  
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Table 5.3: Proportions of types of new medicine prescribed  
Weight Group  
n(%) 
Drug Class n(%) Drug Name n(%) 
Weight 
Reducing   
68 (36) 
GLP-1 agonist 
 
58(31) Exenatide  14(7) 
Exenatide ER  9(5) 
Liraglutide 35(18) 
SGLT-2 Inhibitor 8(4) Dapagliflozin  8(4) 
Anti-Obesity  2(1) Orlistat  2(1) 
Weight 
Neutral  
58 (31) 
Biguanides  
 
22(12) Metformin  13(7) 
Metformin MR 9(5) 
DPP-4 Inhibitor 36(19) Linagliptin  12(6) 
Sitagliptin 19(10) 
Saxagliptin 5(3) 
Weight 
Increasing  
64 (34) 
Sulphonylureas  
 
16(8) Gliclazide  15(8) 
Gliclazide SR  1(0.5) 
Insulin  
 
46(24) Novomix Mixtard 30  12(6) 
Insulin Detemir  13(7) 
Insulin Glargine  9(5) 
Novorapid  2(1) 
Basal Bolus  4(2) 
Humulin I  3(2) 
Humulin M3  2(1) 
Hypurin Porcine  1(0.5) 
Thiazolodinediones  2(1) Pioglitazone  2(1) 
Meglitinides  0(0) Nateglinide  0(0) 
 
Table 5.4 shows participants’ characteristics for each weight-effect group at baseline 
and at 3-month follow-up with comparisons made within time period. At baseline, 
participants were more likely to be prescribed a diabetes medicine with weight 
neutral effect in primary care and be recruited from a community pharmacy than 
from secondary care (p<0.0001). Participants were less likely to be recruited from a 
community pharmacy if they were prescribed a diabetes medicine with WR effect 
(p<0.001).  
 
Those prescribed WR medicines had a significantly higher BMI at baseline than the 
other two weight-effect groups (p≤0.001) and this remained significantly higher at 
three-month follow-up compared to those treated with WN (p<0.05) and WI 
medicines (p≤0.001). Furthermore, at baseline, they were significantly younger than 
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the WN group (p<0.05), and were more likely to be women. Those prescribed WI 
medicines had significantly higher HbA1c at baseline compared to the other two 
groups (p≤0.001) and this remained significantly higher at three month follow-up 
(p<0.01). They also had higher creatinine levels at three month follow-up compared 
to the WR group (p<0.05). Those prescribed WN medicines were taking a significantly 
lower number of medicines overall per day both at baseline and three-month follow-
up compared to the WI group (p≤0.01). In addition, the same group was taking 
significantly less number of diabetes medicines both at baseline (p≤0.001) and at 
three-month follow-up (p≤0.01) compared to the other two groups.  
 
Overall, the whole group significantly lost weight (median=0.9kg, p<0.001) and 
reduced their HbA1c (median=8mmol/mol, p<0.001) at 3-month follow-up. 
However, those prescribed WR medicines lost significantly more weight (p<0.01) and 
those prescribed WN medicines had significant lower HbA1c (p<0.01) at three-month 
follow-up.  
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Table 5.4: Study participant characteristics at baseline and follow-up for each weight-effect group 
 BASELINE 3-MONTH FOLLOW-UP 
Participant 
Characteristics n(%) 
Weight Reducing Weight Neutral Weight Increasing Weight Reducing Weight Neutral Weight Increasing 
Total N 68 58 64 68 58 64 
Centre Site-  
SCDC 
GP Practice 
CP 
 
28(41.2) 
38(55.9) 
2 (2.9) 
 
10(20.1) 
36(62.1) 
12(20.7) 
 
28(43.8) 
33(51.6) 
3(4.7) 
   
Gender-Men  27 (39.7%) 35 (60.3%) 41 (64.1%)    
Age (years)  56.5 ±9.2+ 62 ± 10.6+ 60.6 ± 12    
Diabetes Duration 
(yrs) 
Missing  
7.5(4.0,12.0) 
 
0(0) 
6.0(2.0,13.0) 
 
1 (1.7) 
9.0(4.0,14.0) 
 
2(3.1) 
   
Weight Change(kg) 
Missing Data  
   -2.5 (-5.0, -0.7)***++ 
8(11.8) 
-0.6 (-2.8, 1.2)++$$ 
25(43.1) 
1.0(-0.4, 2.3)***$$ 
18 (28.1) 
BMI(kg/m2) 
 
Missing  
37.8 (35.3,42.0)*** 
+++ 
1 (1.5) 
32.4 (28.1, 38.8) +++ 
 
3(5.2) 
32.5 (30.8, 37.9) *** 
 
1(1.6) 
37.5 (34.0, 42.0) + 
*** 
8(11.8) 
33.6 (30.1, 40.0)+ 
 
23(39.7) 
33.1 (30.3, 38.3) *** 
 
17(26.6) 
HbA1c(mmol/mol) 
Missing  
73 (65, 86)*** 
2 (2.9) 
72 (60, 85.5)+++ 
1(1.7) 
88 (76, 97.5)***+++ 
4(6.3) 
64 (51, 75)** 
19(27.9) 
60 (53, 79)++ 
13(22.4) 
76 (62, 91)**++ 
13(20.3) 
HbA1c Change 
(mmol/mol) 
Missing  
   -8 (-16, -2) 
 
21 (30.9) 
-8 (-17, -2.5) 
 
13 (22.4) 
-13 (-22, -1.5) 
 
15 (23.4) 
BP systolic 136.12±14.6 130.49±13.93 136.10±18.24  131(120, 140) 125(116, 136) 136(120, 153) 
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Missing  3(4.4) 1(1.7) (6.3) 33(48.5) 27(46.6) 27(42.2) 
BP diastolic 
Missing  
76.26±11.5 
3(4.4) 
72.51±10.9 
1(1.7) 
77.35±9.6 
4(6.3) 
76(70, 81) 
33(48.5) 
70(63, 80) 
27(46.6) 
77(70, 84) 
27(42.2) 
Total Cholesterol 
Missing  
4.1 (3.5, 5.0) 
19(27.9) 
3.9 (3.5, 5.1) 
11(19) 
4.2 (3.6, 5.0) 
6(9.4) 
3.7 (3.5, 4.4) 
49(72.1) 
3.7 (3.5, 4.4) 
35(60.3) 
4.2(3.4, 5.6) 
33(51.6) 
LDL 
Missing  
1.9 (1.5, 2.6) 
25(36.8) 
2.0 (1.4, 2.9) 
15(25.9) 
2.1 (1.6, 2.6) 
16(25) 
1.75 (1.4, 2.2) 
50(73.5) 
1.78(1.3, 2.1) 
41(70.7) 
2.2(1.1, 3.4) 
41(64.1) 
HDL 
Missing  
1.1 (0.9, 1.4) 
20 (29.4) 
1.1 (1.0, 1.3) 
11(19) 
1.0 (0.9, 1.2) 
8(12.5) 
1.1(0.9, 1.2) 
49 (72.1) 
1.1(0.9, 1.2) 
36 (62.1) 
1.1(0.9, 1.4) 
35(54.7) 
Triglycerides 
Missing  
2.3 (1.6, 2.7) 
22(32.4) 
1.8 (1.3, 2.8) 
13(22.4) 
2.2 (1.5, 3.4) 
11(17.2) 
1.95 (1.6, 2.6) 
50(73.5) 
1.6 (1.2, 3.2) 
39(67.2) 
2.0 (1.5, 3.2) 
37(57.8) 
Creatinine 
Missing  
73 (65, 90) 
7(10.3) 
79 (68, 124) 
4(6.9) 
81 (69, 108) 
5(7.8) 
75(65, 93)+ 
28(41.2) 
83(69, 133) 
20(34.5) 
84(76, 109)+ 
21(32.8) 
eGFR  
Missing  
81 (68, 90) 
6(8.8) 
76 (50, 90) 
4(6.9) 
74 (54, 90) 
5(7.8) 
73(65, 89) 
29 (42.6) 
80(44, 89) 
21(36.2) 
66(57, 84) 
23(35.9) 
Total Medication 
Burden 
Missing  
7 (4, 11) 
 
4 (5.9) 
6 (4, 9)** 
 
2(3.4) 
9 (6, 11)** 
 
2(3.1) 
7 (5,11) 
 
13(19.1) 
6 (4,9)** 
 
10(17.2) 
9 (6,11)** 
 
16(25) 
Total Diabetes 
Medication Burden 
Missing  
2(1, 3)+++ 
 
0(0) 
1 (1,2) +++*** 
 
1(1.7) 
2 (1, 3)*** 
 
1(1.6) 
2 (2, 3)++ 
 
10 (14.7) 
2 (1,3)++** 
 
9(15.5) 
3 (2, 3)** 
 
16(25) 
Diabetes 
Complications  
Missing  
1 (0, 1) 
 
1(1.5) 
1 (0, 1) 
 
1(1.7) 
1 (0, 2) 
 
0(0) 
1 (0, 2) 
 
12(17.6) 
0 (0, 1) 
 
10(17.2) 
1 (0, 2) 
 
15(23.4) 
Data are Median (IQR) Or n(%) Or Mean(±SD). Difference between pairs within time period: +p<0.05, **p≤0.01, ++p≤ 0.01, $$p≤0.01, +++p≤0.001***p≤0.001, Bonferroni 
Correction p<0.017 
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Table 5.5: Baseline and Follow-up scores for all scales for the whole group and each weight-effect group 
 Baseline  Follow-up  
Medication 
Adherence Level 
Whole Group Weight 
Reducing 
Weight 
Neutral 
Weight 
Increasing 
P value Whole 
Group 
Weight 
reducing 
Weight 
Neutral 
Weight 
Increasing 
P value 
Total N 188 67 57 64  188 67 57 64  
EITQ (baseline)/ 
PITQ (Follow-up) 
5.5 (5.1, 6.0) 5.6 (5.1, 6.0) 5.6 (5.1, 6.1) 5.5 (4.9, 5.9) 0.301 5.6(5.1,6.0) 5.6 (5.2, 6.0) 5.6 (5.3, 6.0) 5.6(5.0,6.0) 0.594 
SIMS 13 (9, 16) 13 (8, 16) 13 (10, 16) 13 (9, 18) 0.730 15 (9, 17) 16 (12, 18) 15 (8, 17) 14 (9, 18) 0.243 
SIMS-AU 8 (6, 9) 7 (6, 9)* 8 (6, 9) 9 (7, 9)* 0.008 8 (6, 9) 8 (7, 9) 7 (6, 9) 9 (7, 9) 0.048 
SIMS-PPM 5(2,8) 5 (3, 8) 5 (3, 8) 5 (2, 9) 0.885 7 (3, 9) 7 (5, 9) 6 (2,9) 6 (3, 9) 0.208 
BMQ-Concerns 2.9 (2.4, 3.3) 2.9 (2.4, 3.1) 2.9 (2.4, 3.4) 3.0 (2.4, 4.4) 0.944 2.7(2.3,3.3) 2.7 (2.3, 3.1) 2.7 (2.3, 3.3) 2.9(2.2,3.5) 0.189 
BMQ-Necessity 4(3.4, 4.2) 3.8(3.4, 4.2)* 3.8(3.4, 4.2) 4.0(3.6, 4.8)* 0.015 3.8(3.4,4.4) 3.8 (3.2, 4.2) 3.8(3.2, 4.0) 4.0(3.6,4.6) 0.061 
BMQ Necessity –
Concern 
Differential 
0.94 (0.46, 
1.51) 
0.93 (0.46, 
1.45) 
0.73 (0.28, 
1.44) 
1.11 (0.60, 
1.69) 
0.124 0.91 (0.41, 
1.67) 
0.89 (0.43, 
1.71) 
0.89 (0.35, 
1.44) 
1.14 (0.44, 
1.66) 
0.602 
BMQ-Overuse 2. 7 (2.3, 3.3) 2.7 (2.3. 3.3) 2.7 (2.3, 3.3) 2.7 (2.3, 3.3) 0.936 3.0(2.3,3.3) 3.0 (2.7, 3.3) 3.0 (2.3, 3.7) 3.0(2.3,3.5) 0.736 
BMQ-Harm 2.5 (2.0. 2.8) 2.5 (2.0, 2.8) 2.5 (2.0, 2.8) 2.3 (2.0. 2.8) 0.483 2.5(2.0,2.8) 2.5 (2.0, 2.8) 2.5 (2.3, 2.8) 2.5(2.0,2.8) 0.620 
BMQ-Benefits 4.0 (3.8, 4.3) 4.0 (3.5, 4.3) 4.0 (3.8, 4.1) 4.0 (4.0, 4.5) 0.056 4.0(3.8,4.3) 4.0 (3.8, 4.0) 4.0 (3.8, 4.5) 4.0(4.0,4.5) 0.075 
SEAMS 3.7 (3.0, 4.0) 3.4 (2.9, 3.9) 3.7 (3.1, 4.2) 3.9 (3.1, 4.4) 0.117 3.8(3.1,4.1) 3.7 (3.2, 4.4) 3.8 (3.1, 4.0) 3.8(2.9,4.2) 0.774 
SEAMS-UCU 3.5 (2.7, 4.0) 3.3 (2.3, 4.0) 3.4 (2.7, 4.0) 3.8 (2.8, 4.2) 0.108 3.7(3.0,4.0) 3.9 (3.0, 4.1) 3.7 (3.0, 4.0) 3.8(2.8,4.0) 0.544 
SEAMS-UDC 3.8 (3.1, 4.1) 3.6 (3.0, 4.0)* 4.0 (3.6, 4.4)* 4.0 (3.0, 4.4) 0.039 4.0(3.3,4.1) 3.9 (3.4, 4.8) 4.0 (3.4, 4.0) 3.8(2.8,4.0) 0.93 
OWLQOL 65.7 (33.1, 
84.5) 
42.6 (23.8, 
68.1)*^ 
71.6 (56.6, 
91.2)* 
78.3 (39.7, 
89.9)^ 
<0.001 72.0 (43.6, 
86.5) 
53.4(27.2, 
76.5)+^ 
77.4 (83.2, 
90.7)+ 
78.4, 52.2, 
90.7)^ 
0.001 
Total N 170 64 45 61  170 64 45 61 170 
MMAS-8 6.8 (5.5, 7.8) 6.8 (4.8, 7.7) 7.0 (5.7, 7.7) 6.8 (5.7, 8.0) 0.513 7.0(5.7,8.0) 6.5 (4.7, 8.0) 7.0 (6.0, 8.0) 6.8(5.1,8.0) 0.120 
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Total N  166 65 43 58  166 65 43 58  
DiabMedSat 65.2 (55.6, 
75.4) 
66.7 (56.6, 
75.1) 
71.8 (52.9, 
80.8) 
63.1 (55.0, 
70.6) 
0.061 72.5 (61.3, 
80.4) 
73.6 (65.0, 
80.3) 
73.5 (58.8, 
82.9) 
68.5 (57.9, 
77.0) 
0.174 
DiabMedSat- 
Efficacy 
53.3 (36.7, 
63.3) 
55.0 (37.5, 
63.3) 
60.0 (48.3, 
69.6)* 
45.0 (28.5, 
56.7)* 
0.003 61.7 
(48.376.7) 
62.5 (48.7, 
76.7) 
60.0 (49.6, 
76.7) 
61.7 (41.7, 
78.3) 
0.938 
DiabMedSat 
Burden 
81.8 (68.9, 
91.3) 
86.4 (68.6, 
91.7) 
82.6 (68.4, 
93.4) 
77.6 (71.2, 
87.1) 
0.20 84.9 (75.0, 
93.3) 
87.1 (78.2, 
94.5)* 
87.1 (75.4, 
95.5) 
79.5 (68.9, 
89.4)* 
0.027 
DiabMedSat 
Symptoms 
68 (52, 80) 64 (52, 78) 68 (49, 84) 68 (52, 76) 0.642 72 (56, 78) 72 (60, 80) 72 (56, 80) 64 (55, 76) 0.135 
TRIM-Wt-DL 66.7 (54.2, 
79.2) 
66.7 (50.0, 
79.2) 
70.8 (54.2, 
79.2) 
66.7 (58.3, 
75) 
0.552 75.0 (58.3, 
79.2) 
72.9 (62.5, 
79.2) 
75.0 (62.5, 
83.3) 
70.8 (50.0, 
100) 
0.106 
TRIM-Wt-WM 33.3 (16.7, 
50.0) 
25.0 (16.7, 
33.3)* 
33.3 (25.0, 
50.0) 
41.7 (25.0, 
58.3)* 
0.002 41. 7 (25.0, 
66.7) 
50.0 (25.0, 
66.7) 
41.7 (29.2, 
66.7) 
41.7 (25.0, 
66.7) 
0.908 
TRIM-Wt-PH 75.0 (50.0, 
93.7) 
71.9 (39.1, 
92.2) 
75.0 (56.2, 
100) 
75.0 (50.0, 
100) 
0.168 75.0(50.0, 
93.7) 
75.0 (50.0, 
93.7) 
75.0 (56.2, 
100) 
75.0 (56.2, 
93.7) 
0.468 
Values are Median (Q1, Q3), Significant difference between weight-effect groups, Bonferroni correction *p<0.017, +p<0.017, ^p<0.017 
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5.5 Changes in expectations, beliefs and attitudes overtime  
This section describes in detail how participants’ expectations, beliefs, attitudes, and 
adherence levels changed over time, as well as any differences between weight-
effect groups. The Table 5.5 (previous page) presents participants’ scale scores at 
both baseline and follow-up for the whole group and for each weight-effect group.  
 
5.5.1 Expectations and perceptions of new medicine (EITQ, PITQ) 
5.5.1.1 Whole Group- Baseline versus Follow-up 
There was no significant difference between participants’ perceptions (median=5.6) 
and expectations (median=5.5) about their new diabetes treatment, (p=0.463). 
(Figure 5.4; Table 5.5).  
 
Figure 5.4: Expectations (EITQ) and Perceptions (PITQ) about new medicine at baseline and 
follow-up 
 
Although the majority of participants were classified as having their expectations met 
or exceeded by experience13, there was still a third of the group (33%) who felt that 
their expectations of their new medicine were unmet (Figure 5.5, Appendix 5.5).  
                                                     
13 Changes were calculated based on SEM (Section 4.2.4 and Appendix 5.4) 
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Figure 5.5: Percentage of participants whose expectations of new medicine were unmet, 
met or exceeded by experience 
 
5.5.1.2 Weight-Effect Groups – Baseline versus Follow-up 
For each weight–effect group (Figure 5.4, Table 5.5), there were no significant 
differences between participants’ perceptions and expectations about their new 
diabetes treatment (WR Group: baseline median 5.6 Vs follow-up median 5.6 
p=0.221, WN Group: baseline median 5.6 Vs follow-up median 5.6 p=0.582, WI 
Group: baseline median 5.5 Vs follow-up median 5.6 p=0.658).  
 
Weight Reducing Group 
A closer look at single items from the EITQ/PITQ revealed that a significantly higher 
proportion of this group agreed with the statements that their new medicine will 
make it easier to control their blood sugars (p=0.001), and make them feel better 
(p<0.001) compared to follow-up (Figures 5.6 and 5.7), suggesting that they had 
higher expectations prior to taking their new medicine than perceptions at three 
month follow-up.  
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Figure 5.6: Percent agreement to EITQ/PITQ item “taking this new medicine (will/makes) 
it easier to control my blood sugars” at baseline and follow-up for WR group.  
 
 
Figure 5.7: Percent agreement to EITQ/PITQ item “taking this new medicine (will/makes) 
me feel better” at baseline and follow-up for WR group.  
 
In addition, a significantly higher proportion of participants in this group, disagreed 
with the statement that the delivery system was physically painful (or difficult to 
swallow) (p=0.049) (not shown), and agreed that it was easy to use away from home 
(or as prescribed) (p=0.004) (Appendix Figure 5.1) and that it was convenient 
(p=0.007) (Appendix Figure 5.2). This shows that this group were more positive about 
their new medicine at follow-up than at baseline.  
 
P<0.001 
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Weight Neutral Group 
Those treated with weight neutral medicines also had higher expectations about 
their new medicine in relation to how easy it was going to be to control their blood 
sugars (p=0.001) (Figure 5.8), and make them feel better (p<0.001) (Figure 5.9). They 
also had more positive perceptions about their new medicine as they thought it did 
not cause them to have severe episodes of low blood sugar (p=0.026) (not shown).  
 
 
Figure 5.8: Percent agreement to EITQ/PITQ item “taking this new medicine (will/makes) 
it easier to control my blood sugars” at baseline and follow-up for WN group.  
 
Figure 5.9: Percent agreement to EITQ/PITQ item “taking this new medicine (will/makes) 
me feel better” at baseline and follow-up for WN group. 
  
P<0.001 
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Weight Increasing Group 
Those treated with weight increasing medicines also had higher expectations about 
their new medicine in relation to how easy it was going to be to control their blood 
sugars (p=0.042), and make them feel better (p=0.001) (Figure 5.10). They also had 
more positive perceptions about it, as they thought it did not cause them to have 
severe episodes of low blood sugar (p<0.001) (Figure 5.11). In addition, they had 
more positive perceptions about the delivery system, particularly that it was easy to 
get the dose or amount with the delivery system (p=0.046) (not shown).  
 
 
Figure 5.10: Percent agreement to EITQ/PITQ item “taking this new medicine (will/makes) 
me feel better” at baseline and follow-up for WI group.  
 
Figure 5.11: Percent agreement to EITQ/PITQ item “taking this new medicine (will 
cause/causes) me to have severe episodes of low blood sugar” at baseline and follow-up 
for WI group.  
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5.5.1.3 Weight-Effect Groups – Comparison between groups 
There were no statistical differences between baseline expectation scores (EITQ 
p=0.301) or follow-up perception scores (PITQ p=0.594), when all three weight-effect 
groups were compared (Table 5.5). Overall, those treated with weight reducing 
medicines had the highest proportion of participants in whom their expectations 
were exceeded by experience (45%, n=30), and those treated with weight neutral 
medicines had the highest proportion of participants in whom their expectations 
were unmet (39%, n=22), (Figure 5.5). There was no statistical difference between 
the groups in relation to changes in scores (p=0.560) (Appendix 5.5). 
 
5.5.2 Satisfaction with information about medicines (SIMS) 
5.5.2.1 Whole Group- Baseline Versus Follow-up 
Participants were significantly more satisfied with the overall information they 
received about their new medicine at three month follow-up (median=15), than at 
baseline (median=13) (p=0.004) (Figure 5.12; Table 5.5).  
 
 
Figure 5.12: Overall satisfaction with amount of information about new medicine (SIMS) 
at baseline and follow-up. +Indicates significant difference between baseline and follow-up 
for the whole group, * Indicates significant difference between baseline and follow-up in the 
WR group 
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There was no difference in scores about the satisfaction of information received 
relating to the action and usage of their new medicine before (median=8) and after 
treatment (median=8), p=0.353 (Figure 5.13; Table 5.5). However, participants were 
significantly more satisfied with the information they received about the potential 
problems with the new medicine at three months follow-up (median=7), than at 
baseline (median=5), p=0.001 (Figure 5.14, Table 5.5).  
 
 
Figure 5.13: Satisfaction with amount of information related to action and usage of new 
medicine (SIMS-AU) at baseline and follow-up. * Indicates significant difference between 
baseline and follow-up in the WR group 
 
 
Figure 5.14: Satisfaction with amount of information related to potential problems with 
new medicine (SIMS-PPM) at baseline and follow-up. +Indicates significant difference 
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between baseline and follow-up for the whole group,* Indicates significant difference 
between baseline and follow-up in the WR group 
 
Although satisfaction levels with the overall information received about the new 
medicines (SIMS) either increased or remained stable over time, for a quarter of the 
whole group (22%, n=41) the satisfaction levels decreased at three month follow-up 
(Figure 5.15, Appendix 5.6).  
 
 
Figure 5.15: Percentage of participants who showed improvement, no change or reduction 
in satisfaction with information received about new medicine (SIMS) 
 
Similar satisfaction changes can be seen in the whole group in relation to information 
about the action and usage of their new medicine (Figure 5.16) including information 
about potential problems (Figure 5.17). More participants were less satisfied about 
the information relating to action and usage of their new medicine (28%, n=52), 
compared to those who were less satisfied with the information about potential 
problems with their new medicine (18%, n=31). 
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Figure 5.16: Percentage of participants who showed improvement, no change or reduction 
in satisfaction with information received about new medicine related to action and usage 
(SIM-AU)  
 
 
Figure 5.17:  Percentage of participants who showed improvement, no change or reduction 
in satisfaction with information received about new medicine related to potential 
problems with medicine (SIM-PPM) 
 
5.5.2.2 Weight-Effect Groups – Baseline Versus Follow-up 
Weight Reducing Group 
The WR group were significantly more satisfied with the information they had 
received about their new medicine at three months follow-up (median=16) 
compared to baseline (median=13), p<0.001. Similar effects were found for the same 
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group in relation to information about the action and usage of their new medicine 
(median=7 Vs median=8, p=0.006) and the potential problems with their new 
medicine (median=5 Vs median=7, p=0.001) (Figures 5.12-5.14). 
 
There was also significant difference in single items within the SIM scale for the WR 
group. Significantly more participants were satisfied with the following information 
after initiation of the new treatment; how long it will take to work (p=0.025) (not 
shown), how you can tell if it is working (p=0.018) (not shown), how to get further 
supplies (p=0.002) (Appendix  Figure 5.3), whether you can drink alcohol (p<0.001), 
whether medicine will make you feel drowsy (p=0.002) (Appendix Figure 5.4), 
whether medicine will affect your sex life (p=0.002), and what you should do if you 
forget a dose (p<0.001) (Figure 5.18).  
 
 
Figure 5.18: Percent agreement to SIMS item “Have received enough information about 
what you should do if you forget a dose” at baseline and follow-up for WR group.  
 
Weight Neutral Group 
Although there was no overall significant difference before and after their new 
treatment for this scale (SIMS p=0.449, SIMS-AU p=0.542, SIMS-PPM p=0.338, Table 
5.5), the WN group was generally dissatisfied with the information they received 
about their new treatment. They were significantly less satisfied with information 
relating to how it works (p=0.048) (not shown) and what you should do if you 
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experience unwanted side effects (p=0.02) (not shown). On the other hand, they 
were significantly more satisfied with the following items after their new treatment 
started; whether the medicine will affect their sex life (p=0.018) (not shown), and 
what they should do if they forget a dose (p=0.046) (not shown). 
 
Weight Increasing Group 
The WI group had mixed levels of satisfaction with the information they received 
about their new treatment despite no overall significant changes between baseline 
and follow-up (SIMS p=0.233, SIMS-AU p=0.586, SIMS-PPM p=0.194). This group was 
significantly more satisfied at three months follow-up relating to information about 
what they should do if they experience unwanted side effects (p=0.02) (not shown) 
and whether they can drink alcohol (p=0.005) (Appendix Figure 5.5). 
 
5.5.2.3 Weight-Effect Groups – Comparison between groups 
When the three weight-effect groups were compared, there was a statistically 
significant difference in the scores obtained on the SIMS-AU, both at baseline 
(p=0.008) and at follow-up (p=0.048) (Table 5.5). However, after Bonferroni 
correction (p<0.017), only the scores obtained at baseline were statistically 
significant. That is, the WR group were less satisfied with the information they 
received about the action and usage of their new medicine (median=7) compared to 
the WI group (median=9) p=0.002 (Figure 5.19). There were no other significant 
differences between the other groups (Table 5.5).  
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Figure 5.19: Differences in satisfaction with amount of information related to action and 
usage of new medicine (SIMS-AU) at baseline and follow-up. *Indicates significant 
difference between WR and WI groups for baseline scores 
 
Generally, the WR group had the highest proportion of participants in whom 
satisfaction levels about the information they received about their new medicine 
improved (46%, n=31), followed by the WN group (39%, n=22).  However, satisfaction 
levels decreased over time in about a quarter of participants in the WN and WI 
groups (26% n=15; 25% n=16 respectively) (Figure 5.15, Appendix 5.6).  
 
A significantly higher proportion of participants in the WR group (43%, n=29) had 
improved satisfaction levels in relation to the action and usage of the new medicine 
at three month follow-up compared to the weight increasing group (22%, n=14) 
(p=0.012) (Figure 5.16 Appendix 5.6). Almost half of the same group (45%, n=30) had 
increased satisfaction levels regarding the information related to potential problems 
with the new medicine (Figure 5.17, Appendix 5.6). Nevertheless, the WN and WI 
groups appeared to be less satisfied at three months follow–up with the information 
related to action and usage of their new medicine (33% n=19; 31% n=20 respectively) 
compared to potential problems with it (Figure 5.16).  
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5.5.3 Beliefs about Medicines (BMQ)- General and Specific 
5.5.3.1 Whole Group- Baseline Versus Follow-up 
There was no difference in participants’ beliefs relating to the necessity of their 
diabetes medicines before (median=4.0) and after (median=3.8) the new treatment, 
p=0.075 (Figure 5.20; Table 5.5).  
 
Figure 5.20: Beliefs about necessity of new medicine (BMQ-Necessity) at baseline and 
follow-up. 
 
Participants were significantly less concerned about the potential adverse effects of 
their prescribed diabetes medicines at 3-month follow-up (median=2.71) than at 
baseline (median=2.86), p=0.005 (Figure 5.21, Table 5.5). 
 
Figure 5.21: Beliefs about Concerns of new medicine (BMQ-Concerns) at baseline and 
follow-up. +Indicates significant difference between baseline and follow-up for the whole group,* 
Indicates significant difference between baseline and follow-up in the WR group 
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Figure 5.22 shows that the majority of the participants fell into the ambivalent group 
(high necessity and high concerns) at both baseline and follow-up, whereas only a 
fifth of the group (20% and 22% respectively) accepted their new medicines (high 
necessity, low concerns). There was no difference in the necessity-concern 
differential before (median=0.94) and after (median=0.91) the new treatment 
(p=0.370).  
 
Figure 5.22: Diabetes Medicines Belief Groups at baseline and follow-up. Four different 
groups created based on median split for BMQ-Necessity and BMQ-Concerns. No significant 
difference found between belief groups and weight-effect groups both at baseline and 
follow-up.  
 
There was no difference in beliefs that prescribed medicines are harmful and 
addictive before (median=2.5) or after (median=2.5) the new treatment, p=0.293 
(Figure 5.23, Table 5.5), nor was there a difference in participants’ beliefs about the 
benefits of medicines in general before (median=4.0) or after (median=4.0) the new 
treatment, p=0.631, (Figure 5.24, Table 5.5).  
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Figure 5.23: Beliefs about Harm of medicines in general (BMQ-Harm) at baseline and 
follow-up. 
 
 
Figure 5.24: Beliefs about Benefits of medicines in general (BMQ-Benefits) at baseline and 
follow-up. 
 
Participants significantly believed that medicines are overused by doctors; these 
beliefs were stronger at 3-month follow–up (median=3) than at baseline 
(median=2.7), p=0.006, (Figure 5.25, Table 5.5).  
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Figure 5.25: Beliefs about Overuse of medicines in general (BMQ-overuse) at baseline and 
follow-up. +Indicates significant difference between baseline and follow-up for the whole 
group,* Indicates significant difference between baseline and follow-up in the WN group 
 
The majority of participants’ beliefs about their medicines in relation to necessity 
(41%, n=77), concerns (44%, n=83), harm (65%, n=123), benefits (62%, n=116) and 
overuse (60%, n=112) did not change following initiation of new treatment. However, 
about half of the participants’ beliefs did change over time; either becoming stronger 
or decreasing (Figures 5.26-5.30, Appendix 5.7). In particular, 35% (n=66) believed 
the necessity of their new medicine was less at three months follow-up, whereas 24% 
(n=46) had stronger beliefs (Figure 5.26, Appendix 5.7).  
 
Figure 5.26: Percentage of participants who showed stronger beliefs, no change or 
reduction in beliefs about the necessity of new medicine (BMQ-Necessity) 
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A third of the participants (35%, n=66) had less concerns about the potential adverse 
effects of their new medicine, whereas 21% (n=40) had stronger beliefs on this 
aspect.  (Figure 5.27, Appendix 5.7).  
 
 
Figure 5.27: Percentage of participants who showed stronger beliefs, no change or 
reduction in beliefs about concerns over the new medicine (BMQ-Concerns)  
 
Overall a quarter of the group (25%, n=47) had stronger beliefs about the overuse of 
medicines by doctors, whereas a smaller proportion (15%, n=29) felt less strongly 
about this aspect (Figure 5.28, Appendix 5.7).  
 
 
Figure 5.28: Percentage of participants who showed stronger beliefs, no change or 
reduction in beliefs about overuse of prescribed medicines (BMQ-Overuse)  
 
Also, 18% (n=33) had stronger beliefs about the benefits of medicines whereas in 
20% (n=38) this decreased. (Figure 5.29, Appendix 5.7).  
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Figure 5.29: Percentage of participants who showed stronger beliefs, no change or 
reduction in beliefs about benefits of prescribed medicines (BMQ-Benefits) 
 
In addition, 18% (n=34) had stronger beliefs about the harm of medicines in general 
and this decreased in 17% (n=31). (Figure 5.30, Appendix 5.7).  
 
 
Figure 5.30: Percentage of participants who showed stronger beliefs, no change or 
reduction in beliefs about harm of prescribed medicines (BMQ-Harm) 
 
5.5.3.2 Weight-Effect Groups – Baseline versus Follow-up 
Weight Reducing Group 
Participants in the WR group had significantly less concerns about their new medicine 
at follow-up (median=2.71) than at baseline (median=2.86), p=0.001 (Figure 5.21). 
On closer inspection of the BMQ-specific scale; significantly more people in this 
group disagreed at follow-up with the statement that their medicine disrupts their 
life (p=0.016) (not shown) and that taking this medicine will cause them to gain 
weight (p=0.001). Nevertheless, approximately a third (28%) were still uncertain at 
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follow-up whether their new medicine would cause weight gain (Figure 5.31). There 
were no other significant differences in this group regarding their beliefs about their 
diabetes medicines (BMQ-Necessity p=0.3936, BMQ-Harm p=0.803, BMQ-Benefits 
p=0.464, BMQ-Overuse p=0.213).  
 
 
Figure 5.31: Percent agreement to BMQ item “I worry that taking these medicines will 
cause me to gain weight” at baseline and follow-up for WR group.  
 
Weight Neutral Group 
Participants in the WN group had stronger beliefs that medicines are overused by 
doctors at follow–up (median=3.0) than at baseline (median=2.7), p=0.039 (Figure 
5.25). This was specifically influenced by the item “doctors place too much trust on 
medicines”; with a slight increase (5.6%) in proportion of participants who agreed 
with this statement at follow-up. Overall, 39% of participants in this group were 
uncertain about this statement at 3 months whereas 23% agreed. There were no 
other significant differences in beliefs about their diabetes medicines in this group 
(BMQ-Necessity p=0.447, BMQ-Concerns p=0.069, BMQ-Harm p=0.25, BMQ-
Benefits p=0.604). 
 
Weight Increasing Group 
Although the WI group did not show a significant difference in their beliefs about 
medicines scales (BMQ-Necessity p=0.118, BMQ-Concerns p=0.909, BMQ-Harm 
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p=0.348, BMQ-Benefits p=0.632, BMQ-Overuse p=0.121; Figures 5.20-5.25), two 
single items showed significant response from baseline to follow-up. Although the 
majority of participants agreed with the statement that their health in the future will 
depend on these medicines, there was less agreement in that statement at follow-
up (86 % baseline Vs 84% follow-up, p=0.024). Furthermore, at follow-up, a higher 
proportion of patients were uncertain (39% vs 28%) or agreed (39% vs 33%) that if 
doctors had more time with patients they would prescribe fewer medicines 
(p=0.014).  
 
5.5.3.3 Weight-Effect Groups – Comparison between groups 
When the three weight-effect groups were compared, there were no differences in 
their scores related to beliefs about concerns, harm, overuse and benefits of their 
medicines. Whereas, there was a statistical difference in scores relating to the 
necessity of their new diabetes medicines (p=0.015, Table 5.5). The WI group had 
stronger beliefs about the necessity of their new medicine (median=4.0) compared 
to the WR group (median=3.8) at baseline, p=0.002 (Figure 5.32). 
 
 
Figure 5.32: Differences in beliefs about Necessity of new medicine (BMQ-Necessity) at 
baseline and follow-up. * Indicates significant difference between WR and WI groups for 
baseline scores 
Changes in beliefs about harm, overuse and benefits of medicines changed for a small 
proportion of patients for all weight-effect groups (Figures 5.26-5.30). However, 
there was more variation in change scores related to the necessity and concerns of 
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their new diabetes medicine. A quarter of each of the WR and WN groups had 
stronger beliefs about the necessity of their new medicine, whereas for all groups 
approximately a third reduced their beliefs about the necessity of their new medicine 
at follow-up (Figure 5.26). Similarly around a third of all weight-effect groups had less 
concerns about their new diabetes medicines at follow-up. Although there was no 
significant difference between the weight-effect groups, more participants in the WI 
group (36%, n=23) had stronger beliefs about the concerns of their new diabetes 
medicines compared to the WR group (13%, n=9) and the WN group (14%, n=8) 
(Appendix 5.7).  
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5.5.4 Satisfaction with Diabetes Medicines -DiabMedSat  
5.5.4.1 Whole Group- Baseline Vs Follow-up 
On the whole, participants were significantly more satisfied with their diabetes 
medicines (median=72.5) at 3-month follow-up than at baseline (median=65.2), 
p<0.001, (Figure 5.33, Table 5.5).  
 
 
Figure 5.33: Total Satisfaction about diabetes medicines (DiabMedSat) at baseline and 
follow-up. +Indicates significant difference between baseline and follow-up for the whole 
group,* Indicates significant difference between baseline and follow-up in the WR group, ^ 
indicates significant difference between baseline and follow-up in the WI group 
 
They found their diabetes medicines less burdensome at 3-month follow-up 
(median=84.9) than at baseline (median=81.8), p=0.014, (Figure 5.34, Table 5.5), and 
were more satisfied with their efficacy at the 3-month follow-up (median=61.7) than 
at baseline (median=53.3), p<0.001, (Figure 5.35, Table 5.5).  
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Figure 5.34: Total Satisfaction, burden scale, about diabetes medicines (DiabMedSat-
Burden) at baseline and follow-up. +Indicates significant difference between baseline and 
follow-up for the whole group,* Indicates significant difference between baseline and follow-
up in the WR group 
 
 
Figure 5.35: Total Satisfaction, efficacy scale, about diabetes medicines (DiabMedSat-
Efficacy) at baseline and follow-up. +Indicates significant difference between baseline and 
follow-up for the whole group,* Indicates significant difference between baseline and follow-
up in the WR group, ^ Indicates significant difference between baseline and follow-up in the 
WI group 
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However, there was no difference in their satisfaction about the symptoms 
experienced with their diabetes medicines before (median=68) or after (median=72) 
new treatment, p=0.139, (Figure 5.36, Table 5.5). 
 
 
Figure 5.36: Total Satisfaction, symptom scale, about diabetes medicines (DiabMedSat-
Symptom) at baseline and follow-up. * Indicates significant difference between baseline 
and follow-up in the WR group 
 
Overall, almost half (48%, n=80) of participants’ satisfaction levels with their new 
diabetes medicine improved at 3-month follow-up (Figure 5.37), particularly in 
relation to efficacy (49%, n=83) (Figure 5.38). In contrast, satisfaction levels for 
burden (49%, n=82) and symptoms (46%, n=76) did not change over time (Figures 
5.39-5.40) except for a third of participants where an improvement was seen (burden 
32%, n=53, and symptom 31%, n=51), (Figures 5.37-5.40, Appendix 5.8). A smaller 
proportion of patients showed a decrease in satisfaction levels over time (efficacy 
19%, n=31, burden 19%, n=32, and symptom 24%, n=40).   
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Figure 5.37: Percentage of participants who showed improvement, no change or reduction 
in satisfaction of new medicine (DiabMedSat)  
 
 
Figure 5.38: Percentage of participants who showed improvement, no change or reduction 
in satisfaction related to the efficacy of new medicine (DiabMedSat-Efficacy)  
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Figure 5.39: Percentage of participants who showed improvement, no change or reduction 
in satisfaction related to the burden of new medicine (DiabMedSat-Burden)  
 
 
Figure 5.40: Percentage of participants who showed improvement, no change or reduction 
in satisfaction related to the symptoms of new medicine (DiabMedSat-Symptom) 
 
5.5.4.2 Weight-Effect Groups – Baseline Versus Follow-up 
Weight Reducing Group 
The WR group was significantly more satisfied with their diabetes medicines overall 
at follow-up (median=73.6 vs median=66.7, p<0.001). In addition, at follow-up, they 
found their diabetes medicines less burdensome (median=87.1 vs median=86.4, 
p=0.011), less symptomatic (median=72 vs median=64, p=0.038), and more 
efficacious (median=62.5 vs median=55, p=0.001) (Figures 5.33-5.36).  
 
0
10
20
30
40
50
60
70
Weight
Reducing
Weight
Neutral
Weight
Increasing
Whole
Group
%
DiabMedSat Burden Change
Decreased
No Change
Improved
0
10
20
30
40
50
60
Weight
Reducing
Weight
Neutral
Weight
Increasing
Whole
Group
%
DiabMedSat Symptom Change
Decreased
No Change
Improved
212 
 
When inspecting single items, significantly more participants at follow–up were 
satisfied with the ease and convenience of their diabetes medicines (p=0.005) 
(Appendix Figure 5.6). Also, more participants either did not have weight gain as a 
side effect (29%) or they were not bothered by unwanted weight gain (32%) due to 
their diabetes medicines at follow-up (p=0.002) (Appendix Figure 5.7).  
 
A significant shift was seen towards better satisfaction with their diabetes medicine’s 
ability to keep blood sugars stable (avoid highs and lows) (p=0.006) (Appendix Figure 
5.8), as well as a significant shift in the distribution towards being more satisfied that 
the medicine helped them feel less tired and lacking in energy over time (p=0.001) 
(Figure 5.41).  
 
 
 
Figure 5.41: Percent agreement to DiabMedSat item “How satisfied or dissatisfied have 
you been with your diabetes medicine(s) ability to help you from feeling tired and lacking 
energy” at baseline and follow-up for WR group.  
 
Furthermore, significantly more people in the weight reducing group were satisfied 
at follow-up with the impact of their diabetes medicines on their physical well-being 
(p=0.001) (Figure 5.42) and on their emotional well-being (p=0.007) (Appendix 
Figures 5.9).  
 
Ability of your diabetes medicine(s) to help you from feeling tired and lacking energy 
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Figure 5.42: Percent agreement to DiabMedSat item “How satisfied or dissatisfied have 
you been with the impact of your diabetes medicine(s) on your physical well-being” at 
baseline and follow-up for WR group.  
 
Weight Neutral Group 
There were no statistical differences between baseline and follow-up scores for the 
WN group in any of the scales (DiabMedSad p=0.293, Burden Scale, p= 0.386, Efficacy 
Scale p=0.088, Symptom Scale p=0.954). Although, at baseline, 52% were not 
bothered at all by how their medicine interfered with their daily life, and this 
increased to 75% at follow-up (p=0.022) (not shown). More participants (53% in total) 
at follow-up indicated that their medicine never interfered with their ability to follow 
their recommended diet compared to 32% at baseline (p=0.036) (not shown). In 
addition, there was a significant increase in participants who at follow-up were 
extremely or very satisfied with their diabetes medicines’ ability to keep blood sugars 
stable (avoid highs and lows) (p=0.024) (not shown). Finally, more participants at 
follow-up were satisfied with their diabetes medicines’ ability to help them feel less 
tired and lack energy (18% at baseline and 40% at follow-up), although just over a 
third (36%) were neither satisfied nor dissatisfied (p=0.027) (not shown). 
 
Weight Increasing Group 
The WI group was also more satisfied with their diabetes medicines overall at follow-
up (median=68.5) compared to baseline (median=63.1), p=0.004 (Figure 5.33), and 
this was related to how efficacious they found their diabetes medicines at follow-up 
compared to baseline (median=61.7 vs median=45), p<0.001) (Figure 5.35). Yet, 
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there were no statistical differences between baseline and follow-up scores in the 
Burden (p=0.46) and Symptom Scales (p=0.801). 
 
When inspecting single items, there was a significant shift in participants who 
indicated that their medicine never or rarely interfered with their ability to be flexible 
with planning meals (when you eat and what you are able to eat) (p=0.007) 
(Appendix- Figure 5.10). In addition, significantly more participants at follow-up were 
extremely or very satisfied with their diabetes medicine ability to keep blood sugars 
stable (avoid highs and lows) (p<0.001), and were extremely or very satisfied with 
their diabetes medicine ability to help them from feeling tired and lacking in energy 
(p=0.001) (Figures 5.43-5.44). Furthermore, significantly more people in this group 
were satisfied at follow-up with the impact of their diabetes medicines on their 
physical well-being (p=0.01) (not shown) and on their emotional well-being (p=0.023) 
(not shown).  
 
 
Figure 5.43: Percent agreement to DiabMedSat item “How satisfied or dissatisfied have 
you been with your diabetes medicine(s) ability to keep your blood sugars stable (avoid 
highs and lows” at baseline and follow-up for WI group.  
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Figure 5.44: Percent agreement to DiabMedSat item “How satisfied or dissatisfied have 
you been with your diabetes medicine(s) ability to help you from feeling tired and lacking 
energy” at baseline and follow-up for WI group.  
 
5.5.4.3 Weight-Effect Groups – Comparison between groups 
There was no statistical difference between the three weight-effect groups on the 
overall satisfaction about their diabetes medicines (Table 5.5), however there was a 
significant difference between groups in the burden (p=0.027) and efficacy (p=0.003) 
subscales. The WR group found their diabetes medicines less burdensome 
(median=87.1) than the WI group (median=79.5) at follow–up, p=0.01 (Figure 5.45). 
The WN group found their diabetes medicines more efficacious at baseline 
(median=60) than the WI group (median= 45), p=0.001 (Figure 5.45). 
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Figure 5.45: Differences in satisfaction about burden (DiabeMedSat-Burden) and efficacy 
(DiabeMedSat-Efficacy) of diabetes medicines at baseline and follow-up. * Indicates 
significant difference between WR and WI groups for follow-up scores, $ Indicates significant 
difference between WN and WI groups for baseline scores 
 
Generally, overall satisfaction levels with the new diabetes medicine for the majority 
of participants in the three weight-effect groups improved (WR 51%, n=33; WN 37%, 
n=16; WI 53%, n=31), with a smaller proportion whose satisfaction levels decreased 
over time (14%, n=9; 30%, n=13; 22%, n=13 respectively) (Figure 5.37, Appendix 5.8). 
 
The WR (55%, n=36) and the WI (58%, n=34) groups had higher proportions of 
patients whose satisfaction levels related to the efficacy of their new medicines 
increased at 3-month follow-up. However, satisfaction in medication efficacy in 55% 
(n=24) of the WN group did not change over time (Figure 5.38, Appendix 5.8). For the 
majority of participants satisfaction levels related to burden and symptoms of new 
medicines did not change over time. However, the WR group had a higher proportion 
of patients whose satisfaction levels regarding the burden (39%, n=25) and 
symptoms (37%, n=24) of new medicine increased compared to the other two groups 
(WN: burden 28%, n=12, symptoms 27%, n=12; WI burden, 27%, n=16, symptoms 
26%, n=15). Conversely, for a quarter of the WI group, satisfaction levels decreased 
for burden (25%, n=15) and symptoms (26%, n=15). Satisfaction levels related to 
symptoms had also decreased for a third of the WN group (32%, n=14) (Figure 5.39-
5.40, Appendix 5.8).  
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5.5.5 Satisfaction with Diabetes Medicines -TRIM-Weight 
5.5.5.1 Whole Group- Baseline Versus Follow-up 
Participants were significantly more satisfied about the impact of their medicines on 
their daily life after the new treatment (median=75) than before initiation 
(median=66.7), p=0.002, (Figure 5.46, Table 5.5).  
 
Figure 5.46: Satisfaction with the impact of new medicine on daily life (TRIM-Wt-DL) at 
baseline and follow-up. + Indicates significant difference between baseline and follow-up in the 
whole group, * Indicates significant difference between baseline and follow-up in the WR group 
 
Participants were also significantly more satisfied with the impact of their diabetes 
medicines on managing their weight after new treatment (median=41.7) than before 
(median=33.3), p<0.001, (Figure 5.47, Table 5.5).  
 
Figure 5.47: Satisfaction with the impact of new medicine on weight management (TRIM- 
Wt-WM) at baseline and follow-up. + Indicates significant difference between baseline and 
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follow-up in the whole group, * Indicates significant difference between baseline and follow-up in the 
WR group, ^ Indicates significant difference between baseline and follow-up in the WN group 
 
There was no statistical difference in participants’ satisfaction about the impact of 
their diabetes medicines on their psychological health before (median=75) and after 
new treatment (median=75), p=0.335, (Figure 5.48, Table 5.5). 
  
 
Figure 5.48: Satisfaction with the impact of new medicine on psychological health (TRIM- 
Wt-PH) at baseline and follow-up. 
 
The majority of the participants’ satisfaction levels relating to the impact of the new 
diabetes medicine on their daily life (63%, n=105), weight management (45%, n=76) 
and psychological health (51%, n=85) did not change over time. However, for a 
quarter to a third of participants their satisfaction levels increased (26%, n=44; 39%, 
n=66; 29%, n=48 respectively) at 3-month follow-up, and a smaller proportion 
decreased (11%, n=19; 16%, n=26; 21%, n=35 respectively) (Figures 5.49-5.51, 
Appendix 5.9).  
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Figure 5.49: Percentage of participants who showed improvement, no change or reduction 
in satisfaction related to the impact of new medicine on daily life (TRIM-Wt-DL) 
 
 
Figure 5.50: Percentage of participants who showed improvement, no change or reduction 
in satisfaction related to the impact of new medicine on weight management (TRIM-Wt-
WM) 
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Figure 5.51: Percentage of participants who showed improvement, no change or reduction 
in satisfaction related to the impact of new medicine on psychological health (TRIM-Wt- 
PH) 
 
5.5.5.2 Weight-Effect Groups – Baseline Versus Follow-up 
Weight reducing group 
The WR group was more satisfied with their medicine’s impact on their daily life 
(baseline median=66.7 Vs follow-up median=72.9, p=0.006), and on managing their 
weight (baseline median=25 Versus follow-up median=50, p<0.001) at three months 
(Figures 5.46-5.47). However there was no significant difference in their satisfaction 
with their medicine’s impact on their psychological health (p=0.079) 
 
On inspecting the single items within the three subscales, significantly more people 
indicated that it is never or rarely a problem for them to be as active as they would 
like because of their medicine (p=0.015) (not shown), and that their medicine never 
or rarely interferes with being as productive as they would like (either at home or 
work) (p=0.038) (not shown). Additionally, more people in this group indicated that 
they are little or not at all bothered by being tired or drowsy because of their 
medicine (p=0.001) (Figure 5.52).  
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Figure 5.52: Percent agreement to TRIM-Weight item “How bothered or not bothered are 
you by being tired or drowsy during the day because of your medicine(s)” at baseline and 
follow-up for WR group.  
 
Furthermore, more people appeared to be satisfied (somewhat to extremely) at 
follow-up with how well their medicine helps them to lose weight (p<0.001) and with 
their medicines’ ability to control appetite (p<0.001) (Figures 5.53-5.54). Despite this 
improvement in satisfaction, a quarter of participants were not at all satisfied with 
the above aspects. Also, more people at follow-up indicated that they never (almost 
never) or rarely feel stressed because of their diabetes medicines (p=0.048) (not 
shown). Nevertheless, almost half (44%) indicated that they sometimes, often or 
always (almost always) feel stressed because of their diabetes medicines. 
 
Figure 5.53: Percent agreement to TRIM-Weight item “How satisfied or dissatisfied are you 
with how well your medicine helps you lose weight” at baseline and follow-up for WR 
group. 
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Figure 5.54: Percent agreement to TRIM-Weight item “How satisfied or dissatisfied are you 
with your medicine’s ability to control your appetite” at baseline and follow-up for WR 
group.  
 
Weight neutral group 
The WN group was also more satisfied with the impact of their diabetes medicines 
on managing their weight after new treatment (median=41.7) than before 
(median=33.3), p<0.039 (Figure 5.47). Yet, there were no significant differences in 
their satisfaction with their medicine’s impact on their daily life (p=0.055) and their 
psychological health (p=0.708). Single items showed that significantly more people 
at follow-up indicated that it is never or rarely a problem for them to be as active as 
they would like because of their medicine (p=0.04) (not shown) and they are not at 
all bothered by weight loss plateaus (periods of no weight loss) (p=0.038) (not 
shown). However, over half of the group (53%) responded that they were still “a 
little” to “extremely” bothered about weight loss plateaus.  
 
Weight increasing group 
Although the WI group did not show any significant differences overall between 
baseline and follow-up on the three subscales relating to daily life (p=0.567), weight 
management (p=0.421) and psychological health (p=0.974), significantly more 
people in this group indicated at follow-up that they were little or not at all bothered 
by being tired or drowsy because of their medicine (p=0.004) (Appendix Figure 5.11). 
Still, a substantial proportion of patients (44%) indicated that they were “a little” to 
223 
 
“extremely” bothered by it. Furthermore, significantly more people indicated at 
follow-up that they are not at all bothered by weight loss plateaus (periods of no 
weight loss) (p=0.025) (not shown), but over half of the group (56%) responded that 
they were still a “little” to “extremely” bothered. 
 
5.5.5.3 Weight-Effect Groups – Comparison between groups 
When the three weight-effect groups were compared, differences were found only 
on the weight management scale (Table 5.5). The WR group was less satisfied with 
the impact of their diabetes medicines on managing their weight at baseline 
(median=25) compared to the WI group (median=41.7), p=0.001 (Figure 5.55). 
 
Figure 5.55: Differences in satisfaction about impact of new medicine on weight 
management (TRIM-Wt-WM) at baseline and follow-up. * Indicates significant difference 
between WR and WI groups for baseline scores 
 
For most of the weight-effect groups there was no change in satisfaction levels 
relating to impact of their new diabetes medicine on daily life, weight management 
and psychological health over time. Nevertheless, the WR group had a significantly 
higher proportion of participants (59%, n=38) whose satisfaction levels increased in 
relation to impact of their new diabetes medicine on weight management compared 
to the other two groups (WN 30%, n=13 p=0.009; WI 25%, n=15, p<0.001) (Figure 
5.50, Appendix 5.9). The WR group also had a significantly lower proportion of 
participants whose satisfaction levels did not change compared to WN (p=0.009) and 
WI (p<0.001) groups (Appendix 5.9).  
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5.5.6 Medication adherence (MMAS-8) 
5.5.6.1 Whole Group- Baseline Versus Follow-up 
There was no significant difference in reported adherence levels before 
(median=6.75) and after (median=7.0) initiation of new treatment in the medication 
adherence scale, p=0.637 (Figure 5.56, Table 5.5).  
 
 
Figure 5.56: Medication adherence (MMAS-8) at baseline and follow-up. 
 
Medication adherence varied across the whole group. The majority of participants 
were classified as medium adherent both at baseline (44%, n=75) and at three month 
follow–up (37%, n=71) (Figure 5.57). 
 
 
Figure 5.57: Level of adherence with diabetes medicines prior and 3 months after new 
medicine prescription for the whole group 
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Almost half of participants (49%, n=84) reported stable adherence levels over the 
three-month period, whereas 23% (n=39) decreased their adherence levels and 28% 
(n=47) increased their adherence levels (Figure 5.58, Appendix 5.10). 
 
 
Figure 5.58: Percentage of participants whose levels of medication adherence (MMAS-8) 
increased, remained stable or decreased over time 
 
5.5.6.2 Weight-Effect Groups – Baseline Versus Follow-up 
There were no statistical differences for either weight-effect groups between 
baseline and follow-up on the medication adherence scale (Figure 5.56, WR p=0.730, 
WN p=0.147, WI p=0.946), neither was there any significant difference in the single 
items of the scale. Although there is a trend in proportions for lower and medium 
adherence groups to decrease overtime, and high adherence groups to increase over 
time; the WI group is the only group which had higher proportions of low adherence 
levels at 3 months (34%, n=22) compared to baseline (28%, n=17); an increase of 6% 
(Figure 5.59).  
 
Figure 5.59: Medication adherence levels between baseline and follow-up for each weight-
effect group.  
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5.5.6.3 Weight-Effect Groups – Comparison between groups 
There were no statistical differences between groups when their adherence levels 
were compared (Table 5.5). Amongst the three weight groups, the WR group had the 
highest proportion of low adherence (41%, n=26) which appeared to remain high at 
follow–up (41%, n=28). This group also had the lowest proportion of high adherence 
levels before and after new medicine (17%, n=11 and 26%, n=18 respectively) 
compared to the other two groups (Figure 5.60). Despite the WI group having the 
highest adherence levels of the three weight-effect groups at baseline (26%, n=16), 
it was the WN group which had the highest proportion of high adherence levels at 3-
month follow-up (36%, n=21). 
 
 
Figure 5.60: Percentage of baseline and follow-up medication adherence levels (MMAS-8) 
for each weight-effect group  
 
Adherence levels in the majority of the participants (43-56%) in each weight-effect 
group remained stable over time. However, adherence levels increased in 22-33% 
and decreased in 18-28% (Figure 5.58, Appendix 5.10).  
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5.5.7 Self-Efficacy with Medication (SEAMS) 
5.5.7.1 Whole Group- Baseline Versus Follow-up 
There was no significant difference in overall self-efficacy with taking the new 
medicine before (median=3.69) or after (median=3.84) initiation of the new 
treatment, p=0.088, (Figure 5.61, Table 5.5).  
 
Figure 5.61: Self efficacy with taking medication scale (SEAMS) at baseline and follow-up. 
* Indicates significant difference between baseline and follow-up in the WR group 
 
Participants were, however, significantly more confident in taking their new 
medicine under circumstances of uncertainty at follow-up (median=3.7) than at 
baseline (median=3.5), p=0.011 (Figure 5.62, Table 5.5).  
 
Figure 5.62: Self efficacy with taking medication under conditions of uncertainty (SEAMS-
UCU) at baseline and follow-up. + Indicates significant difference between baseline and 
follow-up in the whole group,* Indicates significant difference between baseline and follow-
up in the WR group 
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Participants’ confidence in taking their new medicine under difficult circumstances 
did not change at follow-up (median=4.0) from baseline (median=3.8), p=0.568 
(Figure 5.63, Table 5.5). 
 
Figure 5.63: Self efficacy with taking medication under difficult circumstances (SEAMS-
UDC) scale at baseline and follow-up. * Indicates significant difference between baseline 
and follow-up in the WR group 
 
For the majority, their overall self-efficacy in taking their new medicine improved 
over time (41%, n=76), followed by those whose levels decreased (31%, n=57) and 
those who did not change (29%, n=53) (Figure 5.64, Appendix 5.11).   
 
 
Figure 5.64: Percentage of participants who showed improvement, no change or reduction 
in self-efficacy of appropriate use of new medicine (SEAMS) 
 
A similar pattern can be seen in relation to self-efficacy under difficult circumstances 
(Figure 5.65, Appendix 5.11). 
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Figure 5.65: Percentage of participants who showed improvement, no change or reduction 
in self-efficacy under difficult circumstances (SEAMS-UDC) of appropriate use of new 
medicine 
 
Whereas, over time, 41% (n=77) of participants improved their self–efficacy levels in 
relation to taking their new medicine under conditions of uncertainty, 31% (n=57) 
did not change, and 28% showed a decrease (n=52) (Figure 5.66, Appendix 5.11). 
 
 
Figure 5.66: Percentage of participants who showed improvement, no change or reduction 
in self-efficacy under conditions of uncertainty (SEAMS-UCU) of appropriate use of new 
medicine 
 
5.5.7.2 Weight-Effect Groups – Baseline Versus Follow-up 
Weight Reducing Group 
The WR group was significantly more confident in taking their medicine at follow-up 
(median=3.7) than at baseline (median=3.4), p=0.001 (Figure 5.61). In addition, they 
were confident about taking it under conditions of uncertainty (median=3.9 Vs 
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median=3.3, p<0.001), and under difficult circumstances (median=3.9 Vs 
median=3.6, p=0.01) (Figures 5.62- 5.63). 
 
When inspecting the single items, again only the WR group showed significant 
differences in responses to certain items. Significantly more people at follow-up were 
very or extremely confident that they could take their medicines correctly when they 
took several different medicines each day (p=0.005) (Appendix Figure 5.12), when 
they took medicines more than once a day (p=0.012) (not shown), when they were 
away from home (p=0.047) (not shown) and when their normal routine was messed 
up (p=0.024) (not shown). Although, a third (35.3%) of the group was somewhat 
confident with the latter item at follow-up.  
 
Furthermore, significantly more people in this group at follow-up were very or 
extremely confident to take their medicine when they were not sure how to take it 
(p=0.003), when they were not sure what time of the day to take it (p=0.002) 
(Appendix Figures 5.13-5.14), when they were feeling unwell (like having a cold or 
flu) (p<0.001), when they got a refill of their old medicine and some of the pills looked 
different than usual (p=0.001)  (Figures 5.67-5.68) and when they caused some side 
effects (p=0.015). Although, still a quarter of the group (25%) at follow-up were 
somewhat confident in taking their medicine correctly with the latter aspect.  
 
 
Figure 5.67: Percent agreement to SEAMS item “How confident are you that you could take 
your new medicine correctly when you are feeling unwell (you know like having a cold or 
the flu)” at baseline and follow-up for WR group.  
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Figure 5.68: Percent agreement to SEAMS item “How confident are you that you could take 
your new medicine correctly when you get a refill of your old medicine and some of the 
pills look different than usual” at baseline and follow-up for WR group.  
 
Weight Neutral and Weight Increasing Groups 
There were no significant differences in the WN (SEAMS p=0.827, SEAMS-UCU 
p=0.548, SEAMS-UDC p=0.368) and the weight increasing groups (SEAMS p=0.573, 
SEAMS-UCU p=0.746, SEAMS-UDC p=0.376) in either of the scales at baseline and 
follow up.  
 
5.5.7.3 Weight-Effect Groups – Comparison between groups 
When the three weight-effect groups were compared, the WR group was less 
confident (median=3.6) than the WN group (median=4.0) in taking their medicine 
under difficult circumstances at baseline, p=0.012 (Figure 5.69, Table 5.5). 
 
Figure 5.69: Differences in self-efficacy of taking new medicine under difficult 
circumstances (SEAMS-UDC) at baseline and follow-up. * Indicates significant difference 
between WR and WN groups for baseline scores 
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Despite the WR group being less confident in their self-efficacy in taking their new 
medicine correctly at baseline, it is the only group where self-efficacy levels improved 
over time in over half of participants (55%, n=37), compared to the WN (33%, n=19) 
and WI groups (32%, n=20, p=0.017). This difference was significant between the WR 
and WI groups, following Bonferroni correction p<0.017 (Figure 5.64, Appendix 5.11).  
In contrast to the WR group, where over half (52%, n=35) had improved their self-
efficacy levels under difficult circumstances, 42% (n=24) of the WN and 40% (n=25) 
of the WI groups decreased their levels over time (Figure 5.65, Appendix 5.11). The 
WR group had a higher proportion of patients whose self-efficacy levels improved 
(58%, n=39) under conditions of uncertainty (Figure 5.66, Appendix 5.11) and a lower 
proportion of patients whose levels did not change over time (16%, n=11). This 
pattern was significantly different from the WI group, for whom only 32% (n=21, 
p=0.016), improved their self-efficacy levels, and 34% (n=21, p=0.016), did not 
change over time.  
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5.5.8. Weight Related Quality of Life (OWLQOL) 
5.5.8.1 Whole Group- Baseline Versus Follow-up 
There was a significant improvement in overall weight related quality of life between 
baseline (median=65.7) and follow-up (median=72.0), p<0.001 (Figure 5.70, Table 
5.5).  
 
Figure 5.70: Obesity and weight loss quality of life (OWLQOL) scale at baseline and follow-
up. + Indicates significant difference between baseline and follow-up in the whole group,* 
Indicates significant difference between baseline and follow-up in the WR group 
 
Overall, weight related quality of life improved for most of the participants (43%, 
n=81) over time, whereas 35% (n=66) of the group did not change and 22% (n=43) 
decreased (Figure 5.71, Appendix 5.12).  
 
 
Figure 5.71: Percentage of participants who showed improvement, no change or reduction 
in weight related quality of life (OWLQOL) 
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5.5.8.2 Weight-Effect Groups – Baseline Versus Follow-up 
Weight Reducing Group 
The WR group showed improvement in weight related quality of life over 3 months 
(baseline: median=42.6, follow-up: median=53.4, p<0.001) (Figure 5.70). There was 
a statistical improvement in eight items within the quality of life scale in this group 
(Figures 5.72-5.74, Appendix Figures 5.15-19). In spite of this improvement, there 
was still a large number of individuals (varied from 34%-57% in items) who were 
bothered about these aspects from a ‘good deal’ to ‘a very great deal’, as shown in 
the figures. 
 
 
Figure 5.72: Percent agreement to OWLQOL item “Because of my weight, I try to wear 
clothes that hide my shape” at baseline and follow-up for WR group.  
 
Figure 5.73: Percent agreement to OWLQOL item “I worry about physical stress that my 
weight puts on my body” at baseline and follow-up for WR group.  
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Figure 5.74: Percent agreement to OWLQOL item “I feel depressed because of my weight” 
at baseline and follow-up for WR group.  
 
Weight Neutral and Weight Increasing Groups 
There were no significant differences in the WN and the WI groups (p=0.114 and 
p=0.650 respectively) in this scale from baseline and follow up.  
 
5.5.8.3 Weight-Effect Groups – Comparison between groups 
The WR group had a lower score on quality of life (median=42.6) at baseline 
compared to the WN group (median=71.6, p<0.001) and the WI group (median=78.3, 
p<0.001). The score on quality of life for the WR group remained statistically lower 
at follow-up (median=53.4) compared to the WN (median=77.4, p=0.001) and WI 
groups (median=78.4, p=0.002). (Figure 5.75) 
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Figure 5.75: Differences in obesity and weight loss quality of life (OWLQOL) at baseline and 
follow-up. $ Indicates significant difference between WR and WN groups for baseline scores 
* Indicates significant difference between WR and WI groups for baseline scores, + Indicates 
significant difference between WR and WN groups for follow-up scores, ^ Indicates 
significant difference between WR and WI groups for follow-up scores 
 
Despite the WR group having lower quality of life at both baseline and follow-up 
compared to the other two groups, it was the only group in whom quality of life 
improved over time (57%, n=39). This was statistically different from the WI group 
where only 30% (n=19) improved (p=0.005) (Figure 5.71, Appendix 5.12).  
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5.6 Impact of expectations, beliefs and attitudes on adherence 
There are three adherence groups classified according to the MMAS-8 score; these 
are low (score<6), medium (score=6-7) and high (score=8) adherence groups. Table 
5.6 presents the baseline and follow-up clinical, scale scores and other characteristics 
for each of the three adherence level groups. Also, the table presents statistical 
significant differences (Bonferroni correction p<0.017) between groups at both 
baseline and follow-up. Those classified as high adherent at baseline and follow-up 
were significantly older (baseline p=0.016, follow-up p=0.002), had less concerns 
over the potential adverse effects of their medicines (BMQ-Concerns; baseline 
p=0.04, follow-up p<0.001), were very confident about taking their medicines 
correctly (SEAMS, SEAMS-UCU, SEAMS-UDC; p<0.001 for all comparisons), whereas 
those classified as low adherent had strong beliefs about the medicines being 
harmful (BMQ-Harm; p=0.03) and were less satisfied with the burden of their 
diabetes medicines (DiabMedSat-Burden; baseline p<0.001, follow-up p=0.01) and 
their impact on their psychological health (TRIM-Wt-PH; baseline p=0.004, follow-up 
p=0.01). In addition, at follow-up, those classified as high adherents were more 
satisfied with the information they received about their new medicine in relation to 
the potential problems with them (SIMS-PPM; p=0.03), whereas those classified as 
low adherents had stronger beliefs that medicines are overused by doctors (BMQ-
Overuse; p=0.005).  
 
Furthermore, the high adherents had a higher score on necessity–concern 
differential indicating that the necessity of taking the medication was stronger than 
their concern about potential adverse effects from taking it (BMQ Necessity-Concern 
Differential; p=0.02), yet it appears that the beliefs about necessity of their medicines 
(BMQ-Necessity; median=3.7, p=0.5) were not as strong as those classified low 
(median=4.2) and medium (median=4.0) adherents. A closer look at the four diabetes 
medicines belief groups (sceptical, ambivalent, indifferent and accepting- see section 
5.5.3.1 and figure 5.22) showed that the sceptical group was significantly less 
adherent than the indifferent group at baseline, and the ambivalent group was 
significantly less adherent than the accepting group at follow-up, Bonferroni 
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correction p<0.013 (Figure 5.76). The ambivalent and sceptical groups were generally 
less adherent than the accepting and indifferent groups because of their high 
concerns over potential adverse effects of their medicines (BMQ-Concerns) (Table 
5.6). On the other hand, accepting and indifferent groups had similar adherence 
levels, but these were higher than the sceptical and ambivalent groups, because 
these two groups had lower concerns over the potential adverse effects of their 
medicines (BMQ-Concerns). 
 
 
Figure 5.76: Baseline and follow-up adherence levels for the four diabetes medicines belief 
groups.  
 
Overtime, there was a change in patients’ adherence levels with three distinct 
changes; those who had a decrease in adherence levels from baseline, those who 
remained stable and those who improved their adherence levels (Appendix 5.4 and 
5.10). Table 5.7 presents the baseline and follow-up clinical, scale scores and other 
characteristics for each of the above three groups. Also, the table presents statistical 
significant differences (Bonferroni correction p<0.017) between these groups at both 
baseline and follow-up. 
 
Those who remained stable in their adherence levels over time had significantly 
lower scores at baseline on beliefs about medicines are overused by doctors (BMQ-
Overuse; p=0.014) than the other two groups. Also, they were less satisfied with the 
impact of their diabetes medicines on their weight (TRIM-Wt-WM; p=0.03) than 
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those who had a decrease in their adherence levels. It should be noted that the group 
who had stable adherence levels over time, these levels were generally medium to 
high (median (Q1-Q3)=7(5.8, 8.0) according to the MMAS-8 classification (Morisky et 
al., 2008) (table 5.7). Those who remained stable in their adherence levels over time 
were significantly more confident in taking their medicines correctly (SEAMS; 
p=0.025) at three months after initiation of a new treatment than those who had a 
decrease in their adherence levels. A similar finding can be seen for self-efficacy 
levels under conditions of uncertainty (SEAMS-UCU; p=0.006) between the stable 
group and the other two groups. As expected those who improved their adherence 
levels over time had significantly lower adherence levels at baseline (MMAS-8; 
p<0.001) compared to the other two groups and they had significantly higher 
adherence levels at follow-up (MMAS-8; p<0.001) than those who had a decrease in 
their adherence.  
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Table 5.6: Baseline and Follow-up scores for low, medium and high adherents (MMAS-8) 
Whole Group Baseline  Follow-up  
Medication Adherence 
Level 
Low Medium  High P value Low Medium  High P value 
Total N 49 70 35  35 48 27  
Age(yrs)  55.0(48.0,64.0)* 58.5 (51.8, 69.3) 66.0 (54.0, 71.0)* 0.016 *  * 0.002 
Diabetes Duration(yrs) 8.0 (4.0, 13.0) 7.5 (3.8, 13.0) 10.0 (6.0, 16.0) 0.16     
BMI(kg/m2) 34.1 (30.3, 40.7) 35.5 (31.9, 40.6) 35.3 (29.8, 41.7) 0.57 33.6 (30.8, 40.5) 35.2 37.3 0.81 
HbA1c(mmol/mol) 84 (67, 96) 79 (67, 89) 74 (62, 87) 0.43 74 (60, 88) 63 (52,81) 62 (56, 70) 0.11 
Total Medication 
Burden 
6 (4, 9) 
(range 1-19) 
8 (5, 11) 
(range 1-21) 
9 (6, 11) 
(range 2-17) 
0.04 6 (5, 11) 
(range 2-16) 
8 (6, 11) 
(range 2-21) 
8 (5, 10) 
(range 3-16) 
0.99 
Total diabetes 
medication burden 
2 
(range 0-3) 
2  
(range 0-4) 
2  
(range 1-4) 
0.27 2 (2, 3) 
(range 1-5) 
2 (2,3) 
(range 1-4) 
2 (2,3) 
(range 1-4) 
0.17 
No of Diabetes 
complications 
1 (0, 1) 1 (0, 1) 1 (0, 2) 0.43 1 (0, 1) 1 (0, 2) 0 (0, 2) 0.52 
Total N  56 74 38  60 69 56  
EITQ (baseline)/ PITQ 
(Follow-up) 
5.5 (5.0, 6.0) 5.5 (4.9, 6.0) 5.7 (5.1, 6.0) 0.80 5.6 (5.1, 6.1) 5.6 (5.1, 6.0) 5.7 (5.3, 6.0) 0.41 
SIMS 11 (8, 16) 13 (9, 17) 14 (11, 18) 0.06 14 (9, 17) 14 (9, 17) 16 (11, 18) 0.05 
SIMS-AU 7.5 (6, 9) 8 (6, 9) 8.5 (7, 9) 0.09 8 (7, 9) 8 (6, 9) 8 (7, 9) 0.24 
SIMS-PPM 4 (1, 8) 5 (2, 9) 6 (4, 9) 0.13 6 (3, 8)* 6 (2, 9) 8 (4, 9)* 0.03 
BMQ-Concerns 3.0 (2.7, 3.7)* 2.9 (2.3, 3.2) 2.8 (2.4, 3.1)* 0.04 3.1 (2.4, 3.4)+ 2.9 (2.4, 3.4)* 2.3 (2, 2.7)*+ <0.001 
BMQ-Necessity 4 (3.6, 4.2) 4 (3.6, 4.4) 4 (3.6, 4.7) 0.72 4.2 (3.8, 4.8) 4 (3.4, 4.5) 3.7 (3.2, 4.4) 0.5 
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BMQ Necessity –
Concern Differential 
0.8 (0.2, 1.4) 1.0 (0.5, 1.9) 1.2 (0.6, 1.5) 0.04 0.9 (0.3, 1.4)* 0.9 (0.3, 1.7) 1.2 (0.6, 1.9)* 0.02 
BMQ-Overuse 3.0 (2.3, 3.7) 2.7 (2.3, 3.1) 2.8 (2.0, 3.3) 0.32 3.0 (2.7, 3.7)+ 3.0 (2.7, 3.7)* 2.7 (2.0, 3.3)*+ 0.005 
BMQ-Harm 2.5 (2.1, 3.0)* 2.5 (2.0, 2.8) 2.3 (2.0, 2.5)* 0.03 2.5 (2.3, 2.8) 2.5 (2.3, 2.8) 2.3 (2.0, 2.8) 0.25 
BMQ-Benefits 4.0 (3.5, 4.8) 4.0 (3.8, 4.5)  4.0 (4.0, 4.5) 0.04 4.0 (3.8, 4.4) 4.0 (3.8, 4.4) 4.0 (3.8, 4.3) 0.92 
MMAS-8 4.8 (3.8, 5.5)*^ 7.0 (6.8, 7.0)*+ 8.0 (8.0,8.0)+^ <0.001 4.8 (4.0, 5.8)*^ 7.0 (6.8, 7.0)*+ 8.0 (8.0,8.0)+^ <0.001 
SEAMS 3.1 (2.3, 3.7)*+ 3.9 (3.1, 4.2)* 4.0 (3.8, 4.7)+ <0.001 3.3 (2.5, 3.9)*^ 3.7 (3.2, 4.1)*+ 4.0 (3.9, 4.8)+^ <0.001 
SEAMS-UCU 2.8 (2.0, 3.7)*+ 3.8 (2.8, 4.0)* 3.9 (3.5, 5.0)+ <0.001 3.2 (2.2, 4.0)*^ 3.5 (3.0, 4.0)*+ 4.0 (3.7, 4.7)+^ <0.001 
SEAMS-UDC 3.3 (2.4, 3.8)*+ 4.0 (3.3, 4.2)* 4.1 (4.0, 5.0)+ <0.001 3.4 (2.7, 4.0)*^ 4.0 (3.4, 4.1)*+ 4.0 (4.0, 5.0)+^ <0.001 
OWLQOL 51.5 (21.6, 74.8) 69.6 (30.9, 88.7) 71.6 (40.2, 89.5) 0.02 65.2 (33.1, 84.6) 70.6 (35.3, 87.3) 76.0 (52, 90.9) 0.18 
Total N  57 73 36  63 70 54  
DiabMedSat 59.3 (53.4, 70.2) 67.6 (58.0, 75.9) 69.0 (57.6, 78.8) 0.008 71.4 (54.2, 79.4) 71.3 (62.7, 79.3) 75.5 (65.6, 82.9) 0.03 
DiabMedSat-Efficacy 45.0 (32.5, 58.3) 55.0 (39.2, 66.7) 58.3 (42.1, 70.8) 0.016 60.0 (45.0, 76.7) 60.0 (46.7, 75.4) 69.2 (50.0, 84.2) 0.07 
DiabMedSat-Burden 57.0(64.8,85.2)* 86.4(72.7,93.9)* 84.1 (75.6, 91.7) <0.001 79.6(68.9,91.7)* 84.1 (75, 87.5) 88.3(78.0,96.6)* 0.01 
DiabMedSat-
Symptoms 
60 (48, 78) 68 (52, 78) 68 (52, 80) 0.5 72 (52, 76) 68 (56, 80) 72 (63, 77) 0.4 
TRIM-Wt-DL 62.5 (50.0, 70.8) 70.8 (56.3, 79.2) 66.7 (58.3, 79.2) 0.02 70.8 (58.3, 79.2) 75.0 (58.3, 79.2) 75.0 (58.3, 83.3) 0.2 
TRIM-Wt-WM 33.3 (16.7, 50.0) 33.3 (25, 50) 33.3 (25, 50) 0.53 41.7 (25, 58.3) 41.7 (25, 66.7) 50 (33.3, 66.7) 0.3 
TRIM-Wt-PH 62.5 (34.4, 
84.4)* 
7.05 (50.0, 100) 87.5 (64.1, 100)* 0.004 68.8(50.0,87.5)* 75.0 (48.4, 95.3) 81.3 (67.2, 
100)* 
0.01 
Values are Median (Q1, Q3), Significant difference between adherence groups, Bonferroni correction *p<0.017, +p<0.017, ^p<0.017 
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Table 5.7: Baseline and Follow-up scores for those who improved, decreased or remained stable in adherence levels  
Whole Group Baseline  Follow-up  
Change in Medication 
Adherence Level 
Decreased Stable Improved P value Decreased  Stable Improved P value 
Total N 38 80 41  27 55 28  
Age(yrs)  58.0 (49.0, 67.0) 59.0 (51.0,66.0) 63.0 (53.5, 69.5) 0.17     
Diabetes Duration 9.0 (4.0, 14.5) 8.0 (5.0, 13.0) 10.0 (3.0, 14.0) 0.63     
BMI  34.6 (29.9, 41.3) 35.9 (31.7, 40.7) 35.5 (31.3, 40.7) 0.7 35.0 (31.4, 41.4) 36.5 (32.7, 40.9) 33.6 (30.5, 40.5) 0.66 
HbA1c(mmol/mol) 86 (70, 98) 76 (64, 86) 75 (67, 93) 0.05 74 (61, 90) 67 (56, 80) 62 (56, 79) 0.11 
Total Medication 
Burden 
9 (4, 11) 
Range (1, 21) 
7 (5, 11) 
Range (2, 17) 
7 (5,9) 
 Range (1, 19) 
0.42 9 (6, 11) 
Range 2-17 
7 (5, 10) 
Range 2-19 
7 (5, 10)  
Range 2-21 
0.21 
Total diabetes 
medication burden 
2 (1, 2) 
Range 0-3 
2 (1, 2) 
Range 1-4 
2 (1, 3) 
Range 0-4 
0.76 3 (2, 3) 
Range 2-4 
2 (2, 3) 
Range 1-4 
1 (0, 3) 
Range 1-5 
0.63 
No of Diabetes 
complications 
1 (0, 2) 1 (0, 1) 1 (0, 1) 0.73 1 (0, 2) 1 (0, 1) 0 (0, 1) 0.41 
Total N  39 82 46  39 82 46  
EITQ (baseline)/PITQ 
(Follow-up) 
5.6 (5.2, 5.9) 5.5 (5.1, 6) 5.6 (4.6, 6.1) 0.82 5.5 (5.1, 5.9) 5.5 (5.1, 6) 5.8 (5.3, 6.1) 0.34 
SIMs 15 (9, 17) 13 (9, 16) 12 (8, 18) 0.73 15 (13, 17) 15 (10, 17) 13 (7, 18) 0.33 
SIMS-AU 8 (7, 9) 8 (6, 9) 8 (5.8, 9) 0.30 8 (7, 9) 8 (6, 9) 7.5 (5, 9) 0.08 
SIMS-PPM 6 (2, 9) 5 (2, 8) 5.5 (1.8, 9) 0.86 7 (5, 8) 7.5 (3, 9) 5 (2, 9) 0.39 
BMQ-Concerns 2.7 (2.3, 3.3) 2.9 (2.5,3.3) 3.0 (2.3, 3.4) 0.32 2.7 (2.4, 3.3) 2.7 (2.1, 3.3) 2.6 (2.3, 3.3) 0.53 
BMQ-Necessity 3.8 (3.4, 4.2) 3.9 (3.6, 4.2) 4.0 (3.6, 4.6) 0.44 3.7 (3.1, 4.1) 4.0 (3.4, 4.6) 3.8 (3.4, 4.4) 0.13 
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BMQ Necessity –
Concern Differential 
0.93 (0.54, 1.54) 0.99 (0.45, 1.46) 0.94 (0.46, 1.97) 0.97 0.77 (0.28, 1.38) 1.10 (0.45, 1.86) 1.14 (0.40, 1.86) 0.11 
BMQ-Overuse 3.0 (2.3, 3.7)* 2.7 (2.3, 3.0)*+ 3.0 (2.3, 3.7)+ 0.014 3.0 (2.7, 3.7) 2.7 (2.3, 3.3) 3.0 (2.7, 3.7) 0.09 
BMQ-Harm 2.5 (2.3, 3.0) 2.3 (2.0, 2.8) 2.5 (2.3, 2.8) 0.10 2.5 (2.3, 3.0) 2.3 (2.0, 2.8) 2.5 (2.0, 3.0) 0.08 
BMQ-Benefits 4.0 (3.8, 4.5) 4.0 (3.8, 4.5) 4.0 (3.8, 4.0) 0.15 4.0 (3.8, 4.5) 4.0 (3.8, 4.5) 4.0 (3.8, 4.0) 0.48 
MMAS-8 7.0 (5.8, 8.0)+ 7.0 (5.8, 8.0)* 5.8 (4.5, 7.0)* + <0.001 5.3 (3.9, 6.8)*^ 7.0 (5.8, 8.0)* 7.8 (6.5, 8.0)^ <0.001 
SEAMS 3.8 (3.1, 4.2) 3.8 (3.1, 4.4) 3.4 (2.6, 4.0) 0.08 3.4 (2.8, 4.0)* 4.0 (3.5, 4.3)* 3.7 (2.9, 4.2) 0.025 
SEAMS-UCU 3.9 (2.8, 4.0) 3.7 (3.0, 4.2) 2.8 (2.3, 4.0) 0.06 3.3 (2.5, 4.0)* 4.0 (3.5, 4.0)*+ 3.4 (2.8, 4.0)+ 0.006 
SEAMS-UDC 4.0 (3.3, 4.2) 4.0 (3.3, 4.6) 3.7 (3.0, 4.0) 0.16 3.6 (3.0, 4.0) 4.0 (3.5, 4.3) 4.0 (3.1, 4.3) 0.13 
OWLQOL 71.1 (32.8, 85.3) 63.7 (30.2, 85.5) 58.8 (31.7, 87.3) 0.92 65.2 (43.6, 85.5) 69.6 (35.3, 85.3) 75.5 (40.2, 91.2) 0.59 
Total N  38 80 45  38 80 45  
DiabMedSat 67.8 (54.8, 74.4) 64.0 (57.4, 75.8) 61.8 (47.8, 74.9) 0.33 73.1 (58.3, 77.2) 72.3 (62.0, 80.3) 71.9 (55.6, 81.5) 0.62 
DiabMedSat-Efficacy 50.8 (36.3, 63.3) 51.7 (40.0, 62.9) 53.3 (31.7, 62.5) 0.84 60.0 (46.7, 75.4) 62.5 (48.3, 76.7) 68.3 (40.0, 80.0) 0.59 
DiabMedSat-Burden 86.7 (72.7, 93.9) 81.8 (73.5, 88.6) 73.5 (65.2, 89.4) 0.16 84.5 (72.9, 92.6) 85.2 (77.3, 92.9) 84.1 (71.2, 92.8) 0.42 
DiabMedSat-
Symptoms 
64 (52, 81) 68 (52, 80) 64 (44, 78) 0.44 64 (59, 77) 68 (56, 76) 72 (52, 80) 0.92 
TRIM-Wt-DL 70.8 (54.2, 79.2) 66.7 (54.2, 79.2) 66.7 (47.9, 77.1) 0.54 72.9 (50, 79.2) 70.8 (62.5, 79.2) 75.0 (58.3, 79.2) 0.86 
TRIM-Wt-WM 33.3(31.3,58.3)* 25.0(16.7,41.7)* 33.3 (16.7, 50.0) 0.03 45.8 (31.3, 58.3) 41.7 (18.8, 66.7) 50.0 (25.0, 66.7) 0.50 
TRIM-Wt-PH  71.9 (50.0, 100) 75.0 (56.3, 93.8) 68.8 (37.5, 96.9) 0.42 71.9 (50.0, 93.8) 75.0 (62.5, 93.8) 62.5 (43.8, 93.8) 0.13 
Values are Median (Q1, Q3), Significant difference between (two) adherence groups, Bonferroni correction *p<0.017, +p<0.017, ^p<0.017 
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To examine the impact of participants’ expectations, beliefs and attitudes on 
adherence as well as participants characteristics, demographics and clinical values, a 
univariate analysis was conducted to assess which variables were significant 
predictors of medication adherence. The analysis was split into four separate 
analysis: i) using baseline values to predict three-month adherence status, ii) using 
change values from baseline to follow-up to predict three-month adherence status, 
iii) using baseline values to predict change in adherence and iv) using change values 
from baseline to follow-up to predict change in adherence. Multivariate analysis was 
conducted based on the significant predictors from univariate analyses. All analyses 
was done separately for whole group and weight-effect groups (sections 5.6.1-5.6.2).  
 
5.6.1 Whole Group 
5.6.1.1 Predicting medication adherence at 3-month follow-up from baseline and 
change values  
The univariate analyses showed a number of individual variables significantly 
predicted medication adherence at follow-up, using the three adherence level groups 
(low, medium, high) derived from MMAS-8 scale score as the dependent variable 
(Table 5.8). Results of analyses for all other variables can be found in Appendices 
5.13-5.14. However, the multivariate ordinal analysis showed that only seven 
variables significantly predicted medication adherence at follow-up when entered 
together in the analysis (Table 5.9). The model fit chi-square statistic indicates that 
this full multivariate model (Model 1 or 2 in Table 5.9) is performing better (p<0.001) 
than the baseline intercept-only model (no independent variables) at predicting 
cumulative probability for medication adherence. The goodness of fit tests (both 
Pearson chi-square and Deviance) suggest that the observed data are good fit for the 
model (p>0.05). The pseudo R2 statistics suggest that the variables in the model 
explain 56% of the variance in medication adherence level. However, the test of 
parallelism is rejected as p<0.05 (although only marginal), implying that the effects 
of the explanatory variables are not the same across the different thresholds, 
therefore the assumption of proportional odds, is violated. Hence, separate binary 
logistic regressions were undertaken to explore how the odd ratios or the 
explanatory variables vary at the different thresholds (Table 5.10).  
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Table 5.8: Ordinal Regression using single Baseline and Change Predictors for follow-up 
high medication adherence level for the whole group 
Variable β significance Test for 
parallelism 
Age 0.041 0.001 0.149 
Full time 
Part time 
Unemployed 
Other 
Retired 
-0.822 
-0.200 
-0.758 
-0.200 
Reference 
0.021 
0.697 
0.095 
0.637 
0.308 
SIMS 0.058 0.041 0.546 
SIMS-PPM 0.107 0.013 0.550 
BMQ-Concerns -0.477 0.023 0.299 
Baseline Necessity-Concern Differential  0.427 0.007 0.650 
DiabMedSat 0.023 0.019 0.914 
DiabMedSat-Burden 0.021 0.028 0.505 
DiabMedSat-Efficacy 0.017 0.024 0.869 
Trim-Wt-PH 0.012 0.021 0.937 
Baseline MMAS-8 1.022 <0.001 0.840 
SEAMS 0.848 <0.001 0.750 
SEAMS-UDC 1.046 <0.001 0.549 
SEAMS-UCU 0.556 <0.001 0.865 
Baseline HbA1c   -0.019 0.015 0.396 
Weight-Effects of New Medicine: 
Weight Increasing 
Weight Neutral 
Weight Reducing 
 
0.177 
0.673 
Reference 
 
0.582 
0.043 
0.561 
Expectation Perception Difference  
(EITQ-PITQ Change) 
Expectations Exceeded by Experience 
Expectations Unmet  
Expectations Met 
 
 
Reference 
-0.805 
-0.119 
 
 
 
0.707 
0.019 
 
 
 
0.505 
BMQ-Concern Change 
Stronger 
No Change 
Decreased 
 
Reference 
0.457 
0.933 
 
 
0.203 
0.013 
 
0.138 
BMQ-Necessity Change 
Stronger 
No Change 
Decreased 
 
Reference 
0.439 
0.847 
 
 
0.205 
0.019 
 
0.964 
SEAMS-UDC Change 
Improved 
No Change 
Decreased 
 
Reference 
1.365 
-0.232 
 
 
<0.001 
0.454 
 
0.378 
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Table 5.9: Multivariate Ordinal Analysis predicting adherence at follow-up 
 Whole Group  Whole Group with Weight-Effect Variable 
 Estimate β (95% CI) p value Cumulative Odds 
(95%CI) 
Exp (Cumulative 
Logit) 
Estimate β (95% CI) p value Cumulative Odds 
(95%CI) 
Exp (Cumulative 
Logit) 
Threshold  
Adherence Level=1 /MMAS-8≥6 
Adherence Level=2/MMAS-8=8 
 
10.903 (6.054, 11.434) 
13.578 (8.217, 14.080) 
  
 
 
10.966 (7.828, 14.105) 
13.685 (10.225, 17.145) 
 
 
 
 
 
Variables       
Age 0.034 (0.003, 0.063) 0.031 1.03 (1.00, 1.06) 0.30 (-0.002, 0.061) 0.064 1.03 (1.00, 1.06) 
Baseline MMAS-8 0.912 (0.570, 1.192) <0.001 2.49 (1.77, 3.29) 0.926 (0.602, 1.250) <0.001 2.52 (1.83, 3.49) 
Baseline SEAMS-UDC 1.975 (0.790, 2.357) <0.001 7.20 (2.20, 10.56) 1.939 (1.085, 2.792) <0.001 6.95 (2.96, 16.31) 
Baseline SEAMS-UCU  -1.118 (-1.778, -0.487) 0.001 0.33 (0.17, 0.61) -1.108 (-1.785, -0.431) 0.001 0.33 (0.17, 0.65) 
BMQ-Concerns Change Stable Vs 
Stronger 
1.111 (0.194, 2.028) 0.018 3.04 (1.21, 7.60) 1.174 (0.222, 2.125) 0.005 3.23 (1.25, 8.37) 
BMQ-Concerns Change  Decrease Vs 
Stronger 
1.458 (0.494, 2.423) 0.003 4.30 (1.64, 11.28) 1.604 (0.609, 2.600) 0.002 4.97 (1.84, 13.46) 
SEAMS-UDC Change Decrease Vs 
Improvement 
-1.399 (-2.159, -0.639) <0.001 0.25 (0.12, 0.53) -1.440 (-2.211, -0.670) <0.001 0.24 (0.11, 0.51) 
Weight Neutral Vs Weight Reducing    0.475 (-0.392, 1.341) 0.283 1.61 (0.68, 3.82) 
Weight Increasing Vs Weight Reducing    0.359 (-0.460, 1.179) 0.390 1.43 (0.63, 3.25) 
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Model Statistics Model Fit: χ2 (7)=114.658, p<0.001, Goodness of Fit 
(327)= 293.922, p=0.905, Nagekerke R2=0.557, Test 
of Parallelism χ2(7)=15.014, p=0.04 
Model Fit: χ2 (9)=116.409, p<0.001, Goodness of Fit 
(327)= 297.346, p=0.879, Nagekerke R2=0.561 , Test 
of Parallelism χ2(9)= 17.195, p=0.05 
Multivariate Model 1 for Whole Group: 10.903-0.912(Baseline MMAS-1)–0.034(Age)-1.975(Baseline SEAMS-UDC)+1.118(Baseline SEAMS-UCU)+1.399 
(SEAMS-UDC Change Decrease)-1.458(BMQ-Concern change decrease)-1.111 (BMQ-Concern Change –no change) 
Multivariate Model 2 for Whole Group: 13.578-0.912(Baseline MMAS-8)–0.034(Age)-1.975(Baseline SEAMS-UDC)+1.118(Baseline SEAMS-UCU)+1.399 
(SEAMS-UDC Change Decrease)-1.458 (BMQ-Concern change decrease)-1.111(BMQ-Concern Change –no change) 
Model 1 compares participants with low adherence with those scored as medium and high adherent combined. Model 2 compares those participants 
who scored as low and medium adherent with those who scored as high adherent (the odds of being high adherent). 
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Table 5.10: Separate binary logistic regressions for high adherents and, medium and high 
adherents for key explanatory variables from ordinal regression 
 B co-efficient Relative Odds/  
Odds Ratios (95%CI) 
 
 High  Medium- 
High 
High  Medium- 
High  
Test for 
parallelism 
Intercept -17.293 -10.093    
Age 0.25 0.039* 1.026 
(0.981, 
1.072) 
1.040 (1.0, 
1.081) 
0.149 
Baseline MMAS-8 0.727** 1.027*** 2.068 
(1.231, 
3.473) 
2.793 
(1.857, 4.2) 
0.840 
SEAMS-UDC 2.885*** 1.924** 17.895 
(3.590, 
89.207) 
6.850 
(2.208, 
21.254) 
0.549 
SEAMS-UCU -1.044* -1.370** 0.352 
(0.134, 
0.927) 
0.254 
(0.099, 
0.655) 
0.865 
BMQ-Concern 
Change Decrease 
(Vs Stronger) 
3.247*** 0.530 25.701 
(4.240, 
155.791) 
1.699 
(0.501, 
5.757) 
0.248 
BMQ-Concern 
Change- Stable 
 (Vs Stronger) 
2.878** 0.154 17.775 
(3.027, 
104.389) 
1.167 
(0.3387, 
3.519) 
0.774 
SEAM-UDC Change 
Decrease (Vs 
Improvement) 
-1.749* -1.366* 0.174 
(0.046, 
0.656) 
0.255 
(0.077, 
0.841) 
0.213 
SEAM-UDC Change 
No Change (Vs 
Improvement) 
0.581 -0.485 1.789 
(0.473, 
6.759) 
0.616 
(0.148, 
2.560) 
0.203 
R2 (Nagelkerke) 
Model Chi-squared 
Hosmer & 
Lemeshow test 
 
0.58 
85.675*** 
 
4.5 
(p=0.81) 
86.7% 
Correct 
(70.2% of 
high 
adherers) 
0.54 
81.72*** 
 
6.8 
(p=0.56) 
81.3% 
Correct 
(88.9% of 
medium 
and high 
adherers) 
   
*p<0.05, **p<0.01, ***p<0.001, ns= not significant 
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The logistic regressions indicated that age predicts only those who are medium to 
high adherents, whereas a change in beliefs over concerns of the potential adverse 
effects of the new medicine (BMQ-Concerns Change) predicts those who are high 
adherents. All other explanatory variables predict both those who are medium to 
high adherents and those who are only high adherents (MMAS-8, SEAMS-UDC, 
SEAMS-UCU, SEAM-UDC Change). The p values for the test of parallel lines for all the 
individual variables are above 0.05. In addition, the direction of beta co-efficients is 
the same as in the original ordinal regression model (Table 5.9), as well as the relative 
odds and odds ratios are proportionally across the two groups, with the exception of 
SEAMS UDC, and BMQ-Concern change, which are much higher for the high 
adherence group compared to the medium to high adherence group. Therefore, it is 
reasonable to conclude that the ordinal model (Table 5.9) is a fair summary of the 
patterns of the research data in relation to predicting medication adherence.  
 
Hence, both ordinal models (Table 5.9) suggest that a unit increase in one individual 
predictor variable when all the other predictor variables remain constant increases 
or decreases the odds of becoming highly adherent dependent on whether the 
estimate β (or predicted cumulative logit) has a positive or negative value. The odds 
of becoming highly adherent is calculated by using the exponential value of the 
predicted cumulative logit (Table 5.9). Hence, a unit increase in baseline medication 
adherence score (MMAS-8) increases the odds of becoming highly adherent at 
follow-up after new treatment by 2.49 times p<0.001 (Table 5.9), while a unit 
increase in age increases the odds of becoming highly adherent by 1.03 times, 
p=0.031. Likewise, a unit increase in self-efficacy under difficult circumstances 
(SEAMS-UDC) increases the odds of becoming highly adherent after new treatment 
by 7.2 times, p<0.001, whereas a unit increase in self-efficacy under conditions of 
uncertainty (SEAMS-UCU) decreases the odds of becoming highly adherent after new 
treatment by a third, p=0.001. Similarly, if there is a decrease in confidence levels 
under difficult circumstances over time (SEAMS-UDC Change) then the odds of 
becoming high adherent decreases by a quarter (p<0.001). Finally, if individuals 
become less concerned over their new diabetes medicines or there is no significant 
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change in concerns as opposed to become more concerned over time (BMQ-
Concerns Change), then this increases the odds of becoming highly adherent by 3-4 
times (p≤0.018).  
 
The weight-effect of the medicine was an important comparison in this study and it 
was found that those prescribed a WN medicine were more likely to be adherent at 
follow-up compared to those prescribed a WR medicine (Table 5.8). Therefore, the 
weight-effect variable was forced into the final multivariate model. However, in this 
case, age was not a significant predictor of high adherence, neither were the weight-
effect medicines (WN, WR, WI), perhaps suggesting there is an interaction between 
these two explanatory predictors in relation to medication adherence (Table 5.9). As 
seen in Table 5.4, the weight reducing group was significantly younger than the 
weight neutral group (p<0.05), whilst age was significant predictor for those who are 
medium to high adherent than those who are low adherent (Table 5.10). All other 
predictor variable remained statistically significant and the test of parallel lines was 
met. Furthermore, after a sensitivity analysis controlling for other demographic and 
clinical variables (gender, education status, age, marital status, total medication 
burden, total diabetes medication burden, BMI, HbA1c), the self-efficacy for both 
under difficult circumstances (SEAMS-UDC) and under conditions of uncertainty 
(SEAMS-UCU) (p<0.001 and p=0.008 respectively), the change in confidence levels 
under difficult circumstances (SEAMS-UDC Change) (p<0.001) and the change in 
beliefs over concerns of potential adverse effects of medicines (BMQ-Concerns 
Change) (p=0.002) remained highly significant (results not shown). Collinearity 
diagnostics were checked and no issues were found (Appendix 5.15). 
  
Tables 5.11 shows how the predicted probability of being low, medium and high 
adherent at follow-up changes with various predictors scores identified in 
multivariate analysis. For example, the probability of being high adherent, if scored 
highly adherent (MMAS-8) at baseline, is 61%, whereas the probability of being low 
adherent, when scored low at baseline, is 75%. Because the effects of the predictor 
variables in this multivariate model are the same across the different thresholds, 
according to the assumption of proportional odds (O’Connell, 2006), even though this 
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assumption was only met marginally (p=0.04), it can be concluded that the overall 
probability for being high adherent following initiation of new diabetes treatment is 
28%, whereas the probability of being low adherent is 35% (Table 5.11, final row).   
 
Table 5.11: Predicted probability for Follow-up adherence levels with various baseline 
scores and age for key variables from multivariate analysis    
Predicted probability at various 
scores/ Age(yrs) 
Adherence 
Level Low 
Adherence 
Level Medium 
Adherence 
Level High 
Baseline MMAS-8<6 (Score=5.0) 0.75 0.22 0.03 
Baseline MMAS-8<6 (Score=6) 0.32 0.51 0.17 
MMAS-8 Score=7 0.18 0.47 0.35 
MMAS-8 Score=8 0.07 0.32 0.61 
Age=36 0.99 .01 0.00 
Age=45 0.36 0.40 0.24 
Age=55 0.23 0.39 0.38 
Age=65 0.26 0.48 0.26 
Age=75 0.06 0.34 0.60 
Baseline SEAMS-UDC Score=2 0.95 0.04 0.01 
Baseline SEAMS-UDC Score=3 0.53 0.34 0.13 
Baseline SEAMS-UDC Score=4 0.13 0.46 0.41 
Baseline SEAMS-UDC Score=5 0.14 0.35 0.51 
Baseline SEAMS-UCU Score=2 0.52 0.32 0.15 
Baseline SEAMS-UCU Score=3 0.36 0.43 0.20 
Baseline SEAMS-UCU Score=4 0.29 0.46 0.25 
Baseline SEAMS-UCU Score=5 0.19 0.47 0.34 
BMQ-Concerns change: Increase 
Higher concerns 
0.38 0.38 0.25 
BMQ-Concerns no change 0.33 0.39 0.29 
BMQ-Concerns change: Decrease 
Lower concerns 
0.29 0.36 0.36 
SEAMS-UDC change: Increased self-
efficacy over time 
0.31 0.36 0.33 
SEAS-UDC change: Decreased self-
efficacy over time 
0.41 0.39 0.20 
Total Predictor score 0.35 0.37 0.28 
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5.6.1.2 Predicting a change in medication adherence from baseline and change values 
A univariate analysis was conducted to assess what predicted change in medication 
adherence over the 3-month period. Table 5.12 shows the results of the multinomial 
regression which uses “stable” medication adherence over 3 months as reference. 
The table shows only significant variables that predict medication change, the results 
for all other variables can be found in appendices 5.16-5.17.   
 
Table 5.12: Multinomial Regression using single Baseline and Change Predictors for 
medication adherence change (MMAS-8 Change) at follow-up for the whole group 
Variable β 
Decreased 
Adherence 
significance β 
Increased 
Adherence 
Significance 
Single 
Married 
Widowed 
Divorced 
0.201 
Reference 
1.299 
0.488 
0.735 
 
0.167 
0.476 
0.000 
Reference 
1.946 
-0.405 
1.0 
 
0.019 
0.631 
IMD  
20% Least Deprived 
61%-80% 
41%-60% 
21%-40% 
20% Most Deprived 
 
0.329 
-20.497 
1.245 
-0.875 
Reference 
 
0.728 
 
0.030 
0.198 
 
0.580 
-0.113 
0.868 
-1.030 
Reference 
 
0.495 
0.849 
0.141 
0.127 
SIMS–AU 0.020 0.846 -0.174 0.035 
BMQ-Overuse 0.662 0.013 0.647 0.01 
BMQ-Harm 0.336 0.337 0.743 0.027 
DiabMedSat-Burden -0.003 0.807 -0.030 0.012 
baseline MMAS-8 0.052 0.736 -0.532 <0.001 
SEAMS -0.082 0.707 -0.451  0.026 
SEAMS-UCU -0.040 0.841 -0.446 0.016 
Baseline HbA1c  0.025 0.021 0.006 0.591 
BMQ-Overuse Change 
Stronger 
No Change 
Decreased 
 
Reference 
0.097 
0.687 
 
 
0.835 
0.282 
 
Reference 
0.420 
1.344 
 
 
0.376 
0.026 
DiabMedSat-Burden 
Change 
Improved 
No Change 
Decreased 
 
 
Reference 
-0.205 
0.746 
 
 
 
0.664 
0.186 
 
 
Reference 
-0.959 
-0.148 
 
 
 
0.023 
0.783 
SEAMS Change 
Improved 
 
Reference 
 
 
 
Reference 
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No Change 
Decreased 
-0.221 
1.080 
0.686 
0.021 
-0.266 
-0.351 
0.532 
0.455 
SEAMS-UDC Change 
Improved 
No Change 
Decreased 
 
Reference 
-0.047 
0.533 
 
 
0.934 
0.239 
 
Reference 
-0.550 
-0.925 
 
 
0.243 
0.036 
SEAMS-UCU Change 
Improved 
No Change 
Decreased 
 
Reference 
0.667 
1.383 
 
 
0.190 
0.006 
 
Reference 
-0.271 
0.097 
 
 
0.536 
0.832 
 
The final multivariate analysis (Table 5.13) showed that if individuals have a high 
HbA1c level and they live within the 20% least deprived boundary (as opposed to the 
third most deprived; i.e.-41-60%) prior to initiation of new diabetes treatment, then 
they are more likely to have a decrease in adherence levels at three months than 
remain stable. In addition, if they live within the second most deprived (21-40%) 
boundary (as opposed to 20% most deprived boundary) then it is less likely 
medication adherence levels to increase at follow-up than remain stable. If they have 
high adherence levels at baseline, their adherence levels are more likely to remain 
stable than increase at follow-up. However, medication adherence levels at 3 months 
are more likely to increase (than remain stable) after initiation of new treatment if 
individuals are widowed (as opposed to being married). Furthermore, individuals 
whose confidence levels in taking medicines correctly (SEAMS Change) decreased 
over time, then their adherence levels are more likely to  decrease over time than 
remain stable. Whilst those individuals whose confidence in taking medicines under 
difficult circumstances (SEAMS-UDC Change) decreased (than improved) over time, 
their adherence levels are more likely to remain stable than increase over time.  
 
The multivariate model also showed that strong beliefs that medicines are overused 
by doctors prior to initiation of a new diabetes medicine can either increase or 
decrease the adherence levels than remain stable. Table 5.7 shows that both groups 
who had a decrease and an increase in adherence levels over time had significantly 
stronger baseline beliefs about the overuse of medicines (BMQ-Overuse) compared 
to those who remained stable. Their beliefs also remained stronger at follow-up 
compared to the stable group.  
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Although the weight-effect of the medicine was not a significant predictor in the 
univariate analyses for a medication adherence change (appendix 5.16), it was forced 
in the final multinomial regression analysis, as it was an important comparison in this 
study. The results of this analyses (Table 5.13) show that the weight-effect of the 
medicine remained insignificant in predicting medication adherence change, 
whereas there was no change in any of the other variables.  
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Table 5.13: Multinomial Analysis predicting change in adherence over time following initiation of new diabetes medicine 
 Whole Group Whole Group with Weight-Effect Variable 
 Wald β (SE) Odds Ratio  
(95%CI) 
Wald β (SE) Odds Ratio (95%CI) 
Decreased Adherence Vs Stable Adherence 
Intercept -7.36 (2.11)*** -7.73 (2.20)*** 
Baseline MMAS-8 0.22 (0.19) 1.25 (0.87, 1.79) 0.26 (0.19) 1.29 (0.89, 1.89) 
Baseline BMQ-Overuse 0.77 (0.31)* 2.16 (1.17, 3.97) 0.75 (0.31)* 2.12 (1.16, 3.90) 
Baseline HbA1c  0.03 (0.01)* 1.03 (1.0, 1.06) 0.04 (0.01)* 1.04 (1.0, 1.07) 
Single (Vs Married) 0.90 (0.75) 2.47 (0.57, 10.77) 0.89 (0.76) 2.43 (0.55, 10.74) 
Widowed (Vs Married) 1.44 (1.07) 4.21 (0.52, 34.07) 1.48 (1.09) 4.38 (0.52, 37.30) 
Divorced (Vs Married) 0.39 (0.83) 1.47 (0.29, 7.48) 0.38 (0.84) 1.46 (0.28, 7.51) 
20% Least deprived (Vs 20% 
most deprived) 
0.75 (1.15) 2.12 (0.22, 20.03) 0.75 (1.15) 2.11 (0.22, 20.03) 
IMD 61-80  
(Vs 20% most deprived) 
-19.94 (0.0) 2.18E (2.18E-2.18E) -19.89 (0.0) 2.31E (2.31E, 2.31E) 
IMD 41-60 
(Vs 20% most deprived) 
1.59 (0.67)* 4.93 (1.34, 18.12) 1.75 (0.69)* 5.74 (1.49, 22.16) 
21-40  
(Vs 20% most deprived) 
-1.09 (0.84) 0.34 (0.06, 1.75) -0.92 (0.87) 0.40 (0.07, 2.18) 
SEAMS Change Decrease 
(Vs Improvement) 
2.17 (1.03)* 8.79 (1.17, 65.92) 2.34 (1.07)* 10.39 (1.28, 84.48) 
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SEAMS Change Stable (Vs 
Improvement 
-0.06 (0.84) 0.94 (0.18, 4.90) -0.05 (0.87) 0.95 (0.17, 5.22) 
SEAMS-UDC Change 
Decrease (Vs Improvement) 
-1.38 (1.01) 0.25 (0.03, 1.82) -1.32 (1.04) 0.27 (0.04, 2.07) 
SEAMS UDC Stable (Vs 
Improvement) 
-0.83 (0.87) 0.44 (0.08, 2.40) -0.80 (0.88) 0.45 (0.08, 2.50) 
Weight Neutral (Vs Weight 
Reducing) 
  -0.54 (0.67) 0.58 (0.16, 2.18) 
Weight Increasing (Vs 
Weight Reducing) 
  -0.50 (0.64) 0.61 (0.17, 2.11) 
Increased Adherence Vs Stable Adherence 
Intercept 1.19 (1.94)  1.33 (2.00)  
Baseline MMAS-8 -0.65 (0.17)*** 0.52 (0.37, 0.73) -0.68 (0.18)*** 0.51 (0.36, 0.72) 
Baseline BMQ-Overuse 0.69 (0.31)* 1.99 (1.08, 3.67) 0.68 (0.32)* 1.97 (1.05, 3.67) 
Baseline HbA1c  0.01 (0.01) 1.00 (0.98, 1.03) 0.01 (0.02) 1.00 (0.97, 1.03) 
Single (Vs Married) -0.05 (0.77) 0.95 (0.21, 4.33) 0.03 (0.78) 1.03 (0.23, 4.74) 
Widowed (Vs Married) 2.55 (0.98)** 12.80 (1.87, 87.67) 2.48 (1.00)* 11.88 (1.68, 84.23) 
Divorced (Vs Married) -0.75 (1.10) 0.47 (0.06, 4.11) -0.67 (1.08) 0.51 (0.06, 4.25) 
IMD 20% least deprived 
 (Vs 20% least deprived) 
0.86 (1.08) 2.35 (0.28, 19.61) 0.86 (1.10) 2.37 (0.28, 20.28) 
IMD 61-80  
(Vs 20% most deprived) 
0.43 (0.77) 1.53 (0.34, 6.90) 0.34 (0.80) 1.40 (0.29, 6.75) 
IMD 41-60 0.93 (0.76) 2.53 (0.57, 11.19) 0.94 (0.77) 2.56 (0.56, 11.63) 
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(Vs 20% most deprived) 
IMD 21-40 
(Vs 20% most deprived) 
-2.02 (0.94)* 0.13 (0.02, 0.83) -2.08 (0.97)* 0.13 (0.02, 0.83) 
SEAMS Change Decrease 
(Vs Improvement) 
1.87 (1.01) 6.51 (0.89, 47.36) 1.87 (1.07) 6.49 (0.80, 53.02) 
SEAMS Change Stable (Vs 
Improvement 
0.68 (0.71) 1.98 (0.49, 7.99) 0.59 (0.75) 1.81 (0.42, 7.83) 
SEAMS-UDC Change 
Decrease (Vs Improvement) 
-2.46 (0.96)* 0.09 (0.01, 0.56) -2.58 (0.99)** 0.08 (0.01, 0.53) 
SEAMS UDC Stable (Vs 
Improvement) 
-0.56 (0.74) 0.57 (0.13, 2.45) -0.59 (0.75) 0.55 (0.13, 2.42) 
Weight Neutral (Vs Weight 
Reducing) 
  0.94 (0.60) 2.55 (0.79, 8.27) 
Weight Increasing (Vs 
Weight Reducing) 
  0.42 (0.66) 1.52 (0.42, 5.55) 
Model Statistics Nagelkerke R2=0.50; Model x2 (28)=92.16, p<0.001, 
Goodness of Fit (292)= 279.301, 68% Correct 
Nagelkerke R2=0.52; Model x2 (32)= 96.68, p<0.001, 
Goodness of Fit (288)= 276.574, 65% Correct 
*p<0.05, **p<0.01, ***p<0.001 
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5.6.2 Weight-Effect Groups  
A similar approach to identifying significant predictors was conducted for each 
weight-effect group.  
5.6.2.1 Weight Reducing Group 
As the WR group is a small group (n=68), multivariate regression analysis was not 
performed as the data are not sufficient. The following sections present the 
univariate analysis for both predicting medication adherence and a change in 
medications adherence levels at follow-up.  
 
5.6.2.1.1 Predicting medication adherence at 3-month follow-up from baseline and 
change values  
The univariate ordinal analysis (Table 5.14) indicated that for the WR group, the older 
individuals are, the less concerns they have about how harmful or addictive are 
medicines (BMQ-Harm) and, if these beliefs remain stable over time (BMQ-Harm 
Change), they are more like to be adherent after initiation of a new medicine. 
Furthermore, individuals already highly adherent with their medicines (baseline 
MMAS-8) and confident in taking medicines correctly (SEAMS); particularly under 
difficult circumstances (SEAMS-UDC) and under conditions of uncertainty (SEAMS-
UCU), then for each individual aspect, they are more like to be adherent after 
initiation of a new medicine.  
 
Table 5.14: Ordinal Regression using single Baseline and Change Predictors for follow-up 
high medication adherence level for the WR group 
Variable β significance Test for 
parallelism 
Age 0.072 0.008 0.620 
BMQ-Harm -1.132 0.012 0.408 
BMQ-Harm Change -1.666 0.019 0.064 
Baseline MMAS-8 1.104 <0.001 0.415 
SEAMS 0.999 0.001 0.829 
SEAMS-UDC  1.521 <0.001 0.779 
SEAMS-UCU 0.544 0.024 0.870 
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5.6.2.1.2 Predicting a change in medication adherence from baseline and change 
values 
The univariate multinomial analysis (Table 5.15) which examined what predicts a 
change in adherence levels showed that for women, adherence levels are more likely 
to decrease over time than remain stable, and individuals with beliefs that medicines 
are harmful (baseline BMQ-Harm), are more likely to either decreased or increase 
their adherence levels. Individuals who are highly satisfied with their diabetes 
medicines overall (DiabMedSat), including with how burdensome they are 
(DiabMedSat-Burden) and medicine related symptoms (DiabMedSat-Symptoms) 
prior to initiation of a new treatment then their adherence levels are more likely to 
remain stable than increase. 
 
Individuals satisfied with the impact of their medicine on their weight (TRIM-Wt-WM) 
prior to a new medicine are more likely to decrease their adherence levels over time 
than remain stable. Individuals satisfied with the impact of their diabetes medicines 
on their psychological health (TRIM-Wt-PH), and who are confident in taking 
medication under conditions of uncertainty (SEAMS-UCU) prior to initiation of a new 
treatment, then their adherence levels are more likely to remain stable than increase. 
However, individuals whose beliefs about prescribed medicines are overused by 
doctors (BMQ-Overuse Change) decrease over time then their adherence levels will 
increase over time than remain stable.  
 
Table 5.15: Multinomial Regression using single Baseline and Change Predictors for 
medication adherence change (MMAS-8 Change) at follow-up for the WR group 
Variable β 
Decreased 
Adherence 
significance β 
Increased 
Adherence 
Significance 
Women 
Men 
Reference 
-1.792 
 
0.032 
Reference 
-0.916 
 
0.136 
BMQ-Overuse Change 
Stronger 
Stable 
Decreased 
 
Reference  
-0.379 
0.118 
 
 
0.609 
0.911 
 
Reference 
18.466 
19.299 
 
 
 
<0.001 
BMQ-Harm 1.352 0.032 1.293 0.039 
DiabMedSat -0.003 0.907 -0.064 0.012 
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DiabMedSat- Burden 0.001 0.957 -0.047 0.035 
DiabMedSat-Symptom -0.018 0.324 -0.059 0.003 
TRIM-Wt-WM 0.038 0.032 -0.013 0.524 
TRIM-Wt-PH 0.004 0.731 -0.023 0.045 
SEAMS-UCU -0.330 0.310 -0.775 0.026 
 
5.6.2.2 Weight Neutral Group 
As the WN group is a small group (n=58), multivariate regression analysis was not 
performed as the data are not sufficient. The following sections present the 
univariate analysis for both predicting medication adherence and a change in 
medications adherence levels at follow-up.  
 
5.6.2.2.1 Predicting medication adherence at 3-month follow-up from baseline and 
change values  
The univariate analysis for the WN group (Table 5.16) indicated that individuals highly 
adherent with their medicines (baseline MMAS-8) and confident in taking them 
correctly (SEAMS); particularly under difficult circumstances (SEAMS-UDC) and under 
conditions of uncertainty (SEAMS-UCU), then for each individual aspect, they are 
more like to be adherent after initiation of a new medicine. Individuals who have 
lower HbA1c at baseline, have less amount of diabetes medications at follow–up and 
have a positive change in their HbA1c levels (HbA1c Change) at follow-up, as well as 
their expectations are exceeded by experience (EITQ-PITQ Change) (instead of just 
being met) then they are more likely to be adherent.  
 
Table 5.16: Ordinal Regression using single Baseline and Change Predictors for follow-up 
high medication adherence level for the WN group 
Variable β significance Test for 
parallelism 
Baseline HbA1c -0.046 0.004 0.405 
HbA1c Change 0.053 0.026 0.155 
Baseline MMAS-8 0.895 0.001 0.242 
SEAMS 0.769 0.014 0.215 
SEAMS-UDC  0.766 0.02 0.442 
SEAMS-UCU 0.633 0.018 0.082 
Diabetes Medication Burden F-up -0.972 0.009 0.663 
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Expectation Perception Change (EITQ-PITQ) 
Expectations Unmet 
Expectations Met 
Expectations Exceeded by Experience 
 
-.135 
-1.362 
Reference 
 
.815 
.042 
 
0.266 
 
5.6.2.2.2 Predicting a change in medication adherence from baseline and change 
values 
The univariate analysis examined what predicts change (Table 5.17) showed that for 
individuals who are married or are single than widowed, then their adherence levels 
are more likely to decrease over time than remain stable. Those in full-time 
employment or unemployed, compared to those on benefits (reference “other”), are 
more likely to increase adherence levels than remain stable over time. Those with 
high concerns that prescribed medicines are overused by doctors (BMQ-Overuse) and 
strong beliefs that medicines are harmful (BMQ-Harm) prior to new treatment are 
more likely to increase adherence levels than remain stable over time. On the other 
hand, individuals with strong beliefs about the benefits of medicines (BMQ-Benefits) 
prior to new treatment are more likely to remain stable than increase adherence 
levels over time. Those who are highly satisfied with diabetes medicines 
(DiabMedSat) prior to new treatment, then, are more likely to have stable adherence 
levels than increase over time. Individuals with high adherence levels (Baseline 
MMAs-8) before a start of a new treatment are more likely to remain stable than 
their adherence levels increased. Individuals whom satisfaction levels with diabetes 
medicines remain stable over time (than improve) (DiabMedSat Change) and, those 
whose satisfaction with symptoms remains stable than improve (DiabMedSat-
Symptoms Change), are more likely to remain stable in their adherence levels than 
increase.  
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Table 5.17: Multinomial Regression using single Baseline and Change Predictors for 
medication adherence change (MMAS-8 Change) at follow-up for the WN group 
Variable β 
Decreased 
Adherence 
significance β 
Increased 
Adherence 
Significance 
Single 
Married 
Widowed 
Divorced 
18.081 
18.081 
Reference 
19.180 
<0.001 
<0.001 
 
 
-1.099 
-.223 
Reference 
-19.086 
0.472 
0.835 
 
0.998 
Full time 
Part time 
Unemployed 
Other 
Retired 
0.00 
-19.260 
-0.693 
Reference  
-1.540 
1.0 
 
0.638 
 
0.137 
19.185 
-0.545 
17.393 
Reference 
17.845 
<0.001 
1.0 
<0.001 
 
BMQ-Overuse 0.993 0.152 1.369 0.024 
BMQ-Harm -0.247 0.759 1.953 0.019 
BMQ-Benefits -0.730 0.445 -2.029 0.027 
DiabMedSat -0.034 0.202 -0.045 0.05 
DiabMedSat Change 
Improved 
Stable 
Decreased 
 
Reference 
-1.504 
-1.386 
 
 
0.154 
0.191 
 
Reference 
-1.792 
-1.674 
 
 
0.048 
0.067 
DiabMedSat Symptoms 
Change 
Improved 
Stable 
Decreased 
 
 
Reference 
-1.061 
-0.288 
 
 
 
0.341 
0.803 
 
 
Reference 
-2.719 
-1.030 
 
 
 
0.008 
0.262 
Baseline MMAS-8 0.267 0.540 -0.727 0.011 
BMI Follow-up 0.194 0.048 0.016 0.811 
 
5.6.2.3 Weight Increasing Group 
As the WI group is a small group (n=64), multivariate regression analysis was not 
performed as the data are not sufficient. The following sections present the 
univariate analysis for both predicting medication adherence and a change in 
medications adherence levels at follow-up.  
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5.6.2.3.1 Predicting medication adherence at 3-month follow-up from baseline and 
change values  
The univariate analysis for the WI group (Table 5.18) indicated that, individuals who 
are already highly adherent with their medicines (Baseline MMAS-8), satisfied with 
the information they received about a new medicine in relation to potential problems 
with it (SIMS-PPM), their satisfaction with the impact of the new medicine on daily 
life (TRIM-Wt-DL) improves (as opposed to decrease, or remain stable) and the 
impact of their diabetes medicines on their psychological health at baseline (TRIM-
Wt-PH) is high, then for each individual aspect, they are more like to be highly 
adherent after initiation of a new medicine. If beliefs about necessity (BMQ-
Necessity) remain stable over time (as opposed to become stronger), and if beliefs 
about medication benefits (BMQ-Benefits) decrease (as opposed to become 
stronger) then individuals are more likely to be adherent. Individuals with high self-
efficacy (SEAMS) at baseline particularly under difficult circumstances (SEAMS-UDC), 
are more likely to be adherent over time. Individuals whom self-efficacy, particularly 
with under conditions of uncertainty (SEAMS-UCU), improves over time (as opposed 
to decrease), are more likely to be adherent. However, those whom self-efficacy 
under difficult circumstances (SEAMS-UDC) remains stable as opposed to improve, 
then they are more likely to be adherent. All baseline and follow-up scores indicate 
that the WI group had strong beliefs about necessity and benefits of medicines, as 
well as were very confident with taking their medicines under difficult circumstances 
(Table 5.6).  
 
Table 5.18: Ordinal Regression using single Baseline and Change Predictors for follow-up 
high medication adherence level for the WI group 
Variable β significance Test for 
parallelism 
Baseline MMAS-8 1.055 <0.001 0.643 
SIMS-PPM 0.138 0.046 0.770 
TRIM-Wt-DL Change 
Decreased 
Stable 
Improved 
 
-2.315 
-1.257 
Reference 
 
0.012 
0.049 
0.200 
TRIM-Wt-PH 0.021 0.021 0.627 
264 
 
BMQ-Necessity Change 
Decreased 
Stable 
Stronger 
 
1.148 
1.420 
Reference 
 
0.003 
0.203 
0.942 
BMQ-Benefits Change 
Decreased 
Stable 
Stronger 
 
2.527 
0.893 
Reference 
 
.102 
.036 
0.561 
SEAMS 0.713 0.008 0.033 
SEAMS-UDC  0.834 0.002 0.034 
SEAMS Change 
Decreased  
Stable 
Improved 
 
-1.649 
.108 
Reference 
 
.007 
.855 
 
0.052 
SEAMS- UCU Change 
Decreased  
Stable 
Improved 
 
-1.797 
-0.503 
Reference 
 
0.004 
0.392 
0.036 
SEAMS- UDC Change 
Decreased  
Stable 
Improved 
 
-.590 
2.355 
Reference 
 
0.292 
0.001 
0.037 
 
5.6.2.3.2 Predicting a change in medication adherence from baseline and change 
values 
The univariate analysis examining what predicts change in adherence levels over time  
(Table 5.19) showed that individuals who live in the first [20%], or the second [21-
40%] or the third most deprived area [41-60%] than in the fifth deprived area (or 20% 
least deprived area) then their adherence levels are more likely to remain stable than 
increase. Individuals with high concerns over the potential adverse effects of the 
medicine (BMQ-Concerns) prior to starting a new treatment are more likely to remain 
stable in their adherence levels than increase.  
 
Individuals with strong beliefs about the benefits of taking medicines (BMQ-Benefits), 
are more likely to remain stable in their adherence levels than decrease. Those 
satisfied with the impact of their diabetes medicines on their weight (TRIM-Wt-WM) 
prior to initiation of a new medicine are more likely to increase their adherence levels 
than remain stable. Individuals highly adherent from the start (Baseline MMAS-8) are 
265 
 
less likely to increase their adherence levels over time than remain stable. Individuals 
taking many diabetes medicines prior to initiation of a new treatment (baseline 
medication burden) are more likely to remain stable in their adherence levels than 
increase). 
 
Those whose satisfaction with diabetes medicines decrease over time (DiabMedSat 
Change) are more likely to decrease their adherence levels over time. Individuals 
whose satisfaction levels with the impact of their medicines on psychological health 
(TRIM-Wt-PH Change) remains stable over time than improve their adherence levels 
are more likely to remain stable than decrease. Those whose confidence levels 
decreased over time (SEAMS Change), adherence levels are more likely to decrease 
over time than remain stable, particularly for under conditions of uncertainty 
(SEAMS-UCU Change). 
 
Table 5.19: Multinomial Regression using single Baseline and Change Predictors for 
medication adherence change (MMAS-8 Change) at follow-up for the WI group 
Variable β 
Decreased 
Adherence 
significance β 
Increased 
Adherence 
Significance 
IMD  
20% Least Deprived 
61%-80% 
41%-60% 
21%-40% 
20% Most Deprived 
 
0.057 
-0.491 
0.830 
-16.501 
Reference 
 
1.0 
1.0 
1.0 
0.999 
 
-18.630 
-19.061 
-18.145 
-18.432 
Reference 
 
<0.001 
<0.001 
<0.001 
 
BMQ-Concerns -0.603 0.195 -0.938 0.049 
BMQ-Benefits -1.569 0.043 -0.720 0.298 
Trim-Wt-WM 0.014 0.322 0.034 0.026 
DiabMedSat Change 
Improved 
Stable 
Decreased 
 
Reference 
0.069 
1.764 
 
 
0.935 
0.036 
 
Reference 
-0.154 
-0.405 
 
 
0.837 
0.657 
baseline MMAS-8 0.211 0.432 -0.580 0.010 
Baseline Diabetes 
Medication Burden 
-0.473 0.202 -0.740 0.048 
HbA1c Follow-up 0.038 0.048 0.017 0.371 
Trim-Wt-PH Change 
Improved 
 
Reference 
 
 
 
Reference 
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Stable 
Decreased 
-1.686 
0.511 
0.040 
0.583 
-0.811 
0.511 
0.287 
0.597 
SEAMS Change 
Improved 
Stable 
Decreased 
 
Reference 
1.022 
1.861 
 
 
0.284 
0.044 
 
Reference 
-0.231 
0.203 
 
 
0.756 
0.785 
SEAMS-UCU Change 
Improved 
Stable 
Decreased 
 
Reference 
1.792 
2.708 
 
 
0.125 
0.021 
 
Reference 
-0.693 
0.223 
 
 
0.361 
0.765 
  
5.7. Summary 
Participants were generally significantly more positive with their new treatment at 3-
months follow-up. Despite one third of the group had their expectations unmet with 
their new treatment, on the whole, they were more satisfied with the information 
they have received about their new medicine particularly with the potential problems 
with medicines (side effects etc.). Therefore, they had less concerns about the 
potential adverse effects of their new medicine and, they were more satisfied overall 
with their treatment; including how efficacious and less burdensome this treatment 
has been, and how it had not impacted their daily life or weight management. Yet, as 
time progressed trends of ambivalence towards their new treatment was found when 
inspecting individual scale items. At three months, they had better quality of life in 
relation to their weight and weight loss. Although their confidence in taking their new 
medicine correctly only significantly improved for under conditions of uncertainty, 
they still remained largely low to medium adherent (70%). As it appears, the 
experience of starting a new treatment and experiencing it, did not affect their beliefs 
about the necessity and benefits of their diabetes treatment. On the other hand, they 
had significantly stronger beliefs that prescribed medicines are overused by doctors.  
 
The WR group appears to have the most benefit and positive outcomes of the 
treatment they have received in this study. The difference in the outcomes between 
the WR group and the other two groups (WI and WN) perhaps reflected the support 
they received for the duration of the study or the type of new treatment they were 
prescribed.  
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Although unmodifiable factors such as social and marital status appear to have an 
influence on adherence, the beliefs about medicines (Concerns, Overuse, Harm and 
Benefits), and self-efficacy in taking medicines correctly are making the most impact 
on medication adherence levels following initiation of new treatment for T2D.  
Individuals are seven times more likely to become highly adherent if they are 
confident in taking a new medicine correctly under difficult circumstances and they 
are 3-4 times more likely to become highly adherent if they had less concerns about 
their treatment over time. Moreover, if individuals are highly adherent prior to 
starting new treatment for their diabetes they are almost 2.5 times more likely to be 
highly adherent over time, and if they are initiated a treatment before their HbA1c 
levels reach 75mmol/mol (median HbA1c level for those who improved adherence 
over time) then their adherence levels are less likely to decrease. On the other hand, 
if individuals’ confidence levels in taking their new medicine correctly decreases over 
time, then their adherence levels are twice as likely to decrease.  
 
The next chapter will present the findings from the qualitative interviews. The 
quantitative findings will be further discussed in chapter 7 with the qualitative 
findings. 
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CHAPTER SIX: INTERVIEW RESULTS 
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6.1 Introduction 
This chapter presents the results of the analysis of the interviews (pre and post new 
diabetes treatment) collected in this study. It starts with presentation of the response 
rates to interview participation, and key demographic characteristics of the 
participants who completed both interviews. In addition, each section then presents 
the concepts and themes identified during the analysis. These sections aim to answer 
two of the research questions: 
1. How do the expectations, beliefs and attitudes of people with T2D towards 
different diabetes treatments that either promote weight loss, are weight 
neutral or result in weight gain, change over time? 
 And:  
2. What type(s) of intervention(s) promoting treatment options, focusing on 
effects on body weight, are acceptable to patients in order to increase their 
understanding of their diabetes treatment and improve adherence?   
A summary of the key findings is provided at the end of the chapter. 
 
6.2 Interview Participants  
In total, 29 participants completed the first interview and 24 completed the second 
interview, representing almost 12% of the total sample who completed the 
questionnaires. Two participants, who did not complete the second interview, did 
not start their new medicine, and therefore were withdrawn from the study. Three 
participants, although they completed their second questionnaire, withdrew from 
the second interview. The final interview sample (n=24) was recruited from both 
primary and secondary care (Figure 6.1). Whilst the sample contained less from the 
secondary care (n=5) and the majority from Sefton PCT (n=14), it remained 
representative of the whole group and, therefore, there was no selection bias. The 
average interview lasted 41 minutes (range 20-78 minutes). 
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Figure 6.1: Number of participants completing both interviews in each NHS Trust in primary 
and secondary care 
 
Table 6.1 presents the demographic and clinical characteristics of participants who 
completed both interviews (n=24). Of those participants who completed the 
interviews, three had already started taking their medicine prior to their first 
interview, but they had done so within 24hrs of completing the first questionnaire. 
Furthermore, at the time of the second interview, only one participant had not 
started their new medicine, but instead there was an increase in dose of their current 
medicine (insulin). One participant had changed their new medicine (exenatide) to a 
medicine in the same class (liraglutide). The interview sample provided a good 
representation of the questionnaire sample, both in terms of demographic and 
clinical characteristics, as well as questionnaire scale scores (see Appendix 6.1 and 
Table 5.1-5.2 for comparison).  The results of the questionnaires (Appendix 6.1) were 
not reviewed prior to interviews to minimise any of the effects that might incur to 
the patient interview. Data saturation was reached after interviewing these 
participants, through an iterative process of reviewing transcripts and no new coding 
or themes emerging (Holloway & Wheeler, 2010).  
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Table 6.1: Key Characteristics of interview participants (baseline and change data) 
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Keith SCDC wife Retired 63 41 71 12 Neuropathy Tablets Exenatide, WR 10, 3 L ↑ N/A ↓ 
Teresa SCDC husband Retired 63 36 73 19 CVD, ACR Tablets 
injections 
Exenatide ER, WR 8, 3 M ↑ N/A ↓ 
Robert GP family Full time 52 32 77 2 None tablets Gliclazide, WI 3, 1 M ↑ ↓ ↑ 
Kelly+ MDT family Un-
employed 
55 52 54 9 None tablets Exenatide, WR ~15, 1 L ↑ N/A ↓ 
Andrew MDT wife Retired 72 43 83 8 Nephropathy tablets Gliclazide, WI 8, 2 H ↔ ↓ ↑ 
Vanessa
* 
SCDC alone Un-
employed 
49 44 84 9 None Tablets 
injections 
inhalers 
Liraglutide, WR  20, 3 L ↑ ↑ ↓ 
Julie MDT husband Part time 55 36 86 10 None tablets Liraglutide, WR 6, 3 M ↑ ↓ ↓ 
Edward MDT alone Retired 64 29 92 6.5 Neuropathy 
Nephropathy 
Retinopathy 
Tablets, 
injections 
Insulin BD, WI 7, 3 L ↑ ↓ ↑ 
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Daniel GP alone Un-
employed 
57 32 60 2wks None tablets Metformin, WN 6,0 N/A N/
A 
↓ ↓ 
Karen MDT family Full time 46 36 65 2 None Tablets 
inhalers 
Liraglutide, WR 6, 2 L ↔ ↓ ↓ 
Oliver SCDC wife Full time 49 30 98 10 None tablets Liraglutide, WR 4, 3 L ↓ ↓ ↓ 
Gareth MDT partner Retired 66 28 58 13 None tablets Linaglitpin, WN 7, 3 L ↑ ↓ ↓ 
Patrick MDT alone Full time 58 42 68 7 Neuropathy 
Nephropathy 
Retinopathy 
Tablets 
injections 
Linagliptin, WN 16, 2 L ↓ N/A ↓ 
David MDT wife Retired 76 34 97 1 CVD tablets Metformin MR, WN 7, 1 M ↑ ↓ ↓ 
James MDT wife Retired 72 31 63 12 None tablets Sitagliptin, WN 5, 2 M ↑ ↓ ↓ 
Irene MDT husband Retired 71 39 79 19 CVD tablets Liraglutide, WR 12, 2 M ↓ ↓ ↑ 
Kate** MDT son Un-
employed 
49 33 110 11 None Tablets 
injections 
Sitagliptin, WN 3, 2 L ↔ ↓ ↑ 
Linda MDT family Retired 64 43 52 10 Neuropathy 
Retinopathy 
tablets Dapagliflozin, WR 8, 2 M ↓ ↓ ↓ 
Alison+ MDT son Part time 70 37 87 10 Neuropathy 
Nephropathy 
Tablets, 
injections 
Exenatide, WR ~6, 2 H ↔ ↓ ↓ 
Angela MDT alone Retired 74 30 102 13 None Tablets 
injections 
Insulin BD, WI 6, 4 M ↑ ↔ ↑ 
Christo-
pher 
MDT family Retired 57 31 93 12 CVD, ACR 
Neuropathy 
tablets Insulin OD, WI 9, 2 H ↓ ↓ ↑ 
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Philip  MDT wife Retired 66 35 66 8 CVD 
Nephropathy 
Tablets 
injections 
Exenatide ER, WR ~18, 2 N/A N/
A 
↑ ↓ 
Elizabet
h 
SCDC husband Part time 66 38 78 17 Retinopathy Tablets 
injections 
Insulin BD, WI 14, 1 H ↔ ↑ N/A 
Adam SCDC wife Retired 65 28 73 13 CVD 
Nephropathy 
tablets Insulin OD, WI 10, 3 M ↔ ↓ ↑ 
HCD=Health Care Delivery, MDT=Multidisciplinary Team, ACR=Albumin- Creatinine Ratio a measurement of microalbuminuria, Adherence Level: L=Low, M=Medium, H=High, 
HbA1c and Weight Change: ↔=stable, ↑=Increase, ↓=Decrease, N/A=non-applicable due to missing data *Vanessa started at the same time Levemir (once daily insulin) 
but completed questionnaires based on Liraglutide. Her perceptions on both medicines were explored during the interviews. ** Kate never started sitagliptin, instead her 
insulin dose and frequency of injections increased. + Alison and Kelly reported type and/or number of medicines taken, so total number was estimated as there were not 
accurate clinical records at time of study.     
274 
 
6.3 Central Themes 
Analysis of the interview transcripts identified the following central themes:  
 Diabetes, diabetes medicines and factors influencing perceptions of severity  
(section 6.3.1)  
 Body weight (section 6.3.2) 
 Beliefs and perceptions about medicines (section 6.3.3) 
 Experience of taking medicines (section 6.3.4) and emotional impact (section 
6.3.5) 
 Routine and coping mechanisms (section 6.3.6) 
 Perseverance and compromise with medicines (section 6.3.7) 
 Aspects of helpful and unhelpful support in diabetes management (section 
3.6.8) 
 
The themes presented here follow the trajectory of the participants’ experiences 
from when a diagnosis of T2D was confirmed to being prescribed their new 
medicine(s). This encompasses their understanding of managing their T2D and body 
weight; their experiences of taking diabetes (and where appropriate other) 
medications; their beliefs about their prescribed medicines and their perceptions of 
their effectiveness; and the strategies of adapting (or not) to their prescribed 
medication. Participants’ reflections on their experiences of the support they 
received for managing their diabetes and their recommendations for service 
improvement are also presented. The themes are explored separately. Individual 
participants’ key changes between their two interviews can be found in Appendix 6.2. 
Participants’ names have been changed to protect their anonymity. Participants’ new 
pseudonyms are included after each quote, which is tagged with interview round one 
or two i.e. I1 or I2. The quotes in the following sections aim to give a fair 
representation of the data. 
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6.3.1 My Type 2 Diabetes and my medicines  
6.3.1.1 Diabetes understanding  
Most of participants reported getting diagnosed with T2D by “accident” following an 
infection or other presenting symptoms or a routine test at their GP practice, hospital 
or opticians. Out of all the participants, even those who did not explain the details of 
their diagnosis, almost half either had a parent and/or sibling who had T2D, and few 
had a son, a daughter or a cousin with diabetes. Despite the relative link with 
diabetes, only a few of them described “genes” as a factor for having diabetes. Other 
reasons for having diabetes were being overweight, lifestyle and age, but most of 
them did not provide any explanation.  
 
While diabetes was regarded as a serious/“killer” disease by all, there were different 
elements to its description. Diabetes was described as a “prolific”, but “you can’t 
catch it” kind of disease. Although it is a “silent” and “invisible” condition, it can have 
an “aggressive form”, most commonly referring to limb amputations and blindness, 
with few participants mentioning complications such as heart disease/stroke and 
diabetic coma (associated with either low or high blood glucose control). Hence, in 
that sense, it can be “chronic” and “progressive”, but equally an “inconvenience”, “a 
life sentence” and “a source of by-products” such as having high cholesterol, blood 
pressure and other related conditions. Physically having diabetes means “[body] 
organs [are] not functioning” and emotionally “body lets me down” and “a disease 
not nice to have”.   
 
6.3.1.2. Perceptions of Blood Glucose and Self-monitoring 
Participants regularly made comments about their blood glucose, and their effects 
on their body when these were either high or low. “Early warning signs”, when 
glucose was high, included headaches, feeling “dizzy”, “tired” and “sleep a lot”, 
whereas signs when glucose was low included “shaking like a leaf”, “queasy feeling 
in stomach”, body feeling “weak”, sweating, feeling “hot”, getting “agitated”, waking 
up at night, and a feeling that you “can’t put your finger on it” or “something is not 
quite right”. Although, some participants reported they, too, had headaches, 
dizziness and tiredness as a result of low blood glucose.  
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Also, participants discussed actual blood glucose figures and whether they felt these 
were high, low, stable or unstable. High blood glucose levels were generally in double 
figures. Most commonly these were reported as anything over 10, but if they were 
above 20, they were described as “too high”, “miles”, “dangerously”, or “sky” high. 
Whereas, figures below four were considered low. For example, Elizabeth who 
experienced blood glucose of 3.1 described it as “extremely low”. Some participants 
reported their blood glucose levels were “all over the place” or unstable, as Andrew’s 
quote demonstrates:  
 
“And recently my blood sugar has been up and down, like this morning it was 12-
something, that’s even before I had my breakfast…. And I’m doing nothing different, 
but it’s just going up. I mean it’s 15, 16 sometimes and it shouldn’t be”.  (I1) 
  
They all understood that there are acceptable levels for their blood glucose, although 
not all mentioned what these were. A few participants provided a range, which was 
between four to seven, or four to eight, whereas, Adam and Edward discussed blood 
glucose as having to be in “single figures”. Nevertheless, participants had their own 
perceptions of what was acceptable for them, for example Kelly said “But I mean I 
took my blood sugar today and it was 7.7, which isn’t particularly high, but it is high 
for me” (I2); whereas Kate said: “I feel fine, you know, where they say it’s got to be 
under five my sugars or seven, mine’s always sort of like 11 or 13 around that, and I 
feel fine”(I1). On the other hand, Angela, whose readings were always above 6, said: 
“you see I’ve just taken my reading just before lunch and it was 4.3. Well that’s low” 
(I2), and Adam who experienced blood glucose of 3.4 said he felt fine even though he 
knew this figure was low. Keith, on the other hand, adopted his wife’s interpretation 
of glucose levels as he explains in this quote:  
 
“my wife, she takes insulin and she does her blood sugars a couple of times a day, and 
over the years if she, if it’s five or under, she will not go to bed.  Now if it stays about 
eight, nine, ten, she’ll go to bed. Now that’s, as she said to me, if it’s going sky high, 
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like 14 or 15, there’s something wrong, or if it goes below five there’s something 
wrong, but say between five and ten or 11, you should be all right.” (I2) 
 
During the interview participants provided a number of factors that could influence 
their blood glucose to go high or low, and how they coped with hypo/hyperglycaemia, 
as figure 6.2 demonstrates.  
 
Figure 6.2: Participants’ perceptions of factors affecting blood glucose 
 
Very few of the participants were relying solely on HbA1c testing for assessing their 
diabetes control, whereas the rest of the participants were also familiar with the 
blood glucose monitor but the frequency of testing their blood glucose varied from 
person to person. For some participants, SMBG provided reassurance that they could 
identify certain foods that could cause blood glucose levels to go high, as David 
explains: 
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“I've found if I have a treat, like a jam doughnut, I know what’s going to happen when 
I do my bloods, it’s going to go up.  So what I've done, I've just got to say no to any 
sweet stuff, no, none at all.” (David, I2) 
 
Whereas, Adam prior to starting his new medicine (Insulin) found that “while I was 
on holiday I treat myself [to apple crumble and custard], and my blood sugars weren’t 
that much different so I wasn’t that bothered, because I take my blood sugars every 
day”.  (I1) 
 
Also, SMBG was used by others when symptomatic to ascertain whether their 
symptoms or actions resulted in high or low blood glucose, whereas Karen said: “I 
don’t test myself on a daily basis so I wouldn’t know if there was any difference really 
[in my blood sugars]”(I2), and Julie suggested that not doing the SMBG regularly is 
like “head in the sand business, isn’t it, because you don’t know if you're up, you don’t 
know if you're down”. (I1) 
 
Some participants were aware that their blood glucose had gone “progressively high” 
or “out of control”, but still, did not monitor their glucose regularly and indicated they 
felt fine, as the following quotes describe:  
 
“I don’t do it [SMBG] often to be fair because I’ve had it so long now, my diet’s always 
the same as such, you know, I don’t really help myself so I sort of know. I don’t get 
any highs or lows as such, like I never feel anything.  I just feel normal no matter what 
I do.” (Oliver, I1) 
 
“But I was doing it twice a week and then they [diabetes staff] said well just do it once 
a week because… I don’t like doing it anyway, so.…even doing the blood test I know 
it’s vital but I just hate doing it because it reminds me I’ve got diabetes and why should 
I be doing this when I know I’m okay” (James, I2) 
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Yet, those participants who were SMBG twice a day or more, often described that 
they could not rationalise why their glucose levels were either high or “up and down”, 
despite not making any changes to their diet, eating patterns or their lifestyle in 
general.  
 
“Before my blood sugars were a bit erratic, I was sort of getting six to eight of a 
morning and the same at lunchtime, but just before the evening meal it was going up 
to 13 or something. I wasn’t eating anything mid-afternoon, I was only having the one 
sandwich at lunchtime, so no one could see why this was happening.” (Patrick, I2) 
 
Nevertheless, despite the bewilderment by their readings, most of them provided 
some explanation as to why this was happening, such as stress or illness (Figure 7.2). 
However, Angela, like others who started on insulin as their new medicine, found that 
“It seemed to take a long time to kick in and my readings were very high. But just in 
the last couple of weeks the readings are so much better, the last say three weeks…” 
Therefore, she suggested “it just took some time to change from my old insulin to my 
new [insulin regime]” (I2). This belief was reinforced by HPs who told participants that 
it could take months (Adam, I2) or a year (Christopher, I2) before they see any 
difference in their blood glucose with insulin treatment. Nevertheless, Adam also 
suggested “But I've been without two tablets, a water tablet and a cholesterol tablet, 
and I don’t know whether because I've done without them for a week…” his blood 
glucose levels have “gone quite good” (I2). 
 
On the other hand, Elizabeth, alluded that her husband said “you wonder whether 
you’ve hit a fatty patch there and it’s not really going through.”, hence the high blood 
glucose readings “…could even be the way [insulin is] going in”. (I2). A belief, also, 
shared by Philip. 
 
However, SMBG led to negative feelings of frustration, regardless of participants’ 
effort to control their blood glucose. For example, Christopher said:    
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“It’s down heartening when you think, well I think, I've eaten the right things doing 
this, then you get a 14, and you think where did that come from?”  (I2).  
 
Furthermore, when he was advised to self–monitor his blood glucose more often, as 
a result of initiating insulin, he said:  
 
“What I got fed up with was the pin pricks in your fingers, I was doing it, like twice a 
day every day for a month, which is a bit of a pain to be honest. You think, oh shall we 
go out and have say a pub lunch, oh I can’t I've got to do my bloods, because there’s 
got to be a certain gap which I found irritating, annoying really. Because you’re using 
like, in one month I've used 50 strips of testing strips. So that was getting on my nerves 
a bit I must admit…” (I2) 
 
6.3.1.3 Diabetes Treatment 
Although the first line of treatment for T2D is through lifestyle changes, very few 
participants stated that they started with exercise and diet control. Although most of 
the participants said they used to be more active when they were younger or when 
they were in full-time work, very few participants reported currently doing regular 
physical activity. Most of them suggested they struggled to engage in exercise 
because of their lifestyle, their body weight or other health conditions. Some of them 
said that when it is spring/summer they find it easier to be more active, like 
gardening, cycling and going out for walks.   
 
Nevertheless, as a result of their diagnosis, some people had to think about making 
changes to their diet; most commonly referring to avoiding sugar and sweet foods. 
Other dietary changes included reducing/cutting out alcohol intake and trying to have 
regular and smaller meals throughout the day. Conversely, only very few people said 
they were already eating quite healthy at the time of the diagnosis, as Adam 
explained when his doctor asked about his diet: “… when he realised what my diet 
was, I was on a better diet than a diabetic’s on, because I didn’t eat chips and only 
mainly ate meat and veg, cereal of a morning and things like that. So I didn’t have a 
problem with adjusting diet-wise because I was already on that type of diet.” (I1) 
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Yet, Daniel, who recently had attended a diabetes course, at the second interview 
said: “I always thought I had a healthy diet but obviously I wasn’t because, but I do 
tend now to cut out a lot of chocolates, biscuits. I didn’t eat a lot of the bacon, you 
know, but I've more or less cut them out now. I wasn’t a great eater of them but I've 
cut you know like.  And I always had brown bread but the last nine months I've tended 
to have, I’m tending to go back on white bread for the first time in years. …but I've cut 
that all out again, gone back onto brown bread.  But I’m not eating half as much as 
what I used to.”  (I2) 
 
Despite being aware of the dietary changes needed, many participants said they are 
“not always 100% on it” and “now and again cheat” because “you are only human” 
and “you don’t have to suffer”. The following quotes demonstrate how difficult it has 
been for participants to maintain the dietary changes:  
 
“At first it was diet control, which they tell you to go and do, and then you do to a 
certain extent but you go off, you know. I don’t think any diabetic can really do diet 
control, because you're losing so many, leaving out so many foods that you're 
enjoying.” (Julie, I1) 
 
“I haven’t tried very hard.  The first six months, yeah, you know, I had all the steamed 
fish and the boiled potatoes and the fresh vegetables and all that lark, and to be 
honest with you, it probably done me good, you know, I did feel that I was losing a bit 
of weight. But that’s a bit off putting because you struggle to lose it [off the waist], 
you know, I can lose it off my legs, my arms, everywhere…. Not off the waist, no.  But 
yeah, and then, I suddenly just went back into my old little life, like gradually, like of 
gluttony.” (Oliver, I1) 
 
Alison reported that her doctor did not believe in trying to diet (I1), so she started her 
medication right away, whereas Teresa was advised to start medicine straight after 
her diagnosis but she refused to do so, as she explained:  
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“… for eight months I, I, I just refused point blank to take [the medication], to diet, to 
do anything, but you realise that, you know, if you want to feel better you’ve got to 
take [the medication]… and when I first went to see the dietitian and…. at that stage 
it was you can’t eat that and you can’t eat this, um, so I started to learn that, you 
know, I couldn’t eat all the sweets and, and the rubbish that I was eating and you do 
change your lifestyle a bit.” (I1) 
 
Most of those on diet control moved on to medicines within weeks/months except 
Linda who managed to control her diabetes without medicines for 7-8yrs. 
Participants most usual first drug was Metformin. However, the types and 
progression to treatment differed for every individual. Nevertheless, their experience 
of constant change in their diabetes treatment over the months and years was very 
common. This common change included the types of medicines (tablets and/or 
injections), strength and frequency of doses, as the following quote explains: 
 
 “…originally they put me on metformin, which was six tablets a day…. A few years 
back they called me in and they reduced that, they’ve taken two off, so it was only 
four a day. Then around that time they’d given me what you call another tablet, 
gliclazide…and they’ve given me one [tablet] originally, then a year or so after that 
they knocked it down to half of one, which was a load of messing actually, given me 
half [tablet]. Then they put it back up to one. This is over several years now.” 
(Christopher, I1) 
 
According to participants, most of the changes to their treatment were made because 
their “blood sugars were not coming down”. Still, for Patrick and Irene, medication 
changes were made due to major complications with metformin and their kidney 
function, whilst David, Elizabeth and Karen reported changes as a result of side 
effects of their diabetes medicine. Furthermore, Kelly and James reported their 
medication change was attributed to potential complications of treatment, as James 
explains:  
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“the problem with the tablets I was on at the time was I'd read in magazines and 
various things in America they were trying to ban it because of the side effects and it 
was killing a lot of people,… it was about three years ago, got a phone call from the 
doctor to say we need to speak to you about your medication.  So they took me off 
this tablet and changed it to whatever I'm on now.” (I1) 
 
6.3.1.4 Acceptance to new medicine  
All participants accepted the initiation of their new medicine, and most of them had 
started and continued taking their new medicine at the time of the second interview. 
It was evident from participants’ first interviews that some of them were already 
aware of their new treatment prior to prescription, because; it had been suggested 
in the past, close friends or relatives had been given that treatment or they 
themselves had read about it on the media. Although, Daniel, as others, felt “still 
blasé”(I1) about being prescribed the new medicine, Angela and Vanessa felt relief, 
as Vanessa’s quote portrays:   
 
“You know, instead of, as I said, oh carry on doing what you’re doing, come back in 
three months. I felt like they were doing something for me, and I was going forward 
rather than sitting there and going backwards.” (Vanessa, I1) 
 
Most were willing and keen to try the new medicine in hope for the potential 
benefits, which could lead to living a normal life (Appendix 6.2), as Andrew explains:   
 
“Just want to try and sort myself out.  I want to lead a normal life, I’m not a gymnast 
or skiing or cycling and all that, I just want to live a normal life for my age.” (Andrew, 
I1) 
 
Nevertheless, starting a new treatment was linked with feelings of scepticism, 
apprehension, reluctance and disappointment, as the following quotes reveal:  
 
“I never dreamt I’d be here talking about insulin.” (Christopher, I1)  
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“But to me, it wasn’t desperate that I needed it...  So in some ways I regret coming [to 
clinic to see consultant]… I'm being honest, because I think well nothing was, major 
was happening in my life…” James (I1) 
 
“I was disappointed, probably in myself. But ultimately, I mean I was glad to change, 
I've sort of been expecting it so I figured if it’s got to be, it’s got to be, and if it does 
me good let’s give it a go..” (Oliver, I1)  
 
Keith was “a bit sceptical” (I1) when the doctor suggested exenatide, but because his 
wife was treated with insulin and understood it is a treatment that she has to have, 
he hoped this injectable treatment would be “okay” for him too.   
 
Consistent with participants’ previous experiences with medication changes, the 
most common reason this time for a new medicine was that their recent HbA1c 
results showed that their blood glucose was high. Elizabeth, in addition, willingly 
decided to try her new medicine, as she felt that her symptoms of itchiness may be 
due to her current insulin. However, according to Patrick, and Gareth, their doctor 
suggested that their blood glucose was in control, but their kidney function was 
deteriorating. James, also, was told that his blood glucose was in control, but the new 
treatment may improve this even more.  
 
Whilst participants were discussing the benefits of their new treatment, it became 
apparent that the changes to their treatment had a dual purpose, apart from 
improving their blood glucose. Many of the participants specified that the key 
motivation to accept the new treatment was they believed it would help them lose 
weight (see Appendix 6.2).  
 
“…that’s my aim; lose weight, er, and then for the clothes I’ve got they fit, you know, 
that, that’s what I want.” (Keith, I1) 
 
“I’m hoping it’ll work towards the weight loss as well.” (Andrew, I1)  
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Their motivation for weight loss coincided with the type of medicine they were 
prescribed (i.e. GLP-1 agonist/SGLT-2 inhibitor), except Andrew, who was prescribed 
gliclazide, a medicine known to result in weight gain (see Table 1.1).  
 
Furthermore, another key motivation was to take less medicines; for some 
participants this meant taking less tablets (discontinuing or reducing 
frequency/doses) and for others it meant taking less insulin (dose and frequency of 
injections).  
 
“If this one [Bydureon] doesn’t make me lose weight, at least I’d gain losing tablets.” 
(Philip, I1) 
 
“so hopefully taking this tablet mean I won’t get more insulin” (Kate, I1) 
 
Finally, as noted before, some participants agreed to the new treatment, as it would 
preserve their kidney function.  
 
“[the Doctor] explained to me that he thought that the diabetes was under good 
control, but he thought that the change in this particular medicine, which is called 
linagliptin… it was a medicine that superseded sitagliptin and was better for me and 
was more likely not to affect my kidney function than was sitagliptin... I said that’s 
your best opinion is it? And he said yeah. I said fine I’ll go along with that…” (Gareth, 
I1) 
 
Not all participants were given an option for a new treatment, however for those who 
did, Julie and Teresa opted for an injectable treatment in order to avoid insulin, 
 
“…the doctor I spoke to said, well, it’s either that or its insulin, um, and I really don’t 
want to go onto insulin. I’m big enough already, I don’t want to, to get any bigger.” 
(Teresa, I1) 
 
Instead, Linda who was given three options, opted for a tablet, as she justified: 
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 “well the first [option to remain on the same treatment] didn’t seem reasonable 
because my level was still higher than they wanted…the second option was this 
injection, and … because I told him … I was considering asking for a gastric band so I 
could lose weight, so he said to me this injection, some people have referred to it like 
a gastric band because they didn’t eat as much and it’s made them feel full. So I told 
him that I didn’t know if I liked the idea of that one…. Plus giving yourself injections 
every day is another thing that really, it’s not that nice to have to keep doing it…. and 
I'm on aspirin, so I bruise more easily and all of that. And... I don’t know if it was a risk 
more of cancer or something, I can't remember, I really can't… So then the third 
option, just the fact sounded simple, it was only one tablet a day anyway… So I 
thought no that sounds like it might work for me.” (I1) 
On the other hand, James mentioned he “won’t even consider” the second option he 
was given because “the doctor said… the second one’s got more side effects and 
weight gain and all that…”(I1) 
 
Christopher, too, opted for a medicine with less side effects, as he explained: “Well 
when I spoke to the doctor he said there’s so many options tablet form. One’s better 
than the other and all… or you might get ankle swelling, different things. But they said 
insulin you will end up on it. So I thought well you might as well start now than later. 
So it’s going to do me more good than harm – that’s the way I’m looking at it.” (I1) 
 
Nevertheless, Edward, David, Robert and Daniel were the only participants who did 
not exhibit a dual purpose to their new medicine during their first interview. Initiating 
a new medicine for all of them meant that there was an increase in the number of 
tablets they need to take, except Edward who had an increase in frequency of insulin 
injections. All, except Edward, were recently diagnosed with diabetes (from 2 weeks 
to 2 years). Therefore, they were keen to initiate their new treatment to control their 
diabetes, minimise complications and relieve any symptoms.  
 
Conversely, Edward took some time to consider starting his new medicine as he 
explained:  
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“I’ve got so used to doing the one insulin jab a day. That becomes second nature. You 
take that the same time noon, every day, so you knew where you stood. But when 
they said oh we might think it’s for your benefits to go on two insulin jabs a day, I was 
a bit reluctant at first. But they did persuade me there, it was all for the good like.” 
(I1) 
 
6.3.1.5 Perceptions of Seriousness 
Despite the acknowledgement of Diabetes as a serious condition and the worry about 
future potential complications, the level of seriousness appears to change over time 
depending on several factors (Figure 6.3).  
 
 
Figure 6.3: Perceptions of Seriousness of Type 2 Diabetes 
 
For some, initiation and/or changes to diabetes treatment together with evidence of 
high blood glucose or HbA1c results and symptoms, such as “pins and needles” in 
fingers, suggested an increased level of seriousness of participants’ condition. Hence, 
it is no surprise that any changes to blood glucose, either through SMBG or HbA1c 
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test results, and their own perceptions about blood glucose (section 6.3.1.2) had 
affected their perceptions of their diabetes seriousness.  
 
At first interview, Philip, Christopher and Irene felt that their diabetes is serious 
because of their high blood glucose. At second interview, Philip and Christopher were 
both concerned that their blood glucose was still high. Whereas Irene was more 
concerned about the risk of hypoglycaemia since her new treatment “brought my 
blood sugars right down” (I2), despite this was less likely with her new treatment (see 
Section 1.6.7).  
 
James, at the second interview, had seen, through SMBG, that his blood glucose 
remained stable with his new treatment, he said that “[the diabetes] hasn’t 
progressed any more, and it might have regressed slightly…Well the only one that 
sticks in my mind is… I would say [blood sugar is] always 5.3 and used to be 5.5, so it’s 
minimal.” (I2) 
 
On the other hand, at the second interview, Vanessa expressed that her diabetes 
team “because my blood sugars are so high, they’re trying to get it down. I think 
they’re more bothered about that than I am.” (I2). However, Vanessa’s reason for 
being less concerned about her high blood glucose is because she is more afraid of 
the risk of hypoglycaemia as a result of what happened to her dad, as she explained: 
 
“Because my dad was diabetic and he had quite a few episodes of hypos, and it wasn’t 
nice... he was on the tablets for years and then as he got older into his 60s he got put 
on injections, and that’s when the hypos started more... and he went into a diabetic 
coma and he died, and that did frighten me at first when I got told I was diabetic.  And 
I didn’t really want to take the injections, because of what happened to my dad.” (I1) 
 
Most participants indicated that their diabetes is not serious at the present moment 
because they are “feeling fine”. This means they do not have any symptoms or the 
symptoms they have can be tolerated, as Daniel explains:  
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“[I] feel okay myself, don’t tend to have any of the side effects of diabetes and that. 
Well not that I've noticed, do you know what I mean. The only reason I know, is 
because the doctor said I had diabetes, other than that I've had no [symptoms]… Not 
really, no, apart from the odd dry mouth now and again, but obviously you can live 
with that can’t you, that’s easy solved but other than that no major big complaints 
over it.” (Daniel, I2) 
 
In addition, participants believed that they did not have any complications from their 
diabetes, even though more than half of them had at least one diabetes related 
complication (Table 6.1). It was apparent that participants who did have 
complications, either did not realise their link with their diabetes or focused on 
unrelated issues and/or complications. For example, Andrew, who has nephropathy, 
was concerned and wondered about the deterioration to his kidney function, yet he 
indicated as his “thyroid is on the borderline, so maybe that’s part of it” (I1), whilst 
Adam, who has CVD and nephropathy, focused on avoiding “losing limbs” (I1), a 
complication his mother had from her diabetes.  
 
Still, participants felt reassured by the regular monitoring provided by their GP or 
diabetes team through their regular checks of their feet and their HbA1c test.  
 
“I mean I go for the yearly checks and touchwood they’ve never had any changes in 
me... I just couldn’t imagine living my life if I was visually impaired to such a degree, 
... I couldn’t see where I was going ... I think as soon as something like that was to 
start, I think then I would just basically live on vegetables or something like, ..., and 
just change my life completely.  But until that happens I probably won't.” (Oliver, I1)   
 
“I don’t worry about my condition, do you know what I mean, because my doctors 
have been very helpful with the reviews and that, and checking over me and doing my 
bloods, and they say look this is you know it’s going up.  They’ve kept a good eye on 
me.” (Robert, I1)   
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Some participants compared their health with others, in terms of complications as 
well as the amount and type of health service contact they have received, such as 
whether participants are reviewed by a registrar, a consultant or a GP, and whether 
they are reviewed in hospital or in community:  
“[my daughter has diabetes]… hers is bad… she was undiagnosed diabetic until she 
had to have part of her foot removed, and it had, she’d been missed by different 
people over the years…. she got cellulitis and iritis in her eyes….She’s had heart 
valves…” (Linda, I1) 
 
“my sister’s a diabetic but she’s worse than me, she has fits and that. I mean she goes 
to the hospital; she doesn’t go to the walk in [diabetes clinic]... she has more insulin 
than me, takes more tablets than me. But more seeing people, appointments, and 
things like that, so regular check-ups.” (Kate, I1)  
 
Other participants compared themselves with family or friends in terms of their 
health conditions and amount of medicines prescribed: 
 
“It’s harder for my wife because she takes a lot more tablets. Because she’s got heart 
failure, so she takes about 13 different medications… and her problems are a lot worse 
than my problems” (Robert, I1) 
 
“I’m taking a lady who is nearly 100 to hospital for an operation tomorrow… She had 
cancer on her face here. They took it off last week and I’ve got to pick her up at seven 
o’clock in the morning. Because they can’t change the time she’s going in. And they 
couldn’t take her in tonight… So my worries are nothing in comparison to her. She’s 
got no family, she’s got nothing, and she lives in a place that doesn’t have care or 
anything.” (Angela, I1) 
 
Furthermore, some participants considered other aspects in their health had priority 
than their diabetes, or they justified the seriousness of their diabetes based on the 
amount and/or type of treatment they receive for it: 
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“Well health-wise it’s not my diabetes that’s the problem, at the moment it’s my 
kidneys, so once that’s been put to rights I should be fine again.” (Adam, I2) 
“…if it wasn’t anything to do with the weight I wouldn’t bother about it [increasing 
dose of insulin], just do it.  But they have told me don’t worry, some of them are on 
100 units a day, yours isn’t too bad.  No, but it’s the weight problem.  It’s because I've 
got leg issues.” (Elizabeth, I2) 
 
“But the way this has been, it’s been such a level playing field, I haven’t got this 
dramatic thing of well I've got to get insulin” (James, I1)  
 
6.3.2 My Body Weight  
6.3.2.1 Weight Worry 
The majority of participants worried about their current weight, often discussing the 
difficulties faced in trying to lose weight despite numerous attempts to modify their 
eating patterns or food intake. In addition, some expressed that due to a physical 
impairment, heart/breathing conditions, pain, or their age, they were not able to 
maintain or engage in a regular exercise pattern. These unsuccessful attempts to lose 
weight were coupled with strong feelings of frustration, embarrassment, 
disappointment, and self-blame for not looking after themselves when young.  
 
“I just felt that like it was like a stamp suddenly put on me and it was like saying, you 
know, yes you are fat, but there was always a possibility you’d lose weight and you 
were still active, and then you become a diabetic and they give you all these tablets 
to take then… Makes me feel guilty that I never took care and attention when I was 
younger about my own weight…. I felt invincible when I was younger, because I was 
active, I was able to do things, I had good stamina… if I lost weight that I’d actually 
feel better about myself and so I wouldn’t feel so down and things like that. I feel 
almost like a shadow of my former self.” (Kelly, I1) 
 
On the other hand, Adam, Edward, Gareth, Christopher and Angela stated that they 
are not worried about their weight, because they do not see themselves as “terribly 
overweight” or their weight has been quite “stable”. Nevertheless, Christopher and 
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Angela indicated they would not want to gain any more weight, whereas Adam and 
Edward felt that they could keep an eye on their weight by regularly checking it at 
their home or the diabetes clinic.  
 
6.3.2.2 Medicines and effects of body weight 
Half of the participants felt that their medicines had either contributed to their 
weight or prevented them from losing weight, as the following quotes show: 
 
“anybody on 18 tablets a day at your age is never, ever, ever going to lose weight on 
diets and it works the opposite…I wouldn’t say categorically that they put weight on 
me but I wouldn’t say they help me to lose weight.  It’s a bit of a catch 22 and then 
you’ve got the age thrown in, so you’ve got three factors.” (Philip, I1) 
 
“Well I think because metformin makes you gain weight… because it was every time 
you ate you were supposed to have the metformin, and I never used to eat a midday 
meal. I wouldn’t feel like I'd eaten enough to have the metformin, so I'd be eating for 
the sake of eating, just because I was taking the metformin. (Linda, I1) 
 
Of those with experience of taking insulin, most of them associated this medicine as 
being responsible for their weight gain. Adam and Christopher, who had only just 
started insulin for the first time, were also aware of this fact. However, Kate and 
Angela, although experienced with taking insulin, did not relate insulin with weight 
gain. They did mention, however, that the injection site could have contributed to 
weight around their stomachs as Kate’s quote illustrates: 
 
I don’t know whether it’s because of the tablets or just me putting weight on, I don’t 
know. I mean I do feel… as I said it’s just round my belly and that, and that’s where I 
was doing my insulin anyway in my belly, or some at the top of my thighs, but it’s 
mostly my belly I do my insulin ... (Kate, I2) 
 
The participants who did not associate taking medicines with any effects on their 
body weight, felt that they “always” had a weight problem, even before the diagnosis 
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of diabetes, or that their weight has been stable since they started taking their 
diabetes (or other) medicines, as Gareth described:  
 
“Nothing that I’d taken so far affects my weight; the only thing that affects my weight 
is the volume of food that I take and the lack of exercise.” (Gareth, I1) 
 
6.3.2.3 My diabetes matters Vs my body weight matters 
The balance of keeping the diabetes stable and their body weight manageable can be 
tipped over depending on whether participants believed their medicine is important 
for their diabetes or their weight, and as such, the participants can be split into two 
categories. The first category includes those who adamantly said they would not stop 
their medicine if they gained weight. In addition, this category includes all those 
participants who said that they would stop it, or were unsure at first interview, but 
changed their opinion at the second interview. The second category includes those 
who said they would stop their medicine if they gained weight. Also, this category 
includes those participants who said they would not stop their medicine or were 
unsure about it but changed their mind at the second interview. 
  
Participants, who indicated they would not stop their medicine, even if they gained 
weight, described their medicine as more important for controlling their blood 
glucose and preventing diabetes complications, as the following quote reveals:  
 
“I am overweight but not excessively, I don’t think so.  And it’s more important that 
the insulin I’m taking is going to control my diabetes rather than my being fat.  It’s 
not about being fat it’s about controlling it for me so I don’t go blind and I don’t lose 
my feet.” (Angela, I1) 
 
Some of them even said they would “sacrifice” a couple of pounds extra or did not 
expect a lot of weight gain with their medicine. This group mostly consisted of people 
who did not worry about their weight, and felt it had been relatively stable. However, 
for those who changed their mind, they were all concerned about their weight but 
they experienced both weight loss and improvements in their blood glucose with 
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their new medicine at follow-up. Patrick called the weight gain as “the lesser of two 
evils” (I2). Everyone in this group indicated that in order to manage their weight they 
would look into their diet, possibly by decreasing their portion sizes, and would try to 
increase their exercise or be more active. 
 
Some participants indicated they would be unlikely to stop their medicines, like 
Daniel, for instance, who at the time of the second interview believed his medicine 
had helped him lose weight even though he was unsure if his blood glucose had 
improved. Moreover, Robert, who thought he gained weight at follow-up, reported 
he would be unlikely to stop his medicine because he remembers prior to his 
diagnosis “it wasn’t a nice way of living because I was just constantly on the toilet … I 
couldn’t quench my thirst and I was tired and I was up all night” (I2). Edward raised 
concerns about gaining weight because he had already made drastic changes to his 
diet, and he had seen an improvement in his blood glucose at follow-up. His new 
medicine was, also, much more convenient than the previous one, and he was more 
concerned about the consequences of uncontrolled diabetes. Instead, Oliver, who 
appeared reluctant to make any lifestyle changes (either with diet or exercise), 
suggested that he would not blame the injection as he knew he could be doing more 
and “haven’t given it a fair chance” (I2).  
 
On the other hand, the participants who said they would stop their medicines if they 
gained weight, were all worried about their weight in terms of wanted to lose more, 
felt they had tried everything and there was nothing else they could do. They 
indicated that taking medicines restricted their life. Most of them appeared to grieve 
following their diagnosis of diabetes by blaming themselves for being overweight and 
causing their diabetes. As a result, they believed that by losing weight, they could 
stop taking their medicines and their diabetes might even disappear.  
 
“Well if I lose weight - type 2 diabetes, most of it’s associated with being overweight.  
So if I get down to my normal weight, which I haven’t done for a long time, but if I got 
down to a normal weight of say nine stone then I would imagine all the things of 
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diabetes would disappear with it.  So therefore I need less medication and be fitter.” 
(Linda I2) 
 
“…well I am feeling the benefits of it, and I wouldn’t think that I would be on it long 
term compared to other people who’ve extra weight, who carry more weight.  I mean 
there must be a cut off time when you say well you’re not taking it no more if you’ve 
lost the weight.... I’m thinking oh maybe I’ll cure myself and I won’t be a diabetic at 
the end of it, but what’s the chances of that being like.” (Julie, I2) 
 
Most of the participants in this category were obese and all had lost weight at follow-
up. Of those who changed their mind, (even though they had lost weight), David was 
certain that his diet was healthy and any weight gain would have been as a result of 
taking his medicine. He therefore appeared confident in asking his GP to change his 
medicine if he could not tolerate any of the side effects. Alison said she was “heavy 
enough” and although she had put on weight when she started insulin, this had 
stayed “fairly stable” (I2). Karen, who had experienced nausea with her new 
medicine, said she would rather lose weight naturally than being sick all the time and 
if the medicine had caused weight gain she would have asked for an alternative.  
 
Keith was the only participant who was not asked what he would do if he gained 
weight with his medicine. However, he implied that if he continued with the medicine 
he would like to lose some more weight. At his second interview, he was “made up” 
with his weight loss and was pleased to see that his blood glucose had been stable.   
 
6.3.3 Beliefs and Perceptions about medicines 
6.3.3.1 Trust in Doctors to Prescribe Medicines 
Although the majority of participants have trust in doctors to prescribe appropriate 
medicines, as the following quote illustrates:  
 
“The only medicines I will ever take in conjunction with what… already being 
prescribed is what will be further prescribed by the doctor. …I’ve great faith in the 
British medical profession, at least in my own doctor.” (Gareth, I1) 
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They accepted that they are not in a position to argue otherwise, when it comes to 
changes to medication treatment, since doctors are considered experts in this field. 
However, as Patrick emphasises:   
 
“It’s not something you can decide for yourself what you’ll take, so you’ve just got to 
say, well, they know what they’re doing and I’ll take their word for it and hopefully 
it’s the right one.” (I1) 
 
6.3.3.2 Necessity and Benefits of Prescribed Medicines 
Most participants agreed that their prescribed medicines are essential for the 
management of their diabetes because they help to control blood glucose and, 
therefore prevent complications and keep them ‘alive’. The belief about the necessity 
of their medicines appeared to be closely related to physical evidence, which 
reinforced the belief that their medicines are beneficial, as the following quotes 
illustrate:  
 
“…I found actually that after I’d started with the Metformin that I had a load more 
energy.., I was back to normal…I felt really drained leading up to [the diagnosis], and 
the medicine took away that, and it was positive for me, I felt great…. I know I’ve got 
to take them to look after me.” (Robert, I1) 
 
“The main difference [with the new insulin] is the improving blood levels, which is very 
promising, so hopefully that will continue… and I've been hitting that [normal blood 
sugar range] target a lot more recently than I've ever done before, so that’s very 
reassuring. At least you know you’re on the right track.” (Edward, 2) 
 
Hence, the benefits of their prescribed medicines mainly included; their effectiveness 
in controlling their blood glucose and in alleviating diabetes related symptoms. Other 
benefits to their medicines included the convenience of taking them, and having less 
concerns about taking them.   
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6.3.3.3 Effectiveness of Prescribed Medicines 
Participants’ perceptions of effectiveness of medicines in general and medicines 
specific to diabetes varied from individual to individual, as well as within an individual 
over time. Two key factors were identified that changed their perception of 
effectiveness. These were as a result of evidence from blood tests (i.e. HbA1c, 
cholesterol), blood–pressure monitoring and/or through SMBG, as well as physical 
effects on their body in relation to energy levels, and/or body weight (Figure 6.4).  
 
Figure 6.4: Conceptual Model of Participants’ Beliefs and Perceptions about their Diabetes 
Medicines 
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Thus, medicines were effective if blood glucose levels were improving or becoming 
more stable, and participants were feeling more energetic or losing weight. Whereas 
medicines were ineffective if blood glucose was high or unstable and participants 
were feeling tired and/or were not losing weight as they expected. For example, Irene 
stated that she “did very well on the metformin; [as blood sugar] was around 6.1 up 
until September of last year…” while “… the glimepiride, I've really not seen any 
difference in [blood sugars]… That dosage I've been on for quite a few years. I can’t 
remember how long I've been taking it but it has been quite a few years.” (Irene, I1) 
Elizabeth said she tried “virtually” most of the diabetes medicines available “... like 
gliclazide tablet, Lantus, NovoMix doesn’t really suit me, NovoRapid, I’ve tried them 
all really.” So when she was asked why these did not suited her, she indicated “Well 
just the control isn’t good generally. You know, the readings are all over the place. 
You know, as I said before I can be very low one minute and terrific within a couple of 
hours.” (I1) 
 
Philip, out of all his diabetes medicines, found that “…the metformin wasn’t working, 
my walking wasn’t too good and I was just in pain all the time, my energy level’s zilch, 
but I’ve been off the metformin now for just, it’s... About 18 days and I feel better just 
being off the metformin. Whether it’s mind over matter I don’t know, but I’m in good 
spirits, so.” (I1). However, at the second interview, he suggested that “the Levemir’s 
not doing its duty!” because he “…had ten carbs of a morning and I went from 10.1 
to 13.7 with two eggs and one lousy piece of bread - I shouldn’t have been that figure.” 
(I2) 
 
Whilst Keith confirmed that “[Exenatide] seems to be working, because apparently 
I've lost half a stone… I'm actually refusing food now. I've been on six metformins now 
about eighteen months, maybe two years. And I can't understand why, because the 
doctor told me this will help with your diabetes. It hasn’t. This injection’s helped me 
more.” (I2) 
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Yet, some participants showed ambivalence towards the effectiveness of their 
medicines. Reasons for ambivalence included interactions with HPs, as Alison 
explains:  
“I’m on Humalog Mix 50, but I had stress eczema and was on steroids. Now since I 
was on the steroids, my levels have gone so high, my insulin’s [dose] gone up and up 
and up... and [the diabetes team] just said, you know, we are going to have to do 
something else, was I prepared to try this [exenatide]?…and they’ve said it will cut 
then, my Humalog down.” (Alison, I1) 
 
Also, ambivalence was shown when improvements in either blood glucose or body 
weight, did not meet participants expectations, particularly when they anticipated 
that the treatment would provide instant results, as Robert, Christopher and Adam 
explain: 
 
“I don’t know [the benefits of gliclazide] see because I haven’t had the review which 
is tomorrow. I’ve done my blood [test], I don’t know whether it has benefited me by 
bringing my blood sugar down, and I do feel in a way since I’ve started it I do feel 
bloated….I don’t think it’s been as beneficial in terms of psychologically how I felt. I 
don’t feel, I feel like I have improved but not to the extent I was hoping.” (Robert, I2) 
 
“Well I know [insulin]…, supposed to be doing good for me, but at the moment I don’t 
feel any different from when I first started…  I just feel the same to be honest... It’s a 
slow process, it’s like 14 weeks now and I thought it would have been a bit quicker… I 
mean when I was monitoring myself [blood sugar] was like 19, now the other week it 
was 14. Yeah, and the readings of teatime and dinnertime are quite good. The 
mornings and evenings were slightly higher again” (Christopher, I2) 
 
“Because I honestly thought I’d take the insulin and my blood sugars would be in-
between five and seven, and I was quite shocked…I thought my blood sugars would 
just go to more or less a normal person overnight… It didn’t happen, I was on 12 
units… now I’m on 24, so they’ve doubled the dosage…” (Adam, I2) 
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Whereas, Oliver and David said: 
“Well [liraglutide] does appear to be helping to control my weight… I seem to plateau 
of a morning, around about 12-ish, you know, and I still have plateaus around there, 
but that’s probably more down to me…So I haven’t give it enough time I don’t think 
to notice any big differences, but that’s down to me more what I would imagine. It’s 
probably helped me to a certain degree because otherwise I probably would have 
been worse off.” (Oliver, I2) 
 
“I used to stop and rest. But I did have heart failure and I've had the bypass. But since 
this [new medicine] I've felt better, a bit better, you know, I can do walking a bit and 
a bit more without getting tired. I don’t know if it’s in the mind or it’s the tablets but 
whatever it is I’m not bothered; it’s keeping me happy.” (David, I2) 
 
Nonetheless, overtime, the constant changes in participants’ medicines has resulted 
in the belief of them being ineffective, as Karen describes: “You know, I’ve tried a 
couple of things and they haven’t worked and it’s like we’ve got to try something else 
now, and it’s a bit like, you know, just keep stopping something and trying something 
new, all the time..” (I1) 
 
On the other hand, Oliver suggested: “I'm not medically trained so I don’t know if I’d 
be any worse if I'd stopped taking them, you know, I just don’t… and I have been 
tempted sometimes just to stop taking them and don’t even tell the doctor and then 
go for my blood test and see if it was any different, just to see if these things work. I 
mean we’re presuming, you know, like one size fits all, you know, these tablets work 
on everybody like, but I don’t think they do, you know, I think it’s horses for courses 
and until you get the right one, maybe I’ll begin to feel different.” (Oliver, I1) 
 
While, others, like Daniel, reported that medicines work “hand in hand” (1) with 
lifestyle measures such as diet, in order to “reinforce” (I2) its effectiveness, and Linda 
clarified that:  
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“You’ve got to take some responsibility, like a lot of people today think a tablet fixes 
everything.  So I'm not like that, I know that I've got responsibility for it too.” (Linda, 
I1) 
 
Therefore, ambivalence in the effectiveness of their medicines could result in 
ambivalence in the necessity of their medicines. Some participants, who believed 
their specific medicines were ineffective, they wished to stop taking them, like 
Vanessa, who said “…what’s the use of me taking all these?  I don’t feel like I’m getting 
any better, I don’t feel any different. I wish I could just stop taking them all…” (I1) 
 
Whereas others believed that if their medicines are effective and are able to reduce 
their blood glucose or lose weight, then they would come off their medicines, like 
Daniel:  “But if it works I’ll be able to come off it, you know…” (I2) 
 
6.3.3.4 Concerns about Prescribed Medicines 
Participants frequently expressed their concerns over taking medicines (Figure 6.6). 
These concerns were either for individual medicines (Figure 6.5) or the amount of 
medicines as a whole.  
 
Figure 6.5: Types of medicines participants talked about in their first and second interview.  
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Figure 6.6: Participants’ Medicines Concerns and Polypharmacy 
 
Participants described medicines as unnatural as Gareth portrays in his quote:  
“Because any medicine that I take is a foreign body to my body; it’s a chemical which 
the body doesn’t produce naturally, unless it’s an insulin substitute I suppose. So, no, 
don’t like putting stuff like that in my body, it just goes against the grain.” (I1) 
 
Keith said medicines “must do something to the inside but I, I don’t, I don’t 
understand. You take so many tablets and you swallow them all at once… how do the 
tablets know which way to go when they get to the inside?” (I1) 
 
Consequently, participants voiced their worries regarding their medicines’ side 
effects and complications before and after they started taking them, as Julie and 
James illustrate:  
 
“Well with everything you worry about new medicines, don’t you, because you worry 
about side effects, and I mean may have more side effects than just the vomiting, you 
don’t know, and what effect will that have getting into my system, will that make me 
have the runs...” (Julie, I1) 
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Often the fear of side effects, particularly those affecting the gastrointestinal tract, 
was related to past experiences, as Teresa illuminates: “I was very reluctant to, to go 
on [exenatide ER], very reluctant because I’d had exenatide when I first started 
injecting, um, twice daily, and I was very, very, very sick with it, um, very nauseous 
and, and I thought, I can’t, I can’t do this again…” (I1) 
 
Another major concern was the increasing number of medicines participants needed 
to take for their diabetes and, where relevant, for other conditions. Participants 
considered having to take medicines as being old or getting “sicker”. Some were also 
worried how other people would perceive them if they knew how many medicines 
they take, as Philip articulated:  
 
“If it was less it would make you feel better because if you say to people I take four 
tablets a day and a person who doesn’t take tablets, they’ll think there’s something 
wrong with you, you’re a hypochondriac or something like that.  But how many people 
would stand up and say I take ten tablets in the morning and eight at night?  You’d 
feel like a, well, a phony wouldn’t you…” (I1) 
 
Participants suggested that as a result of taking more medicines to manage their 
condition(s), there was an even more increased risk of drug-drug interactions, 
contraindications, and overdosing. Their perceptions about polypharmacy coupled 
with the increased risk of taking more medicines, made participants believe that 
overtime, they are at higher risk of getting side effects/complications from their 
medicines, and these may become ineffective, as Elizabeth suggests:  
 
“because you’ve been taking [the medicine] for so long, but I’m wondering whether 
maybe my system’s got tired of it, you know, and it’s starting to react now…” 
(Elizabeth, I1)  
 
Therefore, any side effects or complications that arise in the future, would make it 
harder for them to know which of the medicines had caused them.  
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6.3.3.5 Trial and Error when taking Medicines 
Despite participants concerns about medicines overall, they recognised that initiating 
a new medicine is a case of “trial and error”. This is related to how effective the 
medicine would be, what side effects/complications it would cause (if any), how they 
are going to cope with them and whether it would require changes to other 
medicines. The following quotes demonstrate how participants rationalise the risk of 
trying something new, and the timeframe they perceived as acceptable for 
determining whether the medicine causes side effects or its effective.  
 
“But I do expect once I start taking the tablet for a few days to have some side effect 
on me, whether, because as I say I don’t take tablets, never taken tablets so I assume 
that there would be some. There might be and I hope there isn’t, but I’ll give it a week 
and then if it settles down well I’ll just carry on.” (James, I1) 
 
“the medicines, they seem to be working for me, I don’t feel anything [no SE]. But it’s 
only early days, it’s only three or four months ain’t it, so it again in a couple of years 
and see how it goes then.” (Daniel, I2) 
 
“Well, all it is really, if they get the dose right and the mix, I take about 12/15 different 
types of tablets a day, and they’ve all got to work together. I think once they get it 
right it works, but it does take a few years of trial and error really to get to the 
situation where it’s right. I suppose that my, something happened with me health-
wise it would alter it again, probably have to treat me for something else.” (Patrick, 
I2) 
 
6.3.3.6 Tablets versus Injections  
Furthermore, participants seemed to have perceptions related to the form of their 
medicines, whether a tablet or injection. Relative to their past experience with their 
medicines, participants expressed a preference towards tablet or injection. In 
general, tablets appeared to have less impact than the injections, as they are “easy 
to swallow” and “just throw them down, have a drink, its gone that’s it”. However, 
Philip was worried about tablets “mainly the metformin and the gliclazide and a 
305 
 
couple of other tablets that they are not coated” because he believed that coated 
tablets “go past [liver and kidneys] so they don’t affect them”, and blamed these 
tablets for the polyps found in his bowels (I1). For that reason, he revealed that “I’ll 
say, give me two injections a day, sooner than have those tablets, sooner than have 
that.” (I1) 
 
Conversely, those inexperienced with injections but who were prescribed 
insulin/GLP-1 agonists as new treatment, implied that these types of treatment are 
more important because they are likely to be more effective and efficient than 
tablets, as the following quotes illustrate:  
 
“[The diabetes team] put me on [liraglutide] because it’s not controlling my blood 
sugars as in an oral tablet. So this way straight into your blood stream…” (I1), “I don’t 
know, I probably sound ridiculous saying it’s more important doing a needle but no, I 
think it’s just the methodology of the fact that you’re doing a needle feels more like 
you’re taking medication that taking a tablet. I don’t know, it’s just the way I think”. 
(Karen, I2) 
 
“I think [insulin] seems like more serious. That’s what I say, if you miss a pill you don’t 
double up, you just miss it, but insulin you think is that more serious if you miss insulin 
than the odd tablet?… I would say so” (Christopher, I2) 
 
However, both Elizabeth and Christopher, who found that the effect of their insulin 
on their blood glucose was not as expected, articulated that:  
“You know, I’m waiting for the days to come when they produce a tablet, that would 
be wonderful, but there you go.” (Elizabeth, I1) 
 
“Might be better if it was in tablet form but [insulin] doesn’t seem to affect the kidneys 
as much as tablets.” (Christopher, I2) 
 
Regardless whether participants had experience with taking injections, most of them 
discussed about the stigma surrounding injecting in public and how this impacts on 
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lifestyle. Many said they would not like to inject every day or many times throughout 
the day. James went on to say that there is no disadvantage in taking tablets because 
“It’s not as if it’s taken in public view” (I1), whereas Julie said “Taking a tablet you can 
do anywhere out and about, no one notices it” (I1). Those with experience in taking 
injections discussed about the “awkwardness” having to inject outside of home. 
Vanessa said, whilst in a restaurant, “I go into the toilet and sometimes if there isn’t 
a cubicle empty I just do it, and if there’s people there they’re looking at me as if I’m 
a druggy.” (I1) Julie, as a result of taking GLP-1 injections, was worried about going 
on insulin due to “all that paraphernalia of carrying needles round with you and things 
for the rest of your life”. This fear was reinforced after going on holidays and realising 
that she had “to get letters from people to say you’re carrying [needles] like you’re a 
bloody drug dealer… but even that’s like I don’t want to be doing this, I just want to 
slip through like everybody else.” (I2) 
 
Those participants who for the first time were about to experience taking injections 
talked about being “nervous” and “terrified” of having to inject. Adam was worried 
“because actually I was thinking at first, well, do you have to inject it into your veins…” 
(I1). Although some were not afraid of needles because they had relatives who were 
on insulin, others were “apprehensive” about the size of needle like a “hypodermic” 
“syringe”, but justified it as  “probably similar to the finger prick test, like once you’ve 
done it a few times hopefully it will be okay” (Oliver, I1). Adam explained that after 
seeing the insulin injection, it has “shattered a lot of fears” (I1). Following the 
experience of learning to inject for the first time, participants described it as “dead 
easy” to do, “only a little needle” “hidden” in a “fountain pen” that takes “seconds” 
or “minutes” to do. Edward, who has been using insulin injections for two years, said 
“there’s no need to worry about it now on reflection, but at the time, I think it’s the 
unknown isn’t it, you know… But you just do it now and you don’t think anything of 
it.” (I1) 
 
Nevertheless, some participants said that they still feel the “soreness” when they are 
“stabbing” themselves and concerned about the bruises. Karen said “when I first seen 
them I thought it was a little bit disturbing because like you look a bit black and blue 
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where the bruises are” (I2). Elizabeth usually injects around her navel area, but 
recently started to inject in her legs, yet she said she would rather not inject in her 
arms as she “don’t want to get all brown specks; I've got awful brown marks keep 
coming [in legs]... nobody sees [the legs] do they, and if they do they shouldn’t” (I2). 
 
6.3.4 Experiences of taking medicines 
6.3.4.1 Inconvenience and Forgetting to take Prescribed Medicines 
Participants discussed the inconvenience of taking their medicines and how this 
resulted in forgetfulness. Still, only a small number of them were frustrated because 
they found it hard to remember their medicines, and panicked when they realised 
they forgot to take them, and blamed themselves if they did. Aspects of convenience 
were related to how the medicines fit with current lifestyle and routine. In particular, 
they discussed the frequency of taking medicines, how, when and where to take their 
medicines, as well as any related dietary adjustments they had to make. 
For instance, participants found their medicines to be inconvenient if they interfered 
with their lifestyle including family, work and social lifestyle, when routine alters, 
especially when they were going out of the home or when they travelled, as the 
following quotes show:  
 
“It’s hard to remember to take them, sometimes being, having a busy lifestyle, a mum, 
I’ve got a full time job, so sometimes there’s a lot going on after school as well, so it’s 
hard to remember to take them especially at the same time.” (Karen, I1) 
 
 “I mean I've forgot it once or twice, and that’s because I rush out and things like that” 
(Kate, I2) 
 
“If you’re out you think oh take a tablet with me and little things like that not a great 
deal, because nine out of ten I’m in the house so they’re already there to take. It’s just 
if you do pop out. Possibly if you go on holiday you’ve got to make sure you’ve got 
enough, but that’s common sense again, that’s all.” (Christopher, I1) 
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“I don’t like the idea of carrying the needle heads round, and then you’ve got to 
dispose of them when you’ve used them safely…[and if] you’re visiting somebody and 
they’ve got kids, you’ve got to be careful you don’t put them down or that sort of 
thing. When you’re staying in a hotel or something like that, you’ve got to dispose of 
them there because you’ve got people coming. You can’t just throw it in the bin where 
someone might be emptying the bin and put their hand in…” (Patrick, I2) 
 
Although different experiences shape what is perceived as inconvenient, in general, 
having to take medicines more than once per day, which encompasses various 
different doses through the day, was considered a “nuisance”. Examples provided 
below:  
  
“…I know I’ve got to take half and half, whether it’s one, it’d be easier if it was like 
40mg tablets and they’re already split. You don’t have to split it so it’s just one 
[tablet]” (Robert, I2) 
 
“And some tablets I take, the milligram they gave me, it can’t be in one tablet, it has 
to be in two. So I’m trying to like reduce the tablets and taking them, it’s like I’m taking 
twice as many… So if I could just get like them two tablets put into one on a couple of 
them I’d be all right.” (Vanessa, I1)  
 
“And it’s just a damn nuisance having to take large doses because it means sort of, 
instead of two injections a day, it’s three injections a day...” (Alison, I1) 
 
Also having to take medicine (with meals or food) at a specific time of the day as well 
as having to take certain medicines at different times from other medicines, was 
thought to be problematic. Most commonly participants said that it was difficult to 
remember to take their medicines in the “middle of the day”, in the “evening” or at 
“bedtime”.   
 
Although Gareth said “Well breakfast you get up and you have your breakfast in the 
morning but lunchtime with me varies depending on what I’m doing or what I’m not 
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doing, whether I’m at home or out somewhere. Just that’s the one that I tend to forget 
if any...” (I2). Linda found the evening more difficult “…because that’s when I’m busier 
and I’m subjected to getting ten different people wanting me to do different things, 
and that’s when I’d be likely to forget.” (I2), whilst Patrick indicated that “… 
sometimes about nine o’clock if I have to go to the toilet I just don’t bother coming 
back down, I’ll just go to bed. And I think that’s what I done last night… and I was off 
to sleep straightaway.” forgetting to take his medicines. (I2)  
 
Furthermore, some participants said that they found it challenging to take their 
medicines with food, as advised in the instructions, because of their concerns over 
side effects and/risk of hypoglycaemia. This meant that they would either eat more 
or avoid eating altogether, as Kelly and Karen suggested:  
 
“They say they don’t give you hypos, but I have definitely had hypos. Whether it’s 
because not a true hypo, whether it’s just because my blood sugar’s coming down, 
but I’ve had to adapt to that. I have to take things like dextrose tablets, so that if I do 
feel like that way that I can take something. I didn’t have to think about that before.” 
(Kelly, I1)  
 
“I take my two lots of metformin after my tea of a night. But sometimes if I don’t take 
it immediately, because you have to take it with food, … and then I feel like later on 
I’ve got to eat something to remember to take the tablet, do you know what I mean, 
so…  I’d have something to eat, like I like something small to eat to take the tablet, or 
if it’s too late and say I’m going to bed, I just haven’t took them, you know, because 
I’d rather not take them on an empty stomach, so I just haven’t took them.” (Karen, 
I1) 
 
Vanesa, however, claimed “It felt like I was eating all the time because I had to take 
[my insulin] three times a day and going from that to my new medication I feel like 
I’ve gone from eating loads to eating nothing... Whereas before I was eating, I felt like 
I was eating for the sake of eating. Whereas now I’m made up because I’m not sort of 
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tied to, I’ve got have something to eat now because I’ve got to take this…So now I can 
go without either my lunch or my tea so in that way I feel better. (I2) 
Patrick, too, reiterated not being “…tied down to mealtimes. So if for some reason 
you forget [the new medicine], it’s easy enough to take it later on” (I2). 
 
A few participants described how Metformin, due to its size, was particularly 
considered as a “horse” or “elephant” tablet which was difficult to swallow “and 
sometimes get stuck in my throat and I’ve got to gargle water and all that…” (Kate, 
I1). Vanessa said despite taking them for 10 years “all of a sudden because they’re so 
big I feel sick taking them. I feel like I’m choking. And I don’t know why, because it 
didn’t bother me before… [and] it has prevented me from taking them before. The odd 
time… I just look at them and think I can’t swallow you. So I just don’t.” (I2)   
 
In addition, some participants felt that they had to adjust their lifestyle and diet as a 
result of taking their medicines. Especially those on insulin injections who explained 
how insulin made them to be more aware about their food choices and eating 
patterns, because of the direct effect on their blood glucose.  
 
For example, Philip described insulin as “like the weather. You’re taking insulin and 
everything’s great if you eat, it’s all about food. If you have two Weetabix in the 
morning it’s great. If you have your food at around about 12 o’clock it’s good and then 
you have your food at five o’clock, but if you go past five o’clock you’re starting to 
nosedive…that’s all diabetes is, an inconvenience where you’ve got to be awake all 
the time to your body…”. He, then, went on to say that when “my wife’s been out 
shopping… and she’ll come in too late and when I say late, only by half an hour, and 
I’m screaming at her, I live on a clock, I can’t live by when you want to come home 
from the shops. Five o’clock I’ve got to eat, five o’clock, and that’s the part, the 
inconvenience part, that’s all it is.” (I1) 
 
Moreover, insulin injections have an added inconvenience of having to be kept in the 
fridge, because “…it says on the instructions… it’s best to keep them at a certain 
temperature. It must affect the insulin” (Edward, I2), “…And once they got pushed to 
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the back of the fridge and froze.  Well they’re no good; they’ve got to be thrown 
out….” (Alison I2). Also, Angela said “Because although I’ve always kept it refrigerated 
I can’t now [fridge broke down] and I can’t put it in the freezer, so I’ll watch my 
readings and if they suddenly start going sky high or something I’ll know that there’s 
something wrong with the NovoMix, but [the leaflet] does say it can stay up to four 
weeks [in a dark place].” (I2) 
 
Furthermore, participants on certain injectable medicines mentioned that they are 
“more fiddly” because you have to “make sure [the liquid is] well mixed”, and that can 
be “a bit of a performance”, in comparison to the pre-mixed insulins.  
 
Also, participants were worried how the injections might affect their driving licence 
and insurance, but those on non-insulin injections, like Oliver, after searching on the 
government website, was relieved to find “they only need to know if you're injecting 
insulin, unless you're prone to hypos or hypers, which I'm not”.  (I1)  
 
6.3.4.2 Experience of side effects 
Experience with side effects from medicines varied from participant to participant. 
Those who reported never having any “problems” with taking medicines explained 
they were “lucky” and “resilient” in that respect. Those who experienced side effects 
stated that only certain medicines had a “bad” effect on them (most commonly 
metformin) and that some of the side effects were “horrible”, “unpleasant” and 
“embarrassing” and made them feel “lousy”/“drained”. Side effects, therefore, had 
an impact on participants’ lifestyle:  
 
“…I think, if I was at home, if I didn’t work it wouldn’t be as bad, but I think because 
I’m working and I’ve got quite a busy, stressful job, that it’s hard when you’ve got an 
upset stomach to actually concentrate on your job and what you’re doing.” (Karen, 
I1) 
 
“…if it’s like impacting on my life, like diarrhoea, vomiting, nausea, dizziness. Well you 
can cope with the dizziness probably, nausea, but diarrhoea, vomiting, that’s like, 
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you’re out and about, I was really bad when I first started taking my Metformin, that 
didn’t agree with me one bit when I first started on that. The diarrhoea, oh my god, I 
think I knew where every toilet was in [my town], I wouldn’t go out unless I was in the 
car with somebody, wouldn’t go on public transport because I just used to, and I’d 
have to go right away there and then.  How embarrassing.  That was like for about 
two, three years that.” (Julie, I2) 
 
Hence, past negative experiences of side effects made participants worry and wary 
when they start new medicines “…considering that you’ve got a disease, but the 
medication you’re taking is making you feel worse really…” (Karen, I1) and “…because 
when you’re taking a medicine that makes you feel poorly, it’s just an added stress to 
you isn’t it?... and you’re plodding on every day, and you think oh, this is a bit of a 
time waste, but obviously you do it.” (Elizabeth, I2).  
 
6.3.5 Emotional Impact of taking Diabetes medicines 
It is no surprise that participants’ beliefs, perceptions and experience of taking 
medicines for diabetes and other conditions had an impact on their emotional well-
being (Figure 6.4). The majority of participants revealed they do not like taking 
medicines and wished for “the less the better” or “better off without” them. David 
said:  
 
“I'm not taking them because like I want to, I'm taking them because I have to. That’s 
the way I look at it, you know. See some of them will be heart tablets or gout tablets, 
and a cholesterol tablet, you know…and I'm scared to go to the doctor’s in case he 
gives me another one.” (I1) 
 
Many said that they would be more stressed if they thought they had to start taking 
more medicines, particularly if they felt that these were not reviewed as often as they 
would like, as Keith indicated  
 
“And the doctor’s left me on … all this medication, he hasn’t altered it, apart from two 
years ago he put it up. I just worry, I'm a terrible worrier, because I know like if 
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anything happened to me, how would [my wife] cope on her own, I don’t think she 
would.” (I2) 
 
Although Daniel and David felt that there was a lot to learn about their diabetes since 
they recently got diagnosed, and Robert found it was a positive experience after 
starting taking his diabetes medicines, other participants were shocked to find that 
they had to take medicines. Oliver was “a bit shocked when [the doctor] said I'd never 
come off it, I mean he said even if I lost weight and got myself as fit as a fiddle, you 
know… I'd still be on it for the rest of my life. That was a bit, you know, off-putting, to 
be fair…” (I1). Alison, too, was shocked with the amount of her medicines as she 
claimed “Well I never took anything before I was a diabetic. There was never really 
anything wrong with me. Few bouts of depression or, you know, not sleeping but that 
was due to - how can I say it - anxiety. But apart from that I didn’t take medicines so 
it was sort of, you know, gosh, have I got to take all this?” (I1).  
 
Edward never realised there would be constant changes in his medicines, suggesting 
that “When I started off it was only like one or two items, so it has escalated over 
time… It does make you a bit anxious that to remember what time of the day to take 
it and that takes some getting used to, you know.” (I1) 
 
On the other hand, Linda who had diabetes for a number of years said that she “…was 
a bit upset when I had to start taking metformin, because I've been diet control for 
so, you know, for quite a long time. So it was like we was going back a step when I 
had to start taking it.” (I1) Whilst Kate reported she “…didn’t think I’d have to take 
tablets around my age now, or for when I first started them, because I was about 37, 
38 when I started. I didn’t think I’d take tablets that early in my life. You know, for 
every day you’ve got to have them constantly, I didn’t think I’d start that until I was 
older.” (I1) 
 
Other participants wished for a wonder drug or cure, so they could come off their 
medicines. Kelly reported there was no other option but taking her medicines, 
“Unless there was some drug that they could give you and they give you it as a time 
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capsule thing, almost like a capsule in your arm that emitted this drug out so that you 
wouldn’t have to think about it, because it’s a daily reminder for me that I’m 
overweight and I’ve got diabetes…” (I1), whilst Gareth implied “If you give me one of 
those [pancreas] without having to take all the anti-rejection tablets I’d go for one of 
those, but apart from that, and that’s unlikely, then I’m quite happy with what I’ve 
got.” (I1) 
 
While James had felt relief to find he had diabetes, yet, reported, “It was explained 
to me when I first got it, it was like opening a door, once you shut that door, the next 
stage is and then you shut that door, but you can't go back and open that door…  And 
I keep saying well if someone’s drinking, gradually that door’s going to shut and then 
the tablets are going to run out. Whereas to me I’m still at door one. That’s the way I 
think. Okay, the medication’s changed but I keep thinking God that door’s shut and 
then I’m regressing, then I’m regressing, isn’t, yeah. I give up then, you know. That’s 
why I fight it all the time.” (I2). He also said that no-one in his family (except his wife) 
knew about his diabetes because “it’s like if you’ve got a cold or you’re not well and 
people start fussing, you feel worse. You think just go away and leave me, let me 
sniffle in peace.” (I2) So it was no wonder that he “hated” SMBG because it reminded 
him he had diabetes.  
 
Participants stated they often blamed their diabetes and their medicines if they were 
unwell or experienced side effects, as Karen’s quote illuminates:  
 
“Early on in the week I was really quite bad but I put everything down, all the 
symptoms I get I go, oh it’s my needle, oh it’s my diabetes, oh it’s my medication, and 
really it could be others things.” (Karen, I2) 
 
Whereas, Philip stated that his insulin was “…stopping me from doing what I want, 
eating what I want and having the energy I want” (I1) and that “… I just want to get 
on with life. I don’t want to be taking tablets; I don’t want to be doing that. I want to 
be on boats, planes. I would have been still living abroad only for [the diabetes].” (I2) 
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Patrick, as a result of taking insulin, had put weight on: “…But if you’re restricting your 
diet and you’re still not losing the weight or you’re putting it on, it does have a bad 
effect on you because at the end of the day there’s not really much more you can do. 
You’ve lost a lot of the things that you could do. Like going out, socialising, things like 
that, you’re sort of more confined to being at home, and probably one of the 
highlights of the day is your evening meal or something like that. So you want to eat 
what you want to eat, you don’t want to be sitting there eating something you don’t 
want to eat.”(I1) 
 
Julie felt guilty about taking her diabetes medicines because: “…you think oh well I’ll 
have a sandwich, and then you go shall I have a cake, oh yeah I’ll have a cake. But 
then as you're eating it you go oh no, I shouldn’t be eating this. But it goes back to 
like I say because you don’t feel it. You think oh well yeah nothing happened [no 
diabetes complications visible].” (I1) 
 
While Kelly felt “a bit disillusioned, you know, and I think then I start to think well I’m 
taking these medicines and okay and it’s good to see that they are stabilising my blood 
sugar, but I’m not really losing weight. I’m not able to lose weight.” (I1), and whilst 
she had high expectations of her new medicine, she reported “it feels like failure of 
me because I really thought that I would have lost quite a bit of weight by now. And I 
feel like I’ve just gone to a plateau. It might not be the drugs fault, but it doesn’t seem 
to be working as I imagined it would.” (I2) 
 
On the other hand Vanessa had positive experience from her new medicines as she 
explained: “It’s the freedom of not having to take it [insulin] three times a day. That’s 
the only thing, and because I’ve lost the weight, my clothes have gone smaller as well.  
I’ve gone down a size, so that’s made me happy. Although I’m not sort of over-
rejoicing too much because I don’t know whether I’ll stop [taking liraglutide] or I could 
just put [my weight] back on I don’t know.” (I2) 
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6.3.6 Routine and Coping Mechanisms 
6.3.6.1 Medication Routine 
Participants were given the opportunity to discuss about how they were managing 
their medicines on a daily basis or when away from home. Table 6.2 shows that many 
of them used a number of different methods to help them take their medicines as 
prescribed. Most participants explained these methods had become 
“routine”/“habit”, which was done “automatically”, “which doesn’t take thinking 
about” and gradually was “ingrained”, “instilled” and “embedded” in them. Most of 
them associated taking their medicines with a specific time of the day like when they 
get up first thing in the morning, during meal time, or when having a drink. In 
addition, most of them identified a specific location such as their kitchen cupboard 
or fridge (for injectable treatments) or bedroom as to where most of their medicines 
are located. Very few associated their medicines with an event, like taking their 
injectable medicines shortly after they checked their blood glucose, as Alison 
explains: 
 
“See I wouldn’t forget my injection, because I do my finger prick and my injection.  I 
come downstairs, I wash my hands, put the kettle on, do my finger pricks and my 
injection, then get my breakfast.” (I1) 
 
or like James who said: 
 
“Well on my computer, which I go on everyday anyway, I have the boxes underneath, 
the box of tablets, this, that and the other. So first thing of a morning I always check 
my emails so there’s the tablets.”  (I2) 
 
Most of the participants used plastic boxes to organise their tablets into morning, 
afternoon, evening and bedtime as appropriate to them. Some of them used large 
boxes which contained all the original packet of medicines or single strips of their 
medicines. Some of them used small boxes with compartments where they could 
place their daily tablets on a monthly, weekly or daily basis. Others methods included 
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jars or cups, blister packs from chemists, and folders with a medicine checklist. Those 
on injectable treatments used pencil like cases to store their medicine.   
 
Some participants said they were dependent on others to remind them to take their 
medicines as the following quote illustrates:  
 
“If I didn’t have him [my husband] I’ve been a bit fuzzyheaded if you like, nothing to 
do with diabetes …and so without him even reminding me when we’re going on 
holiday have you got enough tablets to go away with, and so it’s good that I’ve got 
him.” (Kelly, I1) 
 
Whereas Kate explained “I just remind myself, if I get hungry I’ll get something to eat 
and then take the insulin.” (I2) 
 
When participants were compared based on their routine practices over time, it 
became apparent that the amount and type of methods they used influenced their 
adherence levels (Table 6.2). Participants who were dependent on others to remind 
them to take their medicines were generally low adherent. Although, Keith’s 
adherence level slightly increased at the time of second interview because his wife 
was also taking an injectable treatment (insulin) and, therefore, he said “…it’s usually 
just before we have our tea, I usually get a clip round my ear or whatever, I haven't 
taken this medication.” (I2) 
 
On the other hand, those who established a routine where they took their medicines 
in conjunction with other events, such as SMBG, they were more likely to be adherent 
to their medicines. Often these combination reminders were mainly to specific 
medicines as Kelly’s quote illustrates:  
 
“What I do is I always do my blood sugar because that’s also next to my chair. I do my 
blood sugars and then straightaway, because I’m going to use the sharp bin, I take 
the liraglutide.” (I2) 
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Table 6.2: Routine and coping mechanisms/ strategies 
A
d
h
er
en
ce
 L
ev
el
s 
 
P
ar
ti
ci
p
an
ts
 
Tr
ig
ge
r 
Se
lf
-
m
o
n
it
o
ri
n
g 
St
o
ra
ge
/ 
sy
st
em
 
Lo
ca
ti
o
n
 
G
o
in
g 
O
u
t/
 
H
o
lid
ay
s 
N
eg
o
ti
at
io
n
 
Sk
ill
s 
Tr
ea
tm
en
t 
In
je
ct
io
n
s 
N
u
m
b
er
 o
f 
in
je
ct
ab
le
 
Tr
ea
tm
en
ts
 
Tr
ea
tm
en
t 
Ta
b
le
ts
 
N
u
m
b
er
 o
f 
ta
b
le
ts
/ 
m
ed
ic
in
es
 
W
o
rd
s 
to
 
d
es
cr
ib
e 
ro
u
ti
n
e 
St
ab
le
 L
o
w
 
Kate Reminder by 
friend (I1,I2), 
Hunger (I2) 
Orders next 
prescription after 
runs out (I1) 
When 
sympto-
matic 
Little tub 
with 
strips 
Kitchen 
cupboard 
(tablets) 
Fridge 
(insulin) 
Insulin purse 
in handbag 
SE BD to 
TDS 
one BD or 
TDS 
3  
In
cr
ea
se
d
 
Lo
w
 
Keith Reminder by 
family (I2) 
SMBG (I2) 
OD Blister 
pack 
Fridge 
(GLP-1) (I2) 
In little bag  None 
to BD 
None 
to one 
QDS 10 Automati
cally 
St
ab
le
 L
o
w
 
Karen Place on kitchen 
table during meal 
or when cleaning 
dishes (I2) 
Rarely none Kitchen 
cupboard/ 
work desk/ 
handbag 
(tablets) 
 SE 
inconve-
nience 
 
None 
to OD 
None 
to one 
BD or 
TDS 
6 Natural 
instinct, 
embedde
d in brain, 
Automati
cally 
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Edward Post –it note in 
blood glucose 
diary, injects with 
meals, knows by 
packet shape and 
tablet size 
Daily Used to 
write 
down in 
diary 
bathroom 
cabinet 
(tablets) 
Fridge 
(insulin) 
Takes 
injection 
with him (I2) 
Inconve-
nience 
OD to 
BD 
one Variou
s times 
6 Just 
comes 
normal 
now, 
second 
nature, 
gradually 
ingrained 
D
ec
re
as
e
d
 
Lo
w
 
Oliver Takes with meals rarely  cupboard 
next to 
dining table 
Keeps in car 
(I1), used to 
keep in work 
(I2) 
Inconve-
nience 
 
 
None 
to OD 
None 
to one 
TDS 4  
D
ec
re
as
e
d
 L
o
w
 Patrick Takes with meals, 
orders repeat 
prescription 1 
week in advance 
OD 2 Plastic 
boxes for 
morning 
& evening  
Kitchen 
cupboard 
Pill box, 2 
compartmen
ts for 
morning and 
evening, 
spares 
SE BD one QDS 
and 2 
tablets 
weekly 
17 Doing it 
without 
thinking, 
got to get 
organised 
Lo
w
 t
o
 M
ed
iu
m
 
Gareth Orders next 
prescription 
before runs out, 
takes with 
morning coffee 
(I1), takes “lot” 
with meals (I2) 
N/A Weekly 
pill box, 4 
compart
ments (I2) 
Kitchen 
cupboard/b
y coffee 
mug 
Pill box Inconve-
nience 
N/A N/A TDS 7 Automati
cally, 
doesn’t 
take 
thinking 
about it 
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Vanessa Sets phone alarm 
but turns off (I1), 
injections when 
gets up, SMBG 
(I2) 
OD  handbag   TDS to 
OD 
(twice) 
two BD 17 automatic
ally 
Lo
w
 t
o
 M
ed
iu
m
 
Kelly Reminder by 
family (I1,I2) 
Takes 
before/after 
meals (I1), SMBG 
(I2) 
random 
to od 
Plastic 
box and 
injection 
on top 
(I2) 
Next to 
chair 
usually sits 
is 
Reminder by 
family for 
early 
prescription 
Effectiv
e-ness 
None 
to BD 
to OD 
None 
to one 
BD or 
TDS 
From 15 to 
14 tablets 
Will have 
to be 
good at 
my 
practice 
and 
routine 
M
is
si
n
g 
to
 M
ed
iu
m
 
Philip Takes when gets 
up (I1), SMBG 
(I2), when runs 
out leaves 
packages open 
(I2) 
All the 
time 
Monthly 
pill box, 2 
compart
ments 
Bedroom- 
by bed/ 
wardrobe 
Takes 
spares/ 
requests 
early 
prescription 
Concern
s 
effectiv
e-ness 
OD to 
OD 
and 
once 
weekly 
One to 
two 
unclea
r 
18 tablets to 
8 tablets 
methodic
al 
N
/A
 t
o
 m
ed
iu
m
 
Daniel Takes with meals, 
places on kitchen 
table 
N/A     N/A N/A OD to 
BD 
2 to 3 Becomes 
matter of 
habit, 
force of 
habit 
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Adam Place pill box on 
windowsill- 
walking past can’t 
help but see (I1), 
injects when gets 
up (I2) 
BD to 
QDS 
Pill box, 4 
compart
ments, 
sorts 
every 3 
days 
Wardrobe 
and 
dressing 
table (I1) 
Injection by 
bed (I2) 
Overcoat/ 
wife’s 
handbag 
(insulin), pill 
box. Checks 
clock/ adjust 
watch, 
writes down 
new timings 
Inconve-
nience 
None 
to OD 
None 
to one 
BD or 
TDS 
10 to 9 Get used 
to it, 
repeating 
all the 
time (I1), 
easier 
routine 
(I2) 
D
ec
re
as
e
d
 M
ed
iu
m
 
Irene Takes with juice 
in the morning, 
coffee or milk in 
the evening (I1), 
injects after 
giving dog food 
(I2) 
All the 
time 
Weekly 
pill box, 4 
compart
ments 
On shelf by 
kettle (I1), 
Shelf 
opposite 
fridge 
(tablets)/ 
Fridge 
(GLP-1) (I2) 
  None 
to BD 
None 
to one 
BD 12 to 11 Ritual, 
Habit 
D
ec
re
as
e
d
 M
ed
iu
m
 
Linda Takes with meals Rarely, 
when 
sympto-
matic 
Weekly 
pill box to 
1 large 
box (I2) 
 In hand bag Inconve-
nience 
N/A N/A TDS 8 Instilled in 
me, feels 
like 
regular 
routine, 
don’t 
dock 
watch 
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 Angela Injects after 
morning shower 
BD & 
when 
sympto-
matic 
Weekly 
pill box 
Fridge 
(insulin) 
Prio bag 
(insulin), 
adjusts 
timing 
Effectiv
e-ness 
OD to 
BD 
one BD 4 to 3 A way of 
life after 
a while 
M
ed
iu
m
 t
o
 H
ig
h
 
Robert Takes with meals 
or milk or juice 
N/A  Kitchen 
cupboard- 
out of 
reach 
Never takes 
to work / 
when out of 
home 
SE N/A N/A BD or 
TDS 
3 to 4 Like a 
ritual, 
automatic
ally (I1), 
more 
organised 
(I2) 
M
ed
iu
m
 t
o
 H
ig
h
 
Teresa  1-2 
times 
per 
week to 
rarely 
  Leave at 
home (I1), 
takes on 
holidays- 
easier (I2) 
SE OD to 
once 
weekly 
one BD 7 Easier 
when at 
home 
M
ed
iu
m
 t
o
 H
ig
h
 Julie Injects when gets 
up (I2) 
Rarely 
to 
stopped 
 In pocket 
(tablets) 
(I1), 
Kitchen 
cupboard 
(GLP-1) 
 SE, 
inconve-
nience 
None 
to OD 
None 
to one 
BD 6 to 5 Not hard, 
easy 
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M
ed
iu
m
 t
o
 H
ig
h
 
David Takes with 
morning tea and 
meals 
None to 
2-3 
times 
per 
week 
Large box 
for 
daytime 
tablets, 
blister 
pack for 
night-
time 
ones, 
daily 
Coffee 
table by 
bed (night 
time 
tablets) 
Pill boxes in 
pocket for 
morning & 
evening 
tablets, 
night-time 
tablets leave 
in hotel 
room  
SE N/A N/A TDS 16 tablets 
per day 
Stickler, 
routinist, 
it’s a 
system, 
get used 
to it 
M
ed
iu
m
 t
o
 H
ig
h
 
James Takes after 
checking email in 
morning, places 
by fork whilst 
meal getting 
ready 
Once a 
week 
Jars for 
morning 
&  
evening 
tablets, 
daily 
Under-
neath 
computer 
In wallet, 
extra if 
staying out  
SE N/A N/A BD 4 boxes and 
4 boxes 
Handy, 
pure 
routine, 
set 
pattern, 
managea
ble 
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H
ig
h
 t
o
 M
ed
iu
m
 
Christo-
pher 
Takes with meals 
and coffee, takes 
all at once 
1-2 
times 
per 
week to 
BD 
Plastic 
beaker- 
daily 
Cupboard, 
coffee 
table for 
morning 
tablets, 
kitchen 
worktop 
evening 
tablets 
Extra tablets, 
keeps in 
hand 
luggage.  
Needs to get 
organised 
(insulin) 
Inconve-
nience 
None 
to OD 
None 
to one 
TDS 9  organised 
H
ig
h
 S
ta
b
le
 
Alison Self- monitoring, 
takes all at once 
(I1, I2) 
Injects after 
swimming (I2) 
OD to 
BD 
pill box, 4 
compart
ments, 
daily, 
insulin in 
fridge, 
GLP-1 in 
case 
Left hand 
side of sink 
In handbag 
(insulin, 
tablets), All-
inclusive 
holidays so 
can leave in 
hotel room 
 BD to 
BD 
(twice) 
One to 
two 
BD Blood 
pressure, 
cholesterol 
Thyroid, 
water tablets 
[&T2D 
tablets] 
automatic
ally 
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H
ig
h
 S
ta
b
le
 
Andrew Takes with 
orange juice, 
SMBG 
BD In a box Kitchen 
(morning 
and 
evening 
tablets), 
bedside 
table 
(bedtime 
tablets) 
 SE N/A N/A TDS 8 to 9 Automa-
tic, all 
organised
comes 
natural 
H
ig
h
 S
ta
b
le
 
Elizabeth SMBG, takes all at 
once 
TDS Computer 
drug tick 
off list in 
plastic 
box, 
insulin 
case, 
daily 
Kitchen 
cupboard 
(tablets), 
Fridge/ 
spares 
upstairs 
(insulin) 
 SE, 
effecti-
veness 
BD one BD or 
TDS 
14 Mentally 
you get 
used to it, 
second 
nature 
NB: OD/BD/TDS/QDS refers to “once”/“twice”/ “three”/“four” times per day as a direction for prescriptions.
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Although the pill boxes helped participants in taking their medicines, those 
participants who used these boxes to assist them to count their medicines on a daily 
basis instead of every week/month were more adherent. In addition, high adherents 
were more likely to take their tablets “all at once” instead of taking some before, 
during and after food. Moreover, those who placed their medicines in a location that 
was visual helped to improve their adherence, as the next quotes demonstrate:  
 
The ones I take of a night time that’s upstairs by the side of the bed.  So before I get 
into bed, I take that tablet then. (Andrew, I2) 
 
“But I keep them both [insulin and Exenatide] by, on the left hand side of the sink 
really just by the unit…. 
[Interviewer] Why there? 
Because that’s the first place I go to of a morning. I come out of the door and go 
straight to the - where if they were on the other side of the room or something like 
that, it’s more convenient it’s straight ahead, first point of call.” (Alison, I2) 
 
Hence, high adherent participants can be defined as those who used a combination 
of methods including triggers associated with time, location, and event, as well as 
repeating their routine on a daily basis and placing their medicines in front of them. 
In contrast, those with low adherence levels often made comments about having to 
get organised after changes in their routine, as a result of new medication changes, 
being busy or “when I've been away, and your routine’s disrupted, you know, and 
you're just a bit out of sync for your everyday things.” (Linda, I2).   
 
Furthermore, participants were less likely to be adherent to their medicines if they 
took their medicine(s) (tablet and/or injections) more than once or twice a day. Both 
Vanessa and Kelly improved their adherence levels, at the time of the second 
interview, after having to take less injections throughout the day, which they found 
much more convenient. 
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6.3.6.2 Self-Regulation 
Self-regulation strategies were a result of concerns and experiences of side effects of 
medicines and forgetfulness. Although some participants suggested that their “body 
got used to” their medicine because they found that the side effects settled relatively 
quickly within 24hrs or two weeks, others had to change treatment because they 
could not cope with them anymore. A few participants resorted to taking over the 
counter/prescription medicines (laxatives, anti-sickness and anti-diarrhoea tablets) 
to relieve the side effects of their new medicines, and found that they were then 
more able to cope with them. Whereas, other participants persevered with the side 
effects for months and years, and others adjusted their treatment to make it less 
interfering with their lifestyle. The quotes below describe the effect of side effects on 
participants’ life and adherence (see Figure 6.7):   
 
“…the effect of metformin can upset the bowel terribly. If I take anything more than 
a 500 dose at a time I can’t cope with it. My body doesn’t cope with that… [so when 
on holidays] it’s that changeover day that’s the difficult one, you’ve got to think to 
yourself hang on what am I taking here. I can’t overdose because if I overdosed on 
metformin I’d be awful for a couple of days but I try and work out the time difference.” 
(Angela, I1) 
 
“…when I was on the metformin I was constantly going to the bathroom, as far as 
bowels being loose. I've put up with that for years, you know, so I used to, if I had to 
go somewhere early, first thing in the morning, I’d take my medicine after I’d been 
where I needed to go, because I knew with the metformin I’d be in trouble.” (Irene, 
I1) 
 
“I wasn’t well with them… I mean to begin with it was fine on that rate, I haven’t took 
them for the last week because I was getting pains in my stomach and vomiting not 
long after them. So I have stopped, and I know I shouldn’t have but I have stopped 
them for the last week and that, because they’re big tablets I've got to take.” (Kate, 
I2) 
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“[Teresa] I don’t tend to eat out as much as we used to for that reason [diarrhoea], 
because I don’t know, I don’t know if it’s going to be something that I'm eating that’s 
going to cause it. But apart from that… 
[Interviewer] So it has affected your social life? 
[Teresa] Yeah, yeah. Especially when we’re away, because as I said when we went 
away in May, we were staying with friends and it was awful. It was, because it was 
the time when it was really bad, and I didn’t want to go out. No, no, I’ll stay in, you go 
out, I’ll stay in.  But it’s alright now that I do manage and it’s a lot easier.” (I2) 
 
 
Figure 6.7: Patterns of Adherence 
 
Participants reported they rarely missed their medicines, and therefore did not 
appear overly concerned about it. Also, few said they had no detrimental effects as a 
result of missing their medicines. Consequently, participants reported doing the 
following, which had an effect on how well they adhered to their medicines (Figure 
6.7):  
 
Angela and Gareth took their medicines later than instructed:  
“…when I’m cooking dinner and suddenly I’m sitting down and I think oh I haven’t had 
my injection, that’s the one which I have to have later then.” (Angela, I2) 
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“And I come in the morning to get my next tablets out and I go oh bloody hell I forgot 
to take that one last night and the instructions are if you forget it, take it when you 
next find out. So I take it before I take my breakfast ones and that’s okay with the 
doctor.” (Gareth, I2) 
 
Irene and Andrew did not want to take their medicine when they realised they had 
missed taking it at the right time: 
“I’d started doing the dinner, putting the dinner out, and I just sat down to eat. And 
I’d started to eat and I went I haven’t done my injection. And [my husband] said well 
can’t you do it now? I said no you’re not supposed to. So I've left it, and that was the 
reason…I said I don’t know what it’ll do, they tell you to just leave it and just do the 
next one…” (Irene, I2) 
 
“If I was out any length of time and I was getting back late, probably have a meal out 
and wouldn’t take the tablets. But I’d just carry on as normal the next day. I wouldn’t 
double the dose, just carry on with the dose. All right you’ve missed one part, forget 
it, carry on next, that’s the way I do it.” (Andrew I1) 
 
More participants at the first interview reported forgetfulness compared to the 
second interview. Those participants who did not report forgetfulness at second 
interview had their levels of adherence increased over time from low to medium or 
medium to high (Table 6.2), with the exception of Elizabeth who was the only 
participant with stable high adherence levels.  
 
6.3.6.3 Negotiation  
Although not all participants provided examples where they had to negotiate changes 
to their treatment, negotiating skills were generally practiced when they wanted to 
avoid insulin treatment (see section 6.3.1.4), reduce the amount of medicines being 
taken, alleviate side effects from their medicines, reduce the risk of hypoglycaemia, 
or identify ways to manage them better (be more convenient or more effective) as 
the following quotes demonstrate: 
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“I would like to discuss with the consultant about maybe just changing the oral 
medication a bit, and seeing if that helps the hypos.” (Teresa, I2) 
 
“[the Diabetes Specialist Nurse -DSN] said obviously [liraglutide] can cause nausea so 
sometimes it’s better taking it of a morning and then, because… you had to do it at 
the same time every day and that was what I was conscious of.  So I thought I don’t 
really get up at the same time every day, sometimes I get up very early and then 
sometimes I don’t, but whereas I do tend to go to bed the same time of a night.  And 
with me taking it in the day and starting feeling sick I thought well I need to change 
it. If I’m going to change it I need to change it right away. And I thought if I just do it 
of a night going to bed it might just be a bit easier with the side effects.” (Karen, I2) 
 
However, negotiating skills did not appear to influence adherence levels in these 
participants (Table 6.2) 
 
6.3.6.4 Seeking information 
Most participants read the leaflets that come with their medicines prior to taking 
their first dose. This was to become aware of the type of side effects associated with 
their medicine(s), any contraindications with other related health conditions and/or 
medicines they take, and what to do if they missed their medicine(s). Yet again, very 
few participants indicated they read the leaflet only after they experienced side 
effects, or forgot to take their medicine on time, as Elizabeth explained:  
“I don’t actually read all the leaflets believe it or not, except when there’s a problem, 
then I have a quick scan…” (I1) 
 
Participants suggested that when they encounter side effects with medicines or are 
made aware of the risk of complications, they tend to seek HPs’ advice by contacting 
them on the phone. Yet, through the interviews, it was evident that they usually 
waited until their next appointment instead of contacting them right away.   
 
“I’m going to speak in detail to the specialist in September. I’m going to have a good 
chat with her over it. [The DSN] allayed my initial fears and put me a little bit more at 
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rest. I mean I waited four or five weeks because I knew I had the appointment. It 
wasn’t a knee-jerk reaction. I didn’t just pick up the phone and say I want to come off 
this, I thought well what’s another four or five weeks. I’m sure they must have been 
inundated with phone calls after that programme, which he said they were because 
there was that many people on the phone over it.” (Oliver, I2) 
 
Only those on insulin treatment seemed to contact their healthcare team when they 
encountered problems, particularly when it was related to adjustment of insulin dose 
as a result of hyper/hypoglycaemia, as Elizabeth suggests:  
 
“[The DSN] said we won’t keep it for weeks on end, I want to see you here [in clinic] in 
two weeks and see how you’re getting on, but I am at the end of the phone and you 
ring me anytime - which I do, because I don’t pester her for no reason.  She said if you 
want to know what to up [the dose of new insulin] to or lower it. She said you might 
find it’s making you hyper because you’re having too much” (I1) 
 
Internet and HPs themselves were the most common sources of information for 
participants. Of those who used the Internet, very few described using recognisable 
and reliable sources for information such as DUK, Patient Access and government 
websites related to diabetes treatment and driving licence. 
 
6.3.7 Compromise and Perseverance 
Participants conferred, through their beliefs, perceptions and experiences in taking 
their medicines, that generally there was no “alternative” treatment to diabetes 
other than taking the medicines they have been prescribed. Particularly with 
diabetes, they felt that there were few treatments available, as James indicated “But 
you know, there’s so few alternatives, it’s either A or B isn’t it with diabetes? We can 
give you another tablet, but once you’ve had so many tablets, there’s nothing to do.” 
(I2). This compromise about their diabetes treatment appeared to be strong among 
those participants who said they had no experience of side effects with their 
medicines.  
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In contrast, participants, mainly women, who had experienced side effects, indicated 
that they had (in the past) and would (in the future) “put up with” their medicines 
and “persevere” with their side effects to achieve diabetes control and/or weight loss.  
 
“Swings and roundabouts really, isn’t it?  I'm disappointed that I haven't [lost weight], 
but the fact that my blood sugars are better, that’s got to be a benefit… You know, 
with all the complications that I could have with high blood sugars… it’s got to be 
beneficial really, hasn’t it?... I've got more energy, so you know, that’s got to be worth 
something as well, hasn’t it?... for all I was very unsure about going onto it originally, 
now I know even with the diarrhoea… It’s a problem but I manage it, so I'd rather do 
that than come off it. Really. And if they said now to come off it, I'd be very reluctant 
to.” (Teresa, I2) 
 
“It would depend on the benefits I was getting from it. If I was getting good weight 
gain [means weight loss], then I know thrush can be treated and I know urine 
infections can be treated. If my bloods were abnormal, then I'd be more worried 
because I'd think my body’s not happy with this really. But I wouldn’t come off them 
straightaway, I would carry on, and I would imagine like thrush or UTIs would be 
treatable, I know they can be. If they progressively got worse and closer together, 
that’s when I'd think maybe of saying well maybe I should come off it.” (Linda, I1)  
 
Whereas a smaller number of participants, mainly men, suggested that “no side 
effects the better” so they would ask for a treatment change, if the side effects could 
not be tolerated, “…because I can’t see why your lifestyle should be changed. You 
know, why should you suffer if there’s an alternative?” (James, I2) 
 
In addition, a few participants felt they had to persevere with the inconvenience of 
their medicines, specifically those taking insulin more than once per day, in order to 
get better diabetes control and improve/prevent deterioration of their kidney 
function.  
 
333 
 
Angela, who had missed her second insulin injection before dinner, when she realised 
that her blood glucose had improved with her new insulin regime, reported: “…now 
I’m sort of quite elated that my readings are coming down and I’m not quite as thirsty 
as I was, I’ll probably have more incentive of taking this injection and keeping it that 
way.” (I2) 
 
It was apparent that participants’ compromise and perseverance was a way of 
considering the risks and benefits of taking their medicines in order to achieve 
balance in their life. However, their acceptance about compromise and perseverance 
affected their adherence levels (Figure 6.7). Those participants who implied that they 
would not persevere with side effects were more likely to be medium to high 
adherents. Participants’ adherence levels ranged from low to high if they persevered 
with their medicines’ side effects for controlling their diabetes. However, those who 
persevered for the benefit of weight loss were more likely to be low to medium 
adherent. 
 
6.3.8 Helpful and Unhelpful Support 
According to participants there were mainly two key avenues of support for the 
management of diabetes. The most prominent support was that provided by HPs. 
However, equally, many participants valued the support from friends and family. A 
small number of participants, who had experience of injectable treatments, 
suggested that other people with T2D diabetes played an important part in giving 
them reassurance when they started those treatments. Most of the participants had 
a relative/ friend/ colleague who was on a similar injectable treatment. Furthermore, 
a very small number of participants found support in other organisations, such as 
DUK. Nevertheless, participants revealed experiences of both helpful and unhelpful 
support with regards to their diabetes management as seen in Figure 6.8.   
 
The following sections will focus on participants’ views of support they received from 
health care services, as this was the dominant issue discussed in both interviews. 
Participants’ experiences of health care services varied, however all had accessed GP 
and PN support at some point since their diagnosis. Almost all of the participants in 
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this study had received support from a dedicated diabetes MDT in the community 
(i.e. a service located at a GP Practice/Health Centre) or at a SCDC. Nearly half of them 
had support from both their GP practice and their diabetes team, whilst the rest of 
the participants received care predominately by their diabetes team. Out of all 
participants, only Irene had experience of all three services.  
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Figure 6.8: Examples of Helpful and Unhelpful Support (CHO= Carbohydrates)
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6.3.8.1 Unhelpful Support 
Participants often discussed their views about NHS care provision as a whole. They 
commented on the constant staff changes and NHS cutbacks, but equally how staff 
are “inundated”, “hard pushed” and do not have the time to give to patients, as a 
result of the increased prevalence of diabetes. They understood that taking too many 
medicines and monitoring people with diabetes is “costing millions” for the NHS.  
Participants who experienced care provision from a diabetes team outside of their 
GP practice, suggested that GPs and practice nurses are lacking the knowledge and 
expertise in treating patients effectively. They are often unaware of available new 
diabetes treatments or if any changes were made to participants’ treatment by their 
diabetes team. This resulted in being referred to various staff within the practice 
producing feelings like “getting pushed from pillar to post” (Keith, I2) and without any 
satisfactory outcome and delays in issuing repeat prescriptions.  
 
Part of the problem was also staff attitude, mainly that of the receptionists, who were 
found to “have too much to say”. For example, David gets annoyed “when the 
receptionist sitting there says to you ‘what do you want to see the doctor for?’ ...why 
should I tell her what’s wrong with me when she can't give me any medication, she 
can't diagnose what’s wrong with me.” (I1). Whereas, Oliver said “I’d have dispensed 
the prescription and then I get a phone call from the receptionist saying the doctor’s 
not giving you that [new medicine]” without giving any reason, despite the medicine 
having already been prescribed by the hospital doctor (I2). Such delays inevitably 
meant delays in managing their diabetes efficiently.  
 
In their view, doctors “watch money” and were “penny pinching”, so they 
“outsourced” diabetes services in different locations. Philip said that “somewhere 
along the line there’s two lots of people being wasted.” To explain this further, he said 
“I don’t know why my own nurse up there [GP practice], why should she test me up 
there when they’ve got one here [IMC diabetes team]? ...I could go to [local hospital 
diabetes centre] and get it all done. And the only reason we don’t go up there is 
money.  It’s too expensive for me to go up there. Yeah. So why is it there?” (I2) 
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Furthermore, doctors seemed to focus on prescribing “cheaper” medicines to save 
money for the NHS, “albeit [these] might not be cheaper in the long run” (Linda, I1), 
because they either take longer to become effective, or are ineffective from the 
outset. On the other hand, Patrick suggested that due to the problems with repeat 
prescriptions and lack of medication reviews, there was a lot of waste of prescribing 
drugs. He provided an example of what had happened when he ordered his repeat 
prescription after he had received a prescription for his new medicine linagliptin from 
the diabetes doctor, 
 
“So Friday I put the request in for my month’s supply of tablets and I didn’t tick the 
box for the sitagliptin [old medicine]. But when the doctor’s done the prescription 
they’d put it on…. they haven’t put the other one on [linagliptin], because they still 
hadn’t the letter from here [diabetes team] to say they’ve changed it… So that’ll go to 
the chemist now and the chemist will put it [sitagliptin] in the bag and I take it home, 
it’s just going to be wasted, end up going in the bin. You know, if that’s happening 
with everybody it can be very expensive” (I1) 
 
Overall, there appeared to be three key aspects which are relevant in contributing to 
delays in reviewing participants’ diabetes and treatment(s), which situates under the 
umbrella of clinical inertia. These aspects include the NHS service organisation, the 
HPs and the patients themselves. Figure 6.9 shows how these aspects are interlinked.  
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Figure 6.9: Interlinked reasons for clinical inertia 
 
6.3.8.2 Helpful Support 
It was clear from participant’s discussions that there were certain vital features which 
determined satisfaction with the support they had received. Figure 6.10 shows the 
suggested model of care in T2D management. As expected, experience of helpful 
support formed suggestions which they deemed useful for future support for 
themselves and others who are prescribed the same type of new treatments they 
had received.  
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Figure 6.10: Model of care in T2D management 
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Participants wished for access to a range of services and HPs which had a focus and 
expertise in diabetes. Furthermore, referral to other services and access to research 
involvement was also thought to be helpful for participants. Accessing or being 
referred to these services was thought to be “a good back up” (I2), as Daniel and 
others reported, because, as Irene suggested, “each one [of these professionals]… is 
for a different thing, so fills in the gaps if there’s anything missing. Because from what 
I can see you all work together, so everybody knows what everybody’s doing, which is 
a good thing” (I2). So, the benefits of using such a service meant that the team would 
communicate with each other, as Irene implied above.   
 
Also, the need for direct access was another key issue surrounding these services. 
Direct access represented services that were provided in one place/location. It is 
important to note that for most participants the exact location did not matter, for 
example whether close to home or at hospital, as long as they had access to these 
services. Opportunity to access the range of HPs gave confidence to participants 
about management of their diabetes, as Patrick indicated:  
 
“So… when they refer you to someone else, it’s someone in the next room, so you can 
see them straightaway. …so instead of saying will you see somebody and then you’ve 
got to wait two months before you see them to get an appointment, with them 
everything’s like compact. It seems to work well together.” (I2). 
 
In addition, Patrick said “when you come to the Diabetes team they allow you a half 
hour appointment, so you’re in with them for half an hour, they do your tests. Then 
you’ll go in to see the [nurse], if you’re seeing the dietician you’re allowed a half hour 
appointment with her. Then you’ve got an appointment with the doctor. So you’ve 
got an hour and a half and all three are done, and it’s explained to you. So by the time 
you get to the doctor you’ve had the chance to think about what the first one said, 
and if there’s something you’re not clear on, you can then ask the doctor. So you get 
all your information in one day.” (I2)  
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Moreover, direct access was discussed in relation to day to day management of 
diabetes, and problems encountered with their medicines or with their blood 
glucose. Direct access, therefore, was also meant to be instant access to these 
services, in order to get instant advice and answers to their questions, as Julie’s quote 
demonstrates:  
 
“But having a contact number and someone that you can call, that’s the key isn’t it?  
As long as you can speak to somebody it’s not necessarily ‘oh I’ll have to come in and 
sit and see you and talk for an hour to you’, if you’ve got a contact number and just 
say this is happening, you know, just someone to say oh yeah that is a side effect, oh 
yeah, it’s fine, then it’s putting your mind at rest, isn’t it? That’s all people want at the 
end of the day. They don’t want to phone an answering machine, we are sure to phone 
back, and they don’t want to hear that, you want a human voice, and preferably 
someone from the diabetic team who knows what they're talking about, yeah.” (I1) 
 
This was in contrast with their experience with their GP practice, as participants 
describe:   
 
“Now you can’t ring your GP practice up and say can I speak to the nurse; you’ve got 
to make an appointment to see the nurse. And you could be dead – which is true.” 
(Alison, I1) 
 
“I know sometimes when I've been in, you know, the doctor said she doesn’t deal with 
[diabetes] and she’d have to go away and then there’d be a good long wait before 
they came back, or I'd go home and get a telephone call a lot later.” (Linda, I1)  
 
Direct access was therefore linked to timely access, which meant patients could 
access the services when needed. Delays in arranging review appointments were 
often disappointing and frustrating, as Robert explained:  
 
“So I went halfway through May to get the blood form and try and make an 
appointment, ‘oh we haven’t got any appointments until June for this’! So I don’t think 
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in a way they’ve helped, because I’m trying to not bother them and trying to organise 
it and do it at the three months stage, early enough to get the blood results back, 
allowing a week and then make the appointment, and they’ve said there are no 
appointments available until a month after that…. Then if you go and try and do it in 
a month in advance ‘oh we’re not doing appointments now’!  So it’s one of them sort 
of thing, why? …Because I’ve done the blood test… so it’s over a month ago. I’m none 
the wiser [whether the medication is working or not].” (Robert, I2) 
 
So timely access was considered when appointments were given “…in advance. When 
you go to the clinic, your next appointment is given to you there and then. So it isn’t 
as though as you are waiting for an appointment to come through the post” (Alison, 
I1). Alternatively, a reminder system to patients to make their appointment was 
proposed as helpful, as Elizabeth mentioned about the diabetes team at her GP 
practice, because  “They write to me and say it’s time for your review, so it’s very well 
organised” (I2). Also, appointments could be re-arranged with “no ifs, no buts” as 
David said “[when] I thought my appointment was the 16th August and I come, [but] 
appointment on it was the 16th September. I said ‘oh no’, but I had to get a letter with 
the needles and what I carry for the going abroad in case they pull me. And they were 
fine, no trouble, they got me the [letter on that day].” (I2).   
 
Timely access was also when there was an appropriate timeframe between diabetes 
and medication reviews. Hence, yearly diabetes reviews were deemed too long and 
careless, as Andrew said: “I only go once a year [at my GP practice]… this is stupid 
once in twelve months. It’s like I could be dead within that twelve months, you know, 
you wouldn’t know nothing about it! No difference just once a year… I don’t think 
they’re really bothered.”(I2) 
 
Regular monitoring was favoured because it meant that any changes regarding their 
diabetes symptoms/complications could be “nipped in the bud” (Kelly, I1). Oliver said 
“I'd like to be every three months, you know, me personally, because again when I 
was first diagnosed I was going every three months and I knew for most of them three 
months I'd have to look after myself, my diet like... And then when I went to six 
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months, to me it got progressively worse because I know no one’s watching me like…” 
(I1). Whereas, Kate explained that “So more I see people the more encouragement [I 
get]” (I1). Hence, most participants suggested a timeframe between 3-6 months 
would be appropriate, unless there was a change in medication, and therefore, more 
frequent contact would be preferable, as James explained: 
 
“[the diabetes nurse] said well we’ll try this new one [tablet]… and that’s the first 
positive thing anyone’s ever really done rather than just keep giving you tablets, …I’m 
back next week so she’s monitored every six weeks which is not leaving it three 
months, six months. So it’s every six weeks. So I feel as if someone is monitoring what 
I’m doing.  So it’s quite good.” (I2) 
 
The frequency of the appointments was related to the type of treatment initiated, so 
those on injectable treatments, particularly on insulin, expected to be reviewed much 
more frequently than those on tablets. Christopher mentioned that,  
 
“Originally I started coming, it might have been a fortnight then, but I phone up 
meanwhile to give my readings to whoever’s on duty, and they’ll tell me over the 
phone if I need to up [the insulin units]… So we have corresponded on the phone, and 
every month I actually come here to have a chat with the girls. So it’s not just monthly, 
it’s weekly on the phone or every two weeks, so yeah I've well looked after I think.” 
(I2) 
 
However, participants felt that if they were confident their diabetes was in control 
and they had no problems with their medicines, they would be happy to be reviewed 
less often.  
 
“I come [to the diabetes service] on a regular basis or I see my doctor on a regular 
basis and I don’t expect to be there every other day or every other week or every other 
month. As far as I’m aware every six months… I come here and get my eyes 
photographed to make sure they’re okay, I get my feet and blood pressure and stuff 
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checked, blood sugar levels…, and they tell me I’m okay and still alive and heart is still 
beating regularly so, can’t be better with life.” (Gareth, I2) 
 
Most participants, in general, were disappointed that medication reviews were not 
performed yearly, as they hoped for, or not at all. Conversely, Elizabeth was the only 
participant who was pleased with her medication review because “that does happen 
about every six months roughly” and “We’ve knocked out quite a lot of drugs with [my 
GP].” (I1) 
  
Another key issue about helpful support was the quality of the service they received. 
Quality included the type of monitoring taking place during their appointments 
(Figure 6.10). It appeared that the more aspects were examined, the service provision 
was of better quality. However, one significant aspect of monitoring was that they 
could receive instant results, as Linda indicated “[the diabetes team] tell you the 
result of the blood that morning when you see the consultant or whoever you see. So 
you know the bloods there and then rather than waiting for them.” (I2).  
 
Furthermore, quality was related to the time available given to patients whilst on 
their appointment. Longer appointment slots were favoured in contrast to short GP 
practice appointments where “You went in, cursory talk, check whatever, and out.” 
(James, I2). Participants who experienced longer appointments perceived that staff 
had more time for them. They had the opportunity to discuss their experiences with 
their diabetes management and their medicines, and receive further information 
about their diabetes which they found educational and informative.  
 
As suggested above, the format, type and amount of information participants 
received about their diabetes and their medication was, also, a characteristic of 
quality. Figure 6.10 shows all aspects of information participants found useful, as well 
as suggestions for future support. Informed choice about new treatments and/or 
medication changes was very important to them, since “I know where I stand” 
(Edward, I1) and “[staff are] not going to leave you in limbo… they are going to make 
it better.” (David, I2). Informed choice helped to gain trust in the staff and, as Adam 
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illustrates, “…if you feel that they’re confident it reflects on you as well… and I felt 
confident with the doctor because I felt he was just giving me a professional honest 
opinion” (I2) 
 
Alison said that her doctor “put it to me that it was entirely up to me [to try the new 
medicine]… That it was my decision and that made a really big difference… And even 
at the end he said, you know, if you’re not going to be happy, you don’t have to do it. 
Which, you know, the ball was in my court then.” (I1) 
 
Christopher, too, felt the staff “don’t push” (I2) about starting his insulin injection. 
However,  after experiencing his insulin treatment, he was wondering whether there 
were easier insulin options from the one he was prescribed, because his friend “…had 
a pen, and … it’s just a click, like a fountain pen and that was his injection. I stick mine 
in and say count to 10, but his was literally seconds… [but mine] you’ve got to shake 
your pen, get the liquid all mixed up” (I2) 
 
In addition, having confidence in staff meant that participants valued when staff were 
happy with their progress/management of diabetes, and were able to cope better 
with their diabetes. Otherwise, as Gareth said, “Well if they were unhappy there 
would be something pretty wrong wouldn’t there…” (I2) 
 
Participants mentioned that being aware of potential side effects of their new 
medicine has helped in coping better with them, like Robert, who realised he was 
having a hypoglycaemic episode during work, because “I was told I might have hypos 
[because of new medicine]… so it was like sort of ‘oh’ this must be what it was… So 
now… I’m more organised with work…” (I2).  
 
Yet, Oliver, echoing some participants’ concerns, said that “too much information is 
bad because if you’re overloaded with it, you’re not taking it in.” (I2). Christopher, 
also, said that when “[the Specialist Diabetes Doctor] told me bits and bobs [about 
the insulin]… I didn’t take it in that much because [I knew] I’m going to have another 
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talk, I’m going to see the products and the diabetes team was going to go through it 
with me [again]...” (I1) 
 
Moreover, participants revealed situations where they felt the lack of continuity had 
an impact on their diabetes management, “because when you go to hospital and you 
see a consultant you might see him once and then you don’t see him again. You see 
all different doctors after that.  And they don’t bother looking at your notes or asking 
you, talking to you, or nothing, so you, they don’t know you and you don’t know them. 
So when you go to see the same doctor they get to know you and you get to know 
them so it feels, it feels a lot more comfortable. You’re at ease so you don’t feel as 
stressed….when you’re seeing different ones you’re like, you’re getting different 
things said to you, like one will say one thing and then you’ll tell another one what 
they’ve said, and they’ll say ‘no, don’t do that’, or ‘that’s wrong’. Whereas, if you’re 
to see the same one you’re getting the same story all the time so, that’s better.” 
(Vanessa, I2). Adam, like others, who had a similar experience of contradicting advice 
between diabetes nurses, was wondering whether “I’ve had two years of being 
wrong… and [could] the diabetes attacked the nerve endings...” (I1) resulting in 
permanent heart failure. Whilst Patrick, at both interviews, expressed that the 
different services he had accessed for his diabetes and his kidneys “don’t seem to be 
on the same wavelength” (I2) with the Doctors at his GP practice. As he put it, 
“Different doctors have different ways of doing things.” (I2) and “the problem with 
dealing with too many people, if one doesn’t agree, nothing happens.” (I1) 
 
Continuity from staff who were viewed as “professional”, “positive”, “understanding” 
and “sympathetic”, helped participants to feel confident in managing their diabetes, 
as Karen and Angela describe:  
 
“knowing that they understand the feelings that you’re going through and the 
symptoms that you have and, [that] it’s a difficult stage in your life learning how to 
do injections and stuff, but they always make you feel like the support is there if 
needed.” (Karen, I2)   
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“Because when you come in and you are spoken to by the diabetic nurses or the 
doctors …you are an individual you are not a number and that’s important. I’ve been 
very comfortable with every aspect of it. …I’m treated as me, not a diabetic. …I’m not 
number 43 on the list this week, I’m me, and that’s what I’ve always felt…. Their whole 
attitude of speaking to me as me, and speaking to me as though I’ve got some 
intelligence and not speaking to me as though I’m dim. And they know that I can 
possibly manage whatever medication I’m taking…  No, it’s just personal, which is 
good, and that’s all I can describe it as really. ” (Angela, I1) 
 
It is no surprise, therefore, that those who had experienced care from a “well 
organised” service, specific to diabetes, with direct, timely and instant access to HPs, 
and of quality, appeared satisfied with their care. These participants felt they had 
been “well looked after “and received excellent support. Nevertheless, it is important 
to note that all participants elucidated that the management of T2D is “down to 
individuals to say ‘right I've got this [diabetes], I've got to fight it’… [and don’t] abuse 
the diabetes by eating a box of chocolates or having ten pints of beer”, (James, I1). 
Individuals’ “mindset has got to be there” (Julie, I2) and be prepared to make lifestyle 
changes, to “take… notice” (Gareth, I1) of their health, and “…need to listen, to read 
and ask questions” (Irene, I1), and “[don’t] muddle on and …think ‘I’ll wait until I see 
[staff] next time’.” (Alison, I1).  
 
Individuals should “just raise [your questions] and it will get sorted for you” (Edward 
I2), “and take somebody with you [at your appointment, as] two minds are better 
than one” (Christopher, I1). Also, individuals should “Let the partner know what 
[medicine’s] for and how it will affect you…, you’ll benefit from it in the long run.” 
(Keith, I1). “People should take the opportunity to do [research] because I think it’s 
really good.” (Karen, I2). Individuals starting insulin injections were advised “…if you 
know somebody that’s on insulin have a little talk with them. And I think you will find 
out it’s not as bad as you imagine.” (Christopher, I2) and “be patient and don’t think 
oh my god what’s going to happen now… it will work out… Not going to happen 
overnight.” (Angela, I2). 
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6.4 Summary 
The qualitative research aimed to answer two of the research questions as stated at 
the beginning of this chapter. Findings have shown, that regardless of the type of 
treatment that participants had received (lifestyle/medicine), they all explained that 
these treatments have not worked for them, and that staff (doctors/diabetes staff) 
were having to keep adjusting their treatment until they got the right one for them. 
Yet, the constant changes to their medicines had a negative impact on their 
emotional well-being and raised doubts towards the effectiveness of their medicines. 
Whether medicines were perceived as effective or ineffective, most participants 
implied that medicines were a temporary measure for controlling diabetes and/their 
body weight and, therefore expressed a perceived need to stop taking them.  
 
Participants were aware of the potential complications of their diabetes despite most 
of them reporting that at the present moment their condition was not serious. In the 
hope of taking less, better, efficient and effective medicines both for their diabetes 
control and body weight, all participants accepted their new medicines considering 
the potential risks associated with taking such treatment along with the rest of their 
medicines. However, participants were in favour of medicines that can be taken at 
home, do not interfere with their work or when going out, and were easy to fit into 
their routine. In addition, preference was given to medicines which were taken only 
once a day, particularly taken at breakfast time or first thing in the morning, or 
flexible without being “tied down” to certain times, and not necessarily taken with 
food or having to adjust their eating patterns. Participants who were faced with the 
possibility of coming off some of their medicines therefore felt relieved and happy. 
 
Nevertheless, participants engaged with a number of strategies to cope with the 
inconvenience, side effects and potential complications of their medicines, however 
even with the best attempts adherence to medicines was not optimal. Participants’ 
adherence levels were more likely to be high when their medicines caused less side 
effects, were convenient and when they used a combination of methods as part of 
their daily routine.    
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Although, generally, participants expressed positive experience about their health 
care they received in relation to their diabetes, they raised issues which they 
considered unhelpful and detrimental to their health. Hence, when participants 
experienced a range of dedicated diabetes services, it gave them confidence that they 
received appropriate and professional advice. Despite acknowledging that they, too, 
have responsibility in managing their diabetes, they felt far more motivated to make 
changes when they were under the care of a diabetes team. Therefore, health care 
that provides timely treatment changes, timely repeat prescription changes, regular 
monitoring, instant advice, adequate time to discuss experiences and time to get 
adequate information would help to ensure diabetes treatment  is effective 
(diet/meds) and get better control of diabetes faster. The sooner their diabetes is 
under control, the sooner they can lead a normal life. 
 
The next chapter will combine the findings from quantitative and qualitative 
chapters. It will provide a discussion of the findings overall comparing and contrasting 
the two sets of findings, along with the findings of the systematic review.  
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7.1 Introduction 
This chapter brings together all the results from the systematic review, and 
quantitative and qualitative chapters following mixed method analysis. It addresses 
the following questions: 
1. How do the expectations, beliefs and attitudes of people with T2D towards 
different diabetes treatments that either promote weight loss, are weight neutral or 
result in weight gain, change over time? 
2. What is the impact of this change on patients’ adherence to their medicine(s)? 
3. What type(s) of intervention(s) promoting treatment options, focusing on 
effects on body weight, are acceptable to patients in order to increase their 
understanding of their diabetes treatment and improve adherence?  
 
The chapter presents the key issues emerging from the study. Two models were 
developed to explain the phenomenon of medicine taking behaviour in people with 
T2D. The first model represents the factors that influence perceptions and beliefs 
about diabetes and diabetes medicines and their impact on emotions, confidence in 
self-managing diabetes and adherence (Figure 7.1). The second model represents the 
spectrum of adherence for people taking T2D medicines (Figure 7.2). Underpinning 
theory and recommendations are presented in light of the findings. The strengths 
and limitations of the research study are covered here too. This chapter concludes 
with the implications for policy and practice, and directions for future research.  
 
7.2 Key Findings  
The findings of this study  support  some,  but  contradict  other  findings  of  previous  
studies  looking  at  patients’  perceptions, understanding and experiences of 
managing T2D. Furthermore, it offers unique insights by identifying factors 
associated with successful and unsuccessful use of T2D medicines, which may impact 
on adherence. Findings from the questionnaires, interviews and systematic review 
are supported by referring to key sections discussed in previous chapters; these are 
in parentheses.  
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7.2.1 Setting the context 
The research study was taking place at a time of major reforms to the health and 
social care system, most significantly the transition of PCTs into numerous (diverse in 
size) clinical commissioning group [CCGs]. These are responsible for the 
commissioning of secondary and community care services based on the needs of the 
population they serve (Naylor et al., 2013), including that of T2D. At the time, there 
was some uncertainty of how these would operate and which services they would 
provide. In this study, there was evidence of an increase in uptake of services 
provided by multidisciplinary teams outside hospitals, which were situated within GP 
practices or health centres. However, the participants of this study appeared to be a 
good representation of patterns of care at the time. The most commonly prescribed 
new medication in this sample was GLP-1 agonist injections (36%), followed by insulin 
(24%) and DPP-4 inhibitors (19%), consistent with current prescription trends for 
diabetes during the recruitment period between 2012 and 2014 (HSCIC, 2014). Those 
participants in the weight reducing group were mostly women with higher BMI than 
the other two groups, probably reflecting guidelines that advise that GLP-1 agonist 
use should be mostly considered in more obese patients (NICE, 2009a). In addition, 
the weight reducing and weight neutral groups had significantly lower HbA1c levels 
than the weight increasing group, suggesting that different medicines are prescribed 
for different patient groups (Wei et al., 2017).  
 
The median HbA1c of this group prior to initiation of their new medicine was 
77mmol/mol signifying that there was already a delay in escalating glucose-lowering 
therapy (NICE, 2009a). According to the national diabetes audit (HSCIC, 2016) 
approximately 66% of T2D patients achieve an HbA1c below 58mmol/mol, however, 
this value could be overestimated, as there was a huge variation in the number of 
practices participating in the diabetes audit between 2012 and 2014 (70% in 2012-
2013 and 57% in 2013-2014).  
 
Furthermore, there is substantial evidence of clinical inertia when initiating oral 
glucose-lowering therapy, which in effect delays initiation to insulin therapy (Peyrot 
et al., 2010). In the UK, some people with diabetes remain on OGDs for a median time 
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of 7.7 years, despite having poor glycaemic control (Calvert et al., 2007; Khunti et al., 
2013). Much of the discussion surrounding clinical inertia has focused on delays in 
insulin initiation and intensification by identifying a set of separate barriers related 
to patient, clinician or system levels (the latter mainly due to time constraints and 
insufficient guidance through clinical guidelines) (Khunti & Millar-Jones, 2017). 
However, evidence is lacking from patients’ perspectives of delays in diabetes 
treatment(s). As seen in chapter 6 (6.3.6.1, Figure 6.9), one aspect that has not been 
considered is that of the NHS service organisation, in particular the lengthy 
administration systems, staff shortages/changes, reception barriers and 
appointment unavailability/cancelations. Most importantly, participants’ interviews 
revealed how such barriers are interlinked with that of clinical and patient–level 
barriers. Therefore, considering the impact of chronic hyperglycaemia and the 
development of possibly irreversible complications in T2D (Inzucchi et al., 2012), 
tackling clinical inertia should be a key goal to help optimise treatment.  
 
The key findings of this research are as follows, and are discussed in detail in 
subsequent sections:  
1. Participants’ views of their medicines and diabetes seriousness change over 
time (section 7.2.2). 
2. Overall, participants were ambivalent about the effectiveness of the 
treatment for their diabetes and body weight (diet/medicines) (section 7.2.2).  
3. The type of medicine initiated and subsequently experienced could influence 
the appraisal of such medicines in management of T2D (whether 
effective/ineffective) (section 7.2.3). 
4. Most patients would accept new medicines if they portray a dual purpose, 
most importantly weight loss and/or reduction in number of medicines/doses 
(section 7.2.3/7.2.3.1). 
5. Adherence to diabetes medicines is suboptimal and levels are influenced by 
perceptions of medicine’s effectiveness, concerns and convenience, 
experience of side effects and everyday practices (self-efficacy levels) 
(sections 7.2.4-7.2.6). 
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6. Perceptions of blood glucose levels and lack/excessive self-monitoring could 
hinder appropriate management of diabetes and weight loss (section 7.2.7).  
7. The level of support from health professionals, family and other people with 
T2D can have both a positive and negative impact on perceptions and 
adherence to their medicines and lifestyle (section 7.2.7). 
8. Complex interventions focussing on individual and health service delivery, 
and utilising theory, could help improve T2D management and adherence 
(section 7.2.7-7.2.9, 7.3).  
 
7.2.2: Perceptions and beliefs of diabetes and diabetes medicines  
The systematic review and the qualitative part of this study showed that perceptions 
of seriousness of T2D change over time (Figure 7.1). The systematic review (2.4.2.1) 
and other previous research (Monsier-Pudar et al., 2009; Majit-Ariss et al., 2013) 
focused on the relation of this perception to the type of treatment patients received, 
for example insulin was considered as the “last resort”. In addition, the quantitative 
part of the study showed that participants generally had strong perceptions about 
the necessity of their new diabetes medicine for the duration of the study (5.5.3.1), 
a finding similar to a cross-sectional study by Aikens and Piette (2009). However, the 
qualitative part of the study uncovered that despite the acknowledgement that T2D 
is a serious condition, for the majority of participants it was not perceived serious at 
the present moment (6.3.1.5). Seriousness was heightened by the presence of 
debilitating symptoms or complications, increase in number and/or changes to 
treatment as a result of consistent high HbA1c test results or unstable/high blood 
glucose, and type of support received by HPs in primary/secondary care services 
(Figures 6.2-6.3). In addition, seriousness was lessened by reprioritising other 
conditions due to a negative experience or other external factors, such as comparing 
themselves to important others. Most of these findings are comparable to other 
research (Lawton et al., 2005b; Morris et al., 2011). 
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Figure 7.1: Conceptual Model on key factors influencing beliefs and adherence to medicines 
over time 
 
Although in this study beliefs relating to the necessity, concerns, benefits, harm and 
overuse of medicines remained generally stable over time, there were variations 
within the whole group and weight-effect groups. For instance, participants felt 
strongly that their present health was dependent on their new medicine, however, 
this was not the case for their future health. Furthermore, there appeared to be an 
increase in uncertainty that these medicines would protect them from becoming 
worse or that they would be very ill without them. Surprisingly, only 19% of the 
weight increasing group had stronger beliefs about the necessity of their new 
treatment at follow-up, although the majority in this group were prescribed insulin 
treatment, the agent considered the most effective for lowering blood glucose levels 
(1.6.9, Table 1.1). Recent qualitative research showed, too, that majority of patients 
did not expect they would need additional medications for diabetes in the future 
(Fairchild et al., 2017) 
 
Ambivalence about the necessity of diabetes medicines was found in interviewees 
since most of them reported ambivalence in their medicines’ effectiveness, coupled 
with the experience of constant changes to their treatments since their diagnosis. 
Hence, ambivalence was related to the duration of taking their diabetes medicines 
(Figure 7.1). As found in interviews (6.3.3.2-6.3.3.3) and the systematic review 
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(2.4.1.4, 2.4.1.7), reasons for ambivalence included participants’ high expectations of 
their medicines in relation to either blood glucose or body weight, particularly when 
they anticipated that the treatment would provide instant results. These 
expectations are common amongst patients on medicines for long-term conditions 
(Dohnhammar et al., 2016). Those interviewees who initiated insulin and were 
insulin-naïve found that at three months their medicine did not have the instant 
effect they expected. Other research supports that those who initiate basal insulin 
rarely achieve glycaemic targets (HbA1c <7%, 53mmol/mol) in the first three months, 
or even within 2 years of initiation (Mauricio et al., 2017). Whilst, some patients 
believed they should come off their ineffective medicines, other patients suggested 
stopping their medicines (completely/intermittently) if they achieved blood glucose 
target and/or weight loss (6.3.3.3), or perceived them as instant relief of diabetes-
related symptoms (2.4.1.11). Fairchild et al. (2017) also found that only one-fifth of 
patients expected to take their diabetes medications for life. 
 
Ambivalence about effectiveness was also linked to the frequent concerns over 
taking medicines expressed by participants in interviews and the systematic review 
(6.3.3.4, 2.4.1.6). These concerns were for both individual medicines and the number 
of medicines as a whole for diabetes and other conditions. Concerns were related to 
side effects, long-term complications/contraindications of taking their medicines, 
type of form (tablet/injection) and convenience, as well as the perceptions of others 
about the type and number of medicines they take. Furthermore, participants’ past 
experiences of side effects, inconvenience and perceptions of injectable treatment 
made them wary of new medicines. Expectations of medicines are also thought to be 
influenced overtime by personal continuous evaluation of these through experience 
and societal negative values upon medicines (Dohnhammar et al., 2016). However, 
analysis from the questionnaires showed that, participants concerns over the 
potential adverse effects of their medicines significantly lessened over time, 
particularly for the weight reducing group (5.5.3). Yet, over a third of the weight 
increasing group (36%) appeared to have stronger concerns about their new 
medicine. Although overall medication burden did not increase over time, diabetes 
medication burden increased for both weight neutral and weight increasing groups 
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(Table 5.4). However, the weight increasing group was prescribed significantly more 
medicines than the weight neutral group.  
 
Increased concerns in the weight increasing group could be associated with insulin’s 
perceived seriousness, as discussed above, or other negative attributes (Brod et al., 
2009c). Most interviewees presenting with either less or stronger concerns at the end 
of the study were on injectable treatments (insulin and GLP-1 agonists). The 
difference between them was that those presenting stronger concerns discussed 
insulin’s ineffectiveness and inconvenience, with two participants reporting stigma 
about injecting in public. Aspects of effectiveness, side effects and convenience of 
new treatments are discussed in detail in section 7.2.3.  
 
At the end of the study, the weight neutral and the weight increasing groups had 
stronger beliefs that medicines are overused by doctors. Whereas, at three months, 
the weight neutral group believed that doctors place too much trust on medicines, 
the weight increasing group believed that doctors will prescribe fewer medicines if 
they had more time with patients. Nevertheless, almost 40% of patients in each of 
these groups were uncertain about these aspects. Both the systematic review and 
the interviews showed that participants display trust in doctors to prescribe 
appropriate medicines (6.3.3.1, 2.4.2.3), despite their general concerns and 
associated negative stigma about taking medicines (6.3.3.4, 6.3.3.6, 2.4.1.2, 2.4.1.6). 
Participants in interviews accepted that starting a new medicine is a case of “trial and 
error” (6.3.3.5), acknowledging the risks and benefits of taking their medicines. Yet, 
there appears to be a complex interplay when it comes to preferences for medicines, 
particularly over efficacy and convenience and less so over safety (Laba et al., 2015, 
Pound et al., 2005).  
 
7.2.3: Expectations and experiences of new diabetes medicines 
Although there was no statistically significant difference between whether overall 
expectations decreased, remained unchanged or were exceeded, it was apparent 
that there were certain aspects about participants’ new medicines that were 
impacted by their experience in taking them. Overall, most participants had their 
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expectations exceeded or met by experience, whilst a third felt their expectations of 
their new medicine(s) were unmet, with 39% of weight neutral group changing in this 
direction (5.5.1). Despite individual variations in satisfaction levels, participants, in 
general, were significantly satisfied with their new medicine(s), and the impact of 
these on managing their weight and daily life, with no change in psychological health 
at three months (5.5.4-5.5.5). However, it was the weight reducing group which had 
significant improvement in satisfaction levels in all aspects of their medicine (burden, 
efficacy, symptoms, impact on weight and daily life) over time. Other studies also 
found that patients treated with GLP analogues over 6 months had greater overall 
treatment satisfaction and well-being scores (Bode et al., 2010) compared to insulin 
treated patients (Grant et al., 2011) and those taking oral medications (Davies et al., 
2011; Davies & Speight, 2012).  
 
7.2.3.1 Effectiveness 
Participants had higher expectations of their new medicine in relation to controlling 
their blood glucose and making them feel better. However, after three months they 
felt their new medicine was not controlling their blood glucose as they thought it 
would, and it did not make them feel any better (5.5.1), perhaps anticipating instant 
results, as discussed earlier (7.2.1). Nonetheless, all weight-effect groups showed 
significant improvement with their diabetes medicine efficacy in relation to the drugs 
ability in helping prevent them feeling tired and lacking energy and, keeping blood 
glucose stable, with the weight reducing and weight increasing groups being 
significantly more satisfied with their medications’ impact on their physical and 
emotional well-being (5.5.4.2). This was evidenced by the improvement in HbA1c 
levels at three months with median reductions of 8-13mmol/mol since initiation of 
their new treatment. 
  
Although, HbA1c levels were decreased at 3 months for all three weight-effect groups 
and some participants were able to reduce HbA1c levels to target (range 35-
123mmol/mol), median HbA1c levels of 66mmol/mol are still considered high based 
on current guidelines (NICE, 2015a). As seen in chapter 6 (6.3.3.2-6.3.3.3), 
participants main focus on drug treatment is the effect on their blood glucose 
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(evident through SMBG or HbA1c tests) and physical effects (energy levels and body 
weight). Furthermore, participants’ expectations of the dual purpose of their new 
medicine (blood glucose control and weight loss/less medication burden) could set 
the bar high, resulting in the ambivalence about the effectiveness of this and/or other 
treatments for their T2D (6.3.1.4). It appears that patients generally overestimate the 
benefits of their medicines (Dohnhammar et al., 2016). In addition, as seen in 
chapters 2 (2.4.1.9) and 6 (6.3.3.3, 6.3.5), both positive and negative experiences of 
diabetes medicines resulted in participants being more reluctant to treatment 
changes or keen to stop them, or even prioritise certain diabetes-related treatments 
over others.  
 
7.2.3.2 Side effects and hypoglycaemia 
Experience of side effects from diabetes medicines varied between, and within, 
individuals and their satisfaction levels, thus, varied over time. Medicines in tablet 
form or non-insulin injections were mostly associated with gastrointestinal effects, 
while insulin was associated with risk of hypoglycaemia (2.4.1.7, 6.3.4.2). Although 
there were no significant changes to satisfaction levels with regards to participants’ 
experiences of side effects with their diabetes medicines over time, more people in 
the weight reducing group (37%) were satisfied in this aspect, whilst more people in 
the weight increasing (26%) and weight neutral (32%) groups were less satisfied 
(5.5.4.3).  
 
As explained previously, past negative experiences of side effects made participants 
worry and wary about starting new medicines. During interviews, participants who 
initiated a new medicine with weight-reducing effect, discussed their awareness of 
the potential side effects of these medicines, mainly affecting the gastrointestinal 
tract. Yet, after the experience of taking them, they indicated that these effects were 
short lived, or were able to cope with them by taking prescribed/over the counter 
medicines (6.3.6.2). On the other hand, interviewees from the weight neutral and 
weight increasing groups did not particularly describe awareness of any side effects 
with their new medicines. Therefore, this explained the reason of no improvement in 
satisfaction levels about the information they received from health professionals 
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compared to the weight reducing group which was significantly satisfied in all aspects 
of their medicine (action and usage and potential problems with medicine) (5.5.2). 
Although the weight neutral and weight increasing groups had mixed views at three 
months, with a substantial proportion of patients whose satisfaction levels decreased 
(33% and 31% respectively), this was in relation to the action and usage of their 
medicine. This suggested that even after taking their medicine for three months they 
were still unsure how it worked, what it did and how long they needed to be on it.   
 
Concerns of (risk of) hypoglycaemia with the new medicine were significantly 
reduced for the weight neutral and the weight increasing groups at follow-up, and to 
a lesser extent for the weight reducing group. It is known that some treatments such 
as insulin and sulphonylureas have higher risk of hypoglycaemia compared to 
biguanides, DPP-4 inhibitors and GLP-1 agonists (Table 1.1.). Yet, fear of 
hypoglycaemia is a general phenomenon for people with T2D regardless of what type 
of treatment they take. Evidence shows that those who are prescribed medicines 
with low risk of hypoglycaemia still display worry about low blood glucose (Lund & 
Knop, 2012). Additionally, some interviewees in this study expressed worry of 
hypoglycaemia as a result of polypharmacy, particularly if part of their treatment 
displayed such risk. Although, it is unknown whether level of risk of hypoglycaemia 
with the new treatment was discussed during participants’ clinical consultation, the 
qualitative interviews revealed that participants became more confident about 
treating hypoglycaemia by ensuring sugary snacks and drinks were available should 
they feel their blood glucose is coming down (6.3.1.2, Figure 6.2).   
 
7.2.3.3 Body weight 
As expected, the weight reducing and the weight neutral groups were significantly 
more satisfied with the impact of their new medicine on their weight at three 
months. The weight reducing group also indicated that they were not bothered by or 
did not experience any weight gain (61% of the group) (5.5.5.2). This is expected with 
the type of treatment they received, as GLP-1 agonist injections, SGLT-2 inhibitors 
and orlistat are drugs that promote weight loss. 
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Although it appears that participants in this study had significantly better weight 
related quality of life, inevitably, in line with the type of treatment, it was the weight 
reducing group which had the most significant improvement in their quality of life, 
whereas quality of life decreased over time in 28% of the weight increasing group 
(5.5.8). Although the data collected in this study are only short term (3 months), the 
weight reducing group had the greatest amount of weight loss during the period of 
the study as a result of taking their new medicine compared to the weight increasing 
group who gained weight (median values -2.5kg Vs +1kg respectively) (Table 5.4).  
 
There is evidence that weight related quality of life improves following GLP-1 
analogue treatment (Davies & Speight, 2012) and greater satisfaction could reflect 
greater weight loss and HbA1c reduction, consistent with previous studies (Davies et 
al., 2011). Yet, the weight reducing group’s quality of life was still lower than the 
weight neutral and weight increasing groups at both baseline and follow-up, 
suggesting that this group of people are still concerned with their weight. In addition, 
quite a substantial proportion of patients (quarter to half) in all groups appeared to 
be not satisfied with how well their new medicine was helping them to lose weight, 
or bothered by weight loss plateaus. The DAWN study (Peyrot et al., 2009) identified 
that weight worry was common amongst T2D patients. Most interviewees in this 
study were worried about their weight but found themselves unable to lose it or 
prevent further weight gain, because of their previous unsuccessful attempts with 
lifestyle changes and/or weight loss treatments (6.3.2.1). Still, individuals’ 
perceptions of the effect of their medicines on their body weight varied (6.3.2.2). As 
a consequence, perceptions of causes of diabetes, type and effectiveness of 
treatment initiated had an impact on the priorities for weight management. This 
meant that some patients would prioritise medicines for diabetes over body weight 
or vice versa (6.3.2.3). Those who prioritised their efforts to decrease their body 
weight suggested that their diabetes might even disappear, contrary to the findings 
of the systematic review, which showed that people varied in their perceptions of 
lifestyle measures resulting in weight loss as an effective way of managing their 
diabetes (2.3.3.3).  
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7.2.3.4: Burden and Convenience 
As described in interviews and the systematic review, different experiences with 
medicines shape what is perceived as inconvenient (2.4.1.6, 2.4.1.7, 6.3.4.1). In 
general, having to take medicines more than once a day, which encompasses various 
different doses through the day, having to take medicine with meals or food or make 
dietary adjustments, or having to take medicines outside of home was considered a 
“nuisance”. Although there was general improvement in satisfaction levels about 
how burdensome the new medicine was, again, the weight reducing group was 
significantly satisfied at follow-up, with the highest proportion (39%) amongst the 
weight–effect groups. Conversely, satisfaction levels decreased for 25% of the weight 
increasing group, the highest proportion between all groups (5.5.4).  
 
Nevertheless, participants’ who initiated injectable treatment (weight reducing and 
weight increasing groups) were more positive about the delivery system at follow-up 
(5.5.1.2). Whilst those who initiated GLP-1 agonists indicated that their new medicine 
was convenient to take, easy to use away from home and not physically painful, those 
initiated insulin found it easy to get the dose (or amount) and were more satisfied 
that it did not interfere with planning meals. There is evidence that insulin-naïve 
patients (and to that effect injectable-naïve patients) are generally concerned over 
technical aspects of injections including mastering the skill of giving oneself an 
injection and preparing the correct dose of this type of treatment (2.4.1.3, 2.4.1.6, 
6.3.3.6). However, when they become experienced in taking insulin, injection-related 
concerns become less of a worry (Brod et al., 2009c; Casciano et al., 2011; Holmes-
Truscott et al., 2017), a finding that resembles interviewees’ experiences on all 
injectable treatments (6.3.3.6).  
 
Furthermore, an advantage of most common GLP-1 agonists and basal insulins 
(prefilled pens) currently prescribed on the NHS is that they are taken once a day, 
and generally T2D patients seem to be more satisfied with this treatment compared 
to oral medications (Bradley & Gilbride, 2008; Davies et al., 2011). During interviews, 
most participants prescribed GLP-1 agonists or insulin expressed preference and 
receptiveness towards injectable treatments compared to tablets, due to the 
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perceived efficiency of injectable treatments, and due to the minimal associated side 
effects with insulin (6.3.3.6). The difference in the interviewees with injectable 
treatment was that those on GLP-1 agonists were on a standard dose which did not 
require to change over time and were less likely to be asked by HPs to SMBG 
excessively as those (starting) on insulin. Also, those on GLP-1 agonists, particularly 
those on once daily or once weekly dose, found it much more convenient to take it 
because it did not affect their food intake, could be taken at their home any time of 
the day, could be kept outside of the fridge, and it did not affect their driving licence 
and car/holiday insurance (6.3.4.1).  
 
On the other hand, 75% of the weight neutral group, at three months, indicated their 
new medicine did not interfere with their daily life, and 53% stated it never interfered 
with following their recommended diet (5.5.4.2). Most patients in this group were on 
DPP-4 inhibitors or on metformin extended release, which both are in tablet form 
taken once a day and are well-tolerated drugs (Richter et al., 2008; Chacra, 2014). 
Furthermore, some participants in the interviews indicated that they did not have to 
take their new medicine with foods or at a specific meal time, particularly those on 
DPP-4 inhibitors. However, participants prescribed metformin as part of their 
diabetes regime, raised concerns over the size of this tablet, which made it difficult 
to swallow. Additionally, those taking metformin more than once a day, found it 
challenging to take this medicine with food, often resulting in eating more food, or 
avoiding eating altogether (6.3.4.1). Thus, participants’ engagement with their 
medicines (tablets/injections) suggests that there is a varying degree of resistance 
and receptiveness to medicines, consistent with other research (Pound et al., 2005; 
Jenkins et al., 2010). 
 
7.2.4: Adherence 
There was no significant change in the medication adherence levels following 
initiation of the new treatment (5.5.6). Despite a slight increase in adherence levels 
at three months, only a third of the group (30%) was classified as high adherent with 
the majority (70%) classified as low to medium adherent (Morisky et al., 2008). This 
is a lower percentage of adherence level than other studies which show adherence 
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levels ranging between 38.5 and 93.1% (Krass et al., 2015). However studies appear 
to use different methods to measure medication adherence (Krass et al., 2015). Only 
two studies in the systematic review by Krass et al. (2015) had used the latest version 
of MMAS (i.e. MMAS-8) and these reported adherence levels of 38.5% and 44.1%. It 
has been argued that there are important factors to consider when interpreting the 
literature on medication adherence. These include whether patients are experienced 
in using medicines or they take medicines for the first time, the way the adherence 
rates are reported (mean or categorical percentages), the different methods of 
assessment (various self-report and quantitative measures) (Blackburn et al., 2013) 
and whether self-management has been taken into account (de Vries et al., 2014).  
 
Adherence levels remained stable for approximately 50% of the individuals in this 
study, although the change in individuals’ levels of adherence varied over time. Of 
the three weight-effect groups, the weight neutral group had the highest proportion 
of patients classified as high adherent (36%) than the other two groups (26%) at three 
months, and the weight increasing group had a higher proportion of patients who 
became low adherents (34%) compared to baseline (28%). Lloyd et al. (2014) 
demonstrated a similar pattern of adherence and non-adherence in a 2-year follow-
up study in T2D patients. Blackburn et al. (2013) describes three patterns of 
medication use in the first year in patients with T2D (primary non-adherence, non-
persistence and poor execution), which require different support strategies to 
encourage patients to enhance adherence. Hence identifying these can ensure 
appropriate preparation of patients at initiation of any new diabetes treatment. A 
meta-analysis found that the proportion of patients who were considered adherent 
with the OGDs was 67.9%, with persistence rates ranging from 41-81.1% and with 
approximately one third of patients discontinuing their medicines at follow-up (Iglay 
et al., 2015).  
 
In this study, just over 7% indicated they had discontinued the medication at follow-
up, although another 16% were missing data. Reasons for discontinuation were not 
recorded, however interviews revealed that reasons for changes to diabetes 
medicines were to protect/preserve kidney function or due to experiencing 
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intolerable side effects (6.3.1.3-6.3.1.4). Although there was no evidence of primary 
non-adherence, interviews and the systematic review showed that most participants 
were poor executers and very few demonstrated non-persistence. While this study 
only measured adherence levels over the first three months of initiating new diabetes 
treatments, patterns of non-persistence and poor execution in the first three months 
can account to up to 50% of non-adherence cases in the first year (Blackburn et al., 
2013), whereas premature discontinuation and non-persistence becomes more 
evident after six months of therapy (Yeaw et al., 2009).  
 
The results of this study suggest that the type of medication does not influence the 
levels of medication adherence (5.5.6, 5.6.1). This is in contrast with the findings from 
other studies. The INITIATOR study (Wei et al., 2017) showed that there are different 
persistence levels at 12 months between patients initiating insulin glargine (64%) 
versus those initiating liraglutide (49%). While the SHIELD study (Grandy et al., 2013) 
showed  patients prescribed medicines promoting weight loss and who actually lost 
weight during the duration of the study (>1yr) had significantly higher medication 
adherence levels than patients who gained weight and were prescribed medicines 
associated with weight gain (insulin, sulphonylureas, thiazolidinedione therapy). On 
the other hand, both the systematic review and the interviews uncovered the 
spectrum of adherence patterns in patients with T2D (Figure 7.2). Adherence, 
therefore, was influenced by convenience, effectiveness, concerns and experience of 
side effects, as well as confidence levels in establishing routine medication practices 
and other self-regulation strategies, which were specific to individual circumstances 
(Figure 7.1).   
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Figure 7.2: Adherence Spectrum 
 
7.2.5 Self-efficacy (Routine practices and Self-regulation)  
Most participants’ self-efficacy in taking medicines correctly improved overtime, 
although this significantly improved in the weight reducing group compared to the 
other two groups (5.5.7). This improvement was specifically in relation to self-efficacy 
under conditions of uncertainty. Conditions of uncertainty include situations such 
that when individuals are not sure how to take their medicine, they don’t know what 
time of the day to take it, when refill medicines look different, when they are feeling 
unwell and when the medicines cause side effects. The weight reducing group also 
showed significant improvement in their confidence levels in taking their medicine 
correctly under difficult circumstances, such as when they take several different 
medicines each day, when they take several medicines more than once a day, when 
they are away from home and when their normal routine gets messed up. Whereas, 
confidence levels in this area decreased over time for most people within the weight 
neutral and weight increasing groups.   
 
When interviewees with high and low baseline self-efficacy levels (6.3.6.1) were 
compared, it became clear that those with more established routines were more 
confident in taking their medicines correctly, including what to do when they forget 
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to take their medicines or how to prevent side effects or hypoglycaemia. Whereas, 
those with low self-efficacy did not have an established routine, especially when they 
went out of their home. So when they forgot to take their medicine (and 
subsequently remembered), they were uncertain whether to take it or omit it. 
Alternatively, those whose confidence levels under difficult circumstances improved 
over time, were more likely to report less (or no) side effects or fear of 
hypoglycaemia, and more convenient medicines, i.e. easy to fit within their current 
routine.   
 
During interviews, it was apparent that a variety of different strategies were used by 
participants to help them remember to take their medicines. Remembering to take 
medication is a prospective memory task relying upon cognitive processes for 
completing an action in the future (Stawarz et al., 2014). As seen in table 6.2, 
participants described that their medication routine was an automatic habit 
associated with specific time, location or event. Yet, habitual memory tasks, over 
time, can introduce errors of repetition or omission (i.e. take more/ less medicines 
than required) particularly when routine is disturbed (Zogg et al., 2012; Staward et 
al., 2014). External cues (such as use of pill boxes and family reminders) along with 
conjunction reminders (a cue paired with an event like SMBG) are more effective than 
internal reminders (based on thoughts/hunger) (Staward et al., 2014). Findings from 
the interviews (6.3.6.1) and the systematic review (2.4.1.11), support that the more 
external cues and conjunction reminders are adopted, the likelihood of medication 
adherence increases. As described earlier, the majority of the participants in this 
study were (low to) medium adherent, partly because combination reminders were 
often adopted only to specific medicines, and partly because participants associated 
taking their various medicines with complex tasks.  
 
As mentioned earlier, SMBG as a self-regulation strategy when used appropriately 
(i.e. conjunction reminder), helped improved adherence in these patients. Evidence 
suggests that SMBG helps improve glycaemic control (measured by HbA1c) in non-
insulin treated T2D, particularly if this was used to adjust therapeutic regimens 
(Poolsup et al., 2008). Despite SMBG being acknowledged as important in 
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determining control and seriousness of diabetes (2.4.1.10, 6.3.1.2, 6.3.1.5), 
interviewees in this study largely used self-monitoring to identify the instant level of 
blood glucose based on their food consumption or presence of symptoms, making it 
a less useful measure for improving glycaemic control (Evans et al., 2013).  
 
In addition, misperceptions of self-monitored blood glucose resulted in 
mismanagement of diabetes control (6.3.1.2). For example, those who excessively 
monitored their readings became obsessed with the types and amount of foods they 
were eating and, those who rarely self-monitored, fear of hypoglycaemia resulted in 
them eating more sugary foods and drinks, therefore consuming more calories than 
necessary. Consequently hindering appropriate management of diabetes and weight 
loss in the long term. Peel et al. (2007), too, found self-monitoring was not 
particularly used to guide ongoing change to T2D patients’ lifestyles. Similar to this 
study, over time, Peel et al. (2007) found patients suggested that HPs do not provide 
guidance on how often to self-monitor, and they are not interested in their readings, 
as these may not be as important as the results of the HbA1c test.  
 
Participants conferred, through their beliefs, perceptions and experiences in taking 
their medicines, that generally there was no “alternative” treatment to diabetes 
other than taking their prescribed medicines. Many studies (Lawton et al., 2006b; 
Monsier-Pudar et al., 2009), including this and the systematic review, showed that 
patients find it difficult to modify their dietary habits and engage in regular physical 
activity and, therefore, rate medication (specifically insulin) as more important than 
these lifestyle measures and report higher medication adherence (Broadbent et al., 
2011). However, lack of appropriate guidance to self-monitoring and lifestyle 
interventions could further impact weight management, an integral outcome of T2D 
management (Aicher et al., 2010).  
 
Self-regulation strategies, such as avoiding social events, changing eating habits, 
adjusting the timing of their medicines or taking other additional medicines, were a 
result of concerns and experiences of side-effects of medicines and forgetfulness. It 
is not uncommon that patients taking medicines for long–term conditions to self-
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regulate and modify their regime (Pound et al., 2005, Mohammed et al., 2016). Other 
self-regulation strategies, for instance, seeking out information about their medicines 
and negotiating their treatment with health professionals were, also, reported in 
chapter 2 and other research (Bajcar, 2006; Rashid et al., 2014, Mohammed et al., 
2016). Identifying which of these strategies have an impact on medication taking 
behaviour could prevent potentially inappropriate therapy outcomes.   
 
7.2.6 Impact of medicines’ concerns and self-efficacy on adherence 
Multivariate analyses showed that medication adherence following initiation of a 
new diabetes treatment was significantly influenced by age, initial adherence levels, 
confidence levels (self-efficacy) in taking medicines correctly and a change in beliefs 
over concerns of potential adverse effects of the new medicine (Table 5.9). 
Multivariate analysis also showed that certain modifiable and unmodifiable factors 
can influence a change in adherence levels (either a decrease or increase) following 
initiation of a new diabetes treatment (Table 5.13). Unmodifiable factors included 
socioeconomic and marital status, whereas modifiable factors included initial 
medication adherence and HbA1c levels, beliefs that medicines are overused by 
doctors, and changes to self-efficacy levels. 
 
Systematic reviews have shown that demographic, socioeconomic and cultural 
factors influence adherence to OGDs in various ethnic groups (Peeters et al., 2011), 
and factors such as age, being female, travelling, type of delivery system related to 
insulin injections, and cost of medication are associated with nonadherence to insulin 
therapy (Davies et al., 2013). Although the current study did not explore all of these 
factors, gender was associated with medication adherence in the weight reducing 
group (Table 5.15). It was predicted that females are more likely to decrease their 
adherence levels following initiation of a new diabetes treatment. Moreover, an 
increase in low adherence levels was observed in participants within the weight 
increasing group, which mostly consisted of patients prescribed insulin (Figure 5.59). 
It is believed factors such as smoking, drinking, and living alone, are associated with 
greater difference in insulin dose timing which results in high frequency of 
hypoglycaemic episodes and being overweight (Nishimura et al., 2017).  
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The multinomial regression analysis showed that those individuals who are widowed 
(as opposed to be married) were more likely to increase their adherence levels 
following an initiation to a new medicine (5.6.1.2). Furthermore, interviews showed 
that some patients found the support of family conflicted with their efforts in 
managing their diabetes (Figure 6.8), whereas those who are widowed had perhaps 
greater support around them particularly from their health care team. Whilst family 
support for people with diabetes is widely acknowledged, families need psychosocial 
and education resources to better support their relatives with diabetes (Kovacs-Burns 
et al., 2013). On the other hand, interviewees who live in the most deprived areas 
were generally low to medium adherents, contrasting with other research (Lloyd et 
al., 2014) but there were interviewees who live in such areas whose adherence levels 
increased during the study. Reasons for enhanced adherence were related to 
modifiable factors such as belief that medicines are effective, convenient, have less 
side effects and increased support from health care team, rather than place of 
residence.  
  
The degree of difference between beliefs over necessity and concerns of medicines 
is thought to predict medication adherence (Clifford et al., 2008). Approximately half 
of the participants were ambivalent towards their new diabetes medicines both at 
baseline and follow-up, based on the necessity-concern framework (i.e. they had 
strong beliefs of both necessity and concerns towards their medicines) (Horne at al., 
1999; Aikens et al., 2005) and were classified as medium adherent (Morisky et al., 
2008). Meta-analyses (Horne et al., 2013; Foot et al., 2016) found that high adherence 
was associated with strong perceptions of necessity of treatment and fewer concerns 
about the treatment, although there were few longitudinal studies in these reviews 
with varied measures of adherence. On the other hand, the current study found that 
only beliefs about concerns of treatment predicted non-adherence. Other studies 
also identified concerns over adverse effects of medicines to be associated with non-
adherence (Mann et al., 2009; de Vries et al., 2014; Holmes et al, 2014), and the key 
motivation for not taking medicines (Pound et al., 2005).  
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Additionally, gender perspectives may have an influence on whether patients 
persevere with the side effects of their medicines (6.3.7). Nevertheless, interviewees’ 
compromise and perseverance was a way of considering the risks and benefits of 
taking their medicines in order to achieve balance in their life. However, their 
acceptance about compromise and perseverance affected their adherence levels 
(Table 6.2). Those who indicated they would not persevere with side effects were 
more likely to be medium to high adherents, those persevering for the benefit of their 
diabetes control were low to high adherents, whereas those persevering for the 
benefit of weight loss were more likely to be low to medium adherent.  
 
Although strong beliefs that medicines are overused by doctors can influence a 
change in adherence levels (both increase and decrease), medication burden did not 
predict non-adherence, a finding supported by (Grant et al., 2003) and in contrast 
with other research (Lloyd et al., 2014). An increase in diabetes medication burden 
overtime appeared to decrease the odds of becoming highly adherent in the WN 
group (Table 5.16). Essentially, as seen in interviews, beliefs about overuse can be 
overridden by the experience of support patients receive and other modifiable 
factors such as self-efficacy. On the other hand, high HbA1c levels prior to initiation 
of a new treatment predicts a decrease in adherence levels over time. 
  
Self-efficacy has been identified as the most significant predictor of medication 
adherence in chronic disease (Holmes et al., 2014) over time (Schoenthaler et al., 
2016). A comparison of interviewees who were low-to-high adherents and had 
various levels of self-efficacy, showed that high adherents used a combination of 
methods including triggers associated with time, location, and event, as well as 
repeating their routine on a daily basis, placing their medicines in front of them and 
taking them “all at once” (6.3.4.1). In line with Campbell et al.’s (2003) review, less 
guilt as a result of not taking medicines on time was only apparent to those who 
appeared confident and fully aware of the reasons for adhering or not to their 
medicines. Hence, despite most participants being classified as (low-to) medium 
adherent, interviewees reported they rarely missed their medicines, and therefore 
did not appear overly concerned about it, resulting in the spectrum of adherence 
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seen in figure 7.2. On the other hand, for those patients who reported less 
forgetfulness over time, adherence levels increased. However, adherence levels in 
those participants who negotiated or sought further information/advice about their 
medicines were not affected. A meta-analysis by Gherman et al. (2011), identified 
that individuals with diabetes who are more adherent are more confident that they 
can perform behaviours such as taking medication and intent to engage in such 
behaviours compared to individuals who are less adherent, as they are more likely to 
perceive barriers with adherence and feel less confident in dealing with these barriers 
and worry about medication side effects. In addition, Lloyd et al. (2014) found that 
prior adherence status was the most important factor in predicting adherence at 
various points during a 2-year follow-up study.   
 
This study predicted that older individuals with T2D, who are highly adherent and 
extremely confident in taking their medicines correctly under conditions of 
uncertainty and under difficult circumstances, are up to seven times more likely to 
be highly adherent at three months after initiation of a new diabetes treatment, than 
younger, less adherent and less confident individuals. In addition, during the period 
of taking the new treatment, if individuals have fewer concerns about the potential 
adverse effects of their new medicine, and there is no decrease in confidence levels 
in taking their medicines, they are still three to four times more likely to be highly 
adherent at three months after starting the treatment, compared to those individuals 
who have high concerns about their medicines and lose confidence in how to take 
them correctly. On the other hand, individuals whose confidence levels in taking their 
new medicine correctly decreases over time, then they are twice as likely to have 
their adherence levels decrease. There was a noticeable trend that adherence levels 
were less likely to decrease for participants who were prescribed a new treatment 
when their HbA1c levels were below 75mmol/mol (median HbA1c level for those who 
improved adherence over time). This trend could also be related to delays in 
treatment as discussed earlier (7.2.1). Hence, increased clinical inertia could 
potentially be associated with poor adherence.  
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7.2.7: Expectations of Care: Helpful and Unhelpful Support 
This study found that similar avenues of support were used by participants as in other 
studies (Lawton et al., 2005c, Stuckey et al., 2014), such as family, friends, Diabetes 
UK and other people with T2D. However, interviewees placed higher value on the 
support they received from health professionals in managing their diabetes, which, 
in return, gave them confidence to self-manage their condition. Although, in this 
study, the role of health care support in medication adherence was not investigated, 
research has shown that having better provider-patient communication, social 
support mainly by the health care team, and high self-efficacy is associated directly 
with performing diabetes self-care behaviours including medication taking, and 
indirectly to improvements in glycaemic control (Gao et al., 2013).  
 
Like Lawton et al. (2005c), this study found that people with T2D generally want to 
be seen by diabetes experts and appreciate instant access and timely feedback and 
information on their treatment(s). Findings from the questionnaire showed that all 
participants were significantly more satisfied at three months with the information 
they received about their new medicine from HPs, particularly about potential 
problems relating to side effects (for example feeling drowsy, affecting sex life, 
alcohol intake). However, as noted above (7.2.3.2), the weight reducing group had 
the greatest improvement while participants from the other two groups remained 
uncertain about their medicines. 
 
While the interviewees in this study expressed a preference to be seen at a specialist 
diabetes service, whether community or hospital, they found having access to their 
GP practice and to a range of other services as a good back up for their T2D 
management (6.3.7.2). A good quality service was described as providing regular, full 
examination of diabetes related aspects and sufficient time during a visit to discuss 
experiences and concerns (Figure 6.10). However, GPs and practice nurses were 
viewed by patients as lacking knowledge and expertise in diabetes, despite that many 
of them leading diabetes care within the practice. This corroborates findings of 
DAWN2, a multinational large scale study into perceptions of diabetes care, where 
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HPs themselves felt insufficiently equipped to provide diabetes self-management 
education, including emotional and psychological support (Byrne et al., 2017).  
 
Furthermore, during interviews, participants were either underusing dietetic services 
or undervaluing their support in relation to dietary management and weight loss. On 
the contrary, people who attended group sessions run by dietitians and other health 
professionals valued this support with regard to the information provided about 
diabetes, diet, physical activity, SMBG, and medication-related issues. Although, this 
kind of support was only provided when they were diagnosed, formal diabetes 
education is imperative both at the outset and at regular follow-up intervals (Sherr & 
Lipman, 2015). Interviewees seemed to appreciate receiving tailored information 
about their diabetes during appointments, and suggested this should happen more 
often, highlighting the fact that HPs need to reinforce the importance of lifestyle 
behaviours at each clinical visit (Reusch & Manson, 2017) and encourage informed 
treatment choice. Participants’ desire for continuity of care was also paramount in 
maintaining effective and appropriate care and fostering good relationships between 
patients and professionals. Education, informed choice and continuity are aspects in 
line with the National Service Framework Standards for Diabetes (DOH, 2001a), 
recommendations from NICE for the management of T2D (2009a, 2015a), as well as 
guidance on improving the experience of care for people using NHS services, and 
their medicines (NICE, 2012, 2009b, 2015b).  
 
Evidence from interviews suggest that there is a close link between the level of 
support from health professionals and self-management of T2D (Figure 7.1). 
Participants were empowered to make lifestyle changes when they had excellent 
support (as defined by Figure 6.10) and perceived their diabetes treatment was 
effective, convenient and had less side effects. In addition, the systematic review 
showed that HPs could inhibit/impact patients’ views about diabetes and medicines 
and subsequent strategies at various points during their illness journey (Figure 2.4). 
In addition, a recent review (Frost et al., 2014) identified that for effective self-
management strategies, T2D people need to take ownership of their disease, 
fostered by timely and tailored information and support over time. This is important 
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when considering that adherence levels, found in this and other studies (Lloyd et al., 
2014), change over time from high to low and vice versa, and that any changes to 
treatments or treatment intensification may be ineffective if patients are already low 
adherent. Support needs to provide the foundation to explore patients’ perceptions 
and experiences of managing their diabetes and to guide the development of a 
flexible regimen that can facilitate both quality of life and medical outcomes (Frost et 
al., 2014).  
 
This study aimed to identify suitable intervention(s) for T2D patients which would 
enable them to (self) manage weight loss goals and medication adherence. However, 
there was considerable discussion during interviews about health care support for 
these patients, which guided the development of the model of care in Figure 6.10. 
Thus, as expected, experience of helpful support formed suggestions which 
interviewees deemed useful for future support for themselves and others who are 
prescribed the same type of new treatments they had received. Details of these 
suggestions and aspects of information participants found useful can be seen in 
Figures 6.8 and 6.10. Although there is a debate whether to take patients’ 
preferences for granted and change delivery of care based on these preferences 
(Lawton et al., 2013), it has been argued that preferences could change over time in 
light of patients’ direct experiences of care. The interviewees in this study, however, 
had varied experience of health care settings, from either primary or secondary care 
or both, with different prescribed treatments for T2D. In addition, irrespective of care 
received, suggestions outlined in Figures 6.8 and 6.10 were echoed by all participants. 
These suggestions are not uncommon amongst patients (2.4.1.5, 2.4.2.5), as 
evidenced in research and guidance literature (Peyrot et al., 2006; NICE, 2009a,b; 
2015a,b; McMullen et al., 2015; Mohammed et al., 2016; Fairchild et al., 2017) and 
endorsed by UK policy (DOH, 2004a,b, 2005b, 2006). 
 
7.2.8 Emotional impact of taking diabetes (and other) medicines 
It is no surprise that participants’ beliefs, perceptions and experience of taking 
medicines for diabetes, body weight and other conditions had an impact on their 
emotional well-being (Figure 7.1). Furthermore, most participants were worried 
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about their body weight and linked this to either diabetes itself, specific diabetes 
medicines, or the amount of medicines they take. Hence, the majority of participants 
revealed they do not like taking medicines and would prefer to take less or none, 
resonating preferences of other people with long-term conditions (Pound et al., 
2005). This contradicts the progressive nature of T2D from lifestyle management to 
that of lifestyle combined with pharmacotherapy in order to achieve glycaemic 
control. This suggests that regardless of the duration of their condition (median=7yrs) 
and the recognition of self-responsibility of managing their condition, there are still 
unresolved issues when treatment changes occur, involving the acceptance/denial of 
their diabetes. Perception of personal failure when starting/increasing medicines was 
evident in both the systematic review and the interviews, although none of the 
interviewees implied there was a sense of “punishment” as a result of initiating 
insulin. Communicating the progressive nature of the disease process is important 
for minimising ill-perceptions of lifestyle failure or self-blame (Reusch & Manson, 
2017). 
 
The emotional impact of medicines on patients with T2D is not new. Similarly to the 
systematic review, interviewees portrayed representations of grief (Brown, 1985) 
from shock to adjustment, not only to their diagnosis but also to taking medicines for 
diabetes. Taking medicines for diabetes had a greater impact than the actual act of 
swallowing or injecting them. Some interviewees described a sense of restriction in 
the types of foods, their eating patterns and social activities regardless of the form of 
their medicine, and discrimination related to driving licence and holiday insurance. 
Negative impact and feelings of discrimination have also been reported elsewhere 
(Stuckey et al., 2014; Dohnhammar et al., 2016; Holmes-Truscott et al., 2016). As 
mentioned earlier (7.2.3.1, 7.2.3.4), interviewees displayed receptiveness and 
resistance to their medicines, reflecting other qualitative research on T2D patients 
on insulin (Holmes-Truscott et al., 2016). Stigma about taking medicines in public was 
not only related to insulin injections (Polonsky & Jackson, 2004), but also to tablets. 
Although tablets were less visible to others, and participants confined taking them 
whilst at home. Societal stigma was not however the dominant factor, but instead 
the inconvenience of medicines in fitting them to their current routines. 
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Understanding the personal meaning of medicines for patients with long-term 
conditions, whether it is a source to aid control or impose restriction, could help in 
understanding and addressing the management of prescribed medicines 
(Dohnhammar et al., 2016). 
 
This study also adds that as progression to different treatments impacted their 
emotions and how they coped, so too the increased number of medicines over time 
(6.3.7), which included frequency of doses/injections. The level of successful 
management of T2D was affected by the level of self-efficacy and strategies 
employed on a day to day basis. Whilst the experience of successful and unsuccessful 
practices and perceptions of successful and unsuccessful medicines reinforced or 
undermined patients’ beliefs about their diabetes treatment, it also led to a re-
evaluation of self, and the key goal for all was to regain control of their life (Figure 
2.4).  
 
7.2.9 Potential Future Intervention(s)  
This study aimed to identify suitable intervention(s) for T2D patients which would 
enabled them to (self) manage weight loss goals and medication adherence. This 
research question was mainly addressed through the qualitative interviews. 
However, as mentioned previously (7.2.7), participants considerably discussed areas 
to improve the support from their health care team when they were asked how they 
can be supported when starting and experiencing a new diabetes medication. 
Nevertheless, throughout the interviews a number of aspects have been identified 
that could be used in the future (7.2.5, 7.2.6, 7.2.8), either in practice or research, 
and as a result, a range of visual models (Figures 6.2-6.4, 6.6, 6.7/7.2, 6.8-6.10, 7.1) 
were developed to support patients and health professionals.  In summary, evidence 
from this study has highlighted the need for developing interventions that are 
focusing on health care support, communication/education about the disease, self-
efficacy strategies, and psychological help. Future research should focus on 
identifying the complexity of potential interventions, as well as their development, 
execution and implementation (Moore et al., 2015).  
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7.3 Theory review 
Emotional impact, and perceived self-efficacy, beliefs about and experiences of 
taking medicines for T2D and interactions with health professionals were key drivers 
influencing medicine taking behaviour. Theory-based interventions have failed to 
provide substantial evidence in medication adherence and clinical outcomes to adult 
patients prescribed polypharmacy, mainly because they have not been optimally 
used (Patton et al., 2017). Additionally, the systematic review in chapter 2, as others 
(Holmes et al., 2014), demonstrated that no single theory can be used to fully 
illuminate medicine taking behaviour. Likewise, this study demonstrates that more 
than one theory is needed to explain medication taking practices for people with T2D. 
An in-depth analysis of these theories is beyond the scope of this thesis, but brief 
explanations of these can be found in section 2.3.4. Medication taking related 
theories include, in no particular order: 
 
(i) Theories such as social cognitive theory (Bandura, 1977) and the model of 
illness representations (Leventhal et al., 1980 cited in Bower et al., 2012) describing 
perceived self-efficacy and coping efficacy as a key construct that influences one’s 
behaviour including medicine taking. Furthermore, others aspects covered by the 
models include emotional (grief reaction) and other cognitive factors (illness and 
medication related beliefs, and expectations) which are involved in changing the self-
view and self-practices. Although, the environment (physical and social including 
health care support) play an important part in changing individuals’ behaviour, it is 
unclear how other external factors such as health related policies and politics directly 
impact on behaviour. Perhaps the influence of these external factors is an indirect 
one. This study did not explore the role of multi-morbidity on illness representations, 
however, like Bower et als’ study (2012), there is evidence of causal relationships 
between diabetes and obesity and other cardiovascular related conditions, priority 
among conditions resulting in both synergies and antagonisms, medication burden, 
and coherence.  
 
(ii) Although the Necessity-Concerns framework (Horne et al., 1998, 1999) 
proposes that perceived need for diabetes medicines and ongoing concerns about 
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medicines influences patient medication adherence, in this study, concerns about 
side effects and convenience of taking them had the most impact on adherence. 
Nevertheless, patients related the necessity of their medicines if they believed they 
were effective; i.e. reducing blood glucose levels and body weight and increasing 
energy levels. Additionally, necessity and effectiveness corresponded to some 
diabetes medicines rather than the whole diabetes medication regime.  
 
(iii) It is believed that patients and health professionals portray different 
explanatory model of illness (Kleinman et al., 1978). The systematic review and this 
study did not explore health professionals’ views about T2D. However, patients’ 
accounts suggested that there is a discrepancy in views around: severity, treatment 
recommendations by HPs and difficulties encountered, passive/active patient role 
and adherence/non-adherence, which can potentially impact medicine taking 
behaviour.  
 
(iv) Starting a new medicine for T2D and ongoing additional medication therapy, 
and not just at the onset of their chronic illness, indicates a biographical disruption 
(Bury, 1982). Psychological medicine resistance and receptiveness was found in this 
study prior to initiation of the new treatment. There was no resistance to the new 
treatment, as all participants accepted it, however, interviewees discussed other 
treatments that they had refused prior to the new prescription or in the past, which 
included insulin, other injectable treatments and tablets. Therefore psychological 
resistance to medicines appears to be a phenomenon that occurs as a result of 
peoples’ individual experiences and beliefs about their condition and their medicines, 
and interactions with their wider environment. May et al. (2009) advocates that 
medicine taking behaviour is structurally induced by the health care system and the 
way patients utilise health care services. They suggested the burdens of treatments 
are very different from the burdens of illness, referring to the concept of minimally 
disruptive medicine (2009), and the newly proposed Burden of Treatment theory 
(2014). Both of which focus on the relationship of people with chronic conditions, 
their social networks and the healthcare services. The final model in the systematic 
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review (Figure 2.4) clearly demonstrates how patients evaluate their self and 
reconstruct their biography and it is supported by the findings in this study.   
 
7. 4 Strengths and Limitations 
The strengths of this study lie in the mixed methodology approach and study design, 
which not only assessed quantitatively the views of T2D patients about their 
medicines, but explored qualitatively the meaning they attach to their medicines and 
their daily practices which affected or promoted adherence over time. It may be that 
individuals recruited to the study, at both the questionnaire and interview parts, 
were better at self-managing their diabetes. However, this potential bias would have 
underestimated non-adherence. Still, the non-adherence levels reported in this study 
were equal or even higher than seen in other studies (Krass et al., 2015) for T2D 
population, supporting the generalizability of the findings. Also, as seen by the 
findings of the interviews, participants’ adherence levels ranged from low to high. 
Moreover, participants were frank about their management of diabetes and provided 
many insights into their everyday practices with lifestyle measures as well as 
medication. The rapport established between the researcher and the interviewees, 
over the period of this research study, enabled the patients to provide such detail 
strengthening the findings (Legard et al., 2003). 
 
Furthermore, the mixed methods analysis legitimised/validated the findings of the 
study (Onwuegbuzie et al., 2011) together with the findings of the systematic review 
in chapter 2, enabling an evidenced-based explanation of the phenomenon of 
medicine taking behaviour in people with T2D. The mixed method approach is 
consistent with the initial stages of process evaluation for developing complex 
interventions that can have impact on a number of levels from individual, to health 
service delivery and policy by targeting individual, interpersonal and organisational 
components to produce change (Moore et al., 2015). 
 
In addition, the study involved a large sample contributing to a prospective 
longitudinal study which is currently lacking in the literature (Horne et al., 2013; Foot 
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et al., 2016). By employing a multi-sited recruitment strategy across Merseyside, 
participants recruited had both diverse socio-economic background and experiences 
of diabetes services and treatments. While 65% of the participants recruited were 
from primary care, this corresponds to current services provided for T2D in England, 
since there has been a focus on GP practices to deliver care locally (DOH, 2004b; NHS 
England, 2014). Although recruitment rate varied for each primary care trust, this 
may reflect on the services provided in different areas. For example, Sefton and 
Knowsley PCTs have dedicated multidisciplinary teams in some areas running 
frequent community clinics and therefore a greater chance of recruiting participants 
at the point of prescription, compared to the other PCTs where GPs with a specialist 
interest in diabetes or nurse prescribers recruited participants on an ad-hoc basis. A 
small percentage of participants were recruited from community pharmacies (9%) 
suggesting the study was able to identify patients where there may not be a 
dedicated service for diabetes patients.  
 
Other methods of participant recruitment were considered, including sampling from 
the local diabetes register. However, recruiting participants following a clinical 
encounter or collection of a new prescription from a community pharmacy was best 
suited in this study, in order to capture patients at the point of change in their 
medication regime, and therefore this approach was less likely to suffer from a 
selection bias. The sample was representative of those who are changing treatments. 
The median baseline of HbA1c of the research participants was 77mmol/mol, and 
therefore within current practices in UK, where treatment changes occur when mean 
HbA1c range between 72-84mmol/mol (Khunti et al., 2013; Wilding et al., 2017).  
 
Although establishing recruitment sites was a challenge despite the training and 
support provided by the research team and the Primary Care Research Network 
[PCRN], the study had an acceptable, good response from patients for both 
questionnaires and interviews (Sitzia & Wood, 1998; Bowling, 2009), as most 
individuals approached consented to the study. Despite the length of the 
questionnaires, almost 66% of consented participants returned both questionnaires, 
indicating that medication therapy and its effects on weight, adherence and other 
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psychological factors is of interest to people with T2D. Significantly more individuals 
(45.7%) who did not return the second questionnaire were those in full-time 
employment, suggesting the length of the questionnaire might have impacted on 
their time and willingness to complete it. Reasons for participants withdrawing from 
interviews following consent (n=28) were not collected at the time, but 24 of these 
participants completed both study questionnaires. Furthermore, individuals with 
significantly poor kidney function (Median eGFR=78) returned the second 
questionnaire, indicating they may have had additional concerns when taking 
diabetes medicines, as identified during the interviews.  
 
While the study aimed to include patients from a range of ethnic groups, only 1% of 
the sample were from BME groups and all of the interviewees were Caucasian, 
consistent with the regional demographic data (Rasdale, 2013). Therefore, it is not 
possible to generalise the findings beyond this group. Nevertheless, the systematic 
review, which included at least 42% participants from BME groups, showed that these 
patients have similar concerns about their diabetes medicines and patterns of 
adherence. Another potential limitation of this study is the recruitment of 
participants from the UK, particularly to the North West region. However as noted 
above, findings are corroborated with other studies (see 2.5.2). Hence, inference 
validity has been demonstrated by supporting findings from this study with findings 
from other research (Lewis & Ritchie, 2003).  
 
Although the study did not reach the original proposed sample size for the 
questionnaire part of the study (i.e. n=300), the quantitative data collected were 
sufficient to run all statistical analysis as planned. Many of the clinical data collected 
at 3-month follow-up (i.e. cholesterol, blood pressure, renal function) were not 
available to use for statistical analysis, as 36-70% of them were missing. However, 
this reflects real world clinical care for T2D patients, as these clinical values are often 
repeated at 6-month or yearly intervals (rather than at 3-months). Furthermore, 
important clinical data such as HbA1c and BMI were recorded as close as possible to 
three months, ranging from 2-4 months. Therefore, these data were recorded either 
slightly before or after administration of the second questionnaire. This was to 
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minimise missing data (~25%) to enable meaningful statistical analysis. However, this 
approach could have under/overestimated the impact of such clinical data on 
participants’ views on their medicines.  
 
Although there is no gold standard for assessing minimal important change in 
individuals (Wyrwich et al., 1999; Rejas et al., 2008), using the SEM allowed 
exploration of how participants’ medication views changed over time irrespective of 
the type of drug prescribed. Moreover, the quantitative part of the study 
systematically measured low to high adherence levels in these patients prescribed 
different new diabetes treatment at the point of prescription and three months later. 
This established which factors predicted high adherence levels after initiation of new 
treatment and what aspects can influence a change in adherence over time. Although 
there are many “rules of thumb” for calculating appropriate sample sizes for 
regression analysis (Green, 1991; Wilson VanVoorhis & Morgan, 2007) based on the 
number of predictors, the multivariate regression analysis perhaps was lacking 
sufficient numbers, particularly when the whole group was split into the three 
weight-effect groups. An original analysis of the whole group irrespective when 
participants had completed their first questionnaire (n=213), showed that the exact 
same predictors influenced adherence (Psarou et al., 2016). On the other hand, each 
weight-effect group had a small sample size with limited observations across the 
different adherence levels, for example 26% of the WR group (n=68) was high 
adherent at follow-up (section 5.5.6.3). Therefore, more cases are needed in order to 
perform multivariate regression analysis in the individual weight–effect groups and 
further research should address that.  
 
Further limitations could include the lack of use of confidence intervals and a heavy 
reliance on p-values for the majority of analyses. Nevertheless, median values and 
interquartile range provided in the result sections as most of the data were ordinal 
(Field, 2009). These are the preferred measurements when reporting the results of 
nonparametric tests (Field. 2009). In addition, to overcome the likelihood of 
increasing Type I errors (the belief that there is a genuine effect in the sample 
population when there is not one), the Bonferroni correction test was used when 
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multiple testing between pair groups. However, this is a conservative test, which in 
effect could increase type 2 errors, i.e. when there is a genuine effect in the sample 
population but it has been rejected due to decreasing the probability value to below 
0.05 (Field. 2009).  
 
Several approaches were used throughout the study to ensure methodological rigour 
for the interviews. Such approaches included: piloting the interview schedule, 
sampling purposively to reach adequate representation, researcher’s experience in 
conducting research interviews, cross-checking transcripts and original recordings for 
typographical errors or unclear sections, using the framework approach to data 
analysis which is both systematic and comprehensive, the supervisors and/or the 
research steering group reviewing themes generated and confirming the 
interpretation of findings to ensure that the implications of the study are relevant to 
clinical practice (Lewis & Ritchie, 2003; see section 4.3.1). Data saturation was 
reached after interviewing 24 participants, a sample which was considered both 
sufficient and representative of the questionnaire sample. The triangulation of the 
mixed method data in this study further confirms data saturation and limits selection 
bias (Oppong, 2013; Fusch & Ness, 2015). 
 
Furthermore, reflexivity is a tool for bringing transparency to the research process 
and its outcomes (Etherington, 2007) by recognising and acknowledging the pre-
understandings that the researcher and the participants bring to the study, and the 
impact of these in generating the data. Ways to exercise reflexivity during the process 
of analysis have been proposed (Warin, 2011). Yet, Finlay (2002) argues that 
researchers who adopt a reflexive approach risk concentrating on excessive self-
analysis at the expense of focusing on the research participants and developing 
understanding.  
 
Nevertheless, being self-aware throughout the research process helped eliminate 
any influences in the design, analysis and representation of the data. For example, 
during the design and piloting of the interview guide, input from both supervisors 
and the research steering group which consisted of HPs and lay representatives with 
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T2D, ensured that the researcher’s prior professional background did not affect the 
development of the tool (see 4.3.1). Furthermore, to minimise potential influence on 
participants’ responses during interviews, they were informed that the researcher 
was independent to their health care team, and the treatment and services they 
received would not be affected by taking  part  in  the  study, but  it  was  their  views 
and  experiences of the treatment they had received  that  was  sought. Yet, one out 
of the two participants who had a health professional background, was less 
forthcoming on their understanding about diabetes, perhaps because they 
considered the researcher to be a HP too. In addition, a few participants discussed 
the positive impact the research involvement and researcher’s personality had on 
them, which might have inhibited a true appraisal of the health care service. 
Nonetheless, most participants discussed both positive and negative aspects on the 
support they had received for their diabetes. Initial nervousness during the conduct 
of the first few interviews could potentially impact on the outcome of the interview 
and some aspects not being followed up. However as the interviews progressed, 
familiarisation with the interview guide helped to eliminate such impact, and all 
participants were given the opportunity to discuss anything that was not covered 
during the interview. Researcher’s concerns about misunderstandings related to the 
use of dialect or colloquial speech by participants during interviews was overcome by 
questioning them about the meaning of such words or phrases and the use of a 
professional transcription service.  
 
7.5 Implications for policy and practice 
Given the strengths and limitations of the study, this mixed methods study provides 
new insights into the reasons for poor adherence. Specific (practical) issues have 
been identified through the models developed which may help in the development 
of more patient-centred interventions by changing practice and informing policy.  
 
Health professionals can change consultations so that patients feel understood and, 
in return, they understand their diabetes and their medications. Informing patients 
of the variety of medication treatments available for T2D as well as the inevitable 
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progression from tablets to injectable medicines could make patients aware and give 
them time for grieving, so when eventually a prescription is required, these medicines 
are more easily accepted. In addition, weight management is an important aspect of 
diabetes, however amongst patients, there are mixed perceptions of the effects of 
the different medicines on their body weight. Considering that most patients with 
T2D are worried about their weight but only a few patients associated weight 
management with their diabetes management, HPs need to ensure that they 
communicate better the impact of certain treatments on body weight, the role of 
maintaining a healthy body weight, and offer patients guidance on dietary and other 
lifestyle changes that can minimise impact. Nevertheless, recent changes to diabetes 
treatment guidelines (Inzucchi et al., 2015; Handelsman et al., 2015) which opt out 
of phase-level treatment and offering insulin or other injectable treatments at 
various stages of the disease, may be another approach to overcoming barriers with 
managing T2D, although these changes are not supported by current NICE guidelines 
(2015a). The merits of using GLP-1 analogues and SGLT2 inhibitors earlier in the 
management of T2D has been discussed elsewhere (Wilding et al., 2016; Chatterjee 
et al., 2016), yet this study demonstrated these treatments are preferable and 
contribute to significantly more positive patient reported outcomes than other 
treatments, particularly in relation to weight loss.  
 
In addition, focusing on areas of concerns about medicines prior, and during 
treatment is a priority for helping patients to minimise these concerns and accept 
medicines in a way that promotes better adherence. Short term positive impact on 
medication adherence following initiation of chronic disease medication (at 3-
6months) through a tailored intervention based on discussion about medication and 
disease beliefs with a pharmacist has shown potential (Nguyen et al., 2016). It is 
understood that patients may struggle with complex drug regimens, therefore their 
perspective and experience on medicine-taking must be taken into account when 
prescribing new treatments. Prescribers should bear in mind that patients seem to 
prefer medicines taken at home, that do not interfere with work or lifestyle, and are 
easy to fit into routine, particularly if taken only once a day, at breakfast or first thing 
in the morning, or are flexible without being “tied down” to certain times like having 
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to take with food or adjust eating patterns. Additionally, if they have less side 
effects/complications, they are then viewed more favourably by patients and this 
could enhance adherence. Moreover, interventions could be designed to promote 
treatment adherence by taking into account emotional and cognitive factors, as well 
as determining preferences to treatment and building confidence in daily practices 
and social and family support mechanisms. Emotional distress, social support and 
self-efficacy are strongly associated with diabetes self-care behaviours (Walker et al., 
2015; Gonzalez et al., 2015; Sleath et al., 2016) and habit formation has shown to 
predict medication adherence (Phillips et al., 2016). Findings from this study support 
that daily practices and routines should be built with multiple external cues and 
conjunction reminders. 
 
Most patients appear to trust their doctors and accept that doctors make decisions 
about their medicines. Patients prefer expert professionals in diabetes, particularly 
at diagnosis and at every medication change or initiation. If patients receive services 
at both primary and secondary care, then continuity of care is paramount not only 
between services but also between HPs. Furthermore, services should aim to provide 
timely treatment changes, timely repeat prescription changes, regular monitoring, 
instant advice, adequate time to discuss experiences and time to get adequate 
information to ensure diabetes treatment is effective (diet/meds). Patients, 
therefore, can become confident about the care they receive and motivated to make 
changes to better control their diabetes and body weight. Yet the current constraints 
and the increased demands on the health care budget in providing such an intensive 
support through the NHS can be challenging. The role of the community pharmacist 
in the management of people with T2D has been investigated (Twigg et al., 2015; 
Nguyen et al., 2016), as well as recent advances to eHealth via text, voice or video 
(Nelson et al., 2016; Odnoletkova et al., 2016; Peimani et al., 2016; Thakkar et al., 
2016; Car et al., 2017). Whilst these show promise in improving medication 
adherence and/or glycaemic control for a short period, the long term impact and the 
cost-effectiveness of such interventions need to be further explored.  
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Pound et al. (2005) argue that policy needs to change with less emphasis on 
modifying patients’ behaviour but on determining what sort of treatments patient 
prefer and developing and evaluating the safety, efficacy and cost-effectiveness of 
those preferred treatments. Recent guidelines (NICE, 2015b) have been developed 
about medicine optimisation which considers both patients’ perspectives, and 
efficacy and safety of medicines. However, more needs to be done to ensure 
sufficient evidence from patient research and public and patient engagement is 
utilised when developing guidelines (Heaton et al., 2017) and commissioning self-
management support services (Reidy et al., 2016). This is to implement services that 
effectively address peoples’ needs, enhance the management of their condition, and 
improve quality of care and medical outcomes. Such services should further address 
the problem of clinical inertia as reported here and elsewhere (Khunti & Millar-Jones, 
2017). 
7.6 Future Research 
 A potential limitation is that the study only focused on patients’ views and 
accounts of managing their diabetes; hence, future work could focus on the 
perspectives of health professionals involved in their care, as well as those of 
family and friends in order to identify ways that could better support patients 
in managing their diabetes and adhering to their medicines.  
 Although this study provides some of the first longitudinal results for T2D 
patients in respect to medication adherence, the follow-up of three months 
is relatively short, particularly for those on insulin treatment. Therefore future 
research should be extended in order to provide more useful and relevant 
information on the relationship between patients’ beliefs about medicines, 
confidence in self-managing diabetes and the impact on medication 
adherence.  Of particular importance would be identifying the views of people 
who refuse or do not initiate treatment, or those in full-time employment and 
their support mechanisms, and how these may influence adherence.  
 Statistical and qualitative analysis was focused by grouping people into 
weight-effect groups, however, not all drugs are the same in spite of their 
effect on body weight. Therefore, future studies should focus on individual 
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drugs or on drugs with other similar attributes, such as the risk of 
hypoglycaemia, or compare drugs in tablet or injectable form.  
 Although, interview findings suggest that support from health care services 
can improve confidence in self-managing T2D and therefore adherence, it is 
not clear whether this kind of support predicts adherence levels over time. 
Future longitudinal studies should investigate how service delivery/models of 
care can impact on adherence and glycaemic control.   
 This study provides the basis for the development of a complex intervention 
which focuses on both changes to health care delivery and individual’s 
medicine taking practices. However, future interventions should demonstrate 
clearly how related theories, identified here, have been applied and 
contributed to intervention outcomes.  
7.7 Conclusion 
Mixed method studies are used in much policy research and the combination of 
quantitative and qualitative longitudinal data is potentially very powerful in providing 
links between causation, processes and outcomes (Corden & Millar, 2007). This study 
builds on previous cross-sectional and qualitative work around the role of beliefs 
about medicines and self-efficacy in medication adherence. It is the only prospective 
study to date which examined these factors (amongst others) on a large scale using 
multiple health-care sites as well as analysing complex mixed method data. The study 
population is similar to other T2D populations in relation to prescribed medication 
trends, health service provision and sub-optimal medication adherence levels 
supporting the generalisability of the findings. This study contributes to new 
knowledge by highlighting how the needs and desired outcomes of T2D patients 
change over time after an initiation/change to a new medication.   
 
The study showed that patients’ short-term priorities and needs focused on medical 
treatment that is effective, and regular support from expert health professionals to 
manage unanticipated effects of their new treatment. Whereas, in the longer term, 
their priorities and needs focused on sufficient support to prevent further 
complications and a return to meaningful, functional life and normalisation.  
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Furthermore this study revealed that beliefs about medicines (Concerns, Overuse, 
Harm and Benefits), and self-efficacy in taking medicines correctly appear to have the 
greatest impact on medication adherence following initiation of new treatment for 
T2D, instead of the medicines’ effect on body weight. These are modifiable factors 
and patients could benefit from NHS services that provide support in increasing 
confidence levels in taking medicines as well as exploring beliefs about medicines 
particularly in relation to concerns, and overuse, in order to help patients overcome 
these concerns. 
 
Regardless of the type of treatment (lifestyle/medicine), over time, participants 
raised doubts about their effectiveness for T2D management, reinforced by the 
constant changes to treatments by HPs. This has had a negative impact on their 
emotional well-being and implied that medicines were a temporary measure for 
controlling their diabetes and/or body weight and therefore expressed a perceived 
need to stop taking them.  
 
Most of the participants reported that at the present moment their T2D was not 
serious. However, they accepted their new medicines despite the risks associated 
with them, in hope of taking less, better, efficient and effective medicines both for 
their diabetes control and body weight. It is imperative that health professionals 
understand patients’ experiences with their diabetes medications in order to provide 
responsive health care services within the NHS to meet patients’ needs, improve 
quality of life and minimise costs. This study developed a range of visual models that 
could be used in both future research and practice to explore further patients’ views 
and medication adherence. 
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Appendix 2.3 Translational Synthesis: key components of perceptions of T2D and T2D medicine taking, including illustrative quotes (1st and 2nd order constructs) 
from primary studies 
Themes (3rd order constructs) Participants Quotes (1st order constructs) Authors Interpretations (2nd order constructs) 
Emotions- Negative Feelings “I was devastated [about being prescribed glipizide]. I wasn’t 
happy at all. But it was explained to me that diabetes always 
progresses, no matter how careful you are.”1 
"Well me Grandmother used to have diabetes … and I 
remember this dirty great syringe, like an icing sugar thing."3 
Initial Reaction1 
Shock3 
Fear of injections3, Needle Anxiety 
Denial14 
My Diabetes is serious ‘...from my experience of diabetes, it’s just an inevitable part of 
it that you’re going to end up being on insulin anyway...I was 
expecting it .... it was suggested a few times that I took insulin 
as my tablets were going up’9 
Acceptance14, Beliefs about Necessity of Insulin9, 
Priority16, Commitment to taking OGDs2B, 
Perceptions of OGDs1 
My Diabetes is not serious ‘My health will remain good, by the Grace of God, so long as I 
keep praying.’5 
Contextual Knowing2A, Priority16, Disease severity, 
insulin leading to premature death and social 
stigma5 
Expectations of Treatment 
(medicines) 
“Keep me alive”2C, "When I was put on metformin it was almost 
sold as a good one that would help lose weight as well….”2C 
Expectations and Concerns2B 
Expectations of Care 'The right hand doesn't seem to know what the left hand does. 
He looks at his screen and reckons he hasn't heard from the 
hospital yet, but that's always the excuse.'4, “You need to be 
educated to do it correctly [referring to educators]. It can really 
help.”6, "That’s for cholesterol . . . eh, I get (inaudible 00:25:10) . 
. . I have no idea what that’s for . . . ‘cos I go to my doctor; they 
don’t tell me what the tablets are for . . . "16 
Education and Information needs2B, Information 
and Support4, Doctor-Patient Consultation6, The 
message6, experiences of health care interactions10, 
Barriers to knowledge acquisition11 
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Negative Perceptions and 
Experiences with Medicines 
"It’s a foreign substance, and you’re shoving it in your body"3, "I 
can’t do anything and I can’t go abroad. I can’t do anything 
’cause I’ve got to take this insulin, and it devastated me.", 
‘really bad stomach cramps’2B 
Negative experiences2B, Friend or Foe3, Fear of 
causing harm3, Insulin as a restriction3, Knowledge 
adnunderstanding6, mistrust in the value of 
treatment12, beliefs about over prescribing & 
resistance to additional medicines15, Loss of 
control5, treatment convenience8 
Positive Perceptions and 
Experiences with Medicines 
"Feels  like I am normal now, I’ve got strength. I am a normal 
man"3, ‘I was always waking in the morning with it [blood sugar 
levels] very high […]. So, they put me on this one which keeps it 
steady at night.’7B, “[the GP] ‘tested it, and it’s come down to 
seven point something and he’s really pleased’”2A 
Synergies and antagonism in the management of 
multimorbidity16, Regaining Health3, Quality of Life6, 
Receptiveness towards instensification7B, 
Importance of medicines15, Person and context13 
Self-Regulation “And now in the morning I take three pills, sometimes two, 
meaning I check it [blood glucose] and according to that I do or 
don’t take all the pills.”1  
Topping-up7B, Strategies to control diabetes12 
Medicine Taking Behaviour 
- Adherence and 
Unintentional non-
adherence with Guilt 
- Unintentional non-
adherence without guilt 
- Intentional non-
adherence with guilt 
- Intentional non-
adherence without guilt 
“Sometimes you do say that to yourself, you know, you say to 
yourself, ‘Oh I feel fine and I’ll take one today, I won’t take 
two.’1, "I did start to take glucosamine, but I take my tablets 
that I have for my blood pressure, my diabetes and my 
cholesterol and then the aspirin, I forget about the others. I 
think to myself, I’m knocking about, feeling alright, why 
bother?"16, “It’s just slipped into my lifestyle in that come four 
o’clock in the afternoon I take my pill’2B, “I’m very bad for the 
one during the day, I forget that’’2A, “With this injection, aspart, 
you can do it 20 minutes before hand and then it begins to get 
into the bloodstream or you can do it after your meal but I 
Forgetfulness2B, Managing two types of insulin7B, 
The importance of medicines15, Strategies to 
promote adherence2B 
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usually do it before because you have a meal out and then you 
don’t want to dash home.”7B 
Strategies to overcome negative 
aspects of insulin 
 “I wouldn’t go out to lunch with them (friends) and in the end I 
had to tell them why. I said, ‘I can’t. I have got to have insulin. 
And I am not going to go into a toilet”7B, ‘If I go out with 
anybody I always go and do it (inject) in the toilet. I won’t ever 
do it outside.’7B 
Difficulties with injecting in public7B, Managing two 
types of insulin7B Information and support4  
Lifestyle Behaviour “Yeah but sometimes I taste a little thing what I know I don’t 
supposed to really eat … You can eat everything but small 
amount of it.”6, “…we changed our diet overnight, for the whole 
of the family. The sugars went out and the fat went out and 
healthy food just came in immediately and that helps.” 15 
Down to me2C, Activities of daily living4 Attitude to 
self-mangement11, Integrating the diabetic 
regimen10 
NB: 1st order constructs represent the views and understandings of primary research participants and 2nd order constructs represent the interpretations offered by primary 
authors. Please note that some 2nd order constructs are not directly derived by 1st order constructs. Please note not all 1st and 2nd order constructs are represented in this 
table.   
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Appendix 3.1 Research Flyer 
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Appendix 3.2 Potential Participant Research Invitation Letter 
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Appendix 3.3 Study Consent Form 
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Appendix 3.4 Participant Information Sheet 
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Appendix 3.5 – Questionnaire 1 and 2 
Questionnaire 2 is exactly the same except there is no section A (Background 
Information). Sections in questionnaire 2 are labelled from A through to H.  
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Appendix 3.6 Interview Consent From 
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Appendix 4.1 Clinical Data Form 
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Appendix 4.2 Interview Guide 1 and 2 
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Appendix 4.3: Thematic Framework - Node Hierarchy
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Appendix 5.1: Internal reliability of adapted questionnaire scales  
Scale Name Questionnaire 1 Questionnaire 2 Original Scale 
 (sections 4.2.1.1-4.2.1.7  
EITQ 0.71  0.80 
PITQ  0.72 0.72 
BMQ Concerns=0.73 
Necessity=0.83 
Harm=0.65 
Overuse=0.79 
Benefit=0.75 
Concerns=0.79 
Necessity=0.87 
 Harm=0.66 
Overuse=0.75  
Benefit=0.84 
Concerns=0.80 
Necessity=0.74 
Harm=0.62-0.70 
Overuse=0.65-0.72 
Benefit=0.62-0.66 
MMAS-8 0.60  0.65 0.83 (for hypertensive 
patients) 
MMAS-8, plus 2 
Weight related 
questions 
0.64 0.68  
SIMS SIMS=0.90 
SIMS-AU=0.86 
SIMS-PPM=0.89 
SIMS=0.92 
SIMS-AU=0.83 
SIMS-PPM=0.90 
SIMS: 0.81 (insulin 
treated), 0.88 (OGDs) 
Subscales:0.61 -0.79 
DiabMedSat DiabMedSat=0.88 
Burden=0.84 
Symptom=0.80 
Efficacy=0.78 
DiabMedSat=0.89 
Burden=0.84 
Symptom=0.76 
Efficacy=0.87 
DiabMedSat=0.90 
Burden=0.87 
Symptoms=0.89 
Efficacy=0.87 
TRIM-Weight TRIM-Wt-DL=0.59 
TRIM-Wt-WM=0.60 
TRIM-Wt-PH=0.91 
TRIM-Wt-DL=0.62 
TRIM-Wt-WM=0.67 
TRIM-Wt-PH=0.91 
TRIM-Wt-DL=0.91 
TRIM-Wt-WM=0.70 
TRIM-Wt-PH=0.87 
SEAMS SEAMS=0.96 
UDC=0.95 
UCU=0.92 
SEAMS=0.97 
UDC=0.96 
UCU=0.92 
SEAMS=0.86 
UDC=0.86 
UCU=0.79 
 OWLQOL 0.98 0.98 0.93-0.96 
Baseline Cronbach’s alpha calculated based on 248 participants and at follow-up on 213 participants.   
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Appendix 5.2: Demographic characteristics of whole group, participants returned questionnaire 
1 and participants returned both questionnaires.  
  (%) or Median (IQR)  
 Whole Group 
n (%) 
Returned Q1 Only 
n(%) 
Returned Q1 & 
Q2 n(%) 
N 248 35 213 
Centre Site n (%): 
GP Practice 
SCDC 
CP 
 
137(55.2) 
83(33.5) 
28(11.3) 
 
17(48.6) 
12(34.3) 
6 17.1) 
 
120(56.3) 
71(33.3) 
22(10.3) 
Mean Age (yrs)  
 
59 (51,68) 
[Range 24-86] 
55 (51,64) 
[Range 31-73] 
60 (51,69) 
[Range 24-86] 
Gender n(%) 
Men 
Women 
 
132(53.2) 
116(46.8) 
 
19(54.3) 
16(45.7) 
 
113(53) 
100(47) 
Ethnicity n(%): 
Caucasian 
Asian 
Mixed 
 
246(99.2) 
1(0.4) 
1(0.4) 
 
35(100) 
0(0) 
0(0) 
 
211(99) 
1(0.5) 
1(0.5) 
Marital Status: 
Alone/Single  
Married/ with partner 
Divorced/Separated  
Widowed 
 
36(14.5) 
173(69.8) 
20(8.1) 
19(7.7) 
 
10(28.6) 
20(57.1) 
3(8.6) 
2(5.7) 
 
26(12.2) 
153(71.8) 
17(8.0) 
17(8.0) 
Education : 
University /Higher Degree 
A level  
GCSE  
Diploma  
Vocational  
No Formal Qualifications  
Missing 
 
21(8.5) 
28(11.3) 
49(19.8) 
10(4.0) 
35(14.1) 
102(41.1) 
3(1.2) 
 
2(5.7) 
6(17.1) 
7(20.0) 
0(0) 
7(20.0) 
13(37.1) 
0(0) 
 
19(8.9) 
22(10.3) 
42(19.7) 
10(4.7) 
28(13.1) 
89(41.8) 
3(1.4) 
Employment Status: 
Full time  
Part-time  
Unemployed 
Retired  
Other [most on benefits] 
Missing 
 
59(23.8) 
21(8.5) 
32(12.9) 
107(43.1) 
27(10.9) 
2(0.8) 
 
16(45.7)* 
3(8.6) 
7(20.0) 
8(22.9)* 
1(2.9) 
0(0) 
 
43(20.2)* 
18(8.5) 
25(11.7) 
99(46.5)* 
26(12.2) 
2(0.9) 
IMD: 
20% most deprived 
21% to 40%  
41% to 60%  
61% to 80% 
20% least deprived 
Missing 
 
153(61.7) 
35(14.1) 
31(12.5) 
18(7.3) 
11(4.4) 
0(0) 
 
24(68.6) 
4(11.4) 
3(8.6) 
3(8.6) 
1(2.9) 
0(0) 
 
129(60.6) 
31(14.6) 
28(13.1) 
15(7.0) 
10(4.7) 
0(0) 
IQR reported as (Q1,Q3), *Fisher’s Exact test = 15.317, p=0.003 
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Appendix 5.3: Clinical characteristics of whole group, participants returned questionnaire 1 and 
participants returned both questionnaires. 
  (%) or Median (IQR= 25th,75th) Or Mean(±SD) 
 Whole Group 
n (%) 
Returned Q1 Only 
n(%) 
Returned Q1 & Q2 
n(%) 
N 248 35 213 
Years Diagnosed with T2D  
Missing 
7 (3,13) 
[Range 0-59yrs] 
7(2.8) 
8 (4,13) 
[Range 0-24yrs] 
4(11.4) 
7 (3,13) 
[Range 0-59yrs] 
3(1.4) 
Number of Diabetes 
Complications- Baseline: 
None  
One  
Two  
Three  
Four  
Five 
Missing 
 
 
121(48.8) 
67(27) 
35(14.1) 
15(6.0) 
3(1.2) 
2(0.8) 
5(2.0) 
 
 
23(65.7) 
5(14.3) 
4(11.4) 
1(2.9) 
0(0) 
0(0) 
2(5.7) 
 
 
98(46.0) 
62(29.1) 
31(14.6) 
14(6.6) 
3(1.4) 
2(0.9) 
3(1.4) 
Number of Diabetes 
Complications- Follow-up  
None  
One  
Two  
Three  
Four  
Five 
Missing 
 
 
98(39.5) 
50(20.2) 
25(10.1) 
16(6.5) 
2(0.8) 
2(0.8) 
55(22.2) 
 
 
16(45.7) 
3(8.6) 
4(11.4) 
0(0) 
0(0) 
0(0) 
12(34.3) 
 
 
82(38.5) 
47(22.1) 
21(9.9) 
16(7.5) 
2(0.9) 
2(0.9) 
43(20.2) 
Total Medicine Burden 
 
Missing 
7 (5,10) 
[Range 1-21] 
11(4.4) 
7 (4,9) 
[Range 1-11] 
2(5.7) 
7 (5,10) 
[Range 1-21] 
9(4.2) 
Total Medicine Burden – 
Follow-Up 
 
Missing 
8 (5,10) 
[Range 1-20] 
 
57(23.0) 
7 (5,9) 
[Range 1-12] 
 
12(34.3) 
8 (5,11) 
[Range 2-21] 
 
45(21.1) 
Diabetes Regime: 
None 
Tablets only 
Tablets & insulin 
Insulin only 
Insulin & GLP-1 
Tablets, insulin & GLP-1 
Tablets and GLP-1 
Missing 
 
24(9.7) 
145(58.5) 
38(15.3) 
10(4) 
1(0.4) 
2(0.8) 
24(9.7) 
4(1.6) 
 
4(11.4) 
18(51.4) 
4(11.4) 
0(0) 
0(0) 
1(2.9) 
7(20.0) 
1(2.9) 
 
20(9.4) 
128(60.1) 
33(15.5) 
10(4.7) 
1(0.5) 
1(0.5) 
17(8.0) 
3(1.4) 
Diabetes Regime at 
follow-up: 
Tablets only 
Tablets & insulin 
Tablets & GLP-1 
Insulin only  
Insulin & GLP-1 
 
 
76(30.6) 
43(17.3) 
47(19.0) 
7(2.8) 
3(1.2) 
 
 
12(34.3) 
2(5.7) 
6(17.1) 
1(2.9) 
0(0) 
 
 
64(30.0) 
43(20.2) 
39(18.3) 
6(2.8) 
5(2.3) 
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Tablets, insulin & GLP-1 
GLP-1 Only 
Missing 
19(7.7) 
3(1.2) 
50(20.2) 
3(8.6) 
0(0) 
11(31.4) 
14(6.6) 
3(1.4) 
39(18.3) 
Number of Diabetes 
medicines–Baseline: 
None  
One  
Two  
Three 
Four 
Missing 
 
 
24(9.7) 
68(27.4) 
101(40.7) 
48(19.4) 
3(1.2) 
4(1.6) 
 
 
4(11.4) 
7(20.0) 
13(37.1) 
10(28.6) 
0(0) 
1(2.9) 
 
 
20(9.4) 
61(28.6) 
88(41.3) 
38(17.8) 
3(1.4) 
3(1.4) 
Number of Diabetes 
medicines–Follow-Up 
One  
Two  
Three 
Four 
Five 
Missing 
 
 
30(12.1) 
74(29.8) 
81(32.7) 
9(3.6) 
1(0.4) 
53(21.4) 
 
 
5(14.3) 
8(22.9) 
9(25.7) 
1(2.9) 
0(0) 
12(34.3) 
 
 
24(11.3) 
67(31.5) 
73(34.3) 
7(3.3) 
1(0.5) 
41(19.2) 
Baseline Weight (kg)  
 
Missing 
98.35 (85.92, 118) 
 
12(4.8) 
96.9 (86.89, 
109.5) 
2(5.7) 
98.6 (85.9, 118.8) 
 
10(4.7) 
Baseline BMI (kg/m2) 
 
 
Missing 
35.05 (8.70) (31.2, 
39.9) 
[Range 22.1-61.1] 
12(4.8) 
34.8 (30.0, 37.9) 
[Range 23.0-46.8] 
2(5.7) 
35.3  (31.2, 40.7) 
[Range 22.1-61.1] 
 
10(4.7) 
Baseline HbA1c 
(mmol/mol) 
Missing 
77 (66,91.5) 
[Range 42-134] 
11(4.4) 
82 (64.5, 98) 
[Range 55-114] 
2(5.7) 
77 (66,90) 
[Range 42-134] 
9(4.2) 
Blood Pressure-Systolic  
Missing 
134±15 
16(6.5) 
134±12 
4(11.4) 
134±15 
12(5.6) 
Blood Pressure-Diastolic  
Missing 
76±11 
16(6.5) 
77±7 
4(11.4) 
75±11 
12(5.6) 
Cholesterol (mmol/L) 
Missing 
4.1 (3.5, 5.0) 
50(20.2) 
4.2 (3.5, 4.9) 
7(20.0) 
4.1 (3.5, 5.0) 
43(20.2) 
LDL (mmol/L) (n=173) 
Missing 
2 (1.5, 2.69) 
75(30.2) 
2 (1.5, 2.5) 
10(28.6) 
2  (1.5, 2.8) 
65(30.5) 
HDL (mmol/L) (n=194) 
Missing 
1.1 (0.9, 1.21) 
54(21.8) 
1.1 (0.9, 1.3) 
8(22.9) 
1.1 (0.9, 1.2) 
46(21.6) 
Triglycerides (mmol/L)  
Missing 
2.1  (1.5, 2.9) 
63(25.4) 
1.98 (1.3, 2.7) 
10(28.6) 
2.18 (1.5, 2.9) 
53(24.9) 
eGFR (ml/min) (n=226) 
Missing 
78.5 (60,90) 
22(8.9) 
87.5+ (70, 90) 
3(8.6) 
78+ (57,90) 
19(8.9) 
Creatinine (umol/L)  
Missing 
78 (31) (66,97) 
21(8.5) 
71+ (58, 89) 
2(5.7) 
79 + (67, 101) 
19(8.9) 
+Mann-Whitney U Test, Creatinine: U=2373.0 ,z= -2.338, p=0.019, eGFR: U=2335.5, z=-2.242, p=0.025  
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Appendix 5.4: Cronbach’s alpha, baseline standard deviation and Standard Error of Measurement 
for each scale  
Scale Cronbach’s alpha Baseline SD 
  
SEM  
EITQ/PITQ* 0.64 0.82 0.29 
SIMS  0.90 4.83 1.49 
SIMS-AU 0.86 2.25 0.83 
SIMS-PPM 0.89 3.17 1.05 
BMQ-Necessity 0.83 0.66 0.27 
BMQ-Concerns 0.73 0.65 0.33 
Necessity-Concern 
Differential 
Based on Difference between  
SEM-Necessity and SEM-Concerns 
0.06 
BMQ-Overuse 0.79 0.78 0.35 
BMQ-Benefits 0.75 0.52 0.26 
BMQ-Harm 0.65 0.56 0.33 
DiabMedSat 0.88 14.86 5.05 
DiabMedSat-
Burden 
0.84 15.75 6.30 
DiabMedSat-
Efficacy 
0.78 19.02 8.75 
DiabMedSat-
Symptom 
0.80 21.90 9.64 
TRIM-Wt-DL 0.59 17.50 11.20 
TRIM-Wt-WM 0.60 21.88 13.78 
TRIM-Wt-PH 0.91 27.51 8.25 
MMAS-8 0.60 1.52 0.96 
MMAS-8 plus 2 
items  
0.64 1.74 1.04 
SEAMS 0.96 0.90 0.18 
SEAMS-UCU 0.92 0.99 0.28 
SEAMS-UDC 0.95 0.89 0.12 
OWLQOL 0.98 30.92 4.33 
*Cronbach’s α for PITQ-EITQ change score scale and SD is for the change score (see section 4.2.4).  
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Appendix 5.5: Proportion of patients whose expectations were unmet, met, or exceeded by 
experience (EITQ-PITQ) 
 Weight 
Reducing 
Weight 
Neutral 
Weight 
Increasing 
Whole 
Group 
Unmet Expectations  
<-0.29 
30% (n=20) 39% (n=22) 31% (n=20) 33% (n=62) 
Expectations Met  
≥-0.29 and ≤0.29 
25% (n=17) 24% (n=14) 30% (n=19) 27% (n=50) 
Expectations exceeded by 
Experience >0.29  
45% (n=30) 37% (n=21) 39% (n=25) 40% (n=76) 
p=0.560, No significant difference between the three weight-effect groups 
 
 
 
 
Appendix 5.6: Proportion of patients whose satisfaction with information received about new 
medicine had improved, did not change or decreased 
 Weight 
Reducing 
Weight 
Neutral 
Weight 
Increasing 
Whole 
Group 
Decreased SIMS  ≤-1.49 15% (n=10) 26% (n=15) 25% (n=16) 22% (n=41) 
No change in SIMS 
>-1.49 and ≤1.49 
38% (n=26) 35% (n=20) 47% (n=30) 40%(n=76) 
SIMS Improved  SEM >1.49 46% (n=31) 39% (n=22) 28% (n=18) 38% (n=71) 
P=0.089, No significant difference between the three weight-effect groups 
Decreased SIMS-AU  ≤-0.83 19%(n=13) * 33% (n=19) 31%(n=20) * 28% (n=52) 
No change in SIMS-AU 
>-0.83 and ≤0.83 
38% (n=26) 35% (n=20) 47% (n=30) 40%(n=76) 
SIMS-AU Improved  >0.83 43% (n=29) 
* 
32% (n=18) 22% (n=14) 
* 
32% (n=61) 
p=0.37, *Weight Reducing Vs Weight Increasing p=0.012 
Decreased SIMS-PPM ≤-1.05 12% (n=8) 21% (n=12) 17% (n=11) 16% (n=31) 
No change in SIMS-PPM 
>-1.05 and ≤1.05 
43% (n=29) 49% (n=28) 58% (n=37) 50%(n=94) 
Improved SIMS-PPM  >1.05 45% (n=30) 30% (n=17) 25% (n=16) 34% (n=63) 
P=0.055, No significant difference between the three weight-effect groups 
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Appendix 5.7: Proportion of patients whose beliefs about the new medicine had improved, did 
not change or decreased 
 Weight 
Reducing 
Weight 
Neutral 
Weight 
Increasing 
Whole 
Group 
Decreased BMQ-Necessity ≤-
0.27 
34% (n=23) 36% (n=21) 34% (n=22) 35% (n=66) 
No change in BMQ-Necessity 
>-0.27 and ≤0.27 
39% (n=26) 36% (n=21) 47% (n=30) 41%(n=77) 
Stronger BMQ-Necessity >0.27  27% (n=18) 28% (n=16) 19% (n=12) 24% (n=46) 
P=0.838, No significant difference between the three weight-effect groups 
Decreased BMQ-Concerns ≤-
0.33 
39% (n=26) 33% (n=19) 33% (n=21) 35% (n=66) 
No change BMQ-Concerns 
>-0.33 and ≤0.33 
48% (n=32) 53% (n=31) 31% (n=20) 44%(n=83) 
Stronger BMQ-Concerns >0.33  13% (n=9) 14% (n=8) 36% (n=23) 21% (n=40) 
P=0.104, WR Vs WI p=0.046, but not significant after Bonferroni correction p<0.017 
Decreased Necessity–Concern 
Differential ≤-0.06 
31% (n=21) 43% (n=25) 47% (n=30) 40% (n=76) 
No change in Necessity–Concern 
Differential >-0.06 and ≤0.06  
14% (n=9) 7% (n=4) 12% (n=8) 11% (n=21) 
Stronger Necessity–Concern 
Differential >0.06 
55% (n=37) 50% (n=29) 41% (n=26) 49% (n=92) 
P=0.188, No significant difference between the three weight-effect groups 
Decreased BMQ-Overuse  ≤-0.35 15% (n=10) 12% (n=7) 19% (n=12) 15% (n=29) 
No change in BMQ-Overuse 
>-0.35 and ≤0.35 
61% (n=41) 63% (n=36) 55% (n=35) 60%(n=112
) 
Stronger BMQ-Overuse >0.35 24% (n=16) 25% (n=14) 26% (n=17) 25% (n=47) 
P=0.937, No significant difference between the three weight-effect groups 
Decreased BMQ-Benefits ≤-0.26 21% (n=14) 16% (n=9) 23% (n=15) 20% (n=38) 
No change in BMQ-Benefits 
>-0.26 and ≤0.26 
62% (n=41) 63% (n=36) 61% (n=39) 62%(n=116
) 
Stronger BMQ-Benefits >0.26 17% (n=11) 21% (n=12) 16% (n=10) 18% (n=33) 
P=0.484, No significant difference between the three weight-effect groups 
Decreased BMQ-Harm ≤-0.33 16% (n=11) 16% (n=9) 17% (n=11) 17% (n=31) 
No change in BMQ-Harm 
>-0.33 and ≤0.33 
70% (n=47) 67% (n=38) 59% (n=38) 65%(n=123
) 
Stronger BMQ-Harm >0.33 14% (n=9) 17% (n=10) 24% (n=15) 18% (n=34) 
P=0.663, No significant difference between the three weight-effect groups 
 
 
 
 
474 
 
Appendix 5.8: Proportion of patients whose treatment satisfaction of new medicine had 
improved, did not change or decreased 
 Weight 
Reducing 
Weight 
Neutral 
Weight 
Increasing 
Whole 
Group 
Decreased DiabMedSat ≤-5.05 14% (n=9) 30% (n=13) 22% (n=13) 21% (n=35) 
No change in DiabMedSat  
>-5.05 and ≤5.05 
35% (n=23) 33% (n=14) 24% (n=14) 31%(n=51) 
Improved DiabMedSat  >5.05  51% (n=33) 37% (n=16) 54% (n=31) 48% (n=80) 
P=0.156, No significant difference between the three weight-effect groups 
Decreased DiabMedSat-
Efficacy ≤-8.75 
22% (n=14) 16% (n=7) 17% (n=10) 19% (n=31) 
No change in DiabMedSat-
Efficacy >-8.75 and ≤8.75 
23% (n=15) 55% (n=24) 25% (n=15) 32%(n=54) 
Improved DiabMedSat-
Efficacy >8.75 
55% (n=36) 29% (n=13) 58% (n=34) 49% (n=83) 
P=0.087, WN Vs WI, p=0.031 but not significant after Bonferroni Correction p<0.017 
Decreased DiabMedSat-
Burden ≤-6.30 
17% (n=11) 14% (n=6) 25% (n=15) 19% (n=32) 
No change in DiabMedSat- 
Burden >-6.30 and ≤6.30 
45% (n=29) 58% (n=25) 48% (n=28) 49%(n=82) 
Improved DiabMedSat-Burden 
>6.30 
38% (n=25) 28% (n=12) 27% (n=16) 32% (n=53) 
P=0.293, No significant difference between the three weight-effect groups 
Decreased DiabMedSat-
Symptom ≤-9.64 
17% (n=11) 32% (n=14) 26% (n=15) 24% (n=40) 
No change in DiabMedSat- 
Symptom >-9.64 and ≤9.64 
46% (n=30) 41% (n=18) 48% (n=28) 46%(n=76) 
Improved DiabMedSat-
Symptom  >9.64 
37% (n=24) 27% (n=12) 26% (n=15) 30% (n=51) 
P=0.168, No significant difference between the three weight-effect groups 
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Appendix 5.9: Proportion of patients whose impact of new medicine related to daily life, weight 
management and Psychological Health had improved, did not change or decreased 
 Weight 
Reducing 
Weight 
Neutral 
Weight 
Increasing 
Whole 
Group 
Decreased TRIM-Wt-DL 
≤-11.20 
10% (n=6) 11% (n=5) 13% (n=8) 11% (n=19) 
No change TRIM-Wt-DL  
>-11.20 and ≤11.20 
56% (n=36) 66% (n=29) 67% (n=40) 63%(n=105) 
Improved TRIM-Wt-DL>11.20 34% (n=22) 23% (n=10) 20% (n=12) 26% (n=44) 
P=0.191,  No significant difference between the three weight-effect groups 
Decreased TRIM-Wt-WM 
 ≤-13.78 
11% (n=7) 14% (n=6) 21% (n=13) 16% (n=26) 
No change TRIM-Wt-WM 
>-13.78 and ≤13.78 
30% (n=19) 56% (n=24) 54% (n=33) 45%(n=76) 
Improved TRIM-Wt-WM 
>13.78 
59% (n=38) 
**+++ 
30% (n=13)  
** 
25% (n=15) 
+++ 
39% (n=65) 
P=0.001, **WR Vs WN p=0.009, +++WR Vs WI, p<0.001  
Decreased TRIM-Wt-PH 
SEM≤-8.25 
17% (n=11) 23% (n=10) 23% (n=14) 21% (n=35) 
No change TRIM-Wt-PH  
>-8.25 and ≤8.25 
50% (n=32) 52% (n=23) 50% (n=30) 51%(n=85) 
Improved TRIM-Wt-PH >8.25 33% (n=21) 25% (n=11) 27% (n=16) 28% (n=48) 
P=0.518, No significant difference between the three weight-effect groups 
 
Appendix 5.10: Proportion of patients whose medication adherence levels had improved, did not 
change or decreased 
 Weight 
Reducing 
Weight 
Neutral 
Weight 
Increasing 
Whole 
Group 
Decreased MMAS-8 ≤-0.96 22% (n=14) 18% (n=8) 28% (n=17) 23% (n=39) 
No change on MMAS-8 
 >-0.96 and ≤0.96 
56% (n=36) 49% (n=22) 43% (n=26) 49%(n=84) 
Improved MMAS-8 >0.96 22% (n=14)  33% (n=15) 29% (n=18)  28% (n=47) 
P=0.485, No significant difference between the three weight-effect groups 
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Appendix 5.11: Proportion of patients whose self-efficacy with appropriate use of new medicine 
had improved, did not change or decreased 
 Weight 
Reducing 
Weight 
Neutral 
Weight 
Increasing 
Whole 
Group 
Decreased SEAMS≤-0.18 24% (n=16) 33% (n=19) 36% (n=22) 31% (n=57) 
No change SEAMS 
>-0.18 and ≤0.18 
21% (n=14) 33% (n=19) 32% (n=20) 28%(n=53) 
Improved SEAMS>0.18 55% (n=37) 
** 
33% (n=19) 32% (n=20) 
** 
41% (n=76) 
P=0.031, Weight Reducing Vs Weight Neutral p=0.032, **Weight Reducing Vs Weight Increasing 
p=0.017 
Decreased SEAMS-UDC≤-0.12 30% (n=20) 42% (n=24) 40% (n=25) 37% (n=69) 
No change SEAMS-UDC 
>-0.12and ≤0.12 
18% (n=12) 25% (n=15) 24% (n=15) 22%(n=41) 
Improved  SEAMS-UDC>0.12 52% (n=35) 33% (n=19) 36% (n=22) 41% (n=76) 
P=0.092, Weight Reducing Vs Weight Neutral, p=0.049, but not after Bonferroni correction p<0.017 
Decreased SEAMS-UCU≤-0.28 26% (n=17) 24% (n=14) 34% (n=21) 28% (n=52) 
No change SEAMS-UCU 
>-0.28and ≤0.28 
16% (n=11) 44% (n=25) 34% (n=21) 31%(n=57) 
Improved SEAMS-UCU>0.28 58% (n=39) 
** 
32% (n=18) 32% (n=20) 
** 
41% (n=77) 
P=0.33, WR Vs WN p=0.044 not after Bonferroni correction, **WR Vs WI p=0.016 
 
 
Appendix 5.12: Proportion of patients whose weight related quality of life had improved, did not 
change or decreased 
 Weight 
Reducing 
Weight 
Neutral 
Weight 
Increasing 
Whole 
Group 
Decreased OWLQOL≤-4.33 19% (n=13) 20% (n=12) 28% (n=18) 23% (n=43) 
No change on OWLQOL 
 >-4.33 and ≤4.33 
24% (n=16) 40% (n=23) 42% (n=27) 35%(n=66) 
Improved OWLQOL>4.33 57% (n=39) 
*** 
40% (n=23) 30% (n=19) 
*** 
43% (n=81) 
P=0.018, ***WR Vs WI p=0.005 
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Appendix 5.13 Ordinal Regression – Single Baseline (non-significant) Predictors for follow-up 
medication adherence  
Variable β significance Test  for 
parallelism 
Health Care setting 
Primary Care 
Secondary Care  
 
-0.461 
Reference 
 
0.103 
 
0.389 
Gender 0.159 0.554 0.905 
T2D diagnosis  0.021 0.25 0.462 
Single 
Married 
Widowed 
Divorced 
-0.779 
reference 
0.718 
-0.588 
0.079 
 
0.205 
0.233 
0.545 
Higher Education 
A Level 
GCSE 
Diploma 
Vocational 
No Formal Qualification 
-0.061 
-0.061 
-0.500 
-0.275 
-0.147 
Reference 
0.897 
0.897 
0.18 
0.672 
0.716 
0.47 
IMD 
20% Least Deprived 
61% - 80% 
41%- 60% 
21% - 40% 
20% Most Deprived 
 
0.043 
0.809 
-0.361 
-0.442 
Reference 
 
0.944 
0.119 
0.386 
0.267 
 
0.257 
EITQ 0.227 0.214 0.628 
SIMS–AU 0.050 0.402 0.695 
BMQ-Necessity 0.253 0.215 0.131 
Belief Groups Baseline 
Sceptical 
Ambivalent 
Indifferent 
Accepting 
 
-0.625 
-0.387 
-0.305 
Reference 
 
0.175 
0.273 
0.560 
0.718 
BMQ-Overuse -0.331 0.057 0.345 
BMQ-Harm -0.461 0.056 0.402 
BMQ-Benefits 0.303 0.244 0.214 
DibMedSat-Symptoms 0.008 0.212 0.714 
TRIM-Wt-DL 0.005 0.521 0.973 
TRIM-Wt-WM  -0.002 0.809 0.702 
OWLQOL 0.007 0.124 0.968 
BMI Baseline 0.019 0.307 0.699 
HbA1c Change 0.011  0.292 0.565 
Total Medication Burden - Baseline 0.032 0.345 0.836 
Total Diabetes Medication Burden -
Baseline 
-0.224 0.130 0.241 
Total Diabetes Complications Burden  - 
Baseline 
0.148 0.243 0.249 
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Appendix 5.14: Ordinal Regression – Single Change (non-significant) Predictors for follow-up 
medication adherence  
Variable β 
 
significance Test of 
Parallelism 
SEM SIMS 
Improved 
No Change 
Decreased 
 
Reference 
0.368 
0.224 
 
 
0.228 
0.536 
 
0.247 
SEM SIMS-AU 
Improved 
No Change 
Decreased 
 
Reference 
0.322 
-0.015 
 
 
0.310 
0.965 
 
0.151 
SEM SIMS-PPM 
Improved 
No Change 
Decreased 
 
Reference 
0.348 
0.131 
 
 
0.247 
0.746 
 
0.233 
SEM Necessity-Concern Differential 
Stronger 
No change 
Decreased 
 
Reference 
-0.489 
-0.088 
 
 
0.276 
0.758 
 
0.236 
SEM BMQ-Overuse 
Stronger 
No Change 
Decreased 
 
Reference 
0.030 
0.016 
 
 
0.926 
0.971 
 
0.336 
SEM BMQ-Harm 
Stronger 
No Change 
Decreased 
 
Reference 
-0.479 
-0.265 
 
 
0.182 
0.563 
 
0.231 
SEM BMQ-Benefits 
Stronger 
No Change 
Decreased 
 
Reference 
-0.101 
0.602 
 
 
0.172 
0.782 
 
0.237 
SEM DiabMedSat 
Improved 
No Change 
Decreased 
 
Reference 
0.089 
-0.326 
 
 
0.788 
0.387 
 
0.437 
SEM DiabMedSat-Burden 
Improved 
No Change 
Decreased 
 
Reference 
0.177 
-0.166 
 
 
0.586 
0.688 
 
0.938 
SEM DiabMedSat-Symptoms 
Improved 
No Change 
Decreased 
 
Reference 
0.312 
-0.096 
 
 
0.351 
0.806 
 
0.176 
SEM DiabMedSat-Efficacy 
Improved 
 
Reference 
 
 
0.434 
479 
 
No Change 
Decreased 
0.278 
0.098 
0.389 
0.800 
SEM TRIM-Wt-DL 
Improved 
No Change 
Decreased 
 
Reference 
0.055 
-0.153 
 
 
0.868 
0.763 
 
0.260 
SEM TRIM-Wt-WM 
Improved 
No Change 
Decreased 
 
Reference 
-0.306 
-0.320 
 
 
0.325 
0.455 
 
0.957 
SEM TRIM-Wt-PH 
Improved 
No Change 
Decreased 
 
Reference 
-0.402 
-0.244 
 
 
0.228 
0.551 
 
0.619 
SEM SEAMS 
Improved 
No Change 
Decreased 
 
Reference 
0.646 
-0.483 
 
 
0.054 
0.139 
 
0.808 
SEM SEAMS-UCU 
Improved 
No Change 
Decreased 
 
Reference 
0.031 
-0.584 
 
 
0.924 
0.080 
0.785 
SEM OWLQOL 
Improved 
No Change 
Decreased 
 
Reference 
0.060 
-0.202 
 
 
0.843 
0.562 
 
0.262 
Weight Change -0.048 0.244 0.400 
HbA1c Change 0.011 0.292 0.565 
Total Medication Burden change -0.080 0.373 0.776 
Total Diabetes Medication Burden change 0.178 0.386 0.704 
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Appendix 5.15: Correlation Matrix (Pearson Correlation) 
r Age Baseline 
MMAS-8 
SEAMS-
UDC 
SEAMS-
UCU 
BMQ 
Concern 
Change 
(Stronger 
Vs 
Decrease) 
BMQ- 
Concern 
Change 
(Stronger 
Vs Stable) 
SEAMS-UDC 
Change 
(Improvement 
Vs decrease) 
Age 1 0.3 0.1 0.1 .01 -0.1 -0.02 
Baseline 
MMAS-8 
0.3 1 0.6 0.5 -0.01 -0.01 -0.001 
SEAMS-UDC 0.1 0.6 1 0.8* 0.01 -0.01 0.2 
SEAMS-UCU 0.1 0.5 0.8* 1 0.01 -0.1 0.2 
BMQ Concern 
Change 
(Stronger Vs 
Decrease) 
0.01 -0.01 0.01 0.01 1 -0.6 -0.1 
BMQ- Concern 
Change 
(Stronger Vs 
Stable) 
-0.1 -0.01 -0.1 -0.1 -0.6 1 0.1 
SEAMS-UDC 
Change 
(Improvement 
Vs decrease) 
-
0.02 
-0.001 0.2 0.2 -0.1 0.1 1 
*Tolerance Statistic SEAMS- UDC= 0.3, SEAMS-UCU= 0.3, VIF SEAMS-UDC= 4.1, SEAMS-UCU= 3.7 
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Appendix 5.16: Multinomial Regression – Single Baseline Predictors for change in medication 
adherence based on SEM   
Variable β 
Decreased 
Adherence 
Significance β 
Increased 
Adherence 
Significance 
Gender 
Male 
Female 
 
-0.345 
Reference 
 
0.375 
 
-0.063 
Reference 
 
0.863 
Age -0.003 0.852 0.029 0.098 
T2D diagnosis  0.035 0.167 -0.01 0.724 
Higher Education 
A Level 
GCSE 
Diploma 
Vocational 
No Formal Qualification 
0.433 
-0.666 
0.145 
0.838 
-0.037 
Reference 
0.543 
0.426 
0.783 
0.275 
0.952 
0.595 
0.526 
0.202 
-19.183 
0.490 
Reference 
0.376 
0.367 
0.691 
 
0.355 
Full time 
Part time 
Unemployed 
Other 
Retired 
-0.531 
-0.531 
0.211 
0.404 
Reference 
0.334 
0.535 
0.722 
0.464 
-0.223 
-0.336 
-0.693 
-1.076 
Reference 
0.379 
0.127 
0.619 
0.282 
EITQ -0.155 0.568 -0.264 0302 
SIMS  0.018 0.675 -0.038 0.313 
SIMS-PPM 0.030 0.620 -0.002 0.971 
BMQ-Concerns -0.268 0.364 0.071 0.797 
BMQ-Necessity -0.223 0.442 0.156 0.571 
Necessity-Concern 
Differential Baseline 
0.022 0.921 0.049 0.814 
Belief Groups Baseline 
Sceptical 
Ambivalent 
Indifferent 
Accepting 
 
-0.164 
-0.619 
0.288 
Reference 
 
0.804 
0.222 
0.682 
 
-0.077 
-0.491 
-0.606 
Reference 
 
0.900 
0.297 
0.448 
BMQ-Benefits -0.573 0.138 -0.544 0.133 
DiabMedSat -0.008 0.538 -0.024 0.056 
DiabMedSat-Symptoms -0.006 0.486 -0.014 0.106 
DiabMedSat-Efficacy -0.005 0.654 -0.005 0.631 
TRIM-Wt-DL 0.002 0.888 -0.10 0.340 
TRIM-Wt-WM 0.017 0.053 0.011 0.190 
TRIM-Wt-PH -0.007 0.322 -0.010 0.141 
SEAMS-UDC  -0.113 0.607 -0.382 0.059 
OWLQOL 0.001 0.931 0.002 0.695 
Baseline BMI -0.01 0.973 -0.008 0.758 
Total Medication Burden 
Baseline 
0.042 0.376 -0.028 0.555 
Total Diabetes Medication 
Burden Baseline 
0.024 0.919 -0.132 0.553 
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Total Diabetes 
Complications Burden  
Baseline 
0.157 0.396 0.057 0.752 
Weight Effects of New 
Medicine: 
WI 
WN 
WR 
 
 
0.520 
-0.067 
Reference 
 
 
0.241 
0.897 
 
 
0.577 
0.561 
Reference 
 
 
0.222 
0.190 
 
 
Appendix 5.17: Multinomial Regression – Single Change Predictors for change in medication 
adherence based on SEM 
Variable β 
Decreased 
Adherence 
significance β 
Increased 
Adherence 
Significance 
Expectation Perception 
Difference 
Expectations Exceeded by 
Experience 
Expectations Unmet 
Expectations Met 
 
 
Reference 
-0.103 
-0.216 
 
 
 
0.821 
0.661 
 
 
Reference 
-0.772 
-0.461 
 
 
 
 
0.086 
0.306 
SEM SIMS 
Improved 
No Change 
Decreased 
 
Reference 
0.327 
-1.030 
 
 
0.441 
0.143 
 
Reference 
-0.065 
0.377 
 
 
0.880 
0.424 
SEM SIMS-AU 
Improved 
No Change 
Decreased 
 
Reference 
0.316 
-0.606 
 
 
0.487 
0.299 
 
Reference 
-0.629 
-0.182 
 
 
0.157 
0.688 
SEM SIMS-PPM 
Improved 
No Change 
Decreased 
 
Reference 
0.216 
-0.778 
 
 
0.608 
0.276 
 
Reference 
0.662 
0.561 
 
 
0.127 
0.311 
SEM BMQ-Concern 
Stronger 
No Change 
Decreased 
 
Reference 
-0.657 
-0.770 
 
 
0.174 
0.151 
 
Reference 
-0.312 
0.211 
 
 
0.538 
0.682 
SEM BMQ-Necessity 
Stronger 
No Change 
Decreased 
 
Reference 
-0.085 
0.707 
 
 
0.870 
0.179 
 
Reference 
-0.114 
0.647 
 
 
0.813 
0.190 
SEM Necessity- Concern 
Differential 
Stronger 
No change 
Decreased 
 
 
Reference 
0.265 
0.671 
 
 
 
0.693 
0.107 
 
 
Reference 
0.243 
0.138 
 
 
 
0.678 
0.726 
SEM BMQ-Harm 
Stronger 
 
Reference 
 
 
 
Reference 
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No Change 
Decreased 
-0.387 
-0.331 
0.431 
0.612 
-0.198 
0.074 
0.683 
0.903 
SEM BMQ-Benefits 
Stronger 
No Change 
Decreased 
 
Reference 
-0.551 
-1.303 
 
 
0.281 
0.067 
 
Reference 
-0.512 
-0.250 
 
 
0.315 
0.726 
SEM DiabMedSat 
Improved 
No Change 
Decreased 
 
Reference 
0.199 
0.399 
 
 
0.662 
0.427 
 
Reference 
-0.518 
-0.374 
 
 
0.238 
0.453 
SEM DiabMedSat-Symptoms 
Improved 
No Change 
Decreased 
 
Reference 
-0.047 
0.286 
 
 
0.921 
0.593 
 
Reference 
-0.521 
-0.340 
 
 
 
0.222 
SEM DiabMedSat-Efficacy 
Improved 
No Change 
Decreased 
 
Reference 
-0.878 
0.028 
 
 
0.068 
0.955 
 
Reference 
-0.567 
-0.397 
 
 
0.175 
0.450 
SEM TRIM-Wt-DL 
Improved 
No Change 
Decreased 
 
Reference 
0.644 
0.711 
 
 
0.214 
0.325 
 
Reference 
-0.414 
-0.269 
 
 
0.677 
0.311 
SEM TRIM-Wt-WM  
Improved 
No Change 
Decreased 
 
Reference 
0.579 
0.405 
 
 
0.189 
0.506 
 
Reference 
-0.326 
0.047 
 
 
0.421 
0.931 
SEM TRIM-Wt-PH  
Improved 
No Change 
Decreased 
 
Reference 
-0.533 
0.121 
 
 
0.236 
0.834 
 
Reference 
-0.421 
0.680 
 
 
0.341 
0.196 
SEM OWLQOL 
Improved 
No Change 
Decreased 
 
Reference 
-0.546 
0.454 
 
 
0.254 
0.337 
 
Reference 
0.036 
0.080 
 
 
0.931 
0.870 
Weight Change 0.076 0.212 0.006 0.907 
HbA1c Change -0.003  0.843 -0.005 0.751 
Total Medication Burden 
change 
0.078 0.513 0.076 0.530 
Total Diabetes Medication 
Burden change 
0.018 0.950 -0.187 0.497 
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Appendix Figures Chapter 5 
 
 
Figure 5.1: Percent agreement to EITQ/PITQ item “The new medicine delivery system (will be/ is) easy 
for me to use away from home” at baseline and follow-up for WR group.  
 
 
Figure 5.2: Percent agreement to EITQ/PITQ item “The new medicine delivery system (will be/ is) 
convenient” at baseline and follow-up for WR group.  
 
 
Figure 5.3: Percent agreement to SIMS item “Have received enough information about how to get 
further supply” at baseline and follow-up for WR group.  
485 
 
 
Figure 5.4: Percent agreement to SIMS item “Have received enough information about whether 
medicine will make you feel drowsy” at baseline and follow-up for WR group.  
 
 
 
Figure 5.5: Percent agreement to SIMS item “Have received enough information about whether you 
can drink alcohol whilst taking this medicine” at baseline and follow-up for WI group.  
 
 
Figure 5.6: Percent agreement to DiabMedSat item “How satisfied or dissatisfied have you been with 
the ease and convenience of your diabetes medicine(s)” at baseline and follow-up for WR group.  
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Figure 5.7: Percent agreement to DiabMedSat item “Have you been bothered by symptoms of 
unwanted weight gain due to your diabetes medicine(s)” at baseline and follow-up for WR group.  
 
 
Figure 5.8: Percent agreement to DiabMedSat item “How satisfied or dissatisfied have you been with 
your diabetes medicine(s) ability to keep your blood sugars stable (avoid highs and lows)” at baseline 
and follow-up for WR group.  
 
 
Figure 5.9: Percent agreement to DiabMedSat item “How satisfied or dissatisfied have you been with 
the impact of your diabetes medicine(s) on your emotional well-being” at baseline and follow-up for 
WR group.  
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Figure 5.10: Percent agreement to DiabMedSat item “How often has taking your diabetes medicine(s) 
as prescribed interfered with your ability to be flexible with planning meals (when to eat and what you 
are able to eat)” at baseline and follow-up for WI group.  
 
 
 
Figure 5.11: Percent agreement to TRIM-Weight item “How bothered or not bothered are you by being 
tired or drowsy during the day because of your medicine(s)” at baseline and follow-up for WI group.  
 
 
Figure 5.12: Percent agreement to SEAMS item “How confident are you that you could take your new 
medicine correctly when you take several different medicines each day” at baseline and follow-up for 
WR group.  
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Figure 5.13: Percent agreement to SEAMS item “How confident are you that you could take your new 
medicine correctly when you are not sure how to take the medicine” at baseline and follow-up for WR 
group.  
 
 
Figure 5.14: Percent agreement to SEAMS item “How confident are you that you could take your new 
medicine correctly when you are not sure what time of the day to take your medicine” at baseline and 
follow-up for WR group.  
 
 
Figure 5.15: Percent agreement to OWLQOL item “I feel frustrated that I have less energy because of 
my weight” at baseline and follow-up for WR group.  
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Figure 5.16: Percent agreement to OWLQOL item “I feel guilty when I eat because of my weight” at 
baseline and follow-up for WR group.  
 
 
Figure 5.17: Percent agreement to OWLQOL item “I am bothered by what other people say about my 
weight” at baseline and follow-up for WR group.  
 
 
 
Figure 5.18: Percent agreement to OWLQOL item “I worry about the future because of my weight” at 
baseline and follow-up for WR 
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Figure 5.19: Percent agreement to OWLQOL item “I have difficulty accepting my body because of my 
weight” at baseline and follow-up for WR group.  
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Appendix 6.1: Interview Sample Characteristics and Scale scores  
 Baseline n(%) Follow-up (n%) 
Centre Site: 
  GP Practice 
  SCDC 
  CP 
 
16 (67) 
5 (21) 
3 (12) 
 
Age (yrs)  63.5 (55, 69) [Range 46-78]  
Gender 
  Men 
  Women 
 
13 (54) 
11(46) 
 
Marital Status 
  Alone/Single  
  Married/ with partner 
  Divorced/Separated  
  Widowed 
 
3 (13) 
19 (79) 
2 (8) 
0 (0) 
 
Level of Education 
 University /Higher Degree 
 Diploma  
Vocational 
A level  
GCSE  
No Formal Qualifications  
 
1 (4) 
0 (0) 
2 (8) 
4 (17) 
7(29) 
10 (42) 
 
IMD 
  20% most deprived 
  21% to 40%  
  41% to 60%  
  61% to 80% 
  20% least deprived 
 
12 (50) 
2 (8) 
5 (21) 
1 (4) 
4 (17) 
 
Employment Status  
  Full time  
  Part-time  
  Unemployed 
  Retired  
  Other [most on benefits] 
 
4 (17) 
3 (13) 
3 (13) 
13 (54) 
1 (4) 
 
Years Diagnosed with T2D  
 
8.5 (6, 13) 
[Range: 2 weeks- 19yrs] 
 
No of Diabetes Complications 
Missing Data  
1 (0, 2) 
 
1 (0, 2) 
2 (8.3%) 
New Medicine Prescribed- Weight 
Effect 
WR 
WN 
WI 
 
 
11 (46) 
6 (25) 
7 (29) 
 
Total Medicine Burden 
(number/day)  
Missing Data 
7 (5,10) [Range 1-19] 
1 (4.2%) 
7 (5,11) [Range 2-21] 
1(4.2%) 
Total Diabetes Medicine Burden  
(number per day) 
Missing Data 
2 (1,3) Range (0-4) 2 (2,3) Range (1-3) 
 
1(4.2%) 
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BMI (kg/m2)  
 
Missing Data 
35.3 (30.8, 40.2) [Range28.4-
51.8] 
 
33.6 (30.2, 39.5) [Range 
27.4-49.70] 
1 (4.2%) 
HbA1c (mmol/mol)  
Missing Data 
78 (65, 91) [Range 52-110] 
 
65 (56, 81) [Range 43-
104] 
4 (16.7%) 
Adherence Levels 
Low 
Medium 
High 
Not Applicable  
Missing Data 
 
9 (41) 
9 (41) 
4 (18) 
1 (4.2) 
1 (4.2) 
 
6 (25) 
10 (42) 
8 (33) 
Total N 24 23 
EITQ (baseline)/PITQ (Follow-up) 5.8 (5.5, 6.3) 5.5 (5.1, 6.1) 
SIMS 11 (7.3, 15.5) 13 (8, 16) 
SIMS-AU 7 (5,8) 8 (7,9) 
SIMS-PPM 4 (0.8, 6.8) 5 (2, 8) 
BMQ-Concerns 3 (2.5, 3.4) 2.7 (2.3, 3.1) 
BMQ-Necessity 3.9 (3.4, 4.4) 4 (3.6, 4.4) 
BMQ Necessity–Concern Differential   
BMQ-Overuse 2.7 (2.3, 3.3) 3.3 (2.7, 3.7) 
BMQ-Harm 2.4 (2, 2.8) 2.3 (2, 2.8) 
BMQ-Benefits 4 (3.5, 4.4) 4 (3.8, 4.3) 
SEAMS 3.7 (3.0, 4.0) 3.9 (2.9, 4.7) 
SEAMS-UCU 3.4 (2.7, 4.0) 3.8 (2.7, 4.8) 
SEAMS-UDC 3.9 (3.4, 4.1) 4 (3.1, 5.0) 
OWLQOL 57.4 (27.7, 88) 77.5 (29.4, 90.2) 
Total N 22 24 
MMAS-8 6.8 (5.3, 7.2) 6.9 (5.6, 8) 
DiabMedSat 67.1 (55.5, 78.6) 74.6 (63.3, 77.8) 
DiabMedSat-Efficacy 53.3 (35.0, 72.5) 61.7 (47.5, 79.2) 
DiabMedSat-Burden 89.0 (66.5, 95.5) 88.3 (76, 97.2) 
DiabMedSat-Symptoms 70 (50, 80) 66 (56, 79) 
TRIM-Wt-DL  70.8 (56.3, 83.3) 72.9 (58.3, 79.2) 
TRIM-Wt-WM  33.3 (20.8, 50) 50 (25, 66.7) 
TRIM-Wt-PH  84.4 (56.3, 100) 81.3 (64.1, 100) 
Data are % or Median, IQR (Q1, Q3) or mean±SD 
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Appendix 6.2: Key aspects showed change or not change for the duration of the study per participant 
Case What changed How has it changed Why has it changed? What has NOT changed 
Irene Support from both husband 
and health care services 
 
Clinical/Physical Outcomes 
 
Psychological Outcomes 
Treatment 
Routine 
Increased- compliments about weight loss, 
reminders to take injection from husband, regular 
appointments, seen dietitian, DSN, Dr, GP 
Blood sugars improved, retained kidney function, 
Lost weight, less swollen legs  
Feeling good in herself 
Started liraglutide 
Convenient new medicine 
Longing for a new lease of life 
Key motivation to lose weight 
Fear of consequences of 
abnormal sugars (physical 
evidence of medicines 
effectiveness & food on blood 
sugars) 
Self-monitoring 
Motivation to change 
 
Linda Support from health care 
services 
Clinical/Physical Outcomes 
 
Treatment 
Routine 
Increased - regular appointments, seen DSN, Dr, 
GP 
Blood sugars improved, lost weight, some minor 
side effects 
Started dapagliflozin, stopped sitagliptin 
Convenient new medicine 
Key motivation to lose weight 
& stop taking medicines 
Fear of consequences of 
abnormal sugars 
 
Still suffers unexplained pain 
which impacts lifestyle & 
wellbeing 
Concerns over taking medicines 
long term 
Missing other medicines 
Alison Support from health care 
services 
Clinical/Physical Outcomes 
Psychological Outcomes 
Treatment 
 
Routine 
Increased- regular appointments/ telephone 
contact, seen DSN, Dr, GP 
Lost weight, some side effects 
Concerns over increased blood sugars 
Started exenatide, reduced insulin amount then 
increased 
Convenient new medicine 
Key motivation to lose weight 
and reduce amount of insulin 
and Metformin 
 
Continuous family support  
Angela Support health care services 
 
Clinical/Physical Outcomes 
Psychological Outcomes 
Treatment 
 
 
Increased- regular appointments/ telephone 
contact, Seen DSN, Dr, GP 
Eventually blood sugars improving 
Concerns over increased blood sugars 
Started twice daily insulin- dose increased over 
time, stopped liraglutide and once daily insulin, 
stopped gliclazide 
To improve post meal blood 
sugars and stopped liraglutide 
Concerns over increased 
blood sugars- she was not 
concerned at the beginning, 
but became concerned after 
change in treatment 
Perceptions about seriousness 
of diabetes 
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Routine Sometimes delayed taking new medicine, 
considers eating patterns to reduce 
hypoglycaemia risk 
Oliver Support from health care 
services 
Clinical/Physical Outcomes 
Treatment 
Increased- regular appointments/ telephone 
contact, testing HbA1c, seen DSN 
Blood sugar improvement, lost weight 
Started liraglutide, stopped sitagliptin 
Wants to control diabetes 
and lose weight 
Wants to live life without 
making lifestyle changes 
Routine 
Views about support from GP 
and health care organisation 
 
Christopher Support from family and 
health care services 
 
Clinical/Physical Outcomes 
 
 
Psychological Outcomes 
 
Treatment 
 
Routine 
Increased- all family members mentioned, regular 
appointment/ telephone contact, testing HbA1c, 
seen DSN 
Eventually blood sugars improving, gain weight, 
retained kidney function, experienced 
hypoglycaemic episodes, increased self-
monitoring 
Injecting in public uncomfortable, annoyed with 
amount of self-monitoring 
Started once daily Insulin- dose increased over 
time, takes less Metformin and more gliclazide 
Convenient new medicine- becomes inconvenient 
Concerned about health- 
diabetes and other issues. 
Does not want to keep 
changing medicines. 
Motivation to preserve kidney 
function. Insulin means takes 
less metformin 
Beliefs about necessity and 
benefits of medicines 
Continuous family support 
Philip Support from health care 
services 
Clinical/Physical Outcomes 
 
Psychological Outcomes 
 
Treatment 
 
Increased- regular appointment/ telephone 
contact, testing HbA1c, seen DSN 
High blood sugars, weight gain, increased self- 
monitoring 
Frustrated with support and increased blood 
sugars, concerned about weight gain 
Started Exenatide and insulin dose increased, 
stopped metformin and gliclazide 
Wants to live his life, live 
longer 
Wants to be independent and 
control diabetes, wants to be 
normal 
Motivation to reduce amount 
of tablets 
Concerns over taking medicines 
long term 
Routine 
Adam Support from health care 
services 
 
Increased- regular appointment/ telephone 
contact, testing HbA1c, monitoring kidney 
function, seen DSN 
Concerned about health- 
Diabetes and other issues 
Continuous family support, 
trust doctors, belief in benefits 
of medicines 
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Clinical/Physical Outcomes 
 
 
Psychological Outcomes 
Treatment 
 
Routine 
Eventually blood sugars improving, kidneys 
deteriorated, experienced hypoglycaemic 
episodes, increased self-monitoring 
Surprised with slow effectiveness of insulin 
Started once daily insulin- dose increased 
overtime, stopped metformin, less gliclazide 
Convenient new medicine 
Motivation to preserve kidney 
function 
Elizabeth Support from health care 
services 
 
Clinical/Physical Outcomes 
 
Treatment 
 
Increased- regular appointment/ telephone 
contact, testing HbA1c, seen DSN, GP, Matron 
nurse 
Slight improvement on blood sugars, less 
hypoglycaemic episodes 
Started twice daily insulin- dose increased 
overtime, stopped previous twice daily insulin, 
takes less medicines after GP review – not T2D 
medicines 
Concerned of health- 
Diabetes and other issues 
Motivation to prevent weight 
gain, take less medicines and 
minimise side effects and 
Hypoglycaemia 
Continuous family support 
Concerns re: symptoms of 
itchiness, blood sugars and 
weight 
Self-monitoring 
Routine 
Kate Support from health care 
services 
Clinical/Physical Outcomes 
Treatment 
 
Increased- regular appointment/ telephone 
contacts, seen dr, DSN, PN 
Slight improvement on blood sugars, weight gain 
Never started Sitagliptin, Insulin dose increased 
and frequency of injections, more heart 
medicines 
Motivation to take less insulin Unsure of medicines’ benefits 
Continuous family/friend 
support Routine 
 
Keith Support from wife and 
health care services 
 
 
Clinical/Physical Outcomes 
 
Psychological Outcomes 
 
Treatment 
Increased- remind to self-monitor blood sugars 
and take injection, regular appointments/ 
telephone contact, seen DSN, GP, PN 
Weight loss, relatively stable blood sugars, short 
term side effects 
Made up with weight loss, frustrated with GP 
support 
Started Exenatide  
Wants to live a normal life 
Key motivation to lose weight 
Wants to look after wife 
Concerns over taking medicines 
long term 
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Routine Convenient new medicine- although sometimes 
forgets to inject 
Karen Support from family and 
health care services 
 
Clinical/Physical Outcomes 
 
Treatment 
Routine 
Increased- parent support experienced with 
injections, regular appointments/ telephone 
contacts , seen DSN, GP 
Blood sugars improvement, weight loss, body 
bruises at injection site, side effects 
Started Liraglutide  
More organised/ Increased adherence to tablets 
Keen motivation to lose 
weight 
Injectable medicines more 
important than tablets 
Teresa Support from family and 
health care services 
 
Clinical/Physical Outcomes 
 
Psychological Outcomes 
Treatment 
Routine 
Increased- husband aware of hypoglycaemia, 
regular appointment/ telephone contact, seen 
DSN 
Improved blood sugars, experienced 
hypoglycaemic episodes 
Disappointed with no weight loss 
Started Exenatide extended release 
Convenient new medicine 
Key motivation to lose weight 
and avoid insulin 
 
Body weight 
Concerns over amount of 
tablets taken and risk of 
hypoglycaemia 
Robert Support from health care 
services 
Clinical/Physical Outcomes 
 
 
Psychological Outcomes 
 
Treatment 
Decreased- not regular contact, unable to make 
appointment, unaware of HbA1c results 
Blood sugars may have improved, may have 
gained weight, experienced hypoglycaemic 
episodes 
Disappointed with new medicine- not as 
expected, frustrated with GP service 
Started gliclazide, changed eating patterns and 
food amount due to hypoglycaemia 
Key motivation to control 
diabetes  
Wants to function as a normal 
person 
Wants to look after wife 
Continuous family support  
Kelly Support from health care 
services 
Clinical/Physical Outcomes 
 
Psychological Outcomes 
Increased- regular appointment/ telephone 
contact, changes in treatment, seen DSN 
Blood sugars improved then deteriorated, Weight 
lost then gained, experienced side effects 
Key motivation to lose weight 
and stop taking medicines 
Wants to go back to her old 
self 
Continuous family support  
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Treatment 
 
 
Routine 
Disappointed with changes and effectiveness of  
medicines 
Started exenatide then changed to liraglutide, 
stopped pioglitazone, changes to eating patterns 
due to side effects 
Convenient new medicine 
Andrew Support from health care 
services 
 
Clinical/Physical Outcomes 
Treatment 
Increased- regular appointment / telephone 
contact, testing HbA1c, monitoring kidney 
function, seen DSN, dietitian 
Blood sugar improvement,  
Started gliclazide, changes in types and portions 
of food in order to lose weight 
Wants to live a normal life for 
his age 
Wants to control diabetes 
and kidney function 
Key motivation to lose weight 
Continuous family support 
Difficulty in breathing 
Views about medicines 
Body weight 
Edward Support from health care 
services 
Clinical/Physical Outcomes 
Psychological Outcomes 
 
Treatment 
 
Routine 
Increased- regular appointments, testing HbA1c 
Seen DSN 
Blood sugars improved  
Happy with changes to treatment and 
effectiveness 
Started twice daily insulin- dose increased over 
time, stopped once daily insulin, changes in 
eating patterns due to injections 
Convenient new medicine  
 Concerns of complications with 
Diabetes 
 
Vanessa Support from family and 
health care services 
 
 
 
Clinical/Physical Outcomes 
Psychological Outcomes 
Treatment 
 
 
Increased- family provides cooked meals, regular 
appointments/ telephone contacts, seen DSN, Dr, 
dietitian, testing HbA1c 
Decreased- seen GP less due to increase in other 
services 
Blood sugars improved, weight loss, more energy 
Feels better in herself 
Started liraglutide and levemir, stopped 
novorapid and lantus, eating patterns & food 
Key motivation to lose weight 
and stop taking medicines 
wants to live a normal life 
 
Concerns over the number of 
medicines taken 
Omission of tablets 
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Routine amount changed due to side effects from 
medicines 
Convenient new medicines 
Gareth Support from health care 
services 
Clinical/Physical Outcomes 
 
Treatment 
Increased 
 
Blood sugar improvement, retained kidney 
function 
Started linagliptin, stopped sitagliptin 
Trust in doctors 
 
Continuous family support  
Routine 
 
Julie Support from health care 
services 
Clinical/Physical Outcomes 
 
Psychological Outcomes 
Treatment 
 
 
 
Routine 
Increased- regular appointments/ telephone 
contact, seen dietitian, DSN 
Unsure about blood sugars as stopped self-
monitoring, lost weight, more energetic 
Feels good about herself 
Started liraglutide, stopped gliclazide, changes to 
eating patterns, amount and type of foods due to 
side effects of medicine and motivation to lose 
weight 
Convenient new medicine 
Key motivation to lose 
weight, avoid insulin and stop 
medicines 
Fear of diabetes complications 
Continuous family support  
 
Daniel Support from health care 
services 
Clinical/Physical Outcomes 
 
Treatment 
 
Routine 
Increased- regular support , seen practice nurse, 
GP, attended course on diabetes 
Unsure if improvement in blood sugars, lost 
weight, more energetic 
Started metformin dose increased over time, 
lifestyle changes due to effect of medicine 
Convenient new medicine 
Wants to combat diabetes 
and eventually stop taking 
medicines 
Diabetes is serious 
Concerns over taking medicines 
long term 
 
Patrick Support from health care 
services 
Clinical/Physical Outcomes 
 
 
Psychological Outcomes 
Increased- regular appointments, seen DSN, DM 
Dr, Kidney Dr 
Blood sugar improvement, retained kidney 
function, weight loss, blood pressure 
improvement 
Happy with weight loss 
Key motivation to lose weight 
and retain kidney function 
 
Views about support from GP 
and health care organisation 
Routine 
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Treatment Started linagliptin, stopped sitagliptin, insulin 
dose reduced, started orlistat at reduced dose 
David Support from health care 
services 
Clinical/Physical Outcomes 
 
Treatment 
Increased- regular appointments, seen DSN, 
testing HbA1c, shown how to self-monitor 
Blood sugar improvement, weight loss, more 
energetic, self-monitors 
Started metformin MR 
Wants to control diabetes Continuous family support 
Views about support from GP 
and health care organisation 
Routine 
James Support from health care 
services 
Clinical/Physical Outcomes 
 
Treatment 
Increased- regular appointments, seen DSN, 
testing HbA1c 
Slight improvement of blood sugar, lost weight, 
more energetic, self-monitors 
Started sitagliptin, reduced dose of gliclazide 
Wants to control diabetes 
and forgets he has it 
Routine 
Fear of insulin, concerns over 
hypoglycaemia risk 
 
 
 
 
